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Summary of Thesis. 
Breast cancer remains the most common malignancy in women and a major cause of 
morbidity and mortality in the western World, despite the advances in diagnosis and 
treatment. The main challenge remains to identify new, and improve existing treatment 
modalities. Understanding the mechanism by which tumours grow and metastasise is key 
to developing new therapeutic targets 
Similar to most cancers, the incidence of breast cancer increases with age. Therefore, genes 
involved in biological ageing and factors affecting genomic integrity, considered critical to 
cellular senescence and organismal life span, are also relevant to neoplastic transformation 
and tumour growth. Thus exploring factors associated with biological ageing in cancer 
may improve our understanding of the disease as an aberration of normal biological ageing 
and result in new prognostic markers or therapeutic targets. There is increasing evidence 
for the involvement of sirtuins in biological ageing, along with other essential cellular 
processes including cell cycle control, DNA damage repair and differentiation. This is 
suggestive of a possible role for sirtuins in cancer. Therefore, this study was conducted to 
investigate a potential role for sirtuins in breast cancer disease (including anti-tumour 
treatment).  
Firstly, Real time PCR was used to compare the transcriptional expression level of 
individual sirtuin genes in vivo. The experimental result showed that only SIRT1 and 
SIRT4 showed an association with age in  “normal patients” (normal and non malignant 
patient grouped together), with decreasing levels of SIRT1 and increasing levels of SIRT4 
being associated with increasing chronological age. All sirtuin levels were significantly 
decreased in malignant tumours, when compared to either normal and/ or non-malignant 
biopsies. Decreased relative transcriptional expression of SIRT1, SIRT2, SIRT3, SIRT6 
and SIRT7 showed significant association with higher tumour grade, when breast cancer 
patients were divided according to the known histopathological markers.  
The Kaplan-Meier analysis for cancer specific survival and tumour recurrence was 
preformed on entire patient cohorts and in patient subgroups selected to have moderate 
prognosis (ER+ve and NPI between 3.4 and 5.4). The Kaplan-Meier survival analysis 
showed that higher levels of SIRT6 and SRT7 were associated with a longer survival 
period in all patient cohorts. Furthermore, higher levels of SIRT6 remained significantly 
associated with better survival, when breast cancer patients were selected to have 
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intermediate prognosis (ER+ve and NPI between 3.4 and 5.4). Whereas, higher levels of 
SIRT7 remained significantly associated with longer survival period only in patients with 
ER+ve tumours. The Kaplan-Meier analysis showed that lower levels of SIRT1 gene 
expression were associated with longer patient survival and lower tumour recurrence in a 
patient group, selected by NPI, to have an intermediate clinical prognosis. Multivariate 
Cox-regression analysis demonstrated that the relative transcriptional level of the SIRT6 
gene was independent of tumour size, grade, nodal status, oestrogen receptor status, 
lymphovascular invasion status, and the NPI in influencing survival.  
The decreased sirtuin gene expression observed in this study is consistent with an anti-
cancer effect and suggests that sirtuins might be implicated in breast cancer pathogenesis. 
For example, decreased levels of SIRT2 might assist DNA-damaged tumour cells, as 
indicated by the decreased expression of another sirtuin involved in DNA damage 
responses, SIRT6, in escaping cell cycle arrest during tumour initiation and progression. 
Furthermore, The associations between sirtuins and survival period suggest that these 
sirtuins (especially SIRT6) might be used as an additional prognostic marker in breast 
cancer patients, especially in those individuals who have equivocal prognostic pathological 
markers. Therefore, the level of expression of sirtuin genes (SIRT6) might help explaining 
those breast cancer cases, which behave unexpectedly, according to the known 
pathological prognostic markers. 
Secondly, The changes in the relative transcriptional expression levels of the sirtuin genes 
were investigated in response to adjuvant chemotherapy therapies, commonly used in 
breast cancer (Tamoxifen and Docetaxel), in breast caner cell lines. The first experiment 
determining sirtuins changes in response to Docetaxel treatment for 72 hours in ER-ve 
breast cancer cell line (MDA-MB-231) showed significant increase in the relative 
transcriptional expression levels of all sirtuins after Docetaxel treatment. These data were 
consistent with the pro-apoptotic role for SIRT1, SIRT3 and SIRT7, and suggestive of 
DNA damage involvement at higher doses of Docetaxel, as indicated by increased SIRT6 
and XRCC5. Finally, increased SIRT2 levels are suggestive of SIRT2 involvement in the 
mitotic arrest caused by Docetaxel, through its contribution to microtubule dysfunction.  
The second experiment, determining sirtuin changes in response to Tamoxifen treatment in 
ER+ve (MCF-7) and ER-ve (MDA-MB-453) breast cancer cell lines, showed significant 
increase in the relative transcriptional expression levels of all sirtuins after Tamoxifen 
treatment. These data were consistent with the pro-apoptotic role for sirtuins. Furthermore, 
the observed increased levels of SIRT6 are suggestive of DNA damage involvement at 
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higher doses of Tamoxifen. Another noteworthy result of this experiment is the increased 
levels of SIRT2 in response to Tamoxifen treatment. This might explain the failure of a 
TAM-treated cell to proceed through the cell cycle, in spite of the increases in transcription 
factors that promote cell cycle after Tamoxifen treatment. There was no significant 
difference in sirtuin changes after Tamoxifen treatment between these two cell lines to 
indicate that sirtuin changes were ER-dependent. 
In total, the data accumulated from this study demonstrated the involvement of sirtuins in 
breast cancer disease (pathogenesis and anti-tumour treatment) and suggest the possible 
use of SIRT6 as a novel, additional and biological prognostic marker. Finally, this study 
suggests that sirtuins activators, rather than inhibitors, might be beneficial in breast cancer 
disease and enhance the response to adjuvant chemotherapy. 
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1.1 Introduction. 
Breast cancer is the most prevalent female cancer globally and its incidence is increasing in 
the western world. Breast cancer is the second most common cancer in the UK, with over 
44,000 new cases diagnosed every year and 14,500 deaths attributed to this disease 
annually. Breast cancer accounts for one in three of all female cancers and is second to 
lung cancer in causing female-cancer specific deaths. Breast cancer represents a 
heterogeneous group of diseases that display a wide spectrum of behaviour ranging from 
slow growing, non-metastatic disease with good prognosis through to fast growing disease 
with poor prognosis (metastasis and short survival).  Despite the large number of breast 
cancer studies that have been carried out, the underlying molecular changes involved are 
still not fully understood. Identification of novel biological changes associated with this 
disease may improve our understanding and result in new prognostic markers, or 
therapeutic targets being identified. Given the close relationship between the incidence of 
cancer and chronological age, malfunctions of genes involved in biological ageing and 
factors involved in maintaining genomic integrity, have been hypothesised to be involved 
in tumourigenesis (1, 2). These include the BRCA genes, which have a role in DNA double 
strand break repair (3-6). 
Other potential candidate genes include Sirtuins. These comprise a gene family 
phylogenetically conserved from bacteria to man, with known involvement in ageing and 
DNA damage repair. First described in yeast, the Silent Information Regulator 2 (SIR2) 
gene product was demonstrated to function as an NAD+-dependent histone deacetylase (7). 
SIR proteins have subsequently been described in diverse cellular processes, including 
regulation of gene silencing at telomeres and mating type loci, DNA repair, structural and 
functional maintenance of the nucleolus, regulation of the mitotic cell cycle, meiosis and 
ageing (8-11). In humans, seven ortholouges, were identified and termed sirtuins (SIRT1-
7). These will be presented in detail in the following sections.  
The study of breast cancer as an aberration of normal biological ageing may provide an 
alternative platform for understanding the disease. Specifically, a better understanding of 
the molecular processes involved in sensing, assessing and signalling cellular damage 
might be informative in such a context (2). This might be alternative to the traditional 
study of breast cancer biology that focuses on malignancy transformation as a result of 
abnormalities in normal growth and proliferation. Therefore, better understanding of the 
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ageing process and genes involved in biological ageing and factors involved in maintaining 
genomic integrity could be informative in understanding the cancer disease pathogenesis. 
1.2 Breast cancer disease. 
1.2.1 Incidence and mortality. 
Breast cancer is the most common malignancy in women and a major cause of mortality 
and morbidity. Worldwide, it accounts for more than a fifth of all cancers, with an 
estimated recent incidence of more than a million new patients per year, resulting in almost 
373,000 deaths (12, 13). 
The incidence and mortality of breast cancer varies widely around the world, with North 
European countries, North America and Australia having the highest rates, and Asian and 
African countries the lowest (12, 14, 15) .In recent years, breast cancer incidence has been 
increasing in many countries, particularly in several Asian and African countries (15). 
Recent mortality rates have levelled off, or started to decline in many western countries, 
such as the UK, United States, Canada and Australia. Analysis of age-specific mortality 
rates shows that the change in mortality has occurred primarily in middle-age women and 
to a lesser extent, in older women. These trends are, at least in part, attributable to large-
scale use of mammographic screening, early detection of breast cancer and, in particular, to 
the widespread use of adjuvant therapy (15-17).  
In the UK, breast cancer continues to be the commonest cancer to affect women, with a 
recent annual incidence of nearly 44,000 new patients per year, accounting for almost 30 
per cent of all new cancer cases in women, and with an estimated lifetime risk of one in 
nine. However, despite the increase in incidence, mortality rates have being falling steadily 
since 1990, probably due to a combination of factors, including earlier diagnosis and 
improved treatment. In the year 2001, there were 12,994 breast cancer deaths, compared to 
around 15,186 breast cancer deaths in 1992. It has been overtaken by lung cancer as the 
most common cause of death from malignancy in women (18).  
In Scotland, breast cancer is by far the most frequent cancer among women, accounting for 
27% of cancers in women and with approximately 3,533 cases in 2001. Over the last 
decade, a substantial improvement in breast cancer survival has been observed, with an 
obvious increase from 60% for patients diagnosed in 1977-1981 to 77% in 1997-2001. 
This improvement is likely to be due to a combination of new treatments, particularly 
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hormonal therapy, earlier diagnosis of cancers in women participating in the Scottish 
Breast Screening Programme, and better organization and delivery of care for patients. 
Around 1.2% of women are living with breast cancer and the prevalence of breast cancer is 
increasing due to improvements in prognosis and increasing incidence (Scottish Cancer 
Registry, ISD, NHS National Services Scotland; www.isdscotland.org.). 
1.2.2 Aetiology and risk factors. 
The search for specific breast cancer risk factors has been stimulated by the large 
difference in rates of breast cancer among countries worldwide, within countries over time, 
and by changes in rates among migrating populations. In general, the causes of breast 
cancer are not fully understood, but epidemiological researches have clearly identified 
important factors that influence breast cancer risk. 
Several important genetic and environmental risk factors are associated with breast cancer. 
Approximately 5-10% of breast cancers have a genetic link; two thirds of these cases have 
mutations in the tumour suppressor genes BRCA1 and BRCA2. Mutations in these genes 
are associated with familial/hereditary breast and ovarian cancer, early age of onset, and 
cancer in both breasts (19). The main risk factor for sporadic breast cancer is age: the risk 
of developing breast cancer by the age of forty is 0.5%, by the age of eighty; it is 10% (20). 
The incidence of breast cancer increases rapidly with age during the reproductive years, 
being rare before the age of 25 and doubling about every 10 years until the menopause 
(about 50 years of age), when there is a slight levelling off before the incidence again rises, 
although at a reduced rate compared with the pre-menopausal years (21). The cumulative 
incidence of breast cancer among women in Europe and North America is about 2.7% by 
age 55, about 5% by age 65, and about 7.7% by age 75 (14). 
Other risk factors include family history of breast cancer, prolonged exposure to oestrogen 
(onset of menstruation before age 12, menopause after age 50, first child born after the age 
of 30), alcohol abuse and obesity (Table 1.1). 
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Relative risk High risk group
>10 Women aged over 50 years
5 Developed country
3 Menarche before age 11
2 Menopause after age 54
3 First child in early 40s
Breast cancer in first degree  
relative when young (before age  50)
Breast cancer in two first  degree 
relatives (one before age 50)
4-5 Atypical hyperplasia
> 4
2 Group I and II
1.5 High intake of saturated fat
0.7 Body mass index  > 35
2 Body mass index  > 35
1.3 Excessive intake
Abnormal exposure in young 
females after age 10
1.24 Use during pregnancy
1.35 Use for ! 10 years
2 Use during pregnancy
Body weight:
               Premenopausal
               postmenopausal
Alcohol consumption
            Hormone replacement therapy  
           Diethylstilbestrol
Exposure to ionising radiation 3
Taking exogenous hormones:
            Oral contraceptives
Socio-economic group
Diet
! 2
4-6
 Family history                           
Previous benign breast disease     
Cancer in other breast
Age at menopause
Age at first full pregnancy
Factor
Age
Geographical location
Age at menarche
 
Table 0.1:Risk factors for breast cancer, (21).  
 
1.2.3 Normal Breast Anatomy and Physiology.  
1.2.3.1 Anatomy of the breast. 
The female breasts are milk-producing glands, which vary enormously in their number and 
size, composed of lobules/glands, milk ducts, fat and connective tissue. Each breast 
contains 15-20 lobes, comprising lobules, which end in glands that produce milk in 
response to hormone signalling, arranged in a circular fashion. Ducts deliver milk to the 
nipple, thus connecting lobes, lobules and glands. Fatty tissue fills the spaces between the 
lobules and the ducts (Figure 1.1).Blood and lymph vessels form a network throughout 
each breast. The glandular tissue, with its various relative amounts of supporting 
connective tissue and fat, lies within a superficial fascia, in which fibrous processes 
(Cooper’s ligaments) attach firmly to the deep and superficial layers of this fascia, and 
thereby to the overlying breast skin (22). The main bulk of the breast tissue is usually 
localized to its upper outer-quadrant.  
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Figure 0.1: Anatomy of the breast:  
Para- sagittal section of the breast, showing the normal anatomy of the milk-producing 
gland. 
  
The adult female breast extends from the second rib above to the sixth rib below, and from 
the lateral border of the sternum medially to the mid-axillary line laterally; with its 
superiolateral extremity extending into the axilla as the axillary tail. On its deep aspect, 
about two-thirds of the breast lies on the pectoralis major. It overlaps the serratus anterior 
laterally and the upper part of rectus sheath inferiorly (22). 
The nipple with its surrounding areola is usually situated at the level of the fourth 
intercostals space in nulliparous women, but this position tends to be variable with 
pendulous breasts. The nipple contains about 15-20 lactiferous ducts openings, and the 
areola contains numerous sweat and sebaceous glands(22). 
The blood supply of the breast is a rich anastomotic network, which is derived from the 
internal thoracic artery (internal mammary), the intercostal artery, and the axillary artery 
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that branches into superior thoracic, pectoral branch of the acromiothoracic, lateral 
thoracic, and subscapular. These arteries are accompanied by their corresponding veins. 
The lymphatics of the breast drain predominantly into the axillary lymph nodes, which 
receive nearly 75-85% of the breast drainage and into the internal thoracic (internal 
mammary) lymph nodes (Figure: 1.2). The axillary lymph nodes vary in number from 20-
30 nodes, and often defined by clinicians and pathologists into three levels; as level I 
(nodes inferior to pectoralis minor), level II (nodes behind pectoralis minor) and level III 
(nodes above pectoralis minor). The apical nodes are also in continuity with the 
supraclavicular nodes and drain into the subclavian lymph trunk, which enters the great 
veins directly, or via thoracic duct or jugular trunk. The internal thoracic (internal 
mammary) lymph nodes are small, few (3-5 nodes) and lie along the internal thoracic 
vessels, deep to the plane of the costal cartilage (Figure: 1.2) (22). 
 
 
  
   
  
 
 
 
 
 
Figure 0.2. Surgical anatomy of the breast showing the lymphatic drainage of the breast.  
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1.2.3.2 Physiology of the breast. 
The mammary gland undergoes three key phases of development and differentiation under 
the control of hormones and growth factors (23, 24): lobule development, between the ages 
of 10-25; glandular development, under the influence of menstrual hormones between the 
ages of about 13-45, and involution, or shrinkage of the milk ducts, from about age 35. 
During the menstrual cycle, oestrogen stimulates milk duct growth; following ovulation, 
halfway through the cycle the hormone progesterone continues to stimulate milk gland 
formation. If pregnancy does not occur, the breasts return to normal size and the cycle 
begins again. During early (mammogenesis) and late (lactogenesis 1) phases of pregnancy, 
the final stages of development and differentiation occur. Mammogenesis is characterized 
by proliferation of the distal elements of the ductal tree, creating multiple alveoli (acini) of 
variable size and shape. Lactogenesis II occurs later and is characterized by differentiation 
of resting mammary cells into lactocytes, with the potential to secrete the unique fats, 
carbohydrates, and proteins characteristic of milk. The breast of nulliparous women 
contains more undifferentiated structures whereas the breast of parous women is comprised 
of more differentiated lobules (24). During lactation, mammary lobules become enlarged 
and milk is synthesised and released into the ductal system. Accumulation of milk in ducts 
has an inhibitory effect on the production of milk. This results in a series of involutional 
changes in the mammary gland, which reduces the volume of secretory epithelial cells and 
inhibits their secretory activity (24).  
Hormone regulation is important, not only in the development and differentiation of the 
breast but also in the development of disorders, such as benign breast disease, and breast 
cancer. 
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1.2.4 Neoplasm of the breast. 
1.2.4.1 Benign neoplasm. 
  
The most common is a fibroadenoma, characterised by proliferation of the breast ducts and 
stroma. Others include the phyllodes tumour and benign intraduct papilloma. 
1.2.4.2 Malignant neoplasm. 
Breast cancers arise from the epithelial cells that line the terminal duct-lobular unit. The 
transition from a normal breast-epithelial cell into a cancer cell is assumed to proceed in a 
stepwise fashion in the multi-step phenomenon of breast carcinogenesis (Figure 1.3)(22, 
25).  
Breast cancer can be classified into pre-invasive (in situ carcinoma) and invasive cancer as 
follows: 
1.2.4.2.1 In situ carcinomas of the breast. 
In situ carcinoma is the proliferation of epithelial cells that have undergone malignant 
transformation but remain confined within the basement membrane at their site of origin 
within the terminal duct-lobular unit and draining duct. As there are no lymphatics or 
blood vessels in the epithelial layer, in situ carcinoma offers no risk of metastasis until 
malignant cells cross the basement membrane(22, 25).  
Two types of in situ carcinoma of the breast have been described and comprise ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Both arise from the 
terminal duct-lobular unit. However, there are significant clinical, morphological, and 
biological behavioural differences between the two types (Table 1.2,) 
Traditionally, DCIS is classified on the basis of architectural and growth patterns into: 
comedo, cribriform, papillary, solid and micropapillary (Table 1.3). However, this 
classification has been superseded by another pathological classification that includes the 
nuclear grade of the tumour cells and the presence, or absence of necrosis (Van Nuys 
classification) (Figure: 1.4). Van Nuys classification stratifies the DCIS into three grades: 
low, intermediate and high. Higher grade (comedo) DCIS is most likely to develop into 
invasive cancer.  
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Table 0.2: Comparative features of ductal and lobular carcinoma in situ. 
 (26). 
 
 
Table 0.3 Types of carcinoma In situ. 
Carcinoma In Situ can be categorised as ductal or Lobular. 
 
 
 
DCIS LCIS
Average age Late 50s Late 40s
Menopausal status 70% Postmenopausal 70% Premenopausal
Breast mass None
Paget’s disease
Nipple discharge
Mammographic signs Microcalcification None
Risk of subsequent carcinoma 30% to 50% at 10 to 18 years 23% to 30% at 15 to 20 years
Site of subsequent invasive carcinoma 
-Same breast  99% 50% to 60%
-Other breast 1% 40% to 50%
Clinical signs
Type of Carcinoma In Situ Pathological Characteristics
Solid DCIS Cancerous cells completely fill the affected breast ducts
Cribriform
Cells are very uniform in size and very regularly placed in relation to one another. 
Epithelial cells fill and expand the ducts and form defined glandular spaces 
separated by bridges of cells.
Papillary/Micropapillary Commonly occurs in association with cribriform DCIS.
Comedo DCIS Ducts are expanded due to proliferation of large pleomorphic cells. Characterised by mitotic figures and necrosis in the centre of the duct.
LCIS
Cells within breast lobes have undergone morphologic changes but are not 
cancerous. Lobules are expanded and filled by small, evenly spaced epithelial 
cells, which do not form ducts.
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Normal Epithelium  
 
 
 
Ductal Hyperplasia 
 
 
 
Atypical Ductal Hyperplasia 
 
 
 
Ductal Carcinoma In Situ 
 
 
 
Invasive Ductal Carcinoma 
 
 
 
 
Metastasis 
Figure 0.3: Multi-step breast carcinogenesis, (25, 27). 
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                                                                         DCIS  
  
    Non- high grade      High grade  
                   Group 3                                   
  Without necrosis             With necrosis   
        Group 1     Group 2 
Figure 0.4: Van Nuys classification for ductal carcinoma in situ (DCIS) Classification, (28). 
 
1.2.4.2.2 Invasive carcinomas of the breast. 
 
Invasive breast carcinoma is defined as a malignant neoplasm of the mammary epithelial 
cells that have invaded beyond the native basement membrane at their site of origin, in the 
terminal duct-lobular unit, into the surrounding stroma. Invasive tumour cells may access 
lymphatic and blood vessels within the surrounding adjacent normal tissue, through which 
they may metastasise to both regional lymph nodes and distant sites (29) 
Invasive breast cancers constitute a heterogeneous group of lesions that differ with regard 
to their morphological types, pathological features and biological potential. They are 
classified on the basis of the cytological and morphological features and growth pattern of 
the invasive tumour cells. rather than the structure of origin within the mammary duct 
system, as ductal carcinoma does not necessarily arise from the duct (22, 29). The main 
types are described below. 
1.2.4.2.2.1 Invasive ductal carcinoma  
 
Invasive ductal carcinoma is the most common histological type of invasive breast cancer, 
accounting for more than 50-70% of cases (22, 29, 30). It includes tumours with a range of 
histological appearance; from those with well-formed glands to those that have little or no 
evidence of specific differentiation, alternatively known as “carcinoma of no special type 
(NST)” and “carcinoma not otherwise specified (NOS)”, in which they are further 
categorised according to histological grade that takes into account the variation in 
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appearance (Mizrachi, 1999). Histologically, the tumour is often composed of cords and 
sheets of large pleiomorphic malignant epithelial cells that penetrate the stromal fibrous 
tissue haphazardly (Figure: 1.3). 
1.2.4.2.2.2 Invasive lobular carcinoma. 
 
Invasive lobular carcinoma is the second most frequent form, accounting for about 10-15% 
of all invasive breast cancer. It is more frequently multifocal and bilateral than IDC. 
Histologically, it is formed from moderately sized, regular malignant cells often arranged 
in linear cords that diffusely infiltrate within fine collagen bands, giving the “Indian file” 
appearance pattern (22, 30). ILC has a better prognosis than IDC, but is more likely to be 
bilateral. 
1.2.4.2.2.3 Other invasive breast cancers. 
1.2.4.2.2.3.1 Invasive tubular carcinoma. 
Invasive tubular carcinoma is a special type of cancer that is typically associated with 
limited metastatic potential and excellent prognosis (31). It is uncommon in routine 
symptomatic practice.  
1.2.4.2.2.3.2 Inflammatory breast cancer. 
Inflammatory breast cancer is an aggressive type of breast cancer that develops rapidly, 
making the affected breast red, swollen and tender. This clinical manifestation is the result 
of cancer cells blocking the lymph ducts in the breast and prevent fluid from being drained 
from the tissue, resulting in inflammation of the breast. 
1.2.4.2.2.3.3 Paget’s disease of the nipple.  
Paget’s disease of the nipple is a superficial manifestation of an underlying breast 
carcinoma. It usually presents as an eczema-like condition of the nipple and the areola that 
does not response to conventional treatments. 
Other special histological types of invasive breast carcinomas such as mucinous, 
medullary, papillary and invasive cribriform usually have a better prognosis (22, 31). 
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1.2.5 Spread of breast cancer. 
Cancer treatment is challenging due to the ability of cancer disease to spread form the site 
of origin (primary cancer)  to a different part of the body resulting in secondary cancer 
(metastasis).  
In order to spread, some cells from the primary cancer must break away, travel to another 
part of the body and start proliferating. There are three main ways for a cancer to spread:  
 Local invasion. 
 Through the blood circulation (haematogenous spread). 
 Through the lymphatic system. 
1.2.6 Histological grading of breast cancer 
Because of the histological diversity of breast cancer, histological grading is considered as 
an essential component of the pathological assessment of breast cancer. The grading 
system measures the degree of differentiation of a carcinoma by microscopic examination. 
Grading breast tumours is based on tubule formation (% of cancer cells composed of 
tubular structures), nuclear pleomorphism (changes in cell size and uniformity) and mitotic 
count (rate of cell division), each of which is scored from 1 to 3.  Scores are totalled to 
provide a final score, ranging between 3 and 9, dividing tumours into three grades. 
Tumours with scores of 3-5 are considered Grade 1, well-differentiated tumours. Grade 2 
tumours (score 6-7) are moderately differentiated, whilst tumours scoring 8-9 are Grade 3 
(poorly-differentiated) (Table 1.4). Patients with grade 1 tumours have a better prognosis 
than those with grade 3 tumours (31-34). 
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Table 0.4: Histological grading system of invasive breast cancer. 
Elston and Ellis modification of Bloom and Richardson grading system 
 
 
 
 
 
1.2.7 Staging of breast cancer. 
The prognosis of breast cancer is related to the stage of the disease at presentation. The 
staging depends on the size of the primary tumour (T) along with regional lymph nodes 
status (N) and the presence or absence of distant metastases. The T stages are numbered 1 
to 4 and describe the size of the tumour. The N stages are numbered 0 to 3. They describe 
which lymph nodes are affected, if any. The M stages are M0 (no sign of cancer spread) 
and M1 (cancer has spread to another part of the body apart from the lymph nodes under 
the arm). This is known as TNM staging and is related to the clinical prognosis; patients 
with stage I tumours have a better prognosis than those patients with stage IV tumours (22, 
30, 33). 
 
 
Components of grading   Score  
    
Tubules     
> 75% of tumour composed of tubules   1 point 
10-75% of tumour composed of tubules   2 points 
< 10% of tumour composed of tubules   3 points 
      
Nuclear grade     
        Nuclei small and uniform   1 point 
        Moderate variation in nuclear size and 
shape   2 points 
        Marked nuclear pleomorphism   3 points 
      
Mitotic rate     
        Dependent on microscopic field area   1-3 points 
      
Histological grade   Total points 
          1 (Well differentiated)          3-5 
          2 (Moderately differentiated)          6-7 
          3 (Poorly differentiated)          8-9 
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Table 0.5: Breast cancer staging system. 
Staging of a breast tumour depends on the tumour size, lymph node involvement and 
metastasis, and ranges from stage I to stage IV. T = Tumour Size: (T1 = 0-2 cm, T2 = 2-5cm, 
T3 = > 5cm, T4 = ulcerated or attached to skin or muscle), N = Node Status: (N0 = clear, or 
negative nodes, N1 = cancerous, or positive nodes), M = Metastasis: (M0 = no spread of 
tumour, M1 = tumour has spread). 
 
 
1.2.8 Prognostic and predictive factors in breast cancer. 
The clinical course of breast cancer may vary from very slowly progressive to a course 
associated with rapid progression and metastatic spread. Therefore, assessment of certain 
prognostic and predictive ‘markers’ or ‘factors’ in the pathological examination of breast 
tumours, in order to predict disease outcome, is becoming increasingly important in 
understanding the natural history of breast cancer, planning treatment strategies and 
counselling patients. (35-37). 
A prognostic factor is defined as any measurement, or feature, of the patient or tumour 
available at the time of diagnosis, or surgery, that is associated with outcomes, such as 
disease-free or overall survival, in the absence and independent of systemic therapy. As a 
result, is able to correlate with the natural history of the disease.  Whereas, a predictive 
factor is any measurement, or feature, in which its presence, or absence, signals resistance 
or sensitivity, to a particular therapy independently of prognosis; it may, or may not, have 
prognostic value. Some factors, such as hormone receptors and Human Epidermal growth 
factor Receptor 2 (HER2/neu) over-expression, are both prognostic and predictive.(35-37). 
Several established prognostic factors and a few predictive factors are used routinely in the 
clinical management of breast cancer. Through increased understanding of breast cancer 
biology, numerous other novel markers have been identified in recent years. These are in 
general either chronological; indicators of how long the cancer has been present, or 
Stage Tumour Size Lymph Node Involvement Metastasis TNM
I Less than 2cm No No T1, N0, M0
T1, N1, M0
T2, (N0 or N1), M0
T3, N0, M0
T3, N1, M0
T4, Any N, M0
IV Any size Any lymph nodes Yes T Any, N Any, M1
NoYes, on same side of breast (! 4 axillary and/or internal mammary lymph node)More than 5cmIII
no
No, or in same side of breast (0-3 axillary 
lymph nodes involved)2-5cmII
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biological indicators of the metastatic potential behaviour of a tumour (35, 37) and are 
described below. 
1.2.8.1 Age. 
Breast cancer tends to be more aggressive with poor prognosis in younger patients than in 
older patients. Different studies have suggested that a young age of less than 35-40 years 
is, associated with the worst prognostic pattern, such as excess of high-grade tumour and 
axillary lymph-node metastasis, with the highest rates of necrosis, vascular invasion and 
proliferation and lower ER expression levels, and subsequently, a poorer survival rate. This 
poor outcome improves as age increases and is best in patients over 75 years of age. In 
addition, patient age is important for predicting response to chemotherapy and hormonal 
therapy, as menopausal status is an age-dependent factor (38-41). 
1.2.8.2 Tumour size 
Tumour size is a time-dependent prognostic factor that correlates directly with survival. 
The best measure of tumour size is maximum pathological size assessment, since 
radiological and clinical assessments may be inaccurate (38, 42). Patients with small 
tumours have a better prognosis, with a better long-term survival than those with larger 
tumours. The 20-year relapse-free survival rates for patients with tumours ≤ 10 mm in 
diameter have been reported to be around 88%. These rates fall to 72% and 59% for 
lesions measuring 11-30 mm and 31-50 mm in diameter, respectively. Nevertheless, 15-
20% of tumours of ≤ 10 mm in size have nodal metastasis, compared with 40% for lesions 
of more than 15 mm (37, 38, 42-45). 
1.2.8.3 Histological type/ grade.   
The histopathological characteristics of the breast tumour have prognostic significance. 
Favourable prognosis of certain histological subtypes of invasive breast carcinoma, which 
based on architectural pattern of the tumour, is well established. Tubular, mucinous, 
papillary carcinomas, invasive cribriform, medullary, infiltrating lobular and tubulo-
lobular types, together with rare tumours such as adenoid cystic carcinoma, 
adenomyoepithelioma and low-grade adenosquamous carcinoma have all been reported to 
have a better prognosis than carcinoma of no special type (ductal NST)(37, 38, 45). 
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The histological grading of breast cancer, (Table: 1.4), correlates strongly with prognosis. 
Patients with grade I breast cancer have the best survival rate with 85% 10-year survival, 
compare with less than 45% for those patients with grade III tumours. This histological 
grading potentially provides an overview of a number of molecular events that are 
reflected in histological morphology, which includes detail of cell morphology (nuclear 
pleomorphism), with a measurement of differentiation (tubule formation), and an 
assessment of proliferation (mitotic frequency) (34, 42, 44, 45) 
1.2.8.4 Axillary lymph node status. 
The presence, or absence, of axillary nodal metastases is the single most important 
prognostic factor for disease-free and overall survival in breast cancer. It is a time-
dependent factor and has a direct correlation with survival from breast cancer. Clinical 
assessment of nodal status is unreliable; as palpable nodes may be enlarged because of 
benign reactive changes, or secondary to biopsy. Whilst nodes bearing tumour deposit may 
be impalpable. Thus, careful histological examination should be carried out for all excised 
axillary lymph nodes (42, 45, 46). A large number of studies with histologically confirmed 
lymph-node involvement have shown that, on average, 10-year survival is reduced from 
75% for patients with no nodal involvement to 25-30% for those with metastatic disease in 
the locoregional nodes. Prognosis worsens with the greater the number of lymph nodes 
involved and metastasis to the higher axillary lymph nodes level, particularly those at the 
apex, which carries a worsened outcome (37, 38, 42, 43, 45, 46). Node positivity is 
reasonably taken as a marker of metastatic potential. However, this is only a qualitative, 
not a quantitative difference, as many patients with positive lymph nodes never develop 
distant metastases, while many with negative nodes do.  
1.2.8.5  Lymphatic/ vascular invasion. 
Lymphovascular invasion has been shown to be a significant prognostic factor in invasive 
breast cancer, particularly with respect to local recurrence and systemic relapse, and hence 
poorer overall survival. The presence of lymphovascular invasion, also, correlates closely 
with loco-regional lymph node involvement, tumour grade, and size (32, 37, 42, 44, 45).  
1.2.8.6 Hormonal receptors.  
In breast cancer, the levels of oestrogen (ER) and progesterone (PR) hormone receptor 
expression are considered prognostic and predictive factors (36, 37). 
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The oestrogen and progesterone receptors are steroid receptors located in the cell nucleus. 
Hormone is believed to diffuse into, or be transported to the nucleus where a steroid-
receptor complex is formed with receptor dimerization. Some of the genes regulated by 
steroid receptors are involved in cell-growth control and currently, it is believed that these 
effects are the most relevant to oestrogen receptor, which influence the behaviour and 
treatment of breast cancer (45). As a prognostic factor, it has been reported that survival of 
women with ER positive cancers is longer. Again, with node negative breast cancer, ER 
status was a significant predictor of longer survival (38).  
The value of these steroid receptors as a predictive factor for response to systemic 
endocrine therapy is well established. Approximately 30% of unselected patients with 
breast cancer will respond to endocrine therapy. However, with ER positive tumours, a 
response in about 50-60% of patients is seen compared with less than 10% in patients with 
ER-negative tumours (38, 45).  
1.2.8.7 Human epidermal growth factor receptor-2. 
The presence of human epidermal growth factor receptor-2 (HER-2 gene amplification 
and/or protein over-expression), usually detected by Immunohistochemistry (IHC) analysis 
and fluorescent in situ hybridisation (FISH), has been shown to have both prognostic and 
predictive value in human breast cancer (36, 47) 
HER-2 status has attracted great interest as a potential predictor of endocrine and 
chemotherapeutic response, and more directly for the selective use of trastuzumab therapy; 
a humanized monoclonal antibody against HER-2 oncoprotein (35, 37, 47).  
1.2.8.8 Tumour proliferation markers. 
Tumour proliferation plays an important role in the clinical behaviour of breast cancer and 
many prognostic factors are directly, or indirectly, related to proliferation, such as cell-
cycle regulators, growth factors and angiogenesis, respectively (Diest et al., 2004). 
Cellular proliferation takes place through a defined process, in which several phases can be 
recognised. From the resting (G0) phase and after appropriate stimuli, cells join the active 
cycling population that enter the first gap (G1) phase. Both phases have a highly variable 
duration. In G1, the cell prepares for the synthesis (S) phase, in which DNA synthesis and 
doubling of the genome take place. The S phase is then followed by a period of apparent 
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inactivity, the second gap (G2) phase, in which the cell prepares for further separation of 
chromatids during the mitotic (M) phase. After the M phase, each daughter cell may enter 
G0 phase or move on to the G1 phase to repeat the cell cycle (48).  
In invasive breast cancer, the prognostic values of various proliferation assays, including 
the S-phase fraction (SPF), thymidine labelling index (TLI), mitotic rate and Ki-67/ MIB1 
index, have been shown to be associated with prognosis in the majority of studies. 
However, technical difficulties and lack of standardization in measurements, have limited 
their clinical usefulness. Nevertheless, mitosis counting and the Ki-67/MIB-1 proliferation 
index are considered to be the most practical methods to assess proliferation (37, 38, 48). 
Mitosis counting, the oldest form of assessing proliferation, provides the most reproducible 
and independent prognostic value. It is the most well established component of the 
histological grading system in breast cancer (40, 48). Patients with tumour of increased 
mitotic index had a significant poor prognosis for overall and disease-free survival (44, 
48). 
Ki-67 protein expression is strictly correlated to cell proliferation and to the active phases 
of the cell cycle (G1, S, G2 and mitosis), but absent from the resting cells (G0), which 
makes it an excellent marker for assessing the growth fraction of a given tumour cell 
population, (38, 40, 44, 49, 50). The Ki-67 labelling index (Ki-67- positive tumour cells) 
has been shown to have strong correlations with other biological and histopathological 
markers of invasive breast cancer and also with the clinical course and outcome of the 
disease (38, 49, 50). The Ki-67 proliferation indices have been found to correlate directly 
with histological grade, tumour size, axillary lymph node status (51-53), vascular invasion, 
p53 and HER-2 overexpression, DNA and Thymidine labelling index score; and inversely 
with oestrogen and progesterone receptor status (Elston and Ellis, 1991; Querzoli et al., 
1996; Morabito et al., 2003.). 
1.2.8.9 Nottingham Prognostic Index (NPI). 
The value of prognostic factors lies in a better quantifying of risk of recurrence and in 
defining low-risk patients, for whom adjuvant therapy is not indicated, and high-risk 
groups, who would most benefit from treatment. In 1982, a retrospective analysis was 
performed to investigate the prognostic capabilities of nine factors in primary, operable 
breast cancers: age, menopausal state, size, lymph node stage, tumour grade, cellular 
reaction, sinus histiocytosis, and oestrogen receptor expression (54). Three remained 
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NPI Score Annual Mortality 15 years survival Adjuvant Therapy
< 3.4 3% 80% No systemic adjuvant treatment
3.4-5.4 7% 42% Choice dependent on ER/PgR status, menopausal status & axillary disease
> 5.4 30% 13% Aggressive adjuvant treatment: chemotherapy
Tumour grade  Score /factor  
I 1
II 2
III 3>3
Involved nodes  
0
1-3
significant, following multivariate analysis. These independent prognostic markers, lymph 
node stage, histological grade and tumour size were combined to form the Nottingham 
Prognostic Index (NPI) (Table 1.6). The NPI is calculated according to the following 
formula:  
NPI = (0.2 x tumour size (cm)) + lymph node stage (1-3) + histological grade (1-3) 
Currently, the Nottingham Prognostic Index (NPI) is the most practical integral measure 
available to assess individual patient’s prognosis, and thereby, stratify appropriate adjuvant 
therapy for patients with invasive primary operable breast cancer (Table 1.6). In several 
independent prospective studies, the Nottingham Prognostic Index has been found to give 
valuable prognostic information, and due to its simplicity, it is suitable for routine clinical 
use (45, 54-58). 
 
Table 0.6: Nottingham Prognostic Index (NPI). 
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1.2.9 Management of breast cancer disease. 
Breast cancer management is a rapidly evolving field. Optimal management with improved 
outcomes of patients with breast cancer have been achieved through a co-ordinated 
multimodality approach that require inputs from surgeons, radiologists, pathologists, 
oncologists, radiotherapist and psychologists with special interest in breast diseases, as 
well as general practitioners, breast-care nurses and the patient themself. Several studies 
have shown a better outcome with such multidisciplinary specialist treatment, which may 
relate to sufficient workloads and more frequent use of appropriate systemic therapy (59-
61). 
The purpose of the multidisciplinary approach is to design appropriate individualized 
treatment plans for all patients who require coordinated multi-specialty care. It lies in 
having a clear appreciation of the objectives of treatment and knowing its limitations and 
unwanted effects, in the context of the individual patient. The objectives that need to be 
considered include cure, local control, survival, and cosmetic, social and psychological 
consequences of the diagnosis and treatment of breast cancer. 
1.2.10 Breast cancer treatment options. 
1.2.10.1 Surgery. 
In patients with early-stage breast cancer, surgery remains the first treatment modality to 
achieve local control, and in locally advanced breast cancer with fungating tumour, ‘toilet 
mastectomy’ may be required to control symptoms such as bleeding, discomfort, and pain. 
The objective of surgery is to remove disease and identify extent of disease spread 
(staging). The surgical treatment of breast cancer has evolved into two categories; 
mastectomy (with or without breast reconstruction) and breast conserving surgery. Both 
should be combined with an axillary procedure. 
1.2.10.1.1  Axillary management. 
 
In breast cancer, axillary node status is crucial for staging, prognosis, and frequently 
directs the use of adjuvant systemic therapy in the management of early disease. It ranges 
from sampling; which should probably have four or more lymph nodes, to a level III 
clearance; which should yield an average of 20 or more lymph nodes. 
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Sentinel lymph node biopsy, a major development in the field of surgical oncology, has 
rapidly emerged within the last decade, as an alternative staging method to axillary lymph 
node dissection, to detect occult lymph-node metastases in patients with clinically node-
negative invasive breast cancer (62, 63). It is based on the observation that specific areas of 
the breast drain, by way of efferent lymphatics, to a specific lymph node (sentinel lymph 
node), and then to other lymph nodes in the basin. As the sentinel node is the first node to 
receive the lymphatic flow from the primary tumour, it is assumed that if the sentinel node 
is correctly identified and is free of neoplastic cells, then the other axillary nodes are also 
negative. It is a minimally invasive technique that avoids the morbidity associated with 
formal axillary clearance, by excluding negative axillae from unnecessary dissection (63, 
64). 
The sentinel lymph node can be located by injecting a tracer material, such as blue dye, or 
radiolabelled particles, deep into or around the primary tumour (peritumoural), or 
superficially into the skin over the tumour site (subdermal, intradermal), or into the 
subareolar tissue. The blue dye allows the direct visualization of the lymphatic channels 
that lead to the marked lymph node in the axilla, whereas, the radioactive tracer facilitates 
the detection of the radioactive nodes prior to the surgical exposure of tissues by a hand-
held gamma probe (63, 65-67). The identification rates have been demonstrated to be 
superior with a combination of both techniques, rather than either method alone (63, 68).  
1.2.10.2 Radiotherapy. 
Radiation therapy is an essential part of the management of breast cancer. It is indicated as 
a part of the primary treatment if breast-conserving surgery has been performed and in 
selected cases following mastectomy. It may be given to the breast, axilla, chest wall, and 
supra- and infra-clavicular fossa and internal mammary node chain. In patients with 
advanced disease, local radiotherapy may also be used as a palliative therapy to relieve 
symptoms, such as painful bone metastases (69). Radiation therapy uses high-energy 
radiation that kills cancer cells. A review of clinical trials involving radiotherapy over the 
last 40 years showed a significant reduction (~ two-thirds) in the number of patients 
relapsing following radiotherapy. Radiotherapy reduces breast-cancer related deaths, but 
increases deaths from other causes, in particular vascular-related deaths (70)   
Samer Zino, 2010     Chapter I, 51 
1.2.10.3  Chemotherapy. 
The aim of adjuvant chemotherapy is to increase the cure rate after the primary loco-
regional surgery. It is most frequently used in pre-menopausal patients, in patients with 
aggressive disease and with hormonal-receptor negative tumours (71). 
Adjuvant chemotherapy is standard treatment for women with node-positive breast cancer. 
In a 10 year overview of approximately 100 clinical trials, for patients treated with 
adjuvant chemotherapy, recurrence risk was reduced by 22-37 % and risk of death by 14-
27 % (72). Adjuvant poly-chemotherapy produced an improvement of about 7-11% in 10-
year survival for women aged under 50 presenting with early breast cancer and by 2-3% 
for those aged 50-69 (73). Adjuvant chemotherapy is also beneficial to node-negative 
breast cancer patients. However, benefits must outweigh the risks of receiving cytotoxic 
agents. Chemotherapy is recommended for patients with moderately, to poorly 
differentiated, invasive tumours larger than 1cm or ER negative tumours. In the UK, 
patients’ NPI scores guide chemotherapy use and the combination of epirubicin and 
Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF), is a common adjuvant 
practice in general. 
Cyclophosphamide, an alkylating agent that is cell cycle specific, causes DNA strands to 
break apart, and impairs DNA replication. Methotrexate and 5-fluorouracil are cell cycle 
phase specific antimetabolites that inhibit the conversion of folic acid to its active form, 
folinic acid, preventing cell division and killing rapidly dividing cells (74). Anthracyclines, 
such as epirubicin, are antibiotics that induce apoptosis in tumour cells by disrupting the 
structure of the DNA. They do this by intercalating into the base pairs in the DNA minor 
grooves, and by causing free radical damage of the deoxyribose in the DNA (74).  
In the adjuvant setting, currently used regimens include anthracycline-based 
chemotherapy, such as four courses of anthracycline and cyclophosphamide (AC), which 
have been shown to be equivalent to six cycles of classical cyclophosphamide, 
methotrexate and fluorouracil 5FU (CMF). The cyclophosphamide, epirubicin and 
fluorouracil (CEF), cyclophosphamide, anthracycline and fluorouracil (CAF) regimen and 
to some extent fluorouracil, epirubicin and cyclophosphamide (FEC) have yielded superior 
results. The CMF regimen is used less frequently but still valid for lower risk patients.  
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1.2.10.3.1 Taxanes chemotherapy. 
 
In recent years, taxanes, such as paclitaxel and docetaxel, have been shown to be active 
cytotoxic antitumour agents (75). Taxanes act by shifting the dynamic equilibrium between 
tubulin and microtubules in the direction of microtubule assembly. Cells become blocked 
during the G2 and M cell cycle phases and cannot form a normal mitotic spindle and 
divide. Essentially, these microtubules are excessively stable and therefore dysfunctional 
(76).  
Taxanes stabilize microtubules, enhancing the rate and extent of tubulin polymerization, 
and inhibit depolymerization. Microtubules have multiple functions in the eukaryotic cell, 
including the regulation of chromosome movement, cell morphology, hormone secretion, 
granule transport, and cellular motility, as well as the anchorage of receptors in the cell 
membrane (77, 78). Microtubules consist of protofilaments made of alpha- and beta-
tubulin. Microtubule-assembly proteins (MAPs), such as Tau and MAP2, control the 
equilibrium between tubulin and microtubules. Microtubule formation is promoted by 
guanosine 5'-triphosphate (GTP), while depolymerization is promoted by high calcium 
levels and temperatures below 4oC (77). Docetaxel binds to the beta subunit of the tubulin 
within the microtubule, promoting and stabilising microtubule polymerisation, while 
preventing physiological microtubule depolymerisation in the absence of GTP. This leads 
to a significant decrease in the number of free tubulin needed for the formation of 
microtubules which results in inhibition of mitotic cell division and cell proliferation 
leading to cell death by apoptosis (77, 78).   
The taxanes (paclitaxel and docetaxel) are being incorporated into adjuvant regimens on 
the basis of their anti-tumour activity in advanced breast cancer and the absence of cross-
resistance with doxorubicin (79). Many studies support the use of taxanes as adjuvant 
chemotherapy for women with early breast cancer and involved lymph nodes, independent 
of hormone-receptor status. The docetaxel-containing regimen (TAC) proved to be 
superior to CAF in randomized clinical trials and others trials have shown improvement in 
disease-free survival with or without significant improvement in overall survival in 
taxanes-treated patients (80-83). 
 
 
Samer Zino, 2010     Chapter I, 53 
1.2.10.4 Endocrine therapy. 
The aim of endocrine therapy is to decrease the hormonal growth stimulation of hormone- 
sensitive breast cancer cells. It is indicated as adjuvant therapy or as treatment for 
advanced systemic disease and occasionally, as sole treatment in patients who are unfit or 
unwilling to have surgery (71, 84, 85). 
An important determinant of patient treatment is the tumour hormone receptor status. 
Between 70-80% of breast cancers are oestrogen receptor (ER) positive and potentially 
oestrogen dependent. The presence of ER positive cells in breast tumours increases 
patients’ chances of survival following endocrine therapy (86). The current options for 
hormonal manipulation include (71, 84, 85): 
1. Therapies that reduce the levels of oestrogen through either: 
o Suppression or ablation of ovarian function through either: 
 Medically by luteinizing hormone releasing hormone analogues. 
 Surgical removal of the ovaries.  
  Radiation therapy. 
o Blocking the synthesis of oestrogen through the use of aromatase inhibitors  
2. Therapies that antagonise the effects of oestrogen on the receptor by the use of 
o Selective Estrogen Receptor Modulators (SERMs) such as Tamoxifen. 
o Down-regulators of oestrogen receptor (Fulvestrant). 
1.2.10.4.1 Oestrogen and oestrogen receptor targeted therapies. 
1.2.10.4.1.1 Oestrogens. 
 
Oestrogens are steroid hormones. There are three naturally occurring oestrogens . Oestrone 
(E1), 17β oestradiol (E2) and oestriol (E3), of which E2 is the main oestrogen from 
menarche to menopause (87). Oestrogens are synthesised in the ovary and testis, but also in 
peripheral tissues via the aromatisation of androgens. Ovarian synthesis of E2 dramatically 
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declines at menopause. The majority of breast cancers are diagnosed post-menopause, and 
non-ovarian sources of E2 are important in breast cancer development and progression. 
Following menopause, E1 becomes the predominant source of oestrogen.  
In addition to its role in female reproduction, oestrogen is required for maintaining bone 
density and cholesterol levels. The relationship between oestrogen and breast cancer was 
demonstrated over 100 year ago with reports of a decrease in breast cancer growth after 
oopherectomy (surgical removal of the ovaries) reduced breast cancer growth (88). 
Oestrogen antagonists are now vital for the treatment of hormone dependent breast cancer.  
The oestrogen effect is mediated through a receptor protein referred to as Oestrogen 
Receptors ER (89). There are two known isoforms of the oestrogen receptor, ERα and ERβ 
(90). ERα, a member of the steroid hormone nuclear receptor family, is a 65kDA ligand-
activated transcription factor. Oestrogen promotes release of growth factors by ERα 
positive breast cells, which stimulate proliferation, in a paracrine manner, of neighbouring 
ERα negative cells (91). 15-20% of normal breast cells express ERα, and these cells are 
generally non-dividing. Patients diagnosed with ERα positive tumours have a better 
prognosis than patients with ERα negative breast cancers (38, 45), and ERα tumours are 
more responsive to hormonal therapy than ERα negative tumours (92, 93). 
1.2.10.4.1.2 Tamoxifen. 
 
For the last 20 years, Tamoxifen treatment has been the gold standard for ERα positive 
breast cancer patients. It is currently one of the most effective but least toxic drug 
therapies. Tamoxifen, an oestrogen antagonist, it is a non-steroidal drug that acts as a 
selective oestrogen receptor modulator (SERM). It competitively inhibits the interaction of 
E2 with the ERα.  
Tamoxifen inhibits only AF-2 functions; it does not interfere with AF-1 activation. 
Consequently, Tamoxifen may function as both an ERα antagonist and agonist as result of 
its interaction with different functional domains of ERα. This is responsible for the side 
effect of Tamoxifen therapy as it functions as an oestrogen agonist in the uterus, ERα 
activity is more reliant on AF-1 activation; therefore Tamoxifen functions as an agonist. 
Thus stimulates endometrial proliferation, which increases the risk of endometrial cancer 
(~2.5 fold) (94). 
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1.2.10.4.1.3 Fulvestrant. 
 
To combat the agonistic effects of Tamoxifen, “pure antioestrogens” that do not 
demonstrate agonistic behaviour were developed. Fulvestrant (Faslodex), has no agonistic 
effects and has a 100 fold greater binding affinity for ERα than Tamoxifen, and is 
approved for treatment of ERα positive, metastatic, post-menopausal breast cancers. 
Fulvestrant binds ERα, prevents DNA binding and promotes ERα degradation, markedly 
reducing cellular receptor levels (95). Tamoxifen resistant cell lines respond to Fulvestrant 
(96).  
1.2.10.5 Biological therapy in breast cancer. 
Trastuzumab (Herceptin®) is a humanized monoclonal antibodies with anti-tumour 
activity targeted against the epidermal growth factor family oncogene (Her-2/neu). It is a 
novel therapeutic option for patients with aggressive forms of advanced metastatic Her-2/ 
neu-positive breast cancer (Ross et al., 2003; Vogel and Franco, 2003). 
It suppresses tumour growth when used as a single agent, or in combination with other 
chemotherapeutic agents. Single-agent trastuzumab therapy produces objective benefits in 
15-20% of patients with Her-2 positive tumours. Trastuzumab, in combination with 
cytotoxic chemotherapy, either anthracycline plus cyclophosphamide, or taxanes, has been 
shown to improve overall survival, with a higher rate of objective response and a longer 
duration of response, as well as, increased time to disease progression and time to 
treatment failure, in synergistic, rather than an additive, manner. Ongoing trials of 
trastuzumab in combination with various chemotherapy agents are encouraging and 
showing significant clinical activity over chemotherapeutic regimens alone (97-99). 
Trastuzumab therapy is generally well tolerated. Mild side-effects may include fever and 
chills; which are generally seen with first infusion dose, in addition to, diarrhoea, nausea, 
headache, rash and rhinitis. Other severe adverse events include cardiac toxicity, especially 
occurring when used in combination with anthracycline-based chemotherapy regimens. In 
the absence of pre-existing cardiac disorders, or prior anthracycline therapy, intrinsic 
cardiotoxicity with single-agent trastuzumab appears to be rare(97-99). 
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1.3 Biological ageing and cancer.  
1.3.1 Ageing and replicative senescence.   
In man, replicative senescence (RS) occurs when a somatic cell reaches the end of it 
replicative potential. Typically, this is after a finite number of cell divisions and is termed 
the Hayflick limit (100, 101). 
During this active period (proliferation), cells accumulate damage and it is well known that 
ageing is a consequence of this permanent damage accumulation to molecules and cells. In 
wider view, ageing is a result of accumulation of this damage to the cells, organs and 
tissues that compose the organism. This damage is caused by various intrinsic and extrinsic 
biological and biochemical stresses. Different maintenance mechanisms, which are 
designated to control pathways that influence the rate of biological and biochemical 
stresses, and to counterbalance the accumulation of resultant damage, are essential for the 
preservation of health and longevity. Two different concepts of age have been determined: 
chronological age and biological age. Chronological age is dictated by time elapsed since 
birth, whereas the biological age is dictated by how much damage has accumulated over 
the chronological age and how effective maintenance mechanisms were in 
counterbalancing this damage. Chronological age and biological age do not always equate. 
There are striking differences in the life spans and onset of ageing between species. On 
average mice live 2.5 years, monkeys 30 years and humans about 80 years. Organismal 
ageing is manifested by a progressive decline in vitality over time leading to death. At the 
organ level, ageing manifests as declining organ mass, cellular function, and integrity with 
time elapsed since birth. It reflects the lifestyle of the organism, life history and the 
cumulative burden of oxidative insult at the molecular level (102).  
The difference in the organism’s content of post mitotic and/or self-renewable cells might 
be one of the essential factors determining life span in different organisms. In postmitotic 
organisms, the accumulation of damage that underlies ageing will lead to a permanent loss 
of cells which cannot be compensated for. However, organisms with self-renewable tissues 
can replace damaged and lost cells, thus increasing their possibilities for maintenance, 
repair and longer lifespan. However, the capacity for cellular self-renewal also brings an 
enormous danger not experienced by post-mitotic organisms, namely DNA damage 
accumulation, leading to genomic instability and resulting cancers (103).  To protect 
against cancer risk, different tumour suppressor mechanisms have evolved, which can be 
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regarded as caretaker (protecting the genome against mutation) and gatekeeper (inducing 
cell death, or cell cycle arrest of potentially carcinogenic cells) functions. Incremental 
telomere erosion, which accompanies somatic cell division, acts as counting mechanism 
for determining when a cell should enter growth arrest and has been considered as an anti-
neoplastic mechanism. 
1.3.1.1 Telomeres and ageing. 
Telomeres are nucleoprotein complexes found at the end of eukaryotic chromosomes. In 
mammals, telomeres consist of a dynamic complex of proteins bound to a multiple 
TTAGGG nucleotide repeats (104). Mammalian chromosomes undergo attrition with each 
cellular division. Telomere length is, hence, an indicator of the replicative history and 
replicative potential of these cells. This feature of telomere biology is at the core of the 
concept that, at the cellular level, telomeres serve as a mitotic clock. In human beings, 
telomere length is heritable, relatively short, highly variable and inversely related with age, 
especially in replicating somatic cells. Because of the long lifespan of humans and their 
short telomeres, attrition in telomere length may be a major determinant of human ageing, 
not only at the cellular level, but also at the organ and perhaps the systemic levels. Not 
only changes in telomere length, but also changes in its components can trigger senescence 
or apoptosis. These changes can result in the loss of Telomere Positional Effect (TPE) and 
the expression of sub-telomeric genes whose expression may contribute to the senescent 
phenotype.  Since telomeres act as a sink for DNA repair proteins such as Ku, damage 
signalling component such as sirtuins and damage checkpoint regulators, such as taxia 
telangiectasia mutated (ATM), the re-localization degree of proteins from the telomere to 
the injury site, may act as an indicator of damage level (2). This leads to induction of 
apoptosis, growth arrest, or repair. Cells may therefore senesce and exhibit growth arrest 
not solely by replicative senescence and the shortening of telomere lengths but also by 
alterations in telomere status. 
Senescence at the cellular and physiological levels is thought to contribute to both disease 
and ageing (2, 105). Moreover, it is also believed that in order for mammalian cells to 
undergo malignant transformation, senescence associated growth arrest must be overcome. 
Therefore, telomere erosion has been considered as an anti-neoplastic mechanism that 
minimizes the proliferation of mutant cells that may give rise to tumours in long-lived 
mammals such as man. The maintenance of telomeric length would therefore be important 
for cells to overcome this senescent arrest. The finding that telomere lengths are actively 
maintained in many tumours, by compensatory telomere maintenance activity (via  
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telomerase, or alternative lengthening of telomere (ALT), fits with this hypothesis (106). 
Consistent with the concept that telomere status rather than only telomere length, can 
trigger senescence, factors that are involved in maintaining telomeric stability, such as 
sirtuins, might also be involved in tumourigenesis.  
1.3.1.2 Age and disease.  
The central tenet of geriatrics is that ageing is not a disease. This is true when the 
chronological age equals the biological age. The functional decline that accompanies 
normal ageing has been well characterized (107), but under normal circumstances does not 
account for symptoms. For example, that kidney function declines with age is well 
recognized. In fact, this decline in kidney function has proven to be a useful biologic 
marker of ageing in humans (108). However, clinical consequences of this change in renal 
function—in the absence of a disease, or the exposure to an exogenous nephrotoxic 
agent—do not occur, except when the organ is transplanted (109). 
Therefore, biological ageing (accelerated) that does not equate to chronological ageing, 
regardless of the cause that could be either internal (genetic), or external (environmental) 
factors, or a combination of both, is responsible for overt disease, not the normal ageing 
process. Ageing is not a disease process, but the changes in physiological reserves that 
accompany ageing may make an individual susceptible to disease. For example, the 
immune response declines with age, but is not of sufficient magnitude or duration to 
account for the increased incidence of cancer in old people (110).  
Therefore, a different approach to correlating biological ageing and diseases was 
necessary. Utilizing a biological ageing marker (telomere length) proved to be useful and 
informative in heart disease (111), inflammation (112), physical health, cognitive ageing 
(113) and scleroderma (114). Similarly a biological marker (telomere length) was 
informative in chronic kidney disease (115). Furthermore, the biological age of the donated 
kidney, as indicated by a range of biological markers (CDKN2A(p16), CDKN1A(P21), 
SIRT2,  XRCC5 and HPOT), is associated with  kidney function after transplantation 
(109). 
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1.3.1.3 Age and cancer. 
The majority of people diagnosed with cancer are over 65; 60% of newly diagnosed 
cancers are found in people over the age of 65. Overall, people in this age group are 10 
times more likely to get cancer, and 15 times more likely to die from the disease, than are 
people under the age of 65. Therefore, cancer is considered as a disease of ageing because 
it develops primarily in older adults, Furthermore, ageing is considered the most potent of 
all carcinogens (116). In humans, the incidence of cancer rises exponentially in the final 
decades of life, beginning at about the mid-point of the maximum lifespan (116, 117). This 
dramatic age-dependent escalation in cancer risk is fuelled largely by a marked increase in 
epithelial cancers, as opposed to cancers of mesenchymal, or haematopoietic origin. It is 
generally believed that the cancer-prone phenotype of older humans might reflect the 
combined effects of cumulative mutational load, increased epigenetic gene silencing, 
telomere dysfunction and altered stromal milieu (116).  
1.3.1.3.1 Age and  tumour suppressors. 
 
Cancer and ageing are also linked, because the molecules that control tumourigenesis, e.g. 
tumour suppressors, also regulate ageing and lifespan. It turns out that cellular senescence 
and apoptosis, induced by increased expression of tumour suppressors that have evolved to 
protect complex organisms from malignant tumours, may also contribute to development 
of the cancer-prone phenotype in later stages of life. In general, tumour suppressors can be 
divided into caretakers and gatekeepers (103, 118). Caretakers protect the genome from 
damage, or mutation, to ensure genomic stability, but usually do not directly stimulate cell 
proliferation. Candidates for caretaker tumour suppressors are BRCA1 and BRCA2. In 
contrast to caretakers, p53 and Rb functions as gatekeepers to eradicate potential cancer 
cells through apoptosis, or to suppress their proliferation through cellular senescence. 
Mutations inactivating any kind of tumour suppressor will increase the risk of developing 
cancer. Therefore, all tumour suppressors, in theory, should directly promote the longevity 
of the organism by preventing the development of malignant tumours. However, the 
relationship is more complex and tumour-suppressing mechanisms turn out to actually 
accelerate ageing and limit longevity according to an evolutionary hypothesis known as 
antagonistic pleiotropy (119, 120). 
Tumour-suppressor mechanisms, particularly the gatekeeper mechanisms of apoptosis and 
cellular senescence, suppress the development of cancer, but promote the development of 
specific ageing phenotypes. Firstly, both apoptosis and cellular senescence contribute to 
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the depletion of the renewal capacity of tissues by exhausting the supply of progenitors or 
stem cells. Secondly, senescent cells, resembling carcinoma-associated (activated) 
fibroblasts, secrete degradative enzymes, cytokines and growth factors (121) and 
contribute to ageing, by actively disrupting the integrity, function and/or homeostasis of 
tissues as they accumulate. 
The antagonistic pleiotropy hypothesis proposes that traits benefiting young organisms can 
have unselected deleterious effects later in life. Although they protect organisms from 
cancer early in life, they may promote ageing phenotypes, including late life cancer, in 
older organisms. Moreover, when caretaker mechanisms fail, the ageing phenotypes that 
develop might derive not only from the loss of genomic integrity, but also from the 
apoptosis and/or cellular senescence that can occur in response to the accumulated damage. 
So, the caretaker and gatekeeper tumour suppression mechanisms can interact. In addition 
to tumour suppressors, the over-expression of oncogenes is also linked to cellular 
senescence through oncogenic stresses that activate tumour suppressors, further 
complicating the already complex relationship between ageing and tumourigenesis. 
Overall, ageing and tumourigenesis appear not to be separable at the molecular level and 
molecules that regulate one are likely also to regulate the other. Thus, ageing and cancer 
may be considered as distinct phenotypes arising from changes affecting a similar set of 
molecules. For example, senescent cells are arrested mainly in the G1 phase and mutations 
involving the G1 checkpoint are extremely common in human cancer. 
1.3.2 Epigenetics and cancer. 
Much effort has been invested in identifying genetic mutations in cancer. This approach 
has proved to be successful in inherited cancer syndromes.   However, mutations early in 
the genesis of common cancers have also been identified and these are likely to be 
associated with tumour initiation.  In contrast, few specific genetic mutations have been 
linked to tumour progression, leading Feinberg to suggest that epigenetic changes may be 
involved (122).  Epigenetic changes occur without a change in the DNA sequence and they 
can be induced by various factors. Thus it is possible, for example, that a DNA mutation 
leads to cellular transformation, but induced changes in the epigenome of the transformed 
cell enhances the probability that it will be capable of metastasising. In this scenario, a 
genetic mutation initiates the cancer, but epigenetic change promotes its progression. 
It is possible that epigenetic change may lead directly to cancer initiation. Alternatively, 
changes already induced within the epigenome may 'prime' cells in such a way as to 
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promote cellular transformation, upon a subsequent DNA mutagenic event. In this case, the 
epigenetic component of the cancer initiation is intricately entwined with the genetic 
component (122). The involvement of epigenetic change in cancer initiation does not 
exclude it also having a role in cancer progression.  
A genetic alteration in the gene encoding epigenetic enzymes (e.g. histone 
acetyltransferase and deacetylases) may lead to changes within the epigenome.  If, for 
example, these changes cause the activation of an oncogene, then cancer may arise.  In 
addition, mutations in genes that code for proteins that recognize and bind to epigenetic 
marks (e.g. methyl binding domain proteins and bromo/chromo domain proteins which, 
bind to methylated DNA and acetylated/methylated histones respectively) could be as 
important in cancer as mutations in the enzymes themselves.  Although these are genetic 
events that lead to cancer, an alteration in the epigenome most likely also plays a part.  
However, it should be noted that many of the histone-modifying enzymes also modify non-
histone proteins, thus making a direct link between enzyme deregulation, changes in the 
epigenome and cancer extremely difficult to unambiguously demonstrate. In this context it 
is clear that the deacetylase actions of sirtuins implicate them in ageing and cancer 
processes through epigenetic effects. 
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1.4 Sirtuins  
1.4.1 Silent information Regulator2 (SIR2). 
The term silent information regulator 2 (SIR2) was designated to describe a  gene and its 
encoded protein required for the transcriptional repression of the silent mating type loci, 
HML (homothallic left) and HMR (homothallic right), in the budding yeast Saccharomyces 
cerevisiae. Silencing is a regional inactivation of transcription at a specific chromosomal 
domain and requires a set of non-histone chromatin-associated components, including the 
Sir2 protein and its homologues. Silent chromatin has a specialised, packaged, condensed 
and latent structure that prevents transcription, replication and other DNA modifications, 
such as methylation and endonucleation (8, 123). The SIR2 gene belongs to a big family of 
histone deacetylases. The finding of SIR2 homologues in yeast and shortly thereafter, in 
organisms ranging from bacteria to plants and mammals, demonstrated that SIR2 is a 
member of a large and ancient family of genes. In mammals seven Sir2- like proteins, 
termed sirtuins has been characterised.  
1.4.1.1 The histone deacetylase family.  
Transcription in eukaryotic cells is influenced by the manner in which DNA is packaged 
(124). In resting cells, DNA is tightly compacted to prevent accessibility of transcription 
factors. DNA is packaged into chromatin, a highly organized and dynamic protein ± DNA 
complex. The fact that acetylation is a key component in the regulation of gene expression 
has stimulated the study of histone deacetylases (HDACs), in relation to the aberrant gene 
expression often observed in cancer. 
Acetylation is controlled by two classes of enzymes: histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). HATs deliver acetyl groups to the lysine residues in the 
amino terminal tail of core histones, neutralizing the positive charge, and resulting in the 
unwinding of chromatin. This modification provides docking sites for regulatory proteins 
to activate transcription. HDACs, on the other hand, induce transcriptional repression and 
gene silencing by catalyzing the removal of the acetyl groups from core histones.  
In humans, eighteen histone deacetylases (HDACs) have been identified is divided into 
four classes based on their homology to yeast proteins. In general there are two families of 
deacetylases identified in eukaryotes, the classical histone deacetylases family (class I, II, 
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IV), and the recently discovered sirtuins family (Class III). Each of these two families is 
divided into subclasses as follows:  
 The classical HDAC family is divided into three classes based on their homology to 
yeast proteins. The class I HDACs, namely 1, 2, 3 and 8, are ubiquitously 
expressed nuclear proteins and most closely related to the yeast (Saccharomyces 
cerevisiae) transcriptional regulator RPD3. Class II HDACs (4, 5, 6, 7, 9 and 10) 
share domains with similarity to another deacetylase found in yeast HDAC1, and 
can be found in both the nucleus and the cytoplasm. HDAC11 is remotely similar 
to class I and II HDACs but the sequence identity is too weak to be placed in either 
class. It is thus designated as the sole member of class IV. Currently, it is thought 
that HDACs of class I are expressed in most cell types, whereas the expression 
pattern of class II HDACs is more restricted, suggesting that they might be 
involved in cellular differentiation and developmental processes (125, 126). All 
members of class I, II and IV HDACs are sensitive to the inhibition by trichostatin 
A (TSA). 
 Sirtuins family, class III histone deacetylases, is divided into five classes (I, II, III, 
IV, U) SIRT1, SIRT2, and SIRT3 belong to class I, which groups all yeast sirtuins 
and also at least one of the Sir2-related proteins in most eukaryotes. SIRT4 belongs 
to Class II, which also includes sirtuins from bacteria, insects, nematodes, mould 
fungus and protozoans. SIRT5 belongs to class III that is widely distributed in all 
prokaryotes either bacteria or archaea. Finally, SIRT6 and SIRT7 belong to class 
IV, and unlike Class III, sirtuins of this class are not present in prokaryotes, but are 
broadly distributed in metazoans, plants and vertebrates. Additional class (U) has 
been assigned for bacterial Sir2 homologues that have undifferentiated motifs that 
are intermediate between classes II and III, and classes I and IV. Sirtuins from 
Class II, Class III and Class U (undetermined) seem to have evolved earlier than 
the other classes. Thus, SIRT4 and SIRT5 may be the most ancient mammalian 
sirtuins. Class I and Class IV sirtuins, which group SIRT1, SIRT2 and SIRT3 and 
SIRT6 and SIRT7 respectively, are only present in eukaryotes. Thus sirtuins from 
Class II and Class III together with Class U seem to be the ones that appeared 
earliest in evolution (127, 128). 
This classification has been decided upon phylogenetic analysis of 60 core domains from 
different eukaryotes and prokaryotes. All SIR2-like proteins have a common core domain 
which contain a series of conserved sequence motifs, comprising 275 amino acids, in 
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organisms ranging from bacteria to man (129) (Figure 1.5). Sometimes an additional N-
terminal or C terminal sequence is present (127). All have an NAD+-dependent catalytic 
core domain that may act preferentially as a mono-ADP-ribosyl transferase (ART) and/or 
NAD+-dependent deacetylase (DAC). Additional N-terminal and/or C-terminal sequences, 
of variable length, may flank this core domain. The seven sirtuins show different cellular 
localization.  
 
Figure 0.5: The position of the conserved core domain (dark shading) of Sir2 from  
S. cerevisiae and the seven human sirtuins. Modified from Frye, 2000. 
 
1.4.2 Functions of the Silent information regulators (Sir). 
Sir proteins are involved in diverse processes ranging from regulation of gene silencing at 
telomeres and mating type loci, DNA repair (double-strand break repair), structure and 
function of the nucleolus, suppression of ribosomal RNA (rDNA) recombination, 
regulation of the mitotic cell cycle, meiosis and ageing (8, 9, 130). SIR2 in Saccharomyces 
cerevisiae is the best characterized and the best-studied member of this family. The 
enzymatic activity, structure and essential functions are described below:  
1.4.2.1 Sir2 Structure.  
The structure study of Sir2 showed that the conserved core domains of the protein form 
two lobes. The large domain contains a Rossmann fold, and the small domain contains a 
helical loop, a three-stranded zinc ribbon motif and a flexible loop. A conserved large 
groove is inter-positioned between these two domains. The large groove contains, between 
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the Rossmann fold and the helical loop, the NAD binding site, accessibility to which is 
controlled by a flap formed by the flexible loop (131, 132). It also contains conserved 
hydrophobic and a hydrophilic lining motifs. The hydrophobic motif has been proposed to 
be the lysine deacetylation site. Moreover, the hydrophilic motif, containing poorly 
conserved polar residues, has been implicated in control of the enzyme substrate specificity 
(133) (Figure 1.6).  
 
 
 
Figure 0.6: Crystal structure of SIR2. 
The arrow indicates the groove between the two domains, which contains the substrate 
binding site and the NAD binding pocket. The flexible loop (flap) above the DNA-binding 
pocket is also shown. Adapted from Gasser and Cockell, 2001.  
 
1.4.2.2 Enzymatic activity. 
The Sir2 proteins are class III histone deacetylases (127) and the observation that Sir2 
over-expression resulted in global hypoacetylation of histone gave rise to the rational 
thought that Sir2 was responsible for deacetylation of nucleosome-associated histones 
(134). Consistently, further researches suggested that the enzymatic activities were 
important for the role of Sir2 in telomeric, HM, and rDNA repression (133). Even though 
initial studies showed that Sir2 protein functions as a NAD (nicotinamide adenine 
dinucleotide)-dependent ADP (adenosine diphosphate) ribosyl transferase (7), further 
research has provided evidence that Sir2 functions primarily as a deacetylase, which uses 
NAD as a cofactor (135). Consistent with Braunstein’s speculation, deacetylation has been 
confirmed as the main function of Sir2, and the previously mentioned ADP-
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ribosyltransferase activity has been described as a ‘low-efficiency side reaction’ (135). The 
Sir2-dependent deacetylation reaction is tightly coupled with NAD cleavage and the 
formation of a previously unidentified product, 2-O-acetyl-ADP-ribose (OAAR) (Figure 
1.7). The Sir2 histone deacetylase activity has been shown by two different groups to be 
absolutely dependent on NAD+ (136, 137). OAAR is now understood to be a tightly 
coupled by-product of deacetylation reaction catalysed by the Sir2.  Furthermore, the 
production of the OAAR metabolite itself has an important function in delaying/blocking 
oocyte maturation as well as embryo cell division in blastomeres (138, 139). 
Unlike the other deacetylase classes, sirtuins do not have a zinc catalysed function and are 
not inhibited by trichostatin.  
Initially, it has been speculated that Sir2 may have another substrate, other than histones, 
as it present in almost all organisms, including bacteria, which have no histone proteins. 
This was supported by identification of extranuclear locations for Sir2 (140, 141). This has 
been supported by subsequent observations demonstrating that Sir2 orthologues is able to 
deacetylate a number of substrates including p53, Ku70, and Foxo transcription factors 
(142-146) in man and the Taf168 subunit of the Tata-box binding protein-containing factor 
in mice (147).  
1.4.2.3 Nicotinamide and Sir2 enzymatic activity. 
Nicotinamide, a vitamin B3 precursor, is a product of the Sir2 deacetylase reaction and 
potent non-competitive inhibitor of Sir2 NAD-dependent deacetylase activity (137). The 
1:1 requirement of NAD+ for Sir2 deacetylase activity predicts that NAD+ levels may be a 
rate-limiting component for its activity. Indeed, nicotinamide clearance by increased 
expression of PNC1 (pyrazinamidase/ nicotinamidase 1), which encodes an enzyme that 
deaminates nicotinamide, directly regulates Sir2- activity (148, 149). 
1.4.3 Sir functions:  
Four further genes were discovered in Saccharomyces cerevisiae with high homology to 
SIR2 (SIR1, SIR3 and SIR4) (129). None of the four genes were essential for life, but they 
all were involved in silencing at the mating-type loci and telomeres, as well as cell-cycle 
progression and genomic integrity.  
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Figure 0.7: Mechanism of SIR2-dependent deacetylation enzymatic activity. 
An acetylated protein substrate reacts with one molecule of NAD+ in the presence of SIR2 ( 
enzyme) to generate one molecule of deacetylated protein, nicotinamide, and 2-O-acetyle-
ADP-ribose (modified form (150). This reaction is NAD+ dependent.  
1.4.3.1 Silencing at mating type loci:  
Sir2, along with Sir1, Sir3 and Sir4 were first identified as essential components for the 
transcriptional repression of the silent mating type loci HML (homothallic left) and HMR 
(homothallic right), in the budding yeast S. cerevisiae (8, 151). The mating type in S. 
cerevisiae is determined by the expression of genes located in the active mating locus 
called MAT. These three separate loci (MAT, HMR, and HML), located on chromosome 
III, contain either a, or α, mating type genes. Moreover, mating type inter-conversion 
occurs by transposition of either a, or α, mating type cassettes from the inactive loci HMR, 
or HML, to the MAT locus. Co-expression of both a and α mating type genes results from 
loss of silencing at these loci; consequently sterility in haploid strains will ensue (152). In 
addition to SIR proteins, different elements have been shown to be involved in the 
silencing process, including silencers, Rap1 (repressor activator protein 1), ORC (origin 
recognition complex), and Abf1 (Autonomously replicating sequence (ARS) binding factor 
 
SIR2 
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1). Two cis-acting DNA sequences <250-bp, known as E and I silencers, flank HMR and 
HML and serve as binding sites for Rap1, Abf1 and ORC complex. The binding of these 
proteins will recruit the SIR2 proteins, along with other Sir proteins, to the HMR and HMR 
loci to form a complex, which in turn are responsible for the formation of the 
heterochromatin structure in the region adjacent to the silencers. Given the deacetylation 
function of SIR2 protein (136, 153) it will create a specific acetylation pattern in the 
adjacent nucelosomes, consequently increasing their affinity for the Sir proteins. 
Afterwards, another Sir complex will bind to the newly modified nucleosome and modify 
the adjacent one propagating the silenced region (Figure 1.8) (154). Silencers flank the HM 
loci, demarcate the boundaries of SIR protein deposition, thus preventing repression from 
being inappropriately disseminated (155, 156). Availability of SIR proteins also contribute 
to the demarcation of silenced domain (8). 
 
 
 
 
 
 
 
Figure 0.8; A model for silencer-induced heterochromatin formation, and a proposed role for 
acetylation in silencing. 
Rap1(R), Abf1(B), and ORC(O) proteins bind the silencer and recruit additional proteins, 
SIR2, SIR3,and SIR4 (SIR’s) that are themselves responsible for the formation of the 
heterochromatin structure in the region adjacent to the silencer. These SIR proteins induced 
a specific pattern of acetylation in the adjacent nucleosome, which increases the affinity of 
the nucleosome for the SIR proteins. The SIR proteins then bind to the newly modified 
nucleosome and modify the adjacent one. In this manner SIR proteins can propagate the 
silencing domain. Modified from (Braunstein et al. 1996). 
Sir2 along with Sir3, Sir4, telomere repeated binding protein and Rap1 are associated with 
the telomere and involved in its silencing in yeast. (157-159). Rap1 binds the terminal 
telomeric sequence and recruits the Sir proteins, in complex formation for assembling 
histones to form silent chromatin (160). The suppression extends to involve telomere 
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proximal genes, in a process known as Telomere Positional Effect TPE (161, 162). 
Normally, this repression does not extend beyond 3Kb from the telomeric repeat, although 
in strains over-expressing Sir 3, TPE can extend up to 20 Kb from the chromosomal end 
(163). 
SIR proteins also play a role in preserving both the integrity and sub-nuclear localization of 
yeast telomeres. The absence of SIR3 or SIR4 not only decreases TPE, but also leads to 
both telomere shortening and enhanced chromosome loss (162). Silencing of the sub-
telomeric region requires Ku protein, a heterodimereic protein that associates with DNA 
ends. Ku proteins play a role in the integrity of telomere structure, the nuclear localization 
of chromosome ends, and TPE (164, 165). It interacts with SIR4 and recruits SIR proteins 
for silencing, in cooperation with Rap1 (166, 167). 
1.4.3.2 Sir 2 and DNA repair. 
 The Sir proteins may also function, along with Ku protein, in DNA double strand break 
(DSB) repair, in a process known as Non Homologous End Joining (NHEJ) (164, 166, 
167). Consistently, it has been shown that deletion of Sir 2, Sir 3, and Sir 4 results in less 
efficient ligation of DNA, significant decrease in the NHEJ process and increased radiation 
sensitivity (166-169). Sir proteins relocalize from telomeres to sites of DSB, probably 
following the initial Ku relocalization from telomeres to the site of damage (169, 170) 
(Figure 1.9).  
1.4.3.3 Suppression of Ribosomal DNA (rDNA) recombination.  
Besides its role in NHEJ, HM and telomeric silencing, Sir 2 is also involved in a different 
mechanism of silencing at rDNA (171, 172). Initially, Sir2, in the absence of Sir3 and Sir 
4, was shown to be involved in the suppression of rDNA mitotic recombination, as the 
frequency of recombination at the rDNA showed a ten fold increase in SIR2 mutants (9). 
The rDNA locus in yeast is located 450 kb from the left end and 610 kb from the right end 
of chromosome XII and consists of 100 to 200 tandem repeats copies of a 9.1 kb rDNA 
unit (173). Each unit contains genes encoding the 35S rRNA and the 5S rRNA, separated 
by non-transcribed spacer (174-176). The nucleolus is positioned at the periphery of the 
nucleus, where rDNA transcription, rDNA transcript processing, and pre-ribosomal 
particles formation take place (177). Immunoflourescence studies have shwon that the 
majority of Sir2 is located in the nucleolus (178), suggesting an important role. Moreover, 
Sir 2 has the ability to induce alteration in the rDNA chromatin structure, which is 
Samer Zino, 2010     Chapter I, 70 
responsible for transcriptional silencing and suppression of recombination at this locus 
(171). Furthermore, Net1 protein has been found to be required for Sir2 association with 
the rDNA locus and for rDNA silencing (179). This protein is a constituent of a complex 
called regulator of nucleolar silencing and telophase exit, RENT, which is involved in 
control of the cell cycle (as discussed later in the text). 
1.4.3.4 Silent information regulators and life span (Ageing). 
Mutation in either of the SIR3 or SIR4 genes result in a 20% decrease in yeast life span, 
whereas mutation in the SIR2 genes showed a more striking reduction of 50%. This 
implies that various sirtuins can affect yeast life span differently. Three mechanisms have 
been  suggested to account for this. Firstly, mutation in the SIR3 or SIR4 genes results in 
derepression of HM and consequently a simultaneous expression of a and α mating type 
information. This co-expression has been found to be responsible for a small increase in 
recombination at rDNA, thus increasing the formation of  exrtrachromosomal ribosomal 
DNA circles (ERC), which will shorten the life span (152). Secondly, the loss of 
homologous recombination inhibition at rDNA, as a direct result of absence of Sir 2 and 
increased ERC formation are the cause of a significant decrease (50%) in the SIR2 mutant 
lifespan. This mechanism does not involve mating type silencing, as deletion of HMLα 
failed in restoring the normal lifespan of the SIR2 mutant, whereas it extends the lifespan 
in SIR3 or SIR4 mutants. Sir2 acts directly to suppress ERC formation by inhibiting 
homologous recombination at the blocked replication fork (via Fob1 protein) in the rDNA. 
Thirdly, the observation that the SIR2 FOB1 HML mutant strain has a shorter life than that 
of a FOB1 mutant indicates another as yet unknown mechanism plays a role (152). 
The level of SIR2 has also been shown to be a limiting factor in yeast ageing, as a second 
copy of SIR2 can enhance lifespan over those with only a haploid complement (152). 
Increased dose has also been shown to increase life span in the nematode Caenorhabditis 
elegans  (180). 
1.4.3.5 Regulation of cell cycle and meiosis. 
Sir2 is involved in cell cycle control through its contribution in forming a complex known 
as (RENT) regulator of nucleolar silencing and telophase exit. RENT consists of Sir2, 
Net1, Cdc14, and Nan 1 proteins. Net1 is required for Sir2 association with rDNA and its 
recombination suppressive function (179). It also inhibits and anchors the mitotic regulator 
Cdc14 to the nucleolus. Cdc14, in late anaphase, leaves the nucleolus for the cytoplasm 
Samer Zino, 2010     Chapter I, 71 
where it reaches its target and gains activity, thus resulting in the cell exiting mitosis (181, 
182). The fourth protein Nan1, which is essential in the RENT complex, as yet, has no 
known function. 
Moreover Sir2, in the nucleolus, also functions in controlling a meiotic checkpoint. 
Checkpoints are protective mechanisms that block cell cycle development when previous, 
or preparatory, events in the cell cycle have been damaged or, for some reason, not 
completed properly. The pachytene checkpoint stops meiotic progression in the pachytene 
stage of the cell cycle, if the cell is defective in chromosome synapsis and recombination. 
Failure at this checkpoint allows defective yeast cells to proceed through the meiotic cell 
cycle and to sporulate, producing low viability spores due to chromosome mis-segregation. 
Pachytene 2 has been identified as a mediator of the pachytene checkpoint.  It is tethered to 
the nucleolus in meiotic cells by SIR2 (183). Furthermore, it has been suggested that the 
pachytene2-mediated checkpoint involves silent chromatin (8).  
1.4.3.6 Sir, caloric restriction, and life span. 
Calorie restriction  (CR) is a dietary regimen in which an organism is provided with at least 
20 % fewer calories than it would naturally consume ad libitum, while maintaining 
adequate nutrition (184).  CR-mediated lifespan extension has been demonstrated in 
different organisms including yeast(185), fruit flies (D. melanogaster) (186), nematodes 
(C. elegans) (187), spiders (Frontinella pyramitela) (188) and mice (189). This diversity 
argues that the mechanisms underlying CR are ancient and well conserved. 
This lifespan extension can be explained by the attenuation of oxidative damage and 
changes in fuel utilisation. The reliance of Sir2 on its NAD co-substrate is central to this 
lifespan extension. Multiple studies suggested that CR leads to increased mitochondrial 
NAD levels, reduced NADH levels (190), or reduced nicotinamide levels (191, 192) which 
in turn activate Sir2.  
As a result, CR may result in an increase in the Sir2 activity at telomeres and within the 
nucleolar rDNA (193), resulting in, a decrease in the oxidative stresses that may also result 
in a fall in DNA damage  and increased concentration of Sir2 at telomeres and the 
nucleolus. These findings have led to the hypothesis that sirtuins underlie the beneficial 
effects of caloric restriction in diverse species, including mammals. Further support for this 
hypothesis has come from studying the mammalian sirtuins (194). 
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Interestingly, the plant polyphenol, resveratrol, found in large quantities in red wine, has 
been found to be a potent Sir2 activator and can, like CR, increase DNA stability and 
extend lifespan in yeast (195). This function of red wine may further explain the 
‘Mediterranean paradox’ of why ageing-related diseases, such as atherosclerotic arterial 
disease are less common in this red wine drinking population, irrespective of their caloric 
intake (196, 197).  
The diverse functions of Sir2 in yeast are closely linked and reflect the central role that 
Sir2 plays in growth and proliferation, DNA damage repair and ageing in response to 
exogenous stresses and nutritional availability. One of the most exciting discoveries to be 
made in this regard, is that caloric restriction (CR) results in a Sir2-dependent prolongation 
of lifespan. 
 
 
 
 
 
 
Figure 0.9: The main SIR functions in Saccharomyces cerevisiae: 
Silencing at the telomere and HML, DNA repair, nucleolar ERC formation and preferential 
segregation to mother cells. The locations of SIR in Saccharomyces cerevisiae are shown 
together with the preferential segregation of extrachromosomal ribosomal DNA circles 
(ERC) to the mother cells with cell division. 
 
Sir2 has been shown to relocate to the nucleolus with increasing age, and Sir2 
concentration is directly related to life span. Homologous recombination-mediated repair 
of DSB, occurring within the rDNA, results in the formation of extrachromosomal 
ribosomal DNA circles (ERC) (198). These structures are segregated in a biased manner 
towards the yeast mother cell (Figure 1.9). Once accumulation of these ERCs reaches a 
critical level, the mother cell can no longer divide (199). 
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1.4.4 Mammalian Sirtuins.  
In man, seven Sir2 orthologues termed sirtuins have been characterised, (SIRT1-7) (Table 
1.7). These are grouped into four main phylogenetic groups, centred on the characterisation 
of 60 amino acid  ‘conserved core domains’ from different prokaryotic and eukaryotic 
sirtuins (127, 130). A fifth class has been added based on Firmicute (gram positive) 
bacteria and Thermotoga maritima sirtuin proteins, with sequence motifs that seem to be 
intermediate between classes II and III and the classes I and IV. This form of sirtuin has 
been classified as group U. 
In man, the seven sirtuins represent the four known classes. SIRT1, SIRT2, and SIRT3 
belong to class I, SIRT4 to class II, SIRT5 to class III, and SIRT6 and SIRT7 to class IV 
(127). Mammalian sirtuins also differ in their sub-cellular localization. SIRT1, SIRT6 and 
SIRT7 are predominately in the nucleus (although SIRT1 does have some important 
cytoplasmic functions as well). In the nucleus a large fraction of SIRT1 is associated with 
euchromatin, whereas SIRT6 associates with heterochromatin and SIRT7 is found in the 
nucleolus (200). The sirtuin that resides most prominently in the cytoplasm is SIRT2 (7, 
201).  
SIRT3, SIRT4 and SIRT5 have been described as mitochondrial sirtuins (200, 202, 203). 
These mammalian sirtuins differ also in their enzymatic activity: 
 SIRT1 and SIRT5 only exhibit robust and weak deacetylase activity respectively 
(146, 201). 
 SIRT4 is only a mono- ADP-ribosyl tranferase (204). 
 SIRT2, SIRT3 and SIRT6 appear to have both deacetylase and mono-ADP-ribosyl 
tranferase activities (7, 201, 205-207) 
 SIRT7 has NAD deacetylase activity. 
Each of these sirtuins will be described in more detail below.  
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Transcript(s) length Molecular weight
(base pairs) (kilodaltons)
SIRT1 I 10q21.3 Nucleus, 
Cytoplasm
4086 747 82 HDAC, 
SIRT2 I 19q13.2 Cytoplasm 1963, 1931 399 43
HDAC,                          
ADP-ribosyl tranferase
SIRT3 I 11p15.5 Mitochondrion 2900, 2574 399 44
HDAC,                          
ADP-ribosyl tranferase
SIRT4 II 12q24.23 Mitochondrion 1163 314 35 ADP-ribosyl tranferase
SIRT5 III 6p23 Mitochondrion 2350, 1670 310 34 HDAC
SIRT6 IV 19p13.3 Nucleus 1638 355 39
HDAC,                          
ADP-ribosyl tranferase
SIRT7 IV 17q25 Nucleus 1718 400 45 HDAC
Enzymatic function
Cellular 
location Sirtuin Class chromosome 
Amino acid 
residues
Table 0.7: Classification of human sirtuins.  
The table shows the class, location, molecular weight, enzymatic function and biochemical 
features of the human sirtuins and their genes.  
Figure 0.10: Intracellular location of sirtuins.  
SIRT1 may be present in the nucleus and/or cytoplasm, depending on the type of biological 
tissue. SIRT2 is found in the cytoplasm, and is able to shuttle to the nucleus. SIRT3, SIRT4, 
and SIRT5 are present in the mitochondria whereas SIRT6 and SIRT7 are present in the 
nucleus and nucleolus, respectively (208).  
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1.4.4.1 Mamalian Sirtuin1.  
The human sirtuin1 (SIRT1) gene has been mapped to chromosome 10. It is considered the 
human homologue of the yeast SIR2 gene (7). Initially SIRT1 has a postulated nuclear 
localization similar to yeast Sir2, based upon a putative nuclear localization signal coded 
by amino acids 41-46 (7). Mammalian SIRT1 (Figure 1.5) has a long N-terminal sequence 
that shows little conservation with yeast Sir2, but contains functional nuclear localization 
sequences that are conserved among SIRT1 from different mammals. Together with 
nuclear exporting sequences, located in the catalytic domain, the nuclear localization 
sequences control the nucleus-cytoplasm shuttling of SIRT1 (209) 
Similar to yeast Sir2, mammalian Sirt1 exhibits predominantly nuclear localisation and 
facilitates the formation of heterochromatin that is associated with histone hypoacetylation 
and gene repression. SIRT1 targets for deacetylation include lysine residues at positions 9 
and 26 of histone H1, 14 of H3, and 16 of H4 (136, 210). Multiple non-histone targets 
have also been described including p53 (144, 146), p300/CBP-associated factor (PCAF) 
(211), p300 (212), MyoD (213, 214), the Foxo transcription factors (215-217), NF-κB 
(218) and E2F1 (219). In addition, SIRT1 interacts with the HES1/HES2 factors, chicken 
ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2, CTIP-
2  and (Peroxisome proliferator-activated receptor- γ ) PPAR-γ (220, 221). Interaction of 
SIRT1 with these substrates, allows SIRT1 to be recruited to chromatin regions and 
specific promoters, to influence the transcription of other genes, leading to the involvement 
of SIRT1 in a wide variety of important cell processes, including apoptosis (144, 146, 211) 
development and embryogenesis (213, 221-224), glucose and fat metabolism (225-227) 
axonal degeneration (228) and muscle differentiation (213, 229). The involvements of 
SIRT1 in these cellular processes will be explored in the following sections. 
1.4.4.1.1 Posttranscriptional regulation of Sirtuin1. 
 
SIRT1 expression is also regulated at the posttranscriptional level. The RNA binding 
protein HuR regulates the stability of many target mRNAs. It was recently reported that 
HuR associated with the 3' untranslated region of SIRT1 mRNA stabilized the mRNA and 
increased SIRT1 expression (230). This study found that oxidative stress triggered the 
dissociation of the HuR from SIRT1 mRNA, in turn promoting SIRT1 mRNA decay, 
reducing SIRT1 abundance and lowering cell survival. This occurs by the activation of the 
cell cycle checkpoint kinase, Chk2, which interacts with HuR and possibly phosphorylates 
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HuR, an event that appears to be important for HuR dissociation after hydrogen peroxide 
treatment.  
1.4.4.1.2 Sirtuin1, cell survival and apoptosis. 
 
SIRT1 is thought to play an important regulatory role in mediating cell survival by 
preventing p53-mediated growth arrest, senescence and apoptosis. SIRT1 mediates 
apoptosis in response to stimuli including oxidative damage, γ-radiation and exposure to 
tumour necrotizing factor alpha (TNFα) (144, 146, 231). SIRT1 also negatively controls 
p73- mediated apoptosis (232). 
1.4.4.1.2.1 Sirtuin1 and p53. 
 
P53, short lived tumour suppressor protein, is the best known gatekeeper tumour 
suppressor that induces anti-proliferative effects, including growth arrest, apoptosis, and 
cell senescence, in response to different kinds of stress (233-235). Three separate studies 
have shown that p53 activity is negatively regulated by SIRT1-mediated deacetylation 
(144, 146, 231). Strict control of p53 activity is essential to regulate normal development 
in addition to tumour suppression. This control is generally thought to involve a post-
translational modification of p53 (236). p53 is normally phosphorylated in response to 
DNA damage, by means of kinases, such as Ataxia telangiectasia mutated (ATM) (237). 
This phosphorylation does not lead directly to activation of p53, but increases p53 affinity 
for p300 acetylase, eventually leading to acetylation and activation of p53 (238). p53 acts 
as a transcription factor, and upregulates the expression of cycline dependent kinase 
inhibitor p21 that promotes cell cycle exit (239). Alternatively, p53 activation may, 
depending on the degree of DNA damage, upregulate the expression of genes that favour 
apoptosis (240). 
Conversely, if the DNA damage has been successfully repaired, a p53 inhibitory system 
would be needed to regain active cellular growth. SIRT1 can selectively bind and 
deacetylate p53, thus inhibiting its activity. This will impede the p53-dependent apoptosis 
response, or relieve the blockage of cell cycle imposed by p53-dependent p21 up 
regulation. 
Under normal circumstances, murine double minute 2 (Mdm2) is the major negative 
regulation of p53 (241) and is able to block its acetylation by p300 (242). Deacetylated p53 
is unstable and is rapidly degraded through Mdm2-mediated ubiquitination. Thus Mdm2 
maintains p53 at low levels to enable the cell to grow normally. If DNA is damaged during 
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stress, p53 will undergo phosphorylation, a prerequisite for acetylation, which prevent the 
binding of Mdm2 (236).  
However, in a stressed cell, acetylated p53 resists Mdm2-mediated ubiquitination, a 
process that results in protein degradation. This might be the result of acetylation of the 
same site required for Mdm2-mediated ubiquitination (243, 244). Consequently, highly 
acetylated p53 cannot be effectively degraded by Mdm2 until it is deacetylated (245). 
Moreover, ATM also phosphorylates Mdm2 decreasing its inhibitory potential on p53 
(246). Therefore, in DNA damaged cells, the main p53 regulatory pathway, Mdm2-
mediated, is blocked at several levels. Thus SIRT1 may play an important role in 
negatively controlling p53 activity, as the other regulator is inactive. ATM, like its yeast 
mec1 kinase counterpart responsible for the redistribution of the yeast sir complex to areas 
of DSB to facilitate their repair, may also play a similar role in mobilising SIRT and other 
repair machinery to damaged DNA in mammals. 
 
SIRT1 has also been shown to have binding sites for p53 and p53 can itself stimulate 
SIRT1 transcription, in a Foxo-dependent manner (247). Another regulatory mechanism 
for SIRT1/p53 has been described in co-operation with the hypermethylated in cancer 1 
transcriptional repressor (HIC1)(248). SIRT1 mediates a bypass of apoptosis, possibly by 
promoting cell survival, via formation of a complex with HIC1, which binds directly to the 
SIRT1 promoter and represses its expression, thus promoting p53-dependent apoptotic 
responses. Since p53 is able to transactivate HIC1 transcription, it has been proposed that 
SIRT1—HIC1—p53 act in a complex feedback loop. Under normal physiological 
conditions, HIC1 represses SIRT1, promoting p53 activity and apoptosis under stress. 
However, in cells set to recover from DNA damage, p53 down-regulates HIC1, which 
result in the induction of SIRT1 transcription and promotes cell survival (248). The authors 
of the study speculate that HIC1 hypermethylation experienced during ageing may lead to 
increased SIRT1 expression, which may deacetylate p53 and increase cellular risk for 
neoplastic transformation and tumourigenesis.  
There is evidence for several other regulatory negative feed back loops acting on SIRT1: 
 DeltaNp63alpha, a p53 related protein, down-regulates SIRT1 and accelerates the 
ageing phenotype when over-expressed in mice (249). 
 Deleted in Breast cancer 1 protein (DBC1) antagonises SIRT1 deacetyaltion of p53 
resulting in increased levels of acetylated p53 and up regulation of p53-mediated 
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function in human cells (250). Elimination of endogenous DBC1 by RNA 
interference (RNAi) stimulates SIRT1-mediated deacetylation of p53 and inhibits 
p53-dependent apoptosis. (250). 
In response to DNA damage, SIRT1 may therefore play an important regulatory role in 
mediating cell survival by deacetylating and thereby inactivating p53, preventing growth 
arrest, senescence or apoptosis. Levels of SIRT1 might be informative of cellular levels of 
stress and indicative of p53 status. Furthermore, SIRT1 could be an important determinant 
of sensitivity and play a role in dictating the response to antitumour agents, especially 
those that damage DNA. 
1.4.4.1.2.2 Sirtuin1 and FOXO transcription factors.  
 
Another alternative pathway by which SIRT1 increases cell survival is through the 
regulation of Foxo transcription factors. There are four Foxo proteins and so far SIRT1 has 
been shown to deacetylate three of them: Foxo1, Foxo3a and Foxo4. The Foxo factors 
induce the transcription of a wide variety of genes involved in the oxidative stress 
response, DNA repair, cell-cycle control and apoptosis (251). In response to oxidative 
stress, SIRT1-mediated deacetylation of the Foxo forkhead family of transcription factors 
also occurs (215, 217, 252-255). The effects of SIRT1 on Foxo-controlled genes vary 
between tissues and range from their activation to repression. Overall, it appears that 
SIRT1 activity results in a decrease in Foxo3-mediated apoptosis, an increase in Foxo3-
mediated DNA repair and cell-cycle arrest and an increase in both Foxo1 and Foxo4-
mediated stress resistance (215, 217, 254, 256, 257). In addition, it has been shown that 
SIRT1 acting via Foxo4 suppresses the pro-apoptotic proteases caspase-3 and caspase-7 in 
transformed, but not in untransformed epithelial cells (258). In what appears to be a 
feedback loop, caspase-9 and Bcl-xL regulate SIRT1 cleavage during apoptosis, shifting its 
localization from the nucleus to the cytoplasm (249).  
The overall effect of SIRT1 action is to shift Foxo-induced responses away from apoptosis 
towards cell-cycle arrest, perhaps allowing cells time to repair the DNA damage and 
detoxify free radicals. Through its interaction with the Foxo factors, SIRT1 mediates stress 
resistance in a p53-independent manner. Evidence supporting this comes from the 
observation that apoptosis in cells lacking SIRT1 is only partially rescued by transfection 
with a dominant negative p53 mutant (146) and that in cells lacking functional p53, the 
SIRT1 activator, resveratrol, can still increase resistance to γ−radiation (195). 
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1.4.4.1.2.3 Sirtuin1 and NF-κB. 
 
In contrast to the cell survival promoting effects described previously, SIRT1 can exert a 
pro-apoptotic effect through its interaction with nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB). NF-κB is a protein complex that acts as a transcription 
factor. NF-κB is found in almost all animal cell types and is involved in regulating genes 
that control cell survival, and in cellular responses to stimuli such as stress cytokines, free 
radicals, ultraviolet irradiation, and bacterial or viral antigens. NF-κB appears to be an 
important regulator of ageing-related cellular processes. It exists as a heterodimer, 
composed of p50 and RelA/p65 polypeptides. Within the cytoplasm it is normally bound to 
members of the I-κB family of inhibitory proteins. Once activated NF-κB is released into 
the nucleus where it enhances transcription by tethering histone acetyltransferases (HAT) 
that result in an open chromatin structure. Histone deacetylases (HDAC) including SIRT1 
inhibit NF-κB transcription (218, 259). 
NF-κB activity is controlled by multiple layers of regulation (260). All five members of the 
NF-κB family contain a Rel-homology DNA binding domain. These NF-κB proteins 
typically bind to their target DNA sequences as dimers. In unstimulated cells, NF-κB is 
sequestered in the cytoplasm by inhibitory proteins (I-κB). Upon stimulation by diverse 
cell stresses, I-κBs are degraded, allowing NF-κB to translocate into the nucleus and 
activate target genes. NF-κB induces the transcription of IκBα and other negative 
regulators of the pathway, which contribute to signal inactivation. Thus, in individual cells, 
NF-κB signalling is characterized by dynamic patterns of periodic NF-κB nuclear 
localization and target gene activation interspersed with nuclear exit and gene deactivation. 
(260).  
Previously, we described how SIRT1 could provide survival advantage by binding, 
deacetylating and thereby decreasing p53, Foxo and Ku70-mediated apoptosis, however it 
is also known to deacetylate and inactivate NF-κB, thereby sensitising cells to 
(TNFα) induced apoptosis. SIRT1 does this by associating with and deacetylating 
RelA/p65 R, a subunit of NF-κB. Deacetylation inhibits the transactivation potential of 
RelA/p65, thus sensitizing human cells to apoptosis in response to TNFα (218, 259). 
Treatment with, resveratrol, a sirtuin activator and known inhibitor of NF-κB transcription, 
results in a reduction in the transcription of genes, including the anti-apoptotic cIAP-2 
gene, following TNFα stimulation. The cIAP-2 gene product inhibits TNFα-induced 
caspase activation and therefore resveratrol results in sensitisation to TNFα-induced 
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apoptosis. This effect is SIRT 1-dependent, as loss of SIRT1 expression completely 
inhibits this TNFα-induced apoptosis (218). 
Another study showed that the breast cancer associated protein, BCA3, when neddylated 
(modified by Nedd8), interacts with SIRT1 and suppresses NF-kB-dependent transcription, 
also sensitizing human breast and prostate cancer cells (such as MCF-7 and DU145 cells 
respectively) to TNFα-induced apoptosis (261). 
From the previous two sections, it could be argued that SIRT1 plays two different and 
contradictory roles in controlling cell survival. 
Consistent with the pro-survival effect of SIRT1 Kuzmicgev et al. ( 2005) found that 
SIRT1, together with other components of Polycomb Repressive Complex  (PRC), a 
complex that maintains homeotic gene repression during development, are over-expressed 
in colon, breast and prostate cancers as compared to normal tissue controls. (262) 
1.4.4.1.2.3.1 SIRTuin1 and inflammation. 
 
SIRT1 might be involved in modulating the inflammatory response, The pro-inflammatory 
cytokine release is regulated through its interaction with NF-kappaB. It has been shown 
that cigarette smoke extracts decrease SIRT1 activity, reducing its interaction with 
RelA/p65 and increaseing NFκB-dependent release of pro-inflammatory mediators (263).  
1.4.4.1.2.4 Sirtuin1, Ku70 and Bax-induced apoptosis. 
 
SIRT1 plays a role in cell survival by deacetylating Ku70, a DNA repair factor which is 
induced by CR (264). Ku70 is a protein, which in humans is encoded by the XRCC6 gene. 
Together, Ku70 and Ku80 make up the Ku heterodimer, which binds to DNA double-
strand break ends and is required for the non-homologous end joining (NHEJ) pathway of 
DNA repair. The p53 apoptotic response is multifaceted, as it activates numerous pro-
apoptotic genes, including Bax, a proapoptotic member of the Bcl-2 family, whose 
localization to mitochondria triggers cytochrome c release and apoptosis and p53 up-
regulated modulator of apoptosis (PUMA), another pro-apoptotic member of the Bcl-2 
protein family. Bax is normally rendered inactive by its tight association with the Ku70 
protein, leading to sequestering of Bax in the cytoplasm. In response to acute cell damage 
or stress, Ku70 is acetylated at two lysines (K539 and K542) by the CREB-binding protein 
(CBP) and the acetyltransferase, p300/CBP-associated factor (PCAF), disrupting the 
Ku70-Bax association. The Bax protein then initiates apoptosis by re-localizing from the 
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cytoplasm to the outer mitochondrial membrane. The result is the release of cytochrome 
and downstream events including caspase activation (211, 265). SIRT1 deacetylates Ku70 
at the K539 and K542 sites. Such an action strengthens the ability of Ku70 to sequester 
Bax away from mitochondria and inhibits apoptosis mediated by Bax. 
CR induced SIRT1 expression protected embryonic kidney stem cells (293T cells) from 
Bax-induced apoptosis (142). Although the main pro-survival function of SIRT1 is 
attributed to its nuclear action, a recent study (266) showed that SIRT1 is cleaved by 
caspase during the apoptosis of N2a neuroblastoma cells, which is associated with 
increased cytoplasmic localization of SIRT1. The data suggest the possible involvement of 
cytoplasmic action of SIRT1 in cell death. The studies however did not make it clear 
whether the cleavage and increased cytoplasmic localization is a consequence of cell 
apoptosis, or a cause. It is also unclear whether the cleavage product still functions as a 
NAD+-dependent deacetylase. 
1.4.4.1.2.5 Sirtuin1, E2F1 and Retinoblastoma protein. 
 
The E2F family of transcription factors have roles in regulating cell proliferation and 
apoptosis in higher eukaryotes and their activity is controlled by the retinoblastoma protein 
(pRb) tumour suppressor during the cell cycle (267). The pRb protein has a crucial role in 
regulating the G1- to S-phase transition, and its phosphorylation by cyclin-dependent 
kinases is an established and important mechanism in controlling pRb activity. In addition, 
the targeted acetylation of lysine (K) residues 873/874 in the carboxy-terminal region of 
pRb located within a cyclin-dependent kinase-docking site impedes pRb phosphorylation 
and thereby retains pRb in an active state of growth suppression (268). Besides cell cycle 
regulation, some E2F members, particularly E2F1, also have important roles in regulating 
apoptosis. For instance, E2F1 stimulates the transcription of several genes in the apoptotic 
pathways (267) and its over-expression induces premature S-phase entry and apoptosis 
(269, 270).  Similar to ATM and p53, DNA damage results in stabilization of E2F1 thus 
inducing apoptosis. E2F1 might be involved in the apoptotic respond induced by etoposide 
(a chemotherapeutic drug clinically used for treating patients with testicular cancer, or 
small cell lung cancer) in a non-small cell lung carcinoma cell line (H1299) (219, 271). 
SIRT1 deacetylated E2F1, suppressed its transcriptional activity and pro-apoptotic function 
(219). Interestingly, there is a negative feedback loop between E2F1 and SIRT1, as E2F1 
induces SIRT1 expression, which binds to and inhibits E2F1 activity (219). Inhibition of 
SIRT1 results in an increase in E2F1-mediated apoptosis. SIRT1 may prevent E2F1-
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mediated apoptosis, thereby allowing DNA damage repair.  The interaction between 
SIRT1 and E2F1 suggest an involvement of SIRT1 in resistance to chemotherapy. 
Furthermore, pRb can also be negatively regulated by SIRT1. A recent study (272) showed 
that SIRT1 can directly interact with and deacetylate pRb, thus inactivating the growth 
suppression effect of pRB in both in vitro and in vivo.. Furthermore, the deacetylation 
action of SIRT1 on pRb was dependent on NAD and inhibited by the SIRT1inhibitor 
nicotinamide (272). 
1.4.4.1.3 Sirtuin1, growth and differentiation. 
 
Another aspect of SIRT1 controlling cellular fate could be the effect of SIRT1 on cellular 
terminal differentiation. SIRT1 has a physiological role in regulating gene expression and 
differentiation in muscles by sensing changes in the [NAD]/[NADH] ratio. SIRT1 
suppresses myoblast differentiation by deacetylating and inhibiting the transcription factor 
MyoD (209). SIRT1 is able to inhibit skeletal muscle gene expression and differentiation. 
This is achieved by SIRT1 enhancing the transcriptional repression of Hes1 and Hey2, 
members of Hairy-related protein sub-families (221). These are transcriptional repressors 
that prevent cellular differentiation (273). Finally, SIRT1 may also prevent muscle 
differentiation by associating with and deacetylating Pcaf, thereby causing an increase in 
the interaction between Hey1 and the muscle differentiation transcription factor, MyoD, 
Furthermore, SIRT1 directly represses the action of MyoD through direct interaction with 
the two MyoD regulated promoters, MHC and myogenin (213). In skeletal muscles, SIRT1 
also regulates metabolic changes through deacetylation of PGC-1a, which is required for 
activation of mitochondrial fatty acid oxidation genes (213). Increased levels of SIRT1 are 
also seen in satellite muscle cells from older animals. These muscle cells play a role in the 
regeneration and repair of damaged muscle (274). In aged rats, there is lower muscle 
satellite cell proliferation and in a study looking at the protein expression in muscle cells 
from older rats, p21, p53, SIRT1 and Foxo1 were all found to be higher than in cells from 
younger animals (229). Rather than controlling muscle cell growth, increased SIRT1 in 
older animals may reflect the cell’s attempt at limiting the p53 and Foxo-mediated 
apoptosis in muscle cells, as a result of ageing. 
SIRT1 inhibits androgen and regulates the function of the androgen receptor by 
deacetylation and transcription, thus influencing muscle mass (232, 275). It also acts as a 
major repressor of uncoupling protein-3 (Ucp-3), which plays a role in muscle cell 
protection against overload of fatty acids, lowering mitochondrial membrane potential and 
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reducing production of excessive reactive oxygen species (276). SIRT1 has also been 
shown to inhibit androgen receptor dependent cell proliferation in prostate tumour cells 
(277) 
1.4.4.1.4 Sirtuin1, Glucose and fat metabolism. 
 
Skeletal muscle is also the primary site of insulin-mediated glucose uptake and SIRT1 in 
muscle tissue may influence glucose uptake in response to food intake, fasting and 
exercise. In pancreatic β cells of transgenic mice that over-express SIRT1, there is an 
improvement in glucose tolerance and enhanced insulin secretion in response to glucose 
stimulation (225). SIRT1 does this by repressing expression of the mitochondrial 
uncoupling protein Ucp-2 (278). SIRT1 deacetylation of Foxo1 also promotes resistance to 
oxidative stress in pancreatic β cells (279). 
SIRT1 modulates hepatic gluconeogenesis and glycolysis in response to fasting. In this 
situation, SIRT1 expression increases in a Foxo3a and p53-dependent manner (247). 
SIRT1 then deacetylates and decreases the expression of the mitochondrial biogenesis co-
activator Pgc-1α, a regulator of cellular metabolism in response to fasting (226). SIRT1 
thereby induces gluconeogenic genes and glucose release and modulates Pcg-1α mediated 
repression of glycolytic genes (227). 
Genes regulating fat development and mobilisation are also under the control of SIRT1. In 
response to food deprivation, SIRT1 promotes fat mobilisation in white adipocytes by 
binding to and repressing genes controlled by the fat regulator, peroxisome proliferator-
activated receptor-γ, PPAR-γ. It does this by binding with its cofactors, nuclear receptor 
co-factor, NcoR, and the silencing mediator of retinoid and thyroid hormone receptors, 
SMRT. The result is the mobilisation of fatty acids from white adipocytes and decreased 
lipogenesis and fat storage. Over-expression of SIRT1, as well as treatment with 
resveratrol results in an increased SIRT1-mediated reduction in fat (220). 
SIRT1 also deacetylates the metabolic enzyme Acetyl Co-Synthetase 1, AceCS1, resulting 
in an increase in Acetyl-CoA synthesis from free acetate (280). Although the significance 
of this Acetyl-CoA synthesis is unclear, one of its uses may be in fat metabolism. 
1.4.4.1.5 Sirtuin1 and embryonic development.  
 
Multi-cellular organisms employ apoptosis widely during embryogenesis and have adapted 
this mechanism to rid the organism of redundant tissue during organogenesis. The 
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expression of SIRT1 is particularly high during embryogenesis. In animal studies, SIRT1 
levels were highest in early embryogenesis and, in particular, in embryonic heart and 
neural tissue. Furthermore, transgenic mice deficient in SIRT1, display cardiac and 
neurological defects (222, 223).  
SIRT1 enhances the transcriptional repression of the Hes1 and Hey2 transcription factors. 
Hes1 and SIRT1 are both expressed in neural precursor cells and the expression of both 
proteins decreases during neurogenesis (224, 281). Hes1 is thought to prevent neural 
differentiation, and therefore it may be speculated that down-regulation of both Hes1 and 
SIRT1 may be necessary for normal neural development. Hey2 is also detectable in the 
primitive ventricle during embryogenesis and is thought to regulate its morphogenesis 
(282). Here too, SIRT1 may interact with Hey2 to perform this function. SIRT1 may affect 
organogenesis by either fulfilling an anti-apoptotic function or by regulating the 
transcription of other genes that control growth and differentiation. 
1.4.4.1.6 Sirtuin1 and Axonal degeneration.  
 
Axonal degeneration is an active process and is involved in physiological and pathological 
conditions including Alzheimer’s disease, Parkinson’s disease and nerve injury (283). 
NAD and SIRT1 have been shown to prevent axonotomy-associated axonal degeneration 
(228). Treatment with sirtuin inhibitors prior to injury decreased this protection and, pre-
treatment with the SIRT1 activator resveratrol, replicated the axonal protection seen with 
NAD. 
1.4.4.1.7 Sirtuin1 and  Haematopoeisis. 
 
SIRT1 is also implicated in transcriptional repression mediated by chicken ovalbumin 
upstream promoter transcription factor (COUP-TF)-interacting protein 2, (CTIP-2) (284). 
CTIP-2 itself enhances the transcriptional repression of COUP-TF. The CTIP proteins 
were originally identified in cells of lymphoid origin and are implicated in normal 
haematopoietic cell development. Moreover, the CTIP proteins are implicated in the 
aetiology of haematopoietic malignancies. 
1.4.4.2 Mammalian Sirtuin2. 
The human sirtuin2 (SIRT2) gene is located on the long arm of chromosome 19 (Table 
1.7), and its encoded protein has a cytoplasmic localization (Figure 1.10) (140, 285). 
Human SIRT2 protein shows a NAD-dependent deacetylase activity (7, 200, 208). 
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Recently, it has been shown to deacetylate the α-tubulin subunit of microtubules (201, 
286). 
Microtubules are formed by the polymerization of α and β-tubulin units and play an 
important role in cell shape, motility, intracellular transport and cell division (287). Many 
post-translational modifications of microtubules are known to occur, including both 
acetylation and deacetylation (287, 288).  
1.4.4.2.1.1 Sirtuin2, cell cycle and mitosis. 
 
SIRT2 plays an important role in mitosis and cell cycle control. This has been suggested by 
the dramatic increase of SIRT2 within the cytoplasm during mitosis. In fact, 
hyperphosphorylated, activated, forms of SIRT2 are present only in the M phase of the cell 
cycle, at the G2/M phase transition. Over-expression of these enzymatically active forms 
of SIRT2 results in delay in cell cycle progression. It is hypothesised that deacetylation of 
acetylated microtubules in the spindle apparatus results in arrest during cytokinesis (201). 
Furthermore, the CDC14B phosphatase, released in late M phase, may act upstream of 
SIRT2 by indirectly targeting it for turnover by the 26S proteosome (286). This 
phosphatase would therefore negatively regulate the SIRT2-mediated delay in cell cycle 
progression, thereby allowing cell cycle progression. Moreover, SIRT2 also influences 
microtubule dynamics by affecting the redox potential (213). SIRT2 may therefore 
participate in a late mitotic checkpoint to ensure correct chromosome segregation during 
cytokinesis. This is a role consistent with the previously defined relationship between SIR2 
and regulation of the cell cycle in yeast (179, 182).  
SIRT2 has also been shown to interact with the homeobox transcription factor 10 
(HOXA10) suggesting a role for it in mammalian development (289). SIRT2 is expressed 
in both fetal and adult skeletal muscles, regulating the cell cycle during cell differentiation. 
Many post-translational modifications of microtubules are known to occur including both 
acetylation and deacetylation (287, 288). Finally, nucleo-cytoplasmic shuttling of SIRT2 
also occurs in response to ionising radiation suggesting a possible role for it in the DNA 
damage response (290). 
As well as controlling mitotic exit, by modulating microtubule dynamics, a putative role 
for SIRT2 in controlling intracellular transport and motility could be suggested, based 
upon SIRT2-mediated cytoskeleton control.  
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1.4.4.3 Mammalian Sirtuin3.  
The human sirtuin3 (SIRT3) gene is located on the short arm of chromosome 11.  Its 
encoded protein, SIRT3, has been shown to be located within the mitochondrial matrix 
(Figure 1.10), and shows both ADP-ribosyl transferase and NAD-dependent deacetylase 
activity (Table 1.7) (202, 203). 
SIRT3 is a major mitochondrial deacetylase in mice: SIRT3-deficient animals exhibit 
increasing levels of mitochondrial protein hyperacetylation (291). This however has no 
major impact on metabolism, as SIRT3-deficient mice are metabolically unremarkable. In 
contrast, no mitochondrial hyperacetylation was detectable in mice lacking the two other 
mitochondrial sirtuins, SIRT4 and SIRT5 (291). 
SIRT3 is initially synthesized within the cytoplasm as a inactive precursor, and transported 
to the mitochondrial matrix where it acquires its enzymatic activity through a proteolytic 
process (203). Activated SIRT3 is able to deacetylate and thereby activate the 
mitochondrial matrix protein, acetyl-CoA synthetase 2 (AceCS2). The cell requires acetyl-
CoA as an intermediate for the Krebs cycle, as well as other metabolic processes, including 
lipogenesis. Although acetyl-CoA is ordinarily produced via the enzymatic conversion of 
pyruvate, the production of acetyl-CoA by AceCS2 is particularly high during ketogenic 
conditions such as prolonged fasting, or diabetes.  
Indeed, the abundance of AceCS2 within heart and skeletal muscle under ketogenic 
conditions suggests, that SIRT3 may play an important role in AceCS2 activation and 
acetyl-CoA production (292). Substantiating this, high levels of SIRT3 expression are 
found in metabolically active tissue such as muscle, liver, kidney and heart (202). 
This mitochondrial localization of SIRT3 is intriguing for two reasons. Firstly, the 
mitochondrion is the bioenergetic and metabolic centre of eukaryotic cells. Secondly, the 
conserved family of Sir2 proteins have been postulated to be involved in sensing cellular 
energy and the redox state of the cell through their NAD-dependent activity, which links 
their functions including DNA repair, cell cycle regulation, and the control of ageing to 
cellular metabolism (2, 293, 294). However, SIRT3 might differ from other Sir2 proteins 
in its sensitivity to metabolic activity, as the level of NAD within the mitochondrial matrix 
is believed to be stable and not affected by changes in ATP level variations. This might 
ensure constitutive SIRT3 deacetylation activity (203).    
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However, an abrupt decrease in mitochondrial NAD level can result from opening of the 
mitochondrial permeability transition pore (MPTP) opening, which is caused by apoptotic 
stimuli, reactive oxygen species (ROS), or calcium elevation. This will result in inhibition 
of SIRT3 activity. MPTP opening will not only cause a rapid decrease in the NAD within 
the mitochondrial matrix, but will also produce nicotinamide, a known inhibitor of SIR2-
like protein activity, as a result of hydrolysis of NAD in the intermembrane space by 
NADase. In contrast, CR and cold exposure has been reported to be result in upregulation 
of SIRT3 in brown fat (207). 
SIRT3 might play a role in the mitochondrial apoptotic pathway. SIRT3 has been shown to 
possess a pro-apoptotic function in several cell lines (295). Both SIRT3 expression and its 
mitochondrial localization increase after Kaempferol treatment in human leukemia cells 
(296). Kaempferol (3, 4', 5, 7-tetrahydroxyflavone) is a flavonoid with anti- and pro-
oxidant activity that has anticancer properties through the induction of the apoptotic 
programme (296). This study showed that oxidative stress induced by kaempferol in 
leukemia cells lines causes the activation of the mitochondrial phase of the apoptotic 
programme with increased Bax and SIRT3, decreased Bcl-2, release of cytochrome c, 
caspase-3 activation, and cell death, suggesting a role of SIRT3 in apoptosis. 
A recent study demonstrated that SIRT3 acts as endogenous negative regulator of cardiac 
hypertrophy, and protects the heart by suppressing cellular levels of ROS. It has been 
shown that SIRT3 can protect the mouse heart by blocking the cardiac hypertrophic 
response through activation of the Foxo3a-dependent, antioxidant-encoding genes 
manganese superoxide dismutase (MnSOD) and catalase (Cat), thereby decreasing cellular 
levels of ROS (297).  
In view of the evidence presented above, SIRT3 may also act as a sensor of the redox state 
of the cell, permitting the cell to regulate metabolism, DNA repair, cell-cycle control, 
apoptosis and ageing in response to oxidative stimuli (294, 298). This possible role for 
SIRT3 is further supported by a recent study identifying SIRT3 as a novel SIRT1 protein 
interaction partner (299). 
1.4.4.4 Mammalian Sirtuin4. 
The human sirtuin4 (SIRT4) gene maps to chromosome 12 (Table 1.7). SIRT4 has been 
shown to be located within the mitochondrion (Figure 1.10). SIRT4 has NAD-dependent 
ADP-ribosyltransferase activity and has been reported to downregulate mitochondrial 
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glutamate dehydrogenase within pancreatic β cells (204). This effect of SIRT4 may be 
inhibited by CR, perhaps as a result of alterations in the NAD/NADH ratio. The resultant 
reduction in glutamate dehydrogenase represses glucose and amino acid induced insulin 
secretion. This activity is in contrast to that of SIRT1, which increases insulin secretion 
(225). SIRT1-mediated repression of UCP-2 is alleviated by acute starvation and that of 
SIRT4 on glutamate dehydrogenase is alleviated by chronic CR (204). These may reflect 
sirtuin regulation of insulin in response to varying types of nutritional stress. 
1.4.4.5 Mammalian Sirtuin5. 
The human Sirtuin5 (SIRT5) gene maps to chromosome 6 (Table 1.7). SIRT5 has been 
shown to be located within the mitochondrion (Figure 1.10). SIRT5 has NAD-dependent 
deacetylase activity. No specific function has yet been attributed to SIRT5. 
1.4.4.6 Mammalian Sirtuin6.  
The human sirtuin (SIRT6) gene is located on chromosome 19. (Table 1.7).  Its encoded 
protein, SIRT6, has been shown to be located to the nucleus (Figure 1.10), and shows both 
ADP-ribosyl tranferase and NAD-dependent deacetylase activity (Table 1.7) (7, 205, 206). 
1.4.4.6.1 Sirtuin6 and genomic stability.  
 
SIRT6 is a nuclear protein that is associated with heterochromatic regions, including 
centromeres and telomeres (200). Recently, SIRT6 has been shown to be involved in DNA 
Base Excision Repair (BER) (300), processes inherent in repairing reactive oxygen species 
(ROS)-induced DNA damage. SIRT6 was initially thought to be solely a NAD+-dependent 
ADP-ribosyltransferase (205). However, Mostoslavsky et al have demonstrated that SIRT6 
can deacetylate histones and DNA polymerase ß (DNA polß) in vitro (300). The latter is a 
protein involved in BER and is negatively regulated by acetylation via p300 (301). 
Consequently, SIRT6 has been implicated in DNA repair pathways and the maintenance of 
genomic stability in cells. Moreover, SIRT6 knockout mice, lacking a normal BER 
capacity, display numerous progeroid degenerative phenotypes, including lymphopenia, 
loss of subcutaneous fat and lordokyphosis (300). Telomeric dysfunction, with associated 
end-to-end chromosomal fusions, might also be a contributory mechanism to this 
progeroid-like phenotype, as SIRT6 has been shown recently, to also act as a histone H3 
lysine deacetylase that modulates telomeric chromatin (206). Although SIRT6-null mice 
have not been tested under food restriction conditions, the facts that SIRT6-null mice 
exhibit a severe reduction in circulating IGF-1 levels and that SIRT6 requires its enzymatic 
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activity to function suggest that it has the potential to serve as a NAD+ sensor to link 
nutrient status to genome stability (300). 
Recently, SIRT6 has been found to interact with GCIP (106). GCIP is a helix-loop helix 
leucine zipper protein that functions as a negative regulator of cell proliferation. The 
expression of GCIP is significantly down-regulated in several human tumours and it has 
been suggested that it may function as a tumour suppressor gene. Other than acting as a 
transcription repressor for cyclin D1, it is possible that GCIP could suppress 
tumourigenesis and promote DNA damage resistance through its interaction with SIRT6 
(106).  
1.4.4.6.2 Sirtuin6 and NF-κB. 
 
It has been shown that SIRT6 functions at chromatin to attenuate NF-κB signaling. SIRT6 
interacts with the NF-κB RELA subunit and deacetylates histone H3 lysine 9 (H3K9) at 
NF-κB target gene promoters (302). 
SIRT6 is recruited to these genomic loci via a physical interaction with RelA, deacetylates 
histone H3K9, destabilizes RelA from chromatin, and thereby attenuates NF-κB signalling 
by modifying chromatin at NF-κB target genes. Consistent with these data, in-vivo 
evidence of increased expression of NF-κB -dependent genes was observed in SIRT6-
deficient animals (302). 
Since sirtuins are NAD-dependent deacetylases, SIRT6 may act as a nutrient or energy 
sensor, that links NF-κB signaling to the metabolic state of the organism leading to altered 
cellular sensitivity to stress induced apoptosis. 
1.4.4.6.3 Sirtuin6 and inflammation. 
 
SIRT6 plays a role in inflammation through regulating the production of tumour 
necrotizing factor (TNF), thus linking the inflammatory response to the metabolic state of 
the cells (303). Over-expression of wild-type SIRT6, but not the catalytically inactive 
form, consistently resulted in increased TNF protein production relative to its mRNA. 
SIRT6 was the only member of the sirtuin family found to positively regulate TNF 
synthesis (303). The results of this study raised a question concerning the molecular 
mechanism underlying the observed effects of SIRT6 on TNF mRNA since only nuclear 
substrates for SIRT6 have been identified to date (206, 300). However, this study 
demonstrated that optimal TNF translation requires adequate intracellular NAD 
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concentrations, revealing a potentially crucial link between cellular metabolites and 
inflammation that might involve SIRT6 (303). 
1.4.4.7 Mammalian Sirtuin7.  
The human sirtuin7 (SIRT7) gene is located on chromosome 17. No specific enzymatic 
activity has been described for its encoded protein (127). SIRT7 also displays nucleolar 
localisation, but specifically associates with nucleolar rDNA (200, 304). SIRT7 interacts 
with RNA polymerase I (Pol 1) and histones. Overexpression of SIRT7 increases Pol 1-
mediated transcription, whereas knockdown of SIRT7, or inhibition of its catalytic activity, 
results in decreased association of Pol I with rDNA and a reduction of Pol I transcription. 
These findings suggest that SIRT7 is a positive regulator of Pol 1 transcription, which is 
required for cell viability in mammals. Decreased SIRT7 activity reduces cell proliferation 
and triggers apoptosis and increased SIRT7 expression encourages cell growth and 
prevents apoptosis (Ford et al., 2006).  
It was suggested that SIRT7 plays a role in regulating stress response and cell death in the 
heart through its SIRT7 interaction with p53. SIRT7 can efficiently deacetylate p53 in vitro 
thus decreasing the apoptotic rate in the myocardium (305). This study showed that SIRT7-
deficient mice displayed a reduction in mean and maximum lifespan and developed heart 
hypertrophy and inflammatory cardiomyopathy. SIRT7-deficient primary cardiomyocytes 
showed an increase in basal apoptosis and in sensitivity to oxidative and genotoxic stress 
(305). 
In contrast to the positive effect of SIRT7 on proliferation, another study suggested an anti-
proliferative role for SIRT7 (306). SIRT7 over-expression resulted in slowing-down of the 
growth of MEF cells and SIRT7 knockout MEFs showed a significant increase in viability 
rates in both normal and stress conditions (306). The anti-proliferative effect of SIRT7 is 
also believed to be mediated through p53, but by a distinct mechanism and with a different 
biological outcome. Previously it was shown that SIRT7 inactivates p53 through 
deacetylation, thus promoting survival (305).  This study demonstrated that SIRT7 is able 
to activate p53- and c-myc-dependent transcription thus promoting the  apoptotic response 
(306). 
Based on the known role of SIRT7 as an activator of rDNA transcription it was proposed 
that SIRT7 may enable cells to sustain critical metabolic functions by inhibiting cell 
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growth even under severe stress conditions. Thus SIRT7 expression may improve tissue 
integrity in aged animals (306). 
1.5 Sirtuins and the MTR Trinity. 
An interactive trinity controlling the detection of damage associated with ageing and the 
resultant cellular response has been postulated. The MTR trinity consists of the 
Mitochondrion, Telomere nucleo-protein complex, and Ribosome biogenesis. The 
telomere nucleo-protein complexes are part of the DNA damage detection system, the 
mitochondrion produces energy and is involved in apoptosis, and rDNA controls energy 
utilization via ribosome production while being in balance with the telomere for protein 
complex binding (2). 
 It has been suggested that Sirtuins play an important role in connecting the MTR 
components in a system that could sense and assess cellular damage and signal the 
appropriate response in the light of the current redox state (2). This was suggested by the 
various localisations of sirtuins to the three components of the MTR, and by their NAD-
dependent enzymatic activity. Sirtuin activity at the MTR allows the cell to regulate 
telomeric damage, oxidant load and protein biosynthesis. An imbalance in any one of these 
components would have a knock-on effect on the others. For example, the accumulation of 
damage over a cell’s lifespan may be associated with accumulating DNA damage and 
telomere shortening, as well as inefficiency in mitochondrial fuel utilisation, energy 
production and decreased protein biosynthesis (2). Sirtuin activity at each of these sites 
may counteract the accumulation of changes associated with the development of biological 
ageing. Indeed, accelerated ageing is the platform for the development of a number of 
pathologies, and may be associated with aberrant sirtuin expression at any of these sites 
(2). 
Sirtuins could be important determinants of the sensitivity and extent of the response to 
DNA damage. Loss of SIRT1 from the telomere results in activation of p53 (231). A 
further link to ribosomal production may be through p53 activation (controlled in part by 
SIRT1), as p53 forms a part of a complex interacting with ribosomal protein L5 and 
5SrRNA (307). Mitochondrial sirtuins such SIRT3 and SIRT4 , with their NAD-dependent 
enzymatic activity, may also act as sensors of the redox state of the cell, permitting the cell 
to regulate metabolism, DNA repair, cell-cycle control and ageing in response to oxidative 
stimuli (294, 298). SIRT6 may link the DNA damage repair and NF-κB signalling pathway 
and inflammatory response to the metabolic state of the organism,  thus altering the 
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cellular response to damage and sensitivity to stress induced apoptosis. Finally, SIRT7 
controls the transcription of RNA polymerase I, the enzyme that transcribes ribosomal 
RNA (except for 5S rRNA, which is synthesized by RNA Polymerase III) a type of RNA 
which accounts for over 50% of the total RNA synthesized in a cell (308). Therefore, 
sirtuin activity at the MTR allows the cell to regulate telomeric damage, oxidant load and 
protein biosynthesis. Alteration at any of these components would be reflected in changes 
at the others. For example, the accumulation of damage over a cell’s lifespan may be 
associated with accumulating DNA damage and telomere shortening, as well as 
inefficiency in mitochondrial fuel utilisation, energy production and decreased protein 
biosynthesis. 
Sirtuin functions at each of these MTR sites may modulate the response to the changes 
associated with biological ageing. Indeed, accelerated ageing provides the platform for the 
development of a number of pathologies, and may be associated with aberrant sirtuin 
expression at any of these sites (2).   
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1.6 Sirtuins, ageing and cancer.  
As discussed previously (1. 4), accelerated biological ageing is the most potent carcinogen. 
It is becoming increasingly apparent that molecular and sub-cellular factors considered 
critical to biological ageing and life span are also factors relevant to neoplastic 
transformation and tumour growth. There is increasing evidence for the involvement of 
sirtuins in biological ageing, along with other essential cellular processes including cell 
cycle control, DNA damage repair and differentiation. However, the involvement of 
sirtuins in these processes is complex and sometimes apparently contradictory. 
1.6.1 Sirtuin1 and ageing.  
Several studies showed that SIRT1 negatively regulates cellular senescence, raising the 
possibility that SIRT1 may promote tumour initiation through its negative effect on cellular 
senescence. SIRT1 does this by its effect on the expression of tumour suppressors.  
The level of SIRT1 protein decreases significantly with serial cell passage in both human 
lung fibroblasts and mouse embryonic fibroblasts (MFEs) This decrease was inversely 
correlated with senescence-activated β -galactosidase activity (309). Furthermore, 
restoration of SIRT1 levels was associated with the spontaneous immortalisation of these 
cells (309). Consistent with this observation, SIRT1 deacetylates p53 and negatively 
regulates the cellular senescence response to stress (231). 
In contrast, work by various groups raises the possibility that the mammalian SIRT1 may 
suppress tumour initiation by inducing the expression of tumour suppressors and cellular 
senescence. Murine SIRT1 was involved in the induction of p19ARF tumour suppressor and 
cellular senescence induced by chronic oxidative stress (310). This group showed that 
SIRT1-deficient MEF cells fail to normally up-regulate either the p19 (ARF) senescence 
regulator, or its downstream target p53. However, following acute DNA damage, or 
oncogene expression, SIRT1-deficient cells show normal p19 (ARF) induction and cell 
cycle arrest. Together, these findings demonstrate an unexpected SIRT1 function in 
promoting replicative senescence in response to chronic cellular stress and implicate p19 
(ARF) as a downstream effector in this pathway (310) 
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1.6.2 Sirtuin1 and cancer. 
The role of SIRT1 in tumourigenesis appears to be as complex as its role in ageing. 
Currently, information concerning the involvement of mammalian sirtuins in 
tumourigenesis is limited. To date, SIRT1 is not classified as an oncogene, or a tumour 
suppressor. However, a significant number of studies show that SIRT1 functionally 
interacts with tumour suppressors and oncogenes. These molecules are either substrates, or 
interacting proteins, the functions of which are regulated by the enzymatic activity of 
SIRT1 or proteins that modulate SIRT1 expression. Apparently by acting through these 
proteins, SIRT1 can have an effect on tumourigenesis.  
The cancer disease is a multiple-step process that involves initiation, growth, progression 
and finally the development of resistance to anti cancer treatments. The function of SIRT1 
could vary at different stages of this disease and has to be analyzed in a context specific 
manner.  
SIRT1 plays two different and contradictory roles in controlling cell survival. Both SIRT1 
anti-apoptotic and pro-apoptotic effects might be involved in tumourigenesis, and the 
dominating effect might differ between species and tissue, and could be dictated by the 
cellular redox state. 
1.6.2.1 Sirtuin1 and cancer promoting. 
Many studies consistently point to a role for SIRT1 in suppressing cancer cell apoptosis 
and reducing their sensitivity to agents that cause DNA damage, a role similar to that of 
yeast Sir2 in response to DNA damage (8, 167, 258). Consistent with the pro-survival 
effect of SIRT1 (262) found that SIRT1, together with other components of Polycomb 
Repressive Complex (PRC), a complex that maintain homeotic gene repression during 
development, are over-expressed in colon, breast and prostate cancers as compared to 
normal. Another recent study reported that increased SIRT1 expression is associated with a 
unique subtypes of colon cancer suggesting an involvement of SIRT1 in gene silencing in 
these subtypes of colon cancer. (311). 
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1.6.2.1.1 Sirtuin1 and p53 mediated apoptosis. 
 
Various studies showed that p53 activity was negatively regulated by SIRT1-mediated 
deacetylation (144, 146, 231, 312). Furthermore, SIRT1 deacetylases p73 and negatively 
controls p73-mediated apoptosis (232).  
In contrast to the anti-apoptotic role for SIRT1 shown in mouse MEF cells (144), loss of 
SIRT1 in both mouse fibroblasts and embryonic stem cells protects against gentoxic stress, 
in spite of an increase in p53 acetylation (222, 223). Studies with SIRT1-null mice suggest 
that SIRT1 has little effect on p53-mediated biological outcomes in mice (313, 314). It was 
also reported that the p53 activity was not altered in response to DNA damage in MEFs 
engineered so that endogenous p53 could not be acetylated, because six lysine residues 
were mutated, including lysine 379 (the mouse equivalent of human lysine 382)(315). 
1.6.2.1.2 Sirtuin1 and Foxo-mediated apoptosis. 
 
Mammalian Foxo factors are known to cause cancer cell apoptosis, cell cycle arrest and 
resistance to oxidative stress. Recent studies (316, 317) identified Foxo factors, particularly 
Foxo1a (316), as tumour suppressors. Foxo factors have also been identified as critical 
mediators for a stem cell’s ability to handle physiological level of oxidative stresses (318).  
SIRT1 was shown to deacetylate mammalian Foxo1 and Foxo3a (215, 217, 255) and the 
deacetylation was consistently found to suppress their pro-apoptotic activity. However, 
acetylation of Foxo4 by CBP was found to inhibit Foxo4 activity and deacetylation by 
SIRT1 relieved the inhibition and enhanced the expression of CDK inhibitor, p27Kip 
(256). Brunet et al ( 2004) showed that SIRT1 suppressed the induction of pro-apoptotic 
genes by Foxo3a, but enhanced the induction of genes involved in growth inhibition (e.g. 
p27 Kip1) and stress responses(215). These studies lead to the suggestion that the 
deacetylation activity of SIRT1 may suppress Foxo-induced apoptosis, but also induces the 
activation of cell cycle arresting genes and stress-resistant factors, shifting the balance 
from apoptosis to stress resistance and survival (215, 319). It is likely that SIRT1 can 
either lead to activation, or repression, of Foxo-dependent transcription depending on the 
promoters, cellular context, the external signals, or the proteins that regulate the SIRT1-
Foxo interaction (253, 255). For example, the role of SIRT1-mediated deacetylation in 
oxidative stress induced Foxo1 action in HepG2 141 and 293 138 cells, may differ from 
Foxo1 action in prostate cancer cells after stimulation with Lysophosphatidic acid (LPA), a 
potent signalling molecule that stimulates cell proliferation, which was shown to act 
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through Four and a half LIM domains protein 2 (FHL2), a molecular adaptor linking 
various signalling pathways to transcriptional regulation (255). 
It was found that SIRT1 is over-expressed in human prostate cancer cells when compared 
with normal prostate epithelial cells and in human prostate cancer tissues compared with 
adjacent normal prostate tissue (320). Furthermore, its inhibitory actions have anti-
proliferative effects in human prostate cancer cells via increasing the acetylation and 
transcriptional activation of Foxo1(320). 
1.6.2.1.3 Sirtuins1 and tumour suppressor genes. 
 
The available data suggest a reciprocal interaction between SIRT1 and tumour suppressor 
genes (TSGs). 
 
1.6.2.1.3.1 Sirtuin1 and silenced TSGs. 
 
Over-expression of SIRT1 was observed in colon, prostate, breast and lung cancers (262, 
314). The over-expression of SIRT1 in colon prostate and lung cancer tumours was 
correlated with a conserved silencing function of SIRT1 on the promoters of various 
tumour suppressor genes. SIRT1 localizes to the promoters of aberrantly silenced tumour 
suppressor genes (321). Furthermore, inhibition of SIRT1 increases the acetylation of 
histones at endogenous promoters and TSG re-expression despite full retention of promoter 
DNA hypermethylation (321). 
1.6.2.1.3.2 Sirtuin1 and Retinoblastoma protein. 
The tumourigenesis promoting effect of SIRT1 is probably due to its direct and indirect 
negative effects on the biological function of pRb tumour suppressor protein. Wong et al   
demonstrate that SIRT1 can deacetylate pRb tumour suppressor protein in vitro and in 
vivo, thus inactivating the growth suppression effect of pRB (272). The indirect effect of 
SIRT1 on pRb was suggested to be through E2F1. SIRT1 deacetylates E2F1, suppressing 
its transcriptional activity and proapoptotic function (219).   
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1.6.2.1.3.3 SIRT1 regulation by TSG. 
1.6.2.1.3.3.1 Sirtuin1, p53 and H1C1.  
 
Consistent with the increased level of SIRT1 protein in tumours, the promoter activity of 
the SIRT1 gene was found to be negatively regulated by tumour suppressors (p53 and 
DBC1). P53 has been shown to bind to the SIRT1 promoter to repress its expression (247). 
Under nutritional restriction conditions, Foxo3a is induced which binds and relieves p53-
mediated repression, allowing SIRT1 expression to increase. Because the function of p53 
is often compromised in tumours, the decreased activity may contribute to the increased 
expression of SIRT1 in tumour cells. Similar to p53, tumour suppressor HIC1 was found to 
form a transcriptional repression complex with SIRT1, which directly binds to the SIRT1 
promoter and represses its transcription. The loss of HIC1 in tumours results in increased 
SIRT1 expression and the deacetylation/inactivation of p53, allowing cells to bypass 
apoptosis and survive DNA damage (249) As discussed earlier, E2F1 increases the 
expression of SIRT1 by binding to its promoter and directly stimulating SIRT1 
transcription, which is thought to be a negative feedback mechanism to suppress E2F1-
induced apoptosis (219). 
1.6.2.1.3.3.2 Sirtuin1 and Deleted in Breast Cancer 1 (DBC1). 
 
Deleted in Breast Cancer 1 (DBC1) acts as a native inhibitor of SIRT1 activity in human 
cells and in breast cancer cell lines (250, 322). The deleted in breast cancer 1 (DBC1) gene 
was identified as a potential tumour suppressor gene that is either found hypermethylated 
or deleted in cancer (323, 324), and is associated with antiproliferative properties leading 
to cell cycle arrest in the G1 phase (325). DBC1-mediated inhibition of SIRT1 leads to 
increasing levels of p53 acetylation and up-regulation of p53-mediated function. Depletion 
of endogenous DBC1 by RNA interference (RNAi) stimulates SIRT1-mediated 
deacetylation of p53 and inhibits p53-dependent apoptosis (250, 322). 
1.6.2.1.4 Ku70 deacetylation and the suppression of Bax release into 
mitochondria by Sirtuin1.  
 
SIRT1 deacetylates Ku70 at K539 and K542 sites. Such an action strengthens the ability of 
Ku70 to sequester Bax away from mitochondria and inhibited cell death mediated by Bax. 
Bax is a pro-apoptotic member of the Bcl-2 family whose localization to mitochondria 
triggers cytochrome c release and apoptosis, as described in section 1.5.4.1.2.4. 
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1.6.2.1.5 Cytoplasmic action of SIRT1. 
 
Although, the main prosurvival function of SIRT1 is attributed to its nuclear action, a 
recent study (266) showed that SIRT1 is cleaved by caspase during the apoptosis of N2a 
neuroblastoma cells, which is associated with increased cytoplasmic localization of SIRT1. 
The data suggest the possible involvement of cytoplasmic action of SIRT1 in cell death. 
The studies, however, did not make it clear whether the cleavage and increased 
cytoplasmic localization is a consequence of cell apoptosis or a cause. It is also unclear 
whether the cleavage product still functions as a NAD+-dependent deacetylase.  
1.6.2.2 Anticancer effects of sirtuin1. 
Several studies suggest that SIRT1 may act as a tumour suppressor. MEFs derived from 
SIRT1-null mice are prone to spontaneous immortalization, suggesting that SIRT1 behaves 
as a growth-suppressive gene in culture (310). Furthermore, hematopoietic stem cells from 
SIRT1-null mice have increased proliferation potential, and shRNA knockdown of SIRT1 
in human fibroblasts accelerates cell proliferation (230, 326). Transgenic over-expression 
of SIRT1 in the intestine inhibited polyp formation in the ApcMin mice (327), whereas 
SIRT1 deficiency led to increased tumour formation in p53-null mice(328). SIRT1 has also 
been shown to inhibit androgen receptor dependent cell proliferation in prostate tumour 
cells (277). These observations suggest that SIRT1 may suppress tumour growth under 
certain conditions, and that SIRT1 activators could be used for cancer treatment or 
prevention (329). 
1.6.2.2.1 Sirtuin1 and  NF-κB. 
 
An anti-cancer effect has been observed for SIRT1, through its interaction with NF-κB, an 
important regulator of ageing-related cellular processes. Over-expression of SIRT1 in 293 
cells and small cell lung carcinoma cells sensitized the cells to apoptosis induction by 
TNFα (218).  In breast cancer SIRT1 is recruited to suppress the activity of NFκB by 
neddylated breast cancer associated protein 3 (BCA-3) (261).  
Given the known association between inflammation and tumourigenesis, a role for SIRT1 
in suppressing inflammation and tumourigenesis of the lungs has been suggested. Yang et al 
(2007) showed that cigarette smoke extracts decreases SIRT1 activity, consequently 
increasing NFκB-dependent release of pro-inflammatory mediators. 
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1.6.2.2.2 Sirtuin1, Retinoblastoma protein, and E2F1. 
 
Another anti-cancer effect for SIRT1 was observed in colon cancer. It was reported that 
SIRT1 levels were increased in normal colon mucosa and benign adenomas and decreased 
in approximately 30% of carcinomas. Furthermore, pharmacological inhibition of SIRT1 
stimulates cell proliferation under conditions of growth factor deprivation. Consistent with 
this effect, it has been found that found that elimination of SIRT1 accelerates tumour 
xenograft formation by HCT116 cells, whereas SIRT1 over expression inhibits tumour 
formation (330). Paradoxically, SIRT1 inhibition also sensitizes cells to apoptosis by 
chemotherapy drugs (330). This study suggested that pRb hyper-phosphorylation (inactive 
form), as an indirect result of SIRT1 inhibition, is probably responsible for this 
tumourigenic effect of decreased SIRT1. Decrease SIRT1 activity results in activation of 
E2F1 which can promote pRb hyper-phosphorylation indirectly through induction of 
cyclinD/cdk4 activity thus promoting pRb phosphorylation. 
This suggested pathway adds to the intricacy of the role of SIRT1 in tumourigenesis, as it 
apparently contradicts the previously mentioned effect of SIRT1 on pRb (219, 272). It has 
been reported that SIRT1 might promote cancer directly, through deacetylation of pRb that 
results in enhancing pRb phosphorylation (inactivation) (272), and indirectly, through 
deacetylation, and suppression of the E2F1 transcriptional activity and proapoptotic 
function (219).   
1.6.2.3 SIRT1 and cancer treatment.  
The involvement of sirtuins in the cancer disease process suggest that they are potential 
novel molecular targets for anticancer treatment. Consistent with the increased level of 
SIRT1 protein in tumours, SIRT1 inhibitors have been shown to exhibit anti-tumour 
activity (331).  Treatment of BCL6-expressing lymphoma cells with cambinol, an inhibitor 
of the enzymatic activity of SIRT1 and SIRT2, induces apoptosis (331). Moreover, sirtinol 
induces senescence-like growth arrest in human breast cancer MCF-7 cells and lung cancer 
H1299 cells (332). Consistent with the cancer cell specific prosurvival function, SIRT1 
expression also increases the resistance of cancer cells to therapeutic treatments with 
ionizing radiation (146), etoposide (219) or cisplatin treatment (333). In addition, the 
expression of SIRT1 was found to be increased both at the RNA and protein levels in five 
drug-resistant cell lines when compared to their drug-sensitive counterparts (334). Biopsies 
from cancer patients treated with chemotherapeutic agents also expressed high levels of 
SIRT1 but not other sirtuins. 
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Furthermore, the interaction between SIRT1 and E2F1 suggests an involvement of SIRT1 
in resistance to chemotherapy. SIRT1 deacetylates E2F1, and suppresses its transcriptional 
activity and pro-apoptotic function (219). Interestingly, there is a negative feedback loop 
between E2F1 and SIRT1, as E2F1 induces SIRT1 expression, and SIRT1 binds to and 
inhibits E2F1 activity (219). Inhibition of SIRT1 results in an increase in E2F1-mediated 
apoptosis. SIRT1 may prevent E2F1-mediated apoptosis, thereby allowing DNA damage 
repair. 
Finally, inhibition of SIRT1 reactivates the silenced tumour suppressor genes without loss 
of promoter DNA hypermethylation. This was consistent with the silencing effect of 
SIRT1 on TSGs (321). Recently, it has been reported that Salermide, a strong in vitro 
inhibitor of SIRT1 and SIRT2, has a strong cancer-specific proapoptotic effect. The pro-
apoptotic effect of Salermide is probably due to reactivation of proapoptotic genes 
repressed exclusively in cancer cells by SIRT (335). SIRT1 inhibition also sensitizes cells 
to apoptosis by chemotherapy drugs (330).  
1.6.2.3.1 Sirtuin1 and resistance to chemotherapy. 
 
Finally, a role for sirtuins was suggested in developing resistance to chemotherapy. 
Eliminating SIRT1 using the siRNA significantly reversed the resistance phenotype and 
reduced expression of the multidrug resistance molecule P-glycoprotein. Ectopic 
expression of SIRT1 induced expression of P-glycoprotein, and rendered cells resistant to 
doxorubicin. Collectively, these studies suggest that SIRT1 is a molecular target to reverse 
the resistance of cancers to chemotherapy (334). 
1.6.3 Sirtuin2, cancer progression and invasion.   
SIRT2 has a negative effect on tumour progression through its interaction with 
microtubules that are involved in mitosis and cell cycle control. SIRT2 deacetylates the α-
tubulin subunit of microtubules and delayed the progression of cell cycle and participates 
in a late mitotic checkpoint to ensure correct chromosome segregation during cytokinesis 
(201, 286, 336). Consistent with these observations, SIRT2 has been found to be down 
regulated in gliomas (336) and its ectopic expression suppresses the growth of glioma cell 
lines. Therefore, decrease in SIRT2 activity might assist DNA-damaged tumour cells in 
escaping cell cycle arrest. 
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Similarly, since SIRT2 could control the cytoskeleton, a putative negative effect of SIRT2 
on tumour invasion and metastasis could be suggested. 
1.6.4 Sirtuin3, Sirtuin4, Sirtuin5 and cancer. 
Although little is known about the functions and biological roles of SIRT3, SIRT4 or 
SIRT5, their conserved NAD-dependent enzymatic activity and their interesting 
mitochondrial localisation is suggestive of similar involvement in cell responses to various 
kinds of stress, in cell cycle progression and/or DNA repair. Similarly, it is reasonable to 
assume that these sirtuins will play a role in cancer occurrence and/or progression. 
Recently, the availability of more information regarding SIRT3 is supportive of its 
potential role in cancer disease. It was shown that SIRT3 has a pro-apoptotic function and 
might be implicated in the apoptotic mitochondrial pathway (296). Furthermore, the role of 
SIRT3 in cancer might be even more complicate by the recent study identifying SIRT3 as a 
novel SIRT1 protein interacting partners (299). 
1.6.5 Sirtuin6 and cancer. 
SIRT6 deacetylates and activates DNA polymerase ß (a protein involved in BER). Thus 
SIRT6 promotes normal DNA repair and the loss of SIRT6 leads to abnormalities in mice 
that overlaps with ageing-associated degenerative processes (300). SIRT6 also act as a 
histone H3 lysine deacetylase that modulates telomeric chromatin structure, promoting 
telomeric stability (206). Therefore, an anti-cancer role could be suggested, as loss of 
SIRT6 might predispose to cancer in the presence of cellular stress.  
SIRT6 might also be involved in preventing tumour progression. The anti cancer role for 
SIRT6 could be mediated through its negative effect on cellular proliferation resulting 
from: 
SIRT6 interaction with the NF-κB RELA subunit and deacetylates histone H3 lysine 9 
(H3K9) at NF-κB target gene promoters, consequently attenuating NF-κB signalling (302). 
This could increase cellular sensitivity to stress-induced apoptosis.  
SIRT6 interaction with GCIP (a negative regulator of proliferation) (106). The expression 
of GCIP is significantly downregulated in several human tumours and it has been 
suggested that it may function as a tumour suppressor gene. GCIP could suppress 
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tumourigenesis and promote DNA damage resistance through its interaction with SIRT6 
thus reducing the chance of developing genomic instability that might leads to cancer 
(106). Decreased expression of SIRT6 in breast cancer could therefore be an alternative 
and/or synergistic mechanism for cells to overcome the tumour suppressor effect of GCIP. 
Another possible involvement of SIRT6 in cancer disease could be related to it role 
inflammation. Recently, a role for SIRT6 in inflammation has been reported through 
regulating the production of TNF (303) and suggesting link between metabolism and 
inflammatory response. Although, it could be limited to some disease such as ulcerative 
colitis and gastritis the association between inflammation and tumorigenesis is well known. 
It has been shown that the intense of systemic inflammatory response (SIR) (indicated by 
modified Glasgow prognostic score (mGPS) that associated with cancer disease has a 
prognostic value. mGPS is calculated as follows: patients with elevated C-reactive protein 
(CRP) serum levels (>10mg/L) and hypoalbuminaemia (<35g/L) were allocated a score of 
2, patients with elevated CRP serum levels without hypoalbuminaemia were allocated a 
score of 1, patients with normal CRP serum levels with or without hypoalbuminaemia were 
allocated a score of 0. The prognostic value for the mGPS has been proven for different 
cancers such as colon, rectal, gastroesophageal, breast and lung cancers (337-341). The 
involvement of SIRT6 in inflammation could indicate a potential role for SIRT6 in 
modulating SIR and suggest a possibility of novel treatments targeting SIRT6 activity in 
order to dampen the SIR. 
1.6.6 Sirtuin7 and cancer. 
SIRT7 involvements in cancer disease is not simple in as SIRT7 has been shown to have 
both positive and  negative effect on cellular proliferation.   
SIRT7 might promote cancer through its positive effect on the transcription of RNA 
polymerase I (Pol I). Decreased SIRT7 activity reduces cell proliferation and triggers 
apoptosis, while increased SIRT7 expression encourages cell growth and prevents 
apoptosis (Ford et al., 2006). Consistent with these observations, SIRT7 expression was 
reported to be increased in both thyroid cancer cell lines and biopsies (342). Therefore a 
role in the progression of cancer could be suggested for SIRT7. 
On contrary, a negative effect for SIRT7 on cancer was suggested depending on the 
antiproliferation effect of SIRT7 (306). This study showed that increased SIRT7 is able to 
activate p53- and c-myc-dependent transcription thus promoting apoptosis (306). 
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Furthermore, decreased expression of SIRT7 was observed in murine tumourigenic cell 
lines: P19 (teratocarcinoma), NB41A3 (neuroblastoma), C3H/MCA (transformed 
fibroblast-derived cell line) as compared to the control non-tumourigenic cell line 
C3H/10T1/2 (306). Therefore, it has been suggested that decreased SIRT7 levels promote 
the cancer disease process.  
 
 
 
 
 
1.7 Aims. 
 
Breast cancer is one of the most common cancers to affect women, with over 40,000 new 
cases being detected and around 13,000 women dying from the disease in Britain each 
year. Unsurprisingly, the study of breast cancer biology is a major area in cancer research. 
Intensive efforts to define the molecular events that lead to breast cancer and to correlate 
these events with its clinical behaviour have been made in recent years. It is becoming 
increasingly apparent that molecular and sub-cellular factors considered critical to cellular 
senescence and organismal life span are also factors relevant to neoplastic transformation 
and tumour growth. Given the predicted effects of sirtuins on ageing, we hypothesise that 
aberrant sirtuin activity might be involved in the cancer disease process. Sirtuins might 
contribute both to the pathogenesis of cancer and to the response of tissue to anti-tumour 
agents. 
 
(343) 
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To test this hypothesis we decided to compare the relative transcriptional levels of sirtuin 
genes in breast cancer disease with a view to trying to associate the level of transcriptional 
expression with clinico-pathological features of the disease. Furthermore, we sought to 
investigate the relative transcriptional expression levels of sirtuin genes in breast cancer 
cell lines in response to different anti-tumour treatments. Consequently, the study has been 
divided into two main parts: 
A. An In Vivo study that aims to: 
1. Investigate the relative transcriptional expression levels of Sirtuin genes in 
three groups of breast biopsies: 
i. Normal (from breast reduction). 
ii. Non-malignant (normal tissue from mastectomy).  
iii. Malignant (malignant tissue from mastectomy). 
B.  An In Vitro study that aims to: 
1. Investigate the relative transcriptional expression levels of Sirtuin genes in 
response to adjuvant chemotherapy used in breast cancer: 
i. Investigate the relative transcriptional expression levels of Sirtuin genes in 
response to Tamoxifen in : 
1. ER positive breast cancer cell line (MCF-7). 
2. ER Negative breast cancer cell line (MDA-MB-453). 
ii. Investigate the relative transcriptional expression levels of Sirtuin genes in 
response to Docetaxel in: 
1. ER Negative breast cancer cell line (MDA-MB-231).  
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2.1 In vivo study (gene expression in breast biopsies) 
2.1.1 Breast biopsies  
Gene expression was studied in three groups of breast samples. These comprised normal 
breast biopsies (n = 26), non-malignant (n = 78) and malignant (n = 73) breast biopsies. 
Normal breast tissue samples were obtained from patients who had undergone breast 
reduction surgery (reduction mammoplasty) at the Golden Jubilee national hospital 
between 2006 and 2007. The tissue samples were stored in RNA-later (Ambion, UK)                          
at -200C. Non-malignant and malignant breast tissue samples were obtained from 
mastectomy samples following routine histopathological analysis that confirmed the 
presence or absence of malignancy in the biopsy. These operations were carried out for 
potentially curable invasive ductal carcinoma in the period between 1987 and 2000. 
Portions of tissue specimens not required for diagnosis, or staging, were snap frozen and 
stored in liquid nitrogen at Department of Surgery Western Infirmary, Glasgow. Prior 
permission for storage and future analysis of tissue samples was obtained from all patients. 
Ethical approval for this study was obtained from the local ethics committee, to use 
anonymous specimens, banked in this manner, for research purpose and to correlate these 
research findings with additional clinical parameters and outcomes, using the hospital code 
number. 
2.1.1.1 Tissue processing: 
Breast glandular tissue was carefully dissected free from surrounding fatty tissue. Then 
frozen tissues were disrupted under liquid nitrogen, using a mortar and pestle, until a 
powder was obtained. The TRIzol method of total RNA extraction was used; briefly, 1ml 
of TRIzol reagent was added per 50-100 mg of initial breast tissue and homogenised, using 
a series of decreasing gauge needles and a syringe (if required). This was then incubated 
for 10 minutes at 15 to 30°C to permit the complete dissociation of nucleoprotein 
complexes. 0.2 mls of chloroform was then added for each 1 ml of TRIzol reagent used for 
the initial homogenisation. The tubes were left at room temperature for 3 minutes. Samples 
were then centrifuged at 12,000g for 15 minutes at 4°C. The resultant aqueous phase was 
carefully removed and transferred to a fresh tube. The RNA was precipitated from the 
aqueous phase by mixing with isopropyl alcohol; 0.5 ml of isopropyl alcohol was added 
per 1ml of TRIzol reagent used for the initial homogenisation. The tubes were mixed and 
incubated at room temperature for 10 minutes, to allow RNA to precipitate before being 
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centrifuged at 12,000g, for 10 minutes at 4°C, to pellet the RNA. The supernatant was 
removed and the RNA pellet washed by adding 1ml of 75% ethanol, vortexing and 
centrifuging at 7,500g, for 5mins at 4°C. The RNA pellet was air-dried for 10 minutes and 
resuspended in nuclease-free water. Samples were incubated at 57.5°C for 10 minutes to 
enhance dissolution before being chilled on ice for 5 minutes.  
The RNA concentration and purity were determined by measuring absorbance of the 
sample at 260nm, using a GeneQuant capillary spectrophotometer (Pharmacia Biotech). 
Samples were stored at –80°C.  
Initial qualitative assessment of the RNA was tested by running 500ng of each sample on a 
1% (non-denaturing) agarose gel in TBE (Tris Borate Ethylenediaminetetracetic acid 
EDTA) containing 0.5µg/ml Ethidium Bromide and visualising under UV light (Figure 
2.1).   
 
 
 
 
 
 
 
Figure 2.1: Gel analysis of RNA extracted from breast cancer tissue. 
Arrows indicate the two bands that represent the ribosomal RNA (18S and 28S). Samples 
with degraded RNA (6), indicated by the replacement of the two clear bands with unspecific 
smear on the gel, were excluded from further analysis.  
2.1.1.2 DNase treatment: 
DNase treatment was performed using the commercially available DNA-Free Kit 
(Ambion, UK). 20 µL of RNA was added to a tube containing 2-3 units of DNase I and 0.1 
volume of 10× DNase I Reaction Buffer. The contents of the tube were mixed gently and 
         1         1        2       2        3                4       5       6         7       8 
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incubated for 30 minutes at 37°C. The DNase I was then inactivated by adding 0.1 volume 
of DNase Inactivation Reagent. The mixture was incubated for 2 minutes at room 
temperature, and then centrifuged for 1 minute to pellet the DNase Inactivation Reagent. 
The supernatant, which contains the DNase-treated RNA, was transferred to a new 0.5ml 
eppendorf tube and stored at –80°C. 
2.1.1.3 cDNA Synthesis: 
Two micrograms of DNase treated RNA was then reverse transcribed into cDNA using the 
Superscript First-strand Synthesis System (Invitrogen, UK) for reverse transcriptase PCR 
following the manufacturer’s recommendations. This part of the study was performed in 
duplicate with each sample being treated with and without the reverse transcriptase (RT) 
enzyme as a control. Random hexamer based transcription was performed for the breast 
biopsy studies and oligo dT based transcription for experiments using mammary cell lines. 
Random hexamer-based transcription has been shown to generate a more normalised 
cDNA pool from sources that may contain partially degraded RNA (Schwabe, Stein et al. 
2000). 
2.1.1.3.1  Hexamer-based RT reaction:  
 
1 µl of 10 mM dNTP mix and 2 µl hexamers were added for every 2 µg of RNA to be 
reverse transcribed. The total volume was made up to 12 µl using Nuclease-free water. The 
mixture was then incubated at 65°C for 5 minutes before being placed on ice. 4 µl of 5X 
RT Buffer, 2 µl of 0.1M DTT and finally 1 µl of the RNase inhibitor (Rnase OUT) were 
then added, bringing the total volume up to 19µl. This mixture was gently mixed then 
briefly centrifuged before being incubated at 20°C for 2 minutes. 1µl of the reverse 
transcriptase enzyme, SuperScript II, was then added, but only to those samples to be 
reverse transcribed and not to the negative controls (–RT). The total mixture was then 
incubated at 25°C for 10 minutes, at 42°C for 50 minutes, terminated at 75°C for 15 
minutes and finally chilled on ice for 5 minutes. Finally, the reactants were treated with 1 
µl of RNase at 37°C for 20 minutes. Nuclease-free water was then added to obtain a final 
concentration of 100 ng per 8 µl.  The specimens were then stored at -20°C. 
2.1.1.3.2 Oligo dT-based RT reaction: 
 
1 µl of 10 mM dNTP mix and 1 µl oligo dT was added for every 2 µg of RNA to be 
reverse transcribed. The total volume was made up to 12µl using nuclease-free water. The 
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mixture was then incubated at 60°C for 5 minutes before being placed on ice. 4 µl of 5X 
RT Buffer, 2 µl of 0.1M DTT and finally 1µl of the RNase inhibitor, RnaseOUT, were 
then added, bringing the total volume up to 19µl. This mixture was gently mixed then 
briefly centrifuged before being incubated at 42°C. 1µl of the reverse transcriptase 
enzyme, SuperScript II, was then added, but only to those samples to be reverse 
transcribed and not to the negative controls (–RT). The total mixture was then incubated at 
42°C for 50 minutes, terminated at 75°C for 15 minutes and finally chilled on ice for 5 
minutes. Finally, the reactants were treated with 1µl of RNase at 37°C for 20 minutes. 
Nuclease-free water was added to obtain a final concentration of 100ng per 8 µl.  The 
specimens were then stored at -20°C.  
2.1.1.4 Reverse Transcriptase-Polymerase Chain Reaction and Template 
validation. 
A basic Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) analysis was used to 
assess the utility of the cDNA templates using a human β-actin control primer set that has 
been designed using Primer Express (Table 2.1). 
Table 2.1: Forward and reverse primer sequences used for human β-actin Taqman. 
Gene   Forward Primer   Reverse primer 
          
β-actin   GGTCACCCACACTGTGCCCAT   GGATGCCACAGGACTCCATGC 
 
 
The RT-PCR for β-actin was performed on the breast cDNA samples using the DNA 
Engine (PTC-200, Bio–Rad) in a 50 µl reaction in 0.2 ml PCR tube.  
The mixture consisted of 12.5ng of cDNA, 1µl of 20mM forward and reverse primers 
(final concentration of 400 nM), 10 µl of 10X PCR buffer minus Mg, 1µl of 10 mM dNTP, 
1.5 µl of 50 mM Mg Cl2, 0.25 µl of Taq DNA polymerase (5U/µl), and Nuclease-free 
water to make up the reaction volume to 50 µl.  
Cycle conditions that represent the Basic PCR protocol were followed:  
 Denature:                     94°C for 3 minutes. 
 30 cycles of PCR amplification as follow  
o Denature:           94°C for 45 seconds. 
o Anneal:              61°C for 30 seconds.  
o Extend:              72°C for 1 minute and 30 seconds.  
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 Final extension:             72 °C for 10 minutes.  
 
The reaction was then maintained at 4°C until being analysed using gel electrophoresis or 
stored at -20°C.  
The reaction products were analysed by gel electrophoresis. An intact band at the expected 
size of 350 bp indicated RNA of usable quality that could be processed further for gene 
quantification using the Taqman PCR (Figure 2. 2). Only cDNA samples that produced an 
intact β-actin band were selected for subsequent gene expression studies.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Gel analysis of the RT-PCR products for β-Actin.  
The cDNA used was produced from RNA extracted from different breast cancer tissues. 
(Lanes 1 to 8) All samples showed a band at the expected size of 350 bp.  
2.1.2 Relative Quantitative Real Time PCR (Taqman). 
Relative Quantitative Real time PCR was used for cDNA quantitation analysis in order to 
monitor the mRNA expression patterns of the genes of interest. The analysis was 
performed using the ABI Prism® 7700 and 7900 Sequence Detection System.  
2.1.2.1 Basics of the Assay. 
The Real time PCR reaction exploits the 5’ nuclease activity of AmpliTaq Gold TM DNA 
polymerase to cleave a non-extendable oligonucleotide hybridisation probe (Taqman® 
probe) during the PCR reaction. The probe is labelled with a reporter fluorescein dye, 6-
 
600bp 
β-Actin 
            1        2      3     4          100bp            5     6       7      8 
      Ladder 
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carboxy-fluorescein (FAM), at the 5’ end and a quencher fluorescent dye, 6-carboxy-
tetramethyl-rhodamine (TAMRA), at the 3’ end. When the probe is intact, the reporter dye 
emission is quenched due to the physical proximity of the reporter and quencher 
fluorescent dyes. During the extension phase of the PCR cycle, the nucleolytic activity of 
the Taq DNA polymerase cleaves the hybridisation probe and releases the reporter dye 
from the probe (Figure 2. 3). With each cycle of PCR amplification there is an increase in 
fluorescence emission of the reporter which is monitored in real-time using the ABI Prism 
7700 sequence detector (Heid, Stevens et al. 1996). The 3’ end of the probe is blocked to 
prevent extension of the probe during PCR. This process occurs in every cycle and does 
not interfere with the exponential accumulation of product. Briefly, accumulation of PCR 
products is detected directly by monitoring the increase in fluorescence of the reporter dye. 
Since increase in fluorescence signal is detected only if the target sequence is 
complementary to the probe and is amplified during PCR, any non-specific amplification is 
not detected.  
The sequence detector is a combination of a thermal cycler, laser and Sequence Detecting 
system software (SDS) that automates 5’ nuclease-based detection and quantitation of 
nucleic acid sequences. Using the Taqman Universal PCR mastermix provides an internal 
reference to which the reporter dye signal is normalised during data analysis as it contains 
a passive reference dye (ROX). Normalisation is necessary in order to correct for 
fluorescent fluctuations due to changes in concentration or volume, and is achieved by 
dividing the emission intensity of the reporter dye by the emission intensity of the passive 
reference dye to obtain a ratio defined as the Rn (normalised reporter) for a given reaction 
tube. Rn+ is the Rn value of a reaction containing all components including the template. 
Rn- is the Rn value of an untreated sample. This value may be obtained from the early 
cycles of a Real Time run, prior to a detectable increase in fluorescence or from a reaction 
not containing template. Then a computer algorithm compares the two values of Rn 
generating a ΔRn value. The ΔRn value indicates the magnitude of the signal generated by 
the given set of PCR conditions and reflects the amount of hybridised probe that has been 
degraded.  
The following equation expresses the relationship of these terms: 
ΔRn =(Rn+)-(Rn-) 
Rn+= Emission intensity of reporter      (PCR with template) 
          Emission intensity of passive reference 
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Rn- = Emission intensity of reporter      (PCR without template) 
          Emission intensity of passive reference 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic representation of the steps involved in the real-time Taqman PCR 
reaction. 
 First the primers and probe anneal to the cDNA transcript. There is no fluorescence 
because the reporter dye emission is quenched. Then the primers are extended during the 
extension phase of the PCR cycle, during which the 5’-3’ exonuclease activity of the 
AmpliTaq Gold DNA Polymerase cleaves the hybridised probe and releases the reporter dye 
resulting in an increase in reporter fluorescent dye emission. Finally the primers continue to 
be extended until polymerisation of the amplicon is complete [Illustration adapted from 
Applied Biosystems Taqman Manual]. 
2.1.2.1.1 Taqman data parameters. 
The Sequence Detection System (SDS) creates quantifiable relationships between test 
samples based on the number of cycles elapsed before achieving detectable levels of 
fluorescence. For this to be achieved two parameters, Threshold and baseline, have to be 
set.  
The baseline: is the noise level in early cycles, typically measured between cycles 3 and 
15, where there is no detectable increase in fluorescence due to amplification 
products(Figure 2.4). 
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The Threshold: is adjusted to a value above the background and significantly below the 
plateau of an amplification plot. It must be placed within the linear region of the 
amplification, which is automatically determined by the computer software, and defined as 
the average standard deviation of Rn from a predefined range of PCR cycles (baseline), 
multiplied by an adjustable factor (Figure 2.4). The threshold can be adjusted manually 
provided that it lies in the linear phase of the amplification plot where the Rn value doubles 
every cycle.  
The threshold cycle (Ct): The threshold cycle (Ct) for a given amplification curve is the 
cycle number at which the fluorescence generated within a reaction well exceeds the 
defined threshold and indicates a point at which a significant increase in ΔRn is first 
detected (Figure 2.4). The fewer cycles it takes to reach a detectable level of fluorescence, 
the greater the initial copy number of the target nucleic acid. 
2.1.2.1.2 Endogenous reference gene. 
 
This is a gene whose expression level should not differ between samples, such as 
housekeeping genes. Amplification of an endogenous control/ reference gene 
(housekeeping) is vital in order to standardise the amount of cDNA added to each reaction. 
The level of expression of the housekeeping gene should be similar to that of the genes 
being investigated. Initially, two housekeeping genes 18S and Hypoxanthine Ribosyl 
Transferase (HPRT) were tested for this study. Validation experiments showed that HPRT 
is a better housekeeping gene for determining the relative levels of Sirtuin gene expression.  
Therefore, for this study the internal control gene used was Hypoxanthine Ribosyl 
Transferase (HPRT). Taqman PCR was performed using primer/probe sets simultaneously 
for both genes of interest and the housekeeping genes.  
 
Figure 2.4 
Schematic 
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representation of a real time PCR amplification.  
The threshold cycle occurs when the sequence detection application begins to detect the 
increase in signal associated with an exponential growth of PCR product. (illustration 
adopted from PE Applied Biosystems Taqman Manual).  
2.1.2.1.3 Relative gene expression calculation. 
 
 
The threshold cycle number (Ct) for both gene of interest and housekeeping gene was 
recorded for each sample. This allowed the expression of the gene of interest to be 
normalized to the endogenous housekeeping gene. This was performed by calculating the 
ΔCt Sample by subtracting the Ct value of the endogenous housekeeping gene from the Ct 
vale of the gene of interest (ΔCt Sample = Ct Gene of interest – Ct Housekeeping gene).  
The comparative Ct method, also known as the 2–ΔΔCt method (399), was used for 
calculating the relative gene expression. This involved comparing the ΔCt values of the 
samples with a control or calibrator, such as cDNA from a non-treated sample or normal 
tissue. This involves calculating the ΔΔCt, by subtracting ΔCt Calibrator from the ΔCt Sample. 
2.1.2.2 Taqman probe and primer design 
Taqman primer and probe sequences for SIRT1, SIRT2, SIRT3, SIRT7( Appendix 1), p21, 
p16, XRCC5, 18S and HPRT genes were designed de novo from sequences in the 
Genebank database using Primer Express software The sequences of the primers and probe 
for each of these genes are presented in (Table 2.2). All primer/probe sets were designed 
such that at least one of the oligonucleotides crossed an intron/exon boundary. The 
Taqman primers and the FAM-TAMRA-conjugated probe were designed using the Primer 
Express software. The software generates a list of potential probe and primer candidates 
based on default values of melting temperatures (Tms) and GC content.  
However, for successful amplifications the following requirements must be met manually:  
 The probe sequence should contain more Cs than Gs and should not have a G on 
the 5’ end. 
 Both the forward and reverse primers should not have more than two C+Gs within 
the last five bases of the 3’ end.  
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All primer/probe sets were subsequently tested by BLAST searching and in silico  
amplifying the cDNA. This was to ensure that the primers and probe did not bind other 
sequences and that primer dimers were not formed. 
Taqman primers and probes for SIRT4, SIRT5, SIRT6, BCL2, and Ki67 were purchased as 
pre-designed and validated primers and probes from Applied Biosystems UK (Table 2.3). 
 
Table 2.2: A list of the primer and probe sequences used for Taqman analysis. 
   
 
 
 
 
 
 
Table 2.3: A list of  pre designed and validated primers and probes and their manufacturer’s 
code purchased form Applied biosystems. 
 
 
  
 
 
2.1.2.3 Primer and probe  concentration optimisation for real time PCR. 
The primer and probe concentration need to be optimised in order to achieve a satisfactory 
amplification. The purpose of this optimisation experiment is to determine the minimum 
Gene   Manufacturer’s code 
      
SIRT4 HS00202033_m1 
SIRT5 HS00229729_m1 
SIRT6 HS00213036_m1 
KI67 HS00606991_m1 
BCL2 
  
  
  
  
  HS00153350_m1 
  Forward Primer    Reverse Primer    Taqman™  Probe  Gene 
  (5’-3’)   (5’-3’)    (5’ FAM – TAMRA 3’) 
              
SIRT1   TAGAGCCTCACATGCAAGCTCTA   GCCAATCATAAGATGTTGCTGAAC   ACTCCAAGGCCACGGATAGGTCCATATACTT 
SIRT2   CCTCGCCTGCTCATCAACA   TCCTCCGAGGCCCATAATC   TGGCCAGTCGGACCCTTTCCTG 
SIRT3   CATTCGGGCTGACGTGATG   AACCACATGCAGCAAGAACCT   TGCACCGGCGTTGTGAAGCC 
SIRT7   CGTCCGGAACGCCAAATAC   GACGCTGCCGTGCTGATT   TGGTCGTCTACACAGGC 
p21   GCAGACCAGCATGACAGATTTCTA   GCGGATTAGGGCTTCCTCTT   CACTCCAAACGCCGGCTGATCTTC 
p16   CATAGATGCCGCGGAAGT   CCCGAGGTTTCTCAGAGCCT   CCTCAGACATCCCCGATTGAAAGAACC 
HPRT   CTTGCTCGAGATGTGATGAAGG   CAGCAGGTCAGCAAAGAATTTATAG   ATCACATTGTAGCCCTCTGTGTGCTCAAGG 
XRCC5   TTGATTTGCTGGAGGACATTGA    TCCATGCTCACGATTAGTGCAT    CAACCAGGTTCTCAACAGGCTGACTTCC  
18 S   ACCTGGTTGATCCTGCCAGTAG    AGCCATTCGCAGTTTCACTGTAC   TCAAAGATTAAGCCATGCATGTCTAAGTACGCAC 
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50 nM fwd / 50 nM rev 50 nM fwd / 300 nM rev 50 nM fwd / 900 nM rev
300 nM fwd / 50 nM rev 300 nM fwd / 300 nM rev 300 nM fwd / 900 nM rev
900 nM fwd / 50 nM rev 900 nM fwd / 300 nM rev 900 nM fwd / 900 nM rev
primer/probe concentrations that produce the maximum fluorescent signal and the smallest 
Ct number. For that purpose Taqman real time PCR reactions were initially performed with   
50 ng cDNA template, 200nM probe concentration, and different combinations of forward 
(Fwd) and reverse (Rev) primer concentrations as shown on the (Table 2. 4): 
Table 2.4: Combinations of forward and reverse primer final concentrations used in probe, 
primer concentration optimisation experiments for Real time PCR. 
 
 
 
This experiment was performed for SIRT1, SIRT2, SIRT3, SIRT7 only as SIRT4, SIRT5, 
SIRT6, KI67 and BCL2 had been already optimised by the company and their final 
concentration in the PCR reaction is 900 nM for both primers and 225 nM for probe per 
well. This experiment indicated that the optimal combination of primer concentrations for 
the quantitative amplification of SIRT1, SIRT2 and SIRT3 was 900 nM fwd/ 900 nM rev. 
However, the combination of 300 nM fwd / 900 nM rev proved to be most efficient for 
amplifying SIRT7 using the real time PCR.  
The combination of primer concentrations of (300 nM fwd / 300 nM rev) was used for 
quantitative amplification of p16, p21, and XRCC5. This has been adopted from previous 
optimisation experiments performed in our laboratory. 
Using the pre-determined optimal primer concentrations, another experiment was 
performed to determine the optimal probe concentration using the following 
concentrations: 125 nM, 150 nM, 175nM, 200 nM, 225 nM, and 250 nM. The result of this 
experiment indicated that a probe concentration of 225 nM was the optimal concentration 
for SIRT1, SIRT2, SIRT3, and SIRT 7. A probe concentration of 200 nM was used for 
p16, p21, and XRCC5 as recommended from previous experimental results performed in 
our laboratory. 
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2.1.2.4 Taqman cDNA amplification reaction  
Relative Quantitative Real time PCR was performed in 96-well plates using a 25 µl 
reaction. The mixture was prepared in triplicate according to the following recipe:  
12.5 µl of 2X Taqman Universal PCR Mastermix    
1 µl 5 -5.62µM probe    Final concentration of (200- 225 nM)  
1.5 µl 5-15 µM Forward primer   Final concentration of  (300 -900 nM) 
1.5 µl 5-15 µM Reverse primer  Final concentration of  (300- 900 nM) 
8 µl cDNA      Final concentration of  (25-50 ng) 
H20 (Nuclease free water) to 25 µl 
The concentration of primers and probe were used according to the optimisation 
experiment (see above).  
1.25µl of primer and probes mix was used for quantitative amplification of SIRT4, SIRT5, 
SIRT6 and BCL2, and Ki67 according to the manufacturer’s instructions. This produces  
final concentrations of 900 nM fwd / 900 nM rev for the primers and 225 nM for the probe. 
Cycle conditions that represent the Basic Real time PCR protocol were 50°C for 2 minutes, 
followed by 95°C for 10 minutes followed by 50 cycles of 95°C for 15 seconds and 60°C 
for 1 minute. 
No Amplification Control (NAC) or No Template Control (NTC) were always included in 
each real time PCR run.  
2.1.2.5 Primer and probe validation experiment.  
For the ΔΔCt calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference housekeeping gene must be approximately equal. This can be 
established by looking at how ΔCt Sample varies with template dilution. If the gradient of 
cDNA dilution versus ΔCt Sample is close to zero (<0.1) (343) it implies that the 
amplification efficiencies of the target and housekeeping genes are similar.  
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The validation experiments were performed using a 1 in 2 serial dilution for the input 
template (cDNA). Seven dilutions were performed ranging from 100ng to 1.56 ng. At least 
five dilution points were used for future analysis. The same breast biopsy was used to 
perform the validation experiment for all genes of interest. Two housekeeping genes (18S 
rRNA and HPRT) were tested for this study (Results 3.1). 
2.2 In Vitro Studies 
Different types of immortalized tumourogenic human mammary cell lines (MCF-7, MDA-
MB-453 and MDA-MB-231) were used in this study as described below. These cell lines 
were obtained form American Tissue Culture Collection ATCC / European Collection of 
Cell Cultures ECACC). These cell lines represented both ER positive and negative breast 
cancers, and expressed varying degrees of the tyrosine kinase receptors; epidermal growth 
factor receptor HER 2. (Table 2.5) shows the ER and RTK status, growth properties and 
morphology of the cell lines used. 
2.2.1 Culturing the breast cancer cell lines.  
MCF-7, MDA-MB-453 and MDA-MB-231 cells were grown in Dulbecco's Modified 
Eagle Medium (DMEM) (Lonza) with 4.5 g/L glucose. Growth media were supplemented 
with heat-inactivated foetal calf serum (10%) (Invitrogen), 2 mM L-glutamine (Invitrogen) 
and penicillin/streptomycin (50 units/ml, 50 µg/ml) (Invitrogen, UK). Cells were 
maintained in 5% CO2 at 37°C, with their medium changed regularly; they were grown in 
T-75 flasks (Fisher Scientific, UK). 
Table 2.5: ER & HER status of breast cancer cell lines. Three breast cancer lines were used 
in the course of this research: - MCF-7, MDA-MB-231 and MDA-MB-453. 
 
 
 
2.2.2 Trypsinisation of Cells. 
Cells were routinely passaged to prevent cells becoming over-confluent and forming 
clumps. In order to split the growing cells either for passaging and/or seeding for the 
        Cell Line  
Growth 
properties  Morphology  
ER 
Status  
HER2 
Status 
                  
MCF-7   Adherent   Epithelial   +   + 
MDA-MB-231   Adherent   Epithelial   -   -  
MDA-MB-453   Adherent   Epithelial   -   + 
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subsequent experiment, old medium was removed from the flasks and the cells washed 
with warmed Hank’s Balanced Salt Solution (HBSS) without Ca+2, Mg+2 and phenol red 
(Lonza). Then Trypsin EDTA  (Lonza) was added to the flask (3mls Trypsin per T-75 
flask). Cells were incubated with trypsin for 3-5 minutes in 5% CO2, 37°C, in order to 
detach the cells from the flask. Once cells were no longer adherent, twice the volume of 
growth medium was added to inactivate trypsin. Cells were gently pipetted up and down to 
dislodge any cell clumps that may have formed to produce a single cell suspension to allow 
for an accurate cell count using a haemocytometer. Having counted the number of cells 
present within the suspension cells were seeded into new flasks containing 10mls of new 
DMEM at the required density, depending on the cell line being used and the experiment.   
2.2.3 Establishing frozen cell stocks. 
Having trypsinised the cells, aliquots of the cells could be stored for future use. The cell 
suspension was transferred from the flask to a 25 ml centrifuge tube and centrifuged at 
1200 rpm for ten minutes to form a cell pellet. The medium was removed and the pellet 
resuspended gently in 1 ml of appropriate medium containing 10% of Dimethyl sulfoxide 
(DMSO) (Sigma, UK). The cell suspension was immediately transferred to a 1.8 ml 
polypropylene cryo-vial and placed at -80°C overnight before being transferred to liquid 
nitrogen (-180°C) for long-term storage.  
 
If these cell aliquots were required at a later date, they were removed from liquid nitrogen 
and rapidly thawed in a 37°C water bath. Cell clumps were dispersed by pipetting and 
were transferred to a flask containing 10mls of pre-warmed growing medium.  
2.2.4 Immunofluorescence (IF) technique.   
Immunofluorescence (IF) is a technique that permits the detection of a specific protein or 
antigen in cells or tissue sections by fluorescent visualisation. As with 
immunohistochemistry, there are two types of immunofluorescence staining methods, 
direct and indirect immunofluorescence.  
The first requires using a primary antibody labelled with fluorescent dye, whereas the 
indirect approach involves the use of a fluorescent secondary antibody specific for 
immunoglobulin of the species in which the primary antibody was raised. The protein of 
interest is then visualised using a fluorescent microscope. This indirect method was used to 
investigate the expression of ER in breast cancer cell lines.  
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Approximately 3000 MCF-7 or MDA-MB-231 or MDA-MB-453 cells were seeded onto 6 
well culture slides (VWR) and grown for three days. On day 4, serum and phenol-red free 
medium was removed and cells washed twice with ice-cold PBS, before being fixed to the 
culture slides by incubation in ice-cold methanol (500 µl of methanol per well) for three 
minutes. Excess methanol was removed by washing the cells three times in dH20 for five 
minutes. To reduce non-specific binding of the antibody, cells were incubated in 500 µl of 
1.5% normal horse serum ((Vector Laboratories, CA, USA)) in antibody diluent (DAKO) 
for twenty minutes. As of this point all steps were performed on an orbital shaker and at 
room temperature. 
Cells were incubated with ERα (0.2 mg/ml, DAKO) antibody for 1 hour (100 µl of 
antibody per well) before being washed three times with TBS for ten minutes. Following 
this, cells were incubated with 100µl biotinylated mouse secondary antibody (3 µg/ml in 
antibody diluent) (Vector Laboratories) for thirty minutes. Cells were again washed three 
times with TBS for ten minutes, before being treated with 100 µl of Fluorescein Avidin D 
(diluted 1:100 in TBS) (Vector Laboratories) for thirty minutes. Fluorescein Avidin D has 
an excitation at 495 nm and an emission at about 515 nm; therefore treated cells fluoresced 
green. Once the cells were treated with the fluorescent protein, slides were covered in foil 
and all future steps performed in semi-darkness, to prevent the fluorescence from fading. 
Finally cells were washed with TBS three times for ten minutes. At this stage culture slides 
were either mounted onto coverslips, or the procedure continued to enable detection of a 
second protein. 
2.2.5 Protein extraction and Western blotting.  
2.2.5.1 Protein Extraction 
Protein was extracted from growing cells after the trypsinisation step. From this point 
onwards all treated tubes were kept on ice. The cell pellet was dislodged by gently pipetted 
up and down in the ice-cold PBS. Then the cells were centrifuged at 1200 rpm for 5 
minutes to form a cell pellet again. This step was repeated three times to remove any trace 
of growth medium proteins. It was important to remove as much of the PBS after washing, 
using a pipette, since it would dilute the lysis buffer. The next step involved lysing the cells 
to enable collection of the protein. This was done using cell lysis buffer (Cell Signaling 
Technology) and a non-denaturing method. The buffer used was comprised of the 
following: 20 mM Tris-HCl (pH 7.5), 150mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM sodium 
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orthovanadate (Na3VO4), and 1µg/ml leupeptin. Directly before use, this buffer was diluted 
ten times in dH20 and 1 mM phenylmethlysulfonyl fluoride (PMSF), a serine protease 
inhibitor, added. This prepared buffer was stored on ice at all times. 500 µl of buffer was 
added to each 25 ml centrifuge tube and cells were incubated in the buffer on ice for five 
minutes. The cell lysate was transferred to an appropriately labelled 1.5 ml eppendorf tube 
and stored on ice or at -20°C. 
2.2.5.2 Determination of protein concentration in prepared samples. 
Before performing immunoblotting, it was necessary to determine the concentration of 
protein present in the samples to be tested. Knowing this enabled experimental 
consistency, as the same volume of protein was used from all the samples. The method 
used was Bio-Rad's protein assay, which was based on the Bradford dye-binding procedure 
(Bradford 1976), and involves a colorimetric assay for measuring total protein 
concentration. For detailed explanation see appendix 2. 
2.2.5.3 Western blotting technique. 
Western blotting (immunoblotting) is a technique that enables the detection and 
quantification of the levels of a specific protein in tissue or cell samples. The basic 
principle requires preparing protein samples from tissues or cells and then separating the 
denatured proteins by gel electrophoresis using a polyacrylamide gel and transferring them 
to a PVDF (polyvinylidene difluoride) membrane. The membrane is then probed with a 
primary antibody specific to the protein of interest, followed by a secondary antibody that 
recognises the antibody-antigen complex. Proteins are detected using a chemiluminescent 
method.  
Proteins from MCF-7, MDA-MB 231and MDA-MB-453 cells were resolved by 10% SDS-
PAGE at 40mA for 1 hour and transferred to PVDF membrane overnight at 10V. The 
membrane was treated with 5% Non-Fat Dry Milk/ in TTBS (Tris Buffered Saline-Tween) 
for 1 hour and incubated with primary antibody (ERα, 0.2 µg/ml, DAKO, Glostrup, 
Denmark) or (Tubulin 1:1000 Cell Signalling Technology, Rabbit) overnight at 4oC. 
Membranes were incubated in appropriate secondary antibody for 1 hour, anti-mouse IgG 
(CST, 1:10000) for ERα or and anti-Rabbit IgG (CST, 1:5000) for tubulin and visualised 
using ECL Plus chemiluminescent Western blotting detection reagent (Amersham 
Biosciences, Buckinghamshire, UK), and detected on autoradiography film.  
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To avoid re-running of samples, primary antibody was removed from probed membranes 
using Restore Western Blot Stripping Buffer (Pierce). Membranes were incubated in 20 
mls of stripping buffer at 37°C for 15 minutes, before being washed in TTBS three times 
for 10 minutes. Consequently, membranes were blocked in 5% Non-Fat Dry Milk/TTBS 
and then probed with the next primary and secondary antibody as described above.  
2.2.6 Cell Proliferation Assay WST-1. 
Cellular proliferation, after the different treatments used in this thesis, was determined 
using a non-radioactive, spectrophotometric quantification of cell proliferation and 
viability, by the WST-1 assay. The WST-1 assay depends on the cleavage of the 
tetrazolium salt WST-1, to formazan, by mitochondrial dehydrogenases. An expansion in 
the number of viable cells results in an increase in the overall activity of mitochondrial 
dehydrogenases in the sample. This augmentation in enzyme activity leads to an increase 
in the amount of formazan dye produced, which correlates directly to the number of 
metabolically active cells in the culture.  
The formazan dye produced by the proliferating cells was measured at an absorbance of 
450 nm by spectrophotometry (Multiskan EX, Thermo, Electron Coporation). A reference 
reading of an absorbance at wavelength of 600nm was subtracted from the reading for each 
well.  
10 µL of cell proliferation reagent WST-1 (Roche) was added per well, to the cells already 
cultured in 100 µL per well (1 in 10 final dilution). Readings were normalized  to a blank 
control that has no growing cells and contains all reagents. Control wells that contain 
untreated experimental cells were included in every experimental plate. 
Cell proliferation was measured in relation to an untreated control that represents 100% 
proliferation at the selected time point as per the following equation  
Cell proliferation  %  =              Absorbance reading for tested cells                            X 100 
                  Absorbance reading for untreated control 
The optimal incubation period was determined after measuring the absorption repeatedly, 
at different time points of incubation following the addition of WST-1 (0.5, 1, 2 and 4 hrs). 
4 hrs proved to be the optimal incubation period that was associated with higher 
absorbance reading (Figure 2.5). 
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Figure 2.5: Optimal incubation period for WST assay. 
The MDA-MB-231 cells were treated with different concentration of Docetaxel for 72 hours. 
Absorbance (A450nm-A650nm) was measured repeatedly at different time point of incubation 
after adding the WST-1 (0.5, 1, 2 and 4 hrs). Higher reading was associated with 4hrs of 
incubation and has been considered as an optimal incubation period. 
 
2.3 Methodology of the drug experiments. 
2.3.1 Docetaxel. 
Docetaxel is a taxane based anti-cancer agent and part of a relatively new anticancer drugs 
group. These are classified as mitotic poisons that are commonly used as cytotoxic agents 
in treating metastatic and locally advanced breast cancers, especially ER–ve tumours. It 
binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization 
of the mitotic spindle thus leading to cell cycle arrest and apoptosis. 
Since treatment with Docetaxel is mainly indicated in patients with advanced ER-ve breast 
cancers, an established ER–ve mammary cancer cell line (MDA-MB-231) was selected for 
this experiment. 
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Docetaxel (C43 H53 NO14, Molecular weight 807.88 g) was purchased from Sigma-
Aldrich, UK. An initial solution of 5mM Docetaxel was prepared in 100% DMSO and 
stored at 2-8°C, from which a stock solution of 50µM was prepared in (1% DMSO/ 99% 
HBSS) and stored at 2-8°C. The latter was used to prepare all other concentrations of 
Docetaxel in the appropriate growth media. 
2.3.1.1 MDA-MB-231 cell number titration.   
First a cell number titration experiment was performed to determine the optimal number of 
MDA-MB-231 cells to be seeded per well in the 96-well plate for this experiment. MDA-
MB-231 cells were seeded at four different numbers per well  (2500, 5000, 7500, and 
10000) for three different time periods of 3, 4, and 5 days. The experiment with the MDA-
MB-231 cells involves 3 days of incubation with Docetaxel. In order to prepare for a future 
study of the response of Sirtuin genes to Tamoxifen in the MDA-MB-231 cells, the cells 
were also incubated for 4 and 5 days. The data showed that a cell number of between 2500 
and 5000 was the best for a 3-day incubation period. Therefore in the following 
experiments, the number of MDA-MB-231 cells to be seeded was selected depending on 
the incubation period in the 96-well plate, (Results (5. 2. 2. 1). 
2.3.1.2 Optimisation of Docetaxel concentration and treatment period. 
The MDA-MB-231 cells were treated with 1nM, 10nM and 100nM Docetaxel. These three 
concentrations were decided upon following an experiment investigating the effects of 
various concentrations (0.5 nM, 1 nM, 2 nM, 5 nM 10 nM, 20 nM, 50 nM, 100 nM, 1000 
nM) of Docetaxel on cellular proliferation. 1 nM, 10 nM and 100 nM were shown to be the 
optimal concentrations for the purpose of our studies, (Results (5. 2. 2. 2). 
The MDA MB 231 cells were treated with Docetaxel for 72 hrs. This time was decided 
upon following an experiment investigating the effects of four different time points 24 hrs, 
48 hrs, 72 hrs and 96 hrs) (Results (5. 2. 2. 3).The concentration of the DMSO was 
adjusted to be the same in all Docetaxel concentrations: 0.002%. 
In each experiment a DMSO-only control was included which was used as a “Calibrator” 
for determining relative gene expression. 
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2.3.2 Tamoxifen.  
Tamoxifen is commonly used for the treatment of both early and advanced Oestrogen 
Receptor positive (ER+ve) breast cancers, in pre- and post-menopausal women. Tamoxifen 
is a nonsteroidal agent, with potent antioestrogenic properties, which competes with 
oestrogen for binding sites in breast tumour and other tissue targets. TAM is believed to 
inhibit the growth of breast cancer mainly through competing with oestrogen for oestrogen 
receptor binding. 
Tamoxifen citrate (C26H29NO · C6H8O7, Molecular weight 563.6 g) was purchased from 
Sigma-Aldrich. A stock solution of 10 mM Tamoxifen was prepared in 100% DMSO and 
stored at 2-8°C. This was used to prepare all other concentrations of Tamoxifen in the 
appropriate growth media. 
Two different types of immortalized tumourogenic human mammary cell lines (MCF7, and 
MDA-MB-453) were used in this study as described below. The MCF7 cells were selected 
as they represent an established ER+ve mammary cancer cell line. The MDA-MB-453 cells 
were selected as they represent an established ER–ve mammary cancer cell line that 
resembles the MCF7 cells in HER2 status (Table 2.3).  
 
2.3.2.1 MCF7 cell number titration.   
A cell titration experiment was performed first to determine the optimal number of MCF7 
cells to be seeded per well in the 96-well plate for this experiment. MCF7 cells were 
seeded at three different numbers per well (5000, 10000, and 15000 for three different time 
periods of 3, 4, and 5 days. The experiment with the MCF7 cells involve a maximum of 5 
days incubation in the 96-well plate; 2 days in oestrogen free media and then a maximum 
of three days with the drug. The data showed that cell numbers between 5000 and 10000 
were the best for 5 days incubation period in the 96-well plate Therefore in the following 
experiments, the number of MCF7 cells to be seeded was selected depending on the 
incubation period in the 96-well plate (Results (5. 3. 2. 1). 
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2.3.2.2  Optimisation of Tamoxifen concentration and treatment period in the 
MCF7 cell line. 
The MCF7 cells were treated with 5 µM, 8 µM and 10 µM Tamoxifen. These three 
concentrations were decided upon following an experiment investigating the effects of 
various concentrations (2 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 µM and 12 µM 
of Tamoxifen on cellular proliferation. 5µM, 8µM and 10µM were shown to be the 
optimal concentrations for the purpose of our studies (Results (5. 3. 2. 2). 
The MCF7 cells were treated with Tamoxifen for 72hrs. This time was decided upon 
following an experiment investigating the effects of four different time points 24hrs, 48hrs, 
72hrs and 96hrs) (Results (5. 3. 2. 3). 
2.3.2.3 MDA-MB-453 cell number titration.   
A cell titration experiment was performed first to determine the optimal number of MDA-
MB-453 cells to be seeded per well in the 96-well plate for this experiment. MDA-MB-453 
cells were seeded at four different numbers per well (5000, 10000, 15000 and 20000 for 
three different time periods of 3, 4, and 5 days. The experiment with the MDA-MB-453 
cells involve a maximum of 5 days incubation in the 96-well plate; 2 days in oestrogen-
free media and then a maximum of three days with the drug. The data showed that cell 
number equal to 5000 was the best for 5 days incubation period in the 96-well plate. 
Therefore in the following experiments, the number of MDA-MB-453 cells to be seeded 
was decided depending on the incubation period in the 96-well plate Optimisation of 
Tamoxifen concentration and treatment period in the MDA-MB-453 cell line. 
The MDA-MB-453 cells were treated with 5 µM, 8 µM and 10 µM Tamoxifen. These 
three concentrations were decided upon following an experiment investigating the effects 
of various concentrations (2 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 µM and 12 
µM of Tamoxifen on cellular proliferation. 5 µM, 8 µM and 10 µM were shown to be the 
optimal concentrations for the purpose of our studies (Results (5. 4. 2. 2). 
The MDA-MB-453 cells were treated with Tamoxifen for 72 hrs. This time was decided 
upon following an experiment investigating the effects of four different time points 24hrs, 
48hrs, 72hrs and 96hrs) (Results (5. 4. 2. 2). 
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2.3.3 Tamoxifen treatment: experimental design. 
All experiments were carried out in duplicate using the same cell preparation, media and 
treatments in parallel.  
In all Tamoxifen experiments cell lines were treated as follows: 
 Cells were incubated in phenol-free media supplemented with 5% charcoal stripped 
foetal calf serum for 48h before being treated with Tamoxifen for the tested period 
to eliminate the effect of oestrogen on cellular growth. 
 Cells treated for 72 hours using the three selected concentrations of Tamoxifen, in 
phenol-free media supplemented with 5% charcoal stripped fetal calf serum and 
1nM β-estradiol (Sigma Aldrich, uk) . 
 The concentration of the DMSO was adjusted to be the same in all experiments: 
0.1%. 
 In each experiment a DMSO-only control was included which was used as a 
“Calibrator” for determining relative gene expression. 
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3.1 Establishment of Real time PCR procedure.  
 
3.1.1 Primer and probe validation experiment. 
For the ΔΔCt calculation to be valid, the amplification efficiencies of the target and the 
endogenous reference housekeeping gene must be approximately equal. This can be 
established by looking at how ΔCt Sample varies with template dilution. The ΔCT value was 
plotted against the logarithm (Log) of the template amount. If the efficiencies in generating 
the two amplicons are approximately equal, the slope value of the plot will be 
approximately zero. The recommended value for the slope of log input amount vs. ΔCT is 
< 0.1 (343). 
The validation experiments were performed using a 1 in 2 serial dilution for the input 
template (cDNA). Seven dilutions were performed ranging from 100 ng to 1.56 ng. At 
least five dilution points were used for future analysis. The same breast biopsy was used to 
perform the validation experiment for all genes of interest. Two housekeeping genes,18S 
rRNA (18S) and HPRT, were tested for this study. 
 
3.1.1.1 Validation experiments of SIRT4, SIRT5, and SIRT6 primers and 
probes in relation to 18S rRNA. 
The validation experiments were performed first for SIRT4, SIRT5 and SIRT6 primers and 
probes in relation to the 18S housekeeping gene (Figure 3.1). The slope values for SIRT4, 
SIRT5 and SIRT6 in relation to 18S were much greater than 0.1: 0.38, 0.42 and 0.73, 
respectively (Figure 3.1). These data indicated that the 18S was not suitable as a 
housekeeping gene for this experiments. Further analysis for the remaining Sirtuin genes in 
relation to the 18S housekeeping gene was not performed. 
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Figure 3.1: Validation experiments for SIRT4, SIRT5 and SIRT6 primers and probes in 
relation to the 18S housekeeping gene.  
Graphs show the variation of ΔCt value for SIRT4, SIRT5 and SIRT6 in relation to a 18S 
housekeeping gene when template input changes. The x axis represents the log10 of the 
input amount of cDNA, whereas the y axis represents the ΔCt value. It is important for the 2-
ΔΔ
Ct method to be valid, to confirm that the amplification efficiencies are equal for both gene 
of interest and housekeeping gene in the range of template input used. This is confirmed 
when the slope value is less than 0.1. 
 
3.1.1.2 Validation experiments of sirtuin primers and probes in relation to 
HPRT. 
 The ΔCt values for all sirtuin primers and probes in relation to HPRT as the internal 
reference gene were acceptable when the amount of input cDNA was between 100 ng and 
12.5 ng (Figure 3.2). The slope values of: 0.05 for SIRT1, 0.003 for SIRT2, 0.095 for 
SIRT3, 0.008 for SIRT4, 0.081 for SIRT5, 0.063 for SIRT6 and 0.052 for SIRT7 were 
indicative of equal efficiencies in generating the two amplicons using these sets of primers 
and probes for the gene of interest (sirtuin) and housekeeping gene (HPRT) compared 
together in the tested range of  input cDNA ( Figure 3. 2).  
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Figure 3.2: Validation experiments for sirtuin primers and probes in relation to the HPRT 
housekeeping gene.  
Graphs show the variation of ΔCt value for sirtuins in relation to a HPRT housekeeping gene 
when template input changes. The x axis represents the log10 of the input amount of cDNA, 
whereas the y axis represents the ΔCt value. It is important for the 2-ΔΔCt method to be valid, 
to confirm that the amplification efficiencies are equal for both gene of interest and 
housekeeping gene in the range of template input used. This is confirmed when the slope 
value is less than 0.1.  
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3.1.1.3 Validation experiments of XRCC5, p21, BCL2 and KI67 primers and 
probes in relation to HPRT. 
The ΔCt values for XRCC5, p21, BCl2, KI67 primers and probes in relation to HPRT were 
acceptable when the amount of input cDNA was between 100 ng and 12.5 ng. The slope 
values of: 0.081 for XRCC5, 0.007 for p21, 0.064 for BCL2, and 0.009 for KI67 were 
indicative of equal efficiencies in generating the two amplicons using these sets of 
primers/probes for XRCC5, p21, BCl2, KI67 and the housekeeping gene (HPRT) 
compared together in the tested range of input cDNA (Figure 3.3).  
 
 
 
 
 
 
 
 
   
 
Figure 3.3: Validation experiments for XRCC5, p21, BCl2, and KI67 primers and probes in 
relation to the HPRT housekeeping gene.  
Graphs show the variation of ΔCt value for sirtuins in relation to a HPRT housekeeping gene 
when template input changes. The x axis represents the log10 of the input amount of cDNA, 
whereas the y axis represents the ΔCt value. It is important for the 2-ΔΔCt method to be valid, 
to confirm that the amplification efficiencies are equal for both gene of interest and 
housekeeping gene in the range of template input used. This is confirmed when the slope 
value is less than 0.1. 
3.1.2 Conclusion. 
Two housekeeping genes (18S rRNA and HPRT) were tested for this study. The validation 
experiment results indicate that HPRT is a better housekeeping gene for determining the 
relative transcriptional expression of all sirtuin, BCL2, Ki67, XRCC5 and p21 genes under 
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these experimental conditions. Therefore, HPRT was selected as a housekeeping gene and 
a template input between 25 ng-50 ng was used for the subsequent Taqman experiments. 
3.2 Introduction. 
In this experiment the relative transcriptional expression of sirtuins 1-7 was investigated, 
by Real time PCR technique in a sample of archival breast biopsies, obtained from 177 
women. These comprised normal breast biopsies (n = 25) from patients undergoing breast 
reduction surgery (reduction mammoplasty), non-malignant (n = 78) and malignant (n = 
73) breast biopsies, obtained after routine histopathological analysis from patients who had 
undergone breast surgery for potentially curable, invasive ductal adenocarcinomas, 
between 1987 and 2000.  
This study aimed to investigate whether the relative transcriptional expression for sirtuins 
1-7 was altered in breast tumour biopsies when compared to both the normal and non-
malignant biopsies. Furthermore, it sought to determine if there were any associations 
between sirtuin expression levels, clinico-pathalogical features of the disease, including 
histopathological parameters (tumour size, tumour grade, nodal status and oestrogen 
receptor status and lymph-vascular invasion) and patient’s outcome. 
 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
134 
3.3 Characteristics of the studied patient cohorts. 
3.3.1 Age distribution in the patient cohorts. 
Age was normally distributed in all patient groups (normal, non-malignant and malignant; 
Figure 3.4). The median age was 41.6 years (20 years – 63 years) for the normal group, 
61years (32 years - 84 years) for the non-malignant group and 61 years (33 years - 94 
years) for the malignant group (Figure 3. 5). Pairwise comparisons of the three groups 
using the Mann-Whitney test showed that there was no significant difference in age 
between the non-malignant and malignant groups (p = 0.223). However, age in the normal 
group was significantly different from the age in both non-malignant and malignant groups 
(p < 0.001; Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Distribution of patient’s age in the three different groups. 
(a) patient’s age in the entire patient cohort, (b) patient’s age for the normal breast biopsy 
group, (c) patient’s age for the non-malignant breast biopsy group, (d) patient’s age in for 
the malignant breast biopsy group. 
 
  
 
 
 
(a) (b) 
(c) (d) 
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Figure 3.5: Box plot showing patient’s age in normal, non-malignant and malignant breast 
biopsy groups. 
The median value for each patient group is shown in the clear box to the right of each box 
plot. 
3.3.2 Survival according to the known prognostic markers. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to the known prognostic markers; namely tumour grade (G), tumour size (T), 
nodal status (N-ve and N+ve), oestrogen receptor status (ER-ve and ER+ve), Lymphovascular 
invasion status (LV-ve and LV+ve) and Nottingham Prognostic Index (NPI). Patient numbers 
included in each patient group are displayed in (Table 3.1). Furthermore, Cox-Regression 
analysis was calculated for all known prognostic markers and is shown in (Table 3.1). 
Table 3.1: Number of breast cancer patients and cancer specific deaths of all patient groups 
included in the Kaplan-Meier survival analysis according to the known prognostic markers. 
 p values for both Kaplan-Meier and Cox-Regression analyses are also shown.  
G1 G2 G3 T1 T2 T3 T4 N-ve N+ve ER-ve ER+ve LV-ve LV+ve <3.4 3.4-5.4 >5.4
Patients Number 4 30 31 10 45 13 2 20 43 21 32 19 28 3 37 19
Number of Cancer 
specific deaths 1 10 9 3 10 6 1 2 17 7 10 5 7 0 10 9
Cox Regression p p = 0.996 p = 0.003p = 0.909 p = 0.111 p = 0.01 p = 0.834
p = 0.833 p = 0.99 P = 0.015p = 0.013Kaplan-Meier p p = 0.893
p = 0.072 p = 0.003
Prognostic  factors in breast cancer
Tumour Grade (G) Tumour size (T) Nodal ER status LV status NPI
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
136 
3.3.2.1 Survival analysis according to tumour grade. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to tumour grade (G). Patient numbers included in each patient group are 
displayed in (Table 3. 1). The Kaplan-Meier test showed that there was no significant 
difference in the survival period when patients were categorised according to tumour 
grade. The mean survival period was different in patients with G1 tumours (n = 4, 12.79 
years, 95% C.I. 9.73 -15.85), when compared with both patients with G2 tumours  (n = 30, 
10.83 years, 95% C.I. 8.86 -12.78) and with G3 tumours (n = 31, 10.94 years, 95% C.I. 
8.71 -13.17). However, this difference was not significant (Kaplan-Meier, p=0.893, Figure 
3. 6). 
 
 
 
 
 
 
Figure 3.6: Kaplan-Meier survival plot for breast cancer patients according to tumour grade.  
The Kaplan-Meier survival analysis showed that there was no significant difference in the 
mean survival period in patients with G1 tumours (n = 4, 12.79 years, 95% C.I. 9.73 -15.85), 
when compared with both patients with G2 tumours (n = 30, 10.83 years, 95% C.I. 8.86 -
12.78) and with G3 tumours (n = 31, 10.94 years, 95% C.I. 8.71 -13.17; p=0.893). 
 
3.3.2.2 Survival analysis according to tumour size. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to tumour size (T). Patient numbers included in each patient group are displayed 
in Table 3.2. The Kaplan-Meier test showed that there was no significant difference, but a 
strong trend (p = 0.072,) in the survival period when patients were categorised according to 
tumour size (Figure 3. 7). The mean survival period was shorter in patients with larger 
tumour size T3 (n = 13, 8.28 years, 95% C.I. 4.75 -11.82), and T4 (n = 2, 8.16 years), 
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when compared with patients with smaller tumour size T1 (n = 10, 10.27 years, 95% C.I. 
6.49 -14.04) and with T2 tumours (n = 45, 12.19 years, 95% C.I. 10.69 -13.7).  
 
 
 
 
 
 
Figure 3.7: Kaplan-Meier Survival plot for breast cancer patients according to tumour size.  
The Kaplan-Meier test showed that there there was no significant difference (p = 0.072) in 
the survival period when patients were categorised according to tumour size. The mean 
survival period was shorter in patients with larger tumour size T3 (n = 13, 8.28 years, 95% 
C.I. 4.75 -11.82), and T4 (n = 2, 8.16 years), when compared with patients with smaller 
tumour size T1 (n = 9, 10.27 years, 95% C.I. 6.49 -14.04) and with T2 tumours (n = 45, 12.19 
years, 95% C.I. 10.69 -13.7).  
 
As can be seen from Table 3.1 there are very few patients in both the T1 and T4 groups, 
and this could explain the previous result (trend toward significance only). Therefore, 
patients were divided into two groups; those with small tumours (T1 and T2) and those 
with large tumours (T3 and T4). The Kaplan-Meier test showed that the mean survival 
period was significantly shorter in patients with large tumours (n = 15, 8.13 years, 95% 
C.I. 10.48 -13.34) when compared with those with small tumours (n = 54, 11.91 years, 
95% C.I. 10.49 -11.36, Kaplan-Meier, p = 0.013, Figure 3. 8). Furthermore, Cox 
Regression analysis of the Hazard Ratio (HR) showed that patients with large tumours was 
1.11 times (95% CI 1.20 – 7.7, p =0.013) more likely to die as a consequence of the breast 
cancer disease when compared to patients with small tumours. 
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Figure 3.8: Kaplan-Meier Survival plot for breast cancer patients according to tumour size.  
Patients were divided into two groups; a) patients with small tumours, T1 and T2 combined; 
b) patients with large tumours, T3 and T4 combined. The Kaplan-Meier test showed that the 
mean survival period was significantly shorter in patients with large tumours (n = 15, 8.13 
years, 95% C.I. 10.48 -13.34) when compared with those with small tumours (n = 54, 11.91 
years, 95% C.I. 10.49 -11.36, Kaplan-Meier, p=0.013).  
 
3.3.2.3 Survival analysis according to nodal status. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to nodal status (N-ve and N+ve). Patient numbers included in each patient group 
are displayed in (Table 3.1). The Kaplan-Meier test showed that there was a significant 
difference in the survival period when patients were categorised according to nodal status 
(Figure 3.9). The mean survival period was shorter in patients with node positive tumours 
(n = 43, 9.32 years, 95% C.I. 7.38 -11.26) when compared with those with node negative 
tumours (n = 20, 14.18 years, 95% C.I. 13.13 -15.24, Kaplan-Meier p = 0.003). 
Furthermore, Cox Regression (Hazard Ratio) analysis showed that the relative risk of death 
was almost two times more (1.94) in patients with node positive tumours (95% CI 1.6 – 30, 
p=0.01) when compared with patients with node negative tumours. 
 
 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
139 
 
 
 
 
 
 
 
Figure 3.9: Kaplan-Meier Survival plot for breast cancer patients according to nodal status.  
The Kaplan-Meier test showed that there was significant difference in the survival period 
when patients were categorised according to nodal status.The mean survival period was 
shorter in patients with node positive tumours (n = 43, 9.32 years, 95% C.I. 7.38 -11.26) when 
compared with those with node negative tumours (n = 20, 14.18 years, 95% C.I. 13.13 -15.24, 
Kaplan-Meier p = 0.003).  
 
3.3.2.4 Survival analysis according to oestrogen receptor status.  
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to oestrogen receptor status (ER-ve and ER+ve). The oestrogen receptor status was 
determined according to immunohistochemistry staining, performed as part of 
histopathological examination of the surgically removed tumours. Patient numbers 
included in each patient group are displayed in (Table 3.1). The Kaplan-Meier test showed 
that there was no significant difference in the survival period in patients with ER-ve 
tumours (n = 21, 10.74 years, 95% C.I. 8.17 – 13.31) when compared with those with 
ER+ve tumours (n = 32, 10.51 years, 95% C.I. 8.39 -112.64, p = 0.833, Figure 3.10). 
3.3.2.5 Survival analysis according to lymphovascular invasion status. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to lymphovascular invasion status (LV-ve and LV+ve). Patient numbers included 
in each patient group are displayed in (Table 3.1). The Kaplan-Meier test showed that there 
was no significant difference in the mean survival period in patients with LV-ve tumours (n 
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= 19, 11.66 years, 95% C.I. 9.24 – 14.09) when compared with those with LV+ve tumours 
(n = 28, 11.52 years, 95% C.I. 9.32 -13.73, p = 0.99, Figure 3.11). 
 
 
 
 
 
 
Figure 3.10: Kaplan-Meier survival plot for breast cancer patients according to oestrogen 
receptor status.  
The Kaplan-Meier test showed that there was no significant difference in the survival period 
in patients with ER-ve tumours (n = 21, 10.74 years, 95% C.I. 8.17 – 13.31) when compared 
with those with ER+ve tumours (n = 32, 10.51 years, 95% C.I. 8.39 -112.64, Kaplan-Meier p = 
0.833). 
 
 
 
 
 
 
 
Figure 3.11: Kaplan-Meier survival plot for breast cancer patients according to  
lymphovascular invasion status.  
The Kaplan-Meier test showed that there was no significant difference in the mean survival 
period in patients with LV-ve tumours (n = 19, 11.66 years, 95% C.I. 9.24 – 14.09) when 
compared with those with LV+ve tumours (n = 28, 11.52 years, 95% C.I. 9.32 -13.73, Kaplan-
Meier p = 0.99). 
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3.3.2.6 Survival analysis according to the NPI. 
The Kaplan-Meier test was used to analyse the survival data for the entire patient group 
according to the NPI. Patient numbers included in each patient group are displayed in 
(Table 3.1). The Kaplan-Meier test showed that there was a significant difference in the 
survival period when patients were categorised according to the NPI (p = 0.015; Figure 
3.12). The mean survival period was significantly shorter in patients with high NPI (NPI 
>5.4) (n = 19, 7.9 years, 95% C.I. 4.48 -10.93) when compared with those with moderate 
NPI (NPI 3.4 - 5.4) (n = 37, 11.97 years, 95% C.I. 10.37-13.56, p = 0.015). The mean 
survival period could not be calculated for patients with low NPI (NPI < 3.4) because of 
the small number of patients and lack of complete (15 years) follow up data. Cox 
Regression (Hazard ratio) analysis showed that the relative risks of death in patients with 
high NPI was 1.25 times more (95% CI 1.47 – 8.24, p=0.004) when compared with 
patients with moderate NPI. 
 
 
 
 
 
 
 
Figure 3.12: Kaplan-Meier Survival plot for breast cancer patients according to the NPI. 
The Kaplan-Meier test showed that the mean survival period was significantly shorter in 
patients with high NPI (NPI >5.4) (n = 19, 7.9 years, 95% C.I. 4.48 -10.93) when compared with 
those with moderate NPI (NPI 3.4 - 5.4) (n = 37, 11.97 years, 95% C.I. 10.37-13.56, Kaplan-
Meier p = 0.015).  
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3.3.3 Recurrence according to the known prognostic markers. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to the known prognostic markers; namely tumour grade (G), tumour size (T), 
nodal status (N-ve and N+ve), oestrogen receptor status (ER-ve and ER+ve), Lymphovascular 
invasion status (LV-ve and LV+ve) and Nottingham Prognostic Index (NPI). Patient numbers 
included in each patient group are displayed in (Table 3.2). Furthermore, Cox-Regression 
analysis was calculated for all known prognostic markers and is shown in (Table 3.2) 
Table 3.2 : Number of breast cancer patients and tumour recurrences of all patient groups 
included in the Kaplan-Meier recurrence analysis according to the known prognostic 
markers. 
p values for both Kaplan-Meier and Cox-Regression analyses are also shown.  
 
3.3.3.1 Recurrence analysis according to tumour grade. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to tumour grade (G). Patient numbers included in each patient group are 
displayed in (Table 3.2). The Kaplan-Meier test showed that there was no significant 
difference in time to recurrence (p = 0.398) in patients with G1 tumours (n = 4, 8.87 years, 
95% C.I. 2.67 -15.07), when compared with both patients with G2 tumours (n = 30, 10.57 
years, 95% C.I. 9.94 -13.04) and with G3 tumours (n = 31, 12.04 years, 95% C.I. 9.94 -
14.13, Figure 3.13).  
 
 
G1 G2 G3 T1 T2 T3 T4 N-ve N+ve ER-ve ER+ve LV-ve LV+ve <3.4 3.4-5.4 >5.4
Patients Number 4 30 31 10 44 13 2 20 43 20 32 19 27 3 37 19
Number of Cancer 
recurrences 2 10 6 3 12 3 1 2 16 6 11 4 5 0 13 4
P=0.64Cox Regression p p = 0.180 P=0.017
p =0.006p = 0.708p = 0.637 p = 0.604p = 0.771p = 0.637
P=0.639P=0.853 P=0.772 p=0.441
Kaplan-Meier p p = 0.398
Prognostic  factors in breast cancer
Tumour Grade (G) Tumour size (T) Nodal ER status LV status NPI
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Figure 3.13: Kaplan-Meier recurrence plot for breast cancer patients according to tumour 
grade.  
The Kaplan-Meier test showed that time to recurrence was non-significantly different  
(p = 0.398) in patients with G1 tumours (n = 4, 8.87 years, 95% C.I. 2.67 -15.07), when 
compared with both patients with G2 tumours (n = 30, 10.57 years, 95% C.I. 9.94 -13.04) and 
with G3 tumours (n = 31, 12.04 years, 95% C.I. 9.94 -14.13). 
 
3.3.3.2 Recurrence analysis according to tumour size. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to tumour size (T). Patient numbers included in each patient group are displayed 
in (Table 3.2). The Kaplan-Meier test showed that there was no significant difference in 
the time to recurrence between patients with small tumour size T1 (n = 10, 9.72 years, 95% 
C.I. 5.28 -14.16) and T2 (n = 44, 11.53 years, 95% C.I. 9.69 -13.36) when compared with 
patients with larger tumour size T3 (n = 13, 10.45 years, 95% C.I. 6.29 -14.6), and T4 (n = 
2, 5.66 years Kaplan-Meier p = 0.708, Figure 3.14). 
A similar non-significant result was obtained after dividing the patients into two groups; 
patients with small tumours (T1 and T2) and patients with large tumours (T3 and T4) 
(Table 3.2). The Kaplan-Meier test showed that the time to recurrence was non-
significantly shorter in patients with large tumours (n = 15, 9.71 years, 95% C.I. 5.82 -
13.6) when compared with those with small tumours (n = 54, 11.25 years, 95% C.I. 9.53 -
12.9, Kaplan-Meier, p=0.637, Figure 3.15).  
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Figure 3.14: Kaplan-Meier recurrence plot for breast cancer patients according to tumour 
size.  
Recurrence plot analysis showed that there was no significant difference in the time to 
recurrence between patients with small tumour size T1 (n = 9, 9.72 years, 95% C.I. 5.28 -
14.16) and T2 (n = 45, 11.53 years, 95% C.I. 9.69 -13.36) when compared with patients with 
larger tumour size T3 (n = 13, 10.45 years, 95% C.I. 6.29 -14.6), and T4 (n = 2, 5.66 years 
Kaplan-Meier p = 0.708). 
 
 
 
 
 
 
 
Figure 3.15: Kaplan-Meier recurrence plot for breast cancer patients according to tumour 
size.  
Patients were divided into two groups; a) patients with small tumours,T1 and T2 combined; 
b) patients with large tumours, T3 and T4 combined. The Kaplan-Meier test showed that the 
time to recurrence was non-significantly shorter in patients with large tumours (n = 15, 9.71 
years, 95% C.I. 5.82 -13.6) when compared with those with small tumours (n = 54, 11.35 
years, 95% C.I. 9.53 -12.97, Kaplan-Meier, p = 0.637). 
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3.3.3.3 Recurrence analysis according to nodal status. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to nodal status (N-ve and N+ve). Patient numbers included in each patient group 
are displayed in (Table 3.2). The Kaplan-Meier test showed that the mean time to 
recurrence was significantly shorter in patients with node positive tumours (n = 43, 9.28 
years, 95% C.I. 7.03-11.52) when compared with those with node negative tumours (n = 
20, 13.83 years, 95% C.I. 12.31 -15.35, p = 0.006, Figure 3.16). Furthermore, Cox 
Regression (Hazard Ratio) analysis showed that the relative risk of recurrence was 1.8 
times more (95% CI 1.58 – 28.49, p = 0.017) in patients with node positive tumours when 
compared with patients with node negative tumours. 
 
 
 
 
 
 
Figure 3.16: Kaplan-Meier recurrence plot for breast cancer patients according to nodal 
status.  
The Kaplan-Meier test showed that the mean time to recurrence was significantly shorter in 
patients with node positive tumours (n = 43, 9.28 years, 95% C.I. 7.03-11.52) when compared 
with those with node negative tumours (n = 20, 13.83years, 95% C.I. 12.31 -15.35, p = 0.006). 
3.3.3.4 Recurrence analysis according to oestrogen receptor status.  
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to oestrogen receptor status (ER-ve and ER+ve). Patient numbers included in each 
patient group are displayed in (Table 3.2). The Kaplan-Meier test showed that the mean 
time to recurrence was not significantly shorter in patients with ER+ve tumours (n = 32, 
9.74 years, 95% C.I. 7.33 – 12.15.) when compared with those with ER-ve tumours (n = 20, 
10.68 years, 95% C.I. 7.85 -13.51, p = 0.637, Figure 3.17). 
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Figure 3.17: Kaplan-Meier recurrence plot for breast cancer patients according to oestrogen 
receptor status.  
The Kaplan-Meier test showed that the mean time to recurrence was not significantly 
shorter in patients with ER+ve tumours (n = 32, 9.74 years, 95% C.I. 7.33 – 12.15.) when 
compared with those with ER-ve tumours (n = 20, 10.68 years, 95% C.I. 7.85 -13.51, p = 0.637). 
3.3.3.5 Recurrence analysis according to lymphovascular invasion status. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to lymphovasacular invasion status (LV-ve and LV+ve). Patient numbers included 
in each patient group are displayed in (Table 3.2). The Kaplan-Meier test showed that there 
was no significant difference in the mean time to recurrence in patients with LV-ve tumours 
(n = 19, 11.61 years, 95% C.I. 8.73 – 14.49) when compared with those with LV+ve 
tumours (n = 27, 12.79 years, 95% C.I. 10.59 -14.99, p = 0.771, Figure 3.18). 
 
 
 
 
 
Figure 3.18: Kaplan-Meier recurrence plot for breast cancer patients according to 
lymphovasacular invasion status. 
The Kaplan-Meier test showed that there was no significant difference in the mean time to 
recurrence in patients with LV-ve tumours (n = 19, 11.61 years, 95% C.I. 8.73 – 14.49) when 
compared with those with LV+ve tumours (n = 27, 12.79 years, 95% C.I. 10.59 -14.99, p = 
0.771). 
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3.3.3.6 Recurrence analysis according to the NPI. 
The Kaplan-Meier test was used to analyse the recurrence data for the entire patient group 
according to the Nottingham Prognostic Index (NPI). Patient numbers included in each 
patient group are displayed in (Table 3.1). The Kaplan-Meier test showed that there was no 
significant difference in the time to recurrence when patients were categorised according to 
NPI (Figure 3.19, p = 0.604). The mean time to recurrence was (11.14 years, 95% C.I. 8.0 
-14.27) in patients with high NPI (NPI >5.4) (n = 19) and (10.58 years, 95% C.I. 8.46-
12.7) in those with moderate NPI (NPI 3.4 - 5.4) (n = 37). The mean time to recurrence 
could not be calculated in patients with low NPI (NPI < 3.4) because of the small number 
of patients and lack of complete (15 years) follow up data. 
 
 
 
 
 
 
 
Figure 3.19: Kaplan-Meier recurrence plot for breast cancer patients according to the NPI. 
The Kaplan-Meier test showed that there was no significant difference in the time to 
recurrence in patients with high NPI (NPI >5.4)  (n = 19, 11.14 years, 95% C.I. 8.0 -14.27) 
when compared with those with moderate NPI (NPI 3.4 - 5.4)  (n = 36, 10.58 years, 95% C.I. 
8.46-12.7; p = 0.604). 
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3.4 The relative transcriptional expression levels of 
SIRT1 in breast biopsies  
3.4.1 The relative transcriptional expression levels of SIRT1 and 
patients age. 
The relative transcriptional expression levels of SIRT1 gene were determined in (25) 
normal, (76) non-malignant and (72) malignant biopsies (Table 3.3).  
Table 3.3 Patient biopsies used in the SIRT1 study. 
The correlation between the relative level of SIRT1 gene expression and patient’s age was 
investigated in a patient group that combined both normal and non-malignant patients. This 
group of patient represents “normal” breast tissue that derives from a wide range of 
patient’s ages with a normal distribution (Figure 3.20a).  The median age of this patient 
group was 51years (20 years - 84 years).  These data showed that there was a marginally 
significant correlation between increasing chronological age and decreasing relative 
transcriptional levels of SIRT1 (Spearman's rank correlation coefficient; p = 0.059; Figure 
3.20b).  
 
 
 
 
Figure 3.20: (a) Distribution of patient’s age in a patient group that combines both normal 
and non-malignant patients. (b) Correlation between relative transcription levels of SIRT1 
and patient’s age in a patient group that combines both normal and non-malignant patients 
(Spearman test, p = 0.059). 
 
(a) (b) 
N Percent N Percent N Percent
Normal 25 96.20% 1 3.80% 26 100.00%
Non-Malignant 76 97.40% 2 2.60% 78 100.00%
Malignant 72 98.60% 1 1.40% 73 100.00%
Relative SIRT1 
Expression
Sample Type
Cases
Valid Missing Total
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
149 
 
3.4.2 Data distribution of the relative transcriptional expression 
levels of SIRT1. 
The distribution of the relative transcriptional gene expression of SIRT1 was investigated 
in the three different studied biopsy groups, (Figure 3. 21). The histograms of the 
distribution of the relative transcriptional gene expression of SIRT1 showed that the range 
of the SIRT1 gene expression values was not normally distributed; instead the SIRT1 gene 
expression distribution was positively skewed in all patient groups (Figure 3. 21). 
Therefore, non-parametric statistical tests were used to analyse all the data for the relative 
transcriptional gene expression of SIRT1.  
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Distribution of the relative transcriptional gene expression of SIRT1 in three 
different patient groups. 
(a) Relative transcriptional gene expression of SIRT1 in normal breast biopsies, (b) Relative 
transcriptional gene expression of SIRT1 in non-malignant breast biopsies, (c) Relative 
transcriptional gene expression of SIRT1 in malignant breast biopsies. 
  
 
(a) (b) 
(c)  
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3.4.3 Comparison of the relative transcriptional expression levels 
of SIRT1 between patient groups. 
The level of SIRT1 relative transcriptional expression was compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT1 was significantly different between the three groups of breast biopsies 
(p<0.001, Figure 3. 22). This experiment showed that malignant samples had significantly 
lower levels of SIRT1 gene expression compared to both non-malignant and normal 
samples (p<0.001, Figure 3. 22). 
 
 
 
 
 
 
Figure 3.22. Box plot showing the transcriptional expression of SIRT1 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown in the clear box to the right of each box 
plot, (p < 0.001). 
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3.6.) 
showed that all three groups differed significantly in SIRT1 gene expression: Malignant 
versus non-malignant p < 0.001, malignant versus normal; p < 0.001 and malignant versus 
non-malignant p < 0.001. 
3.4.4 Comparison of the relative transcriptional expression levels 
of SIRT1 according to histopathological markers 
The relationships between SIRT1 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
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3.4.4.1 Comparison of the relative transcriptional expression levels of SIRT1 
according to tumour grades. 
Analysis of the data for the relationship between SIRT1 gene expression and tumour grade 
showed a significant difference in the relative transcriptional expression levels of SIRT1 
between all tumour grades when compared together (Kruskal-Wallis test p = 0.018) 
(Figure 3. 23). The expression of SIRT1 decreases with increasing severity (higher grade) 
of tumour. 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3.6) showed 
that grade 1 tumours groups differed significantly in SIRT1 gene expression from both 
grade 2 (p = 0.004) and grade 3 tumours (p = 0.005), whereas there was no significant 
difference between grade 2 and grade 3 tumours (p = 0.130) (Figure 3. 23). 
 
 
 
 
 
Figure 3.23: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by tumour grade. 
n = 4 for grade 1, 32 for grade 2 and 29 for grade 3 (Kruskal Wallis Test, p = 0.018). The 
median value for each patient group is shown in the clear box to the right of each box plot. 
 
3.4.4.2 Comparison of the relative transcriptional expression levels of SIRT1 
according to tumour size, nodal status, oestrogen receptor status 
and lymphovascular invasion 
Analysis of the data for the relationship between SIRT1 gene expression and tumour size, 
nodal status, oestrogen receptor status and lymphovascular invasion, showed no significant 
differences in the relative transcriptional expression levels of SIRT1 between any 
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categories when compared together (Figure 3. 24 a, b, c, and d). Table 3.6 shows the 
Kruskal-Wallis or Mann Whitney p values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Box plots showing the relative transcriptional expression of SIRT1 in breast 
cancer biopsies by known prognostic markers: 
(a) tumour size, n = 11 for T1, 44 for T2, 14 for T3 and 2 for T4 (Kruskal Wallis Test, p=0.312) 
(b) nodal status, n = 20 for node –ve and 43 for node +ve Mann Whitney test p = 0.652, (c) 
oestrogen receptor status, n  = 20 for ER-ve and 32 for ER+ve (Mann Whitney test p = 0.183. (d) 
lymphovascular invasion (LVI) n = 18 for LV–ve and 28 for LV+ve (Mann Whitney test p = 
0.584).  The median value for each patient group is shown right of each box plot. 
3.4.5 The relationship of the relative transcriptional expression 
levels of SIRT1 in breast cancer biopsies to patient survival 
and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT1 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT1 gene expression. In analyses shown below, the two tertiles with lower SIRT1 
gene expression have been combined and are compared to the highest level of SIRT1 gene 
expression tertile group. Table 3.4 and Table 3.5 show the numbers of patients included in 
each group. 
(a) 
(c)  (d) 
(b) 
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Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT1 gene 
expression 45 12 25 5 18 5
High SIRT1 gene 
expression 24 9 11 5 14 5
Overall 69 21 36 10 32 17
SIRT1 Tertile
All breast cancer patients Breast cancer patients with ER+ve
Breast cancer patients with NPI 
between 3.4-5.4
Importantly, this data can be influenced by two key parameters: 
 Some patients have clinical criteria that give a very poor prognosis and such 
patients are likely to die before any differences, due to genetic influences, are 
detectable.  
 Patients with clinically accepted very good prognosis are unlikely to provide useful 
data.  
The data, therefore, were also analysed after focusing on that patient group with an 
intermediate clinical prognosis, identified using the NPI (Material and Methods) 
Specifically, patients with NPI values between 3.4 and 5.4 were included in this analysis. 
 In addition, patients were classified for analysis by oestrogen receptor status, because this 
is considered to be an important clinically prognostic factor, but this is not included in the 
Nottingham Prognostic Index. 
3.4.5.1 SIRT1 and survival.  
3.4.5.1.1 Survival analysis in entire patient cohort according to SIRT1 levels.  
 
Analysis of the survival data for the entire patient group (Table 3.4) using the Kaplan-
Meier test showed that the survival period was non-significantly shorter in patients with 
tumours that express high levels of SIRT1 (n = 24, 9.83 years, 95% C.I. 7.6 -12.06) when 
compared to those whose tumours express low levels of SIRT1 (n = 45, 11.47 years, 95% 
C.I. 9.77 -13.17, Kaplan-Meier p = 0.235; Figure 3. 25). 
Table 3.4: Number of breast cancer patient and cancer specific deaths of all patient groups 
included in the Kaplan-Meier survival analysis.  
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Figure 3.25:  Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT1 expression. 
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a non significant decrease in the survival period for 
patients with tumours that express high levels SIRT1 (n=24, 9.83 years, 95% C.I. 7.6 -12.06) 
when compared to those whose tumours express low levels of SIRT1 (n=45, 11.47 years, 
95% C.I. 9.77 -13.17, Kaplan-Meier p=0.235). 
 
 
 
 
 
 
 
Figure 3.26: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT1 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4).  
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a significant decrease in the survival period for 
patients with tumours that express high levels SIRT1 (n = 11, 9.10 years, 95% C.I. 6.6-12.15) 
when compared to those whose tumours express low levels of SIRT1 (n = 25, 12.85 years, 
95% C.I. 11.11 -14.58, Kaplan-Meier p = 0.03). 
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3.4.5.1.2 Survival analysis in NPI selected patients according to SIRT1 levels.  
 
Analysis of the survival data in patients with moderately good prognosis (NPI between 3.4-
5.4, Table 3.4) demonstrated that survival period was significantly shorter in patients with 
tumours that expressed high levels of SIRT1 (n = 11, 9.10 years, 95% C.I. 6.6-12.15) when 
compared to those whose tumours express low levels of SIRT1 (n = 25, 12.85 years, 95% 
C.I. 11.11 -14.58, Kaplan-Meier p = 0.03; Figure 3. 26). 
3.4.5.1.3 Survival analysis in ER+ve selected patients according to SIRT1 levels. 
 
Analysis of the cancer specific survival data in patients with oestrogen receptor positive 
tumours (ER+ve) tumours did not show any significant differences in the survival period 
between patients with tumours that expressed high levels of SIRT1 (n = 14, 9.46 years, 
95% C.I. 6.35-12.57) when compared to those whose tumours express low levels of SIRT1 
(n = 18, 8.13years, 95% C.I% 8.13-13.88, Kaplan-Meier p = 0.452; Figure 3.27). 
 
 
 
 
 
 
 
 
 
Figure 3.27: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT1 expression in patients with ER+ve. 
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows no significant difference in the survival period for 
patients with tumours that express high levels SIRT1 (n = 14, 9.46 years, 95% C.I. 6.35-12.57) 
when compared to those whose tumours express low levels of SIRT1 (n = 18, 8.13years, 
95% C.I% 8.13-13.88, Kaplan-Meier p = 0.452. 
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3.4.5.2 SIRT1 and recurrence. 
3.4.5.2.1 Recurrence analysis in entire patient cohort according to SIRT1 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, and showed a clear but, 
statistically non-significant trend towards shorter recurrence interval in patients with high 
levels of SIRT1 gene expression when all patients were included. Patient numbers are 
shown in (Table 3.5). Time to recurrence was shorter in patients with tumours that 
expressed high levels of SIRT1 (n = 23, 8.98 years, 95% C.I. 6.16-11.72), when compared 
to those whose tumours expressed low levels of SIRT1 (n = 46, 12.08 years, 95% C.I. 
10.30 -13.86, Kaplan-Meier p = 0.08; Figure 3. 28). 
 
Table 3.5: Number of breast cancer patient and tumour recurrences of all patient groups 
included in the Kaplan-Meier survival analysis. 
 
 
 
 
 
 
 
 
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT1 gene 
expression 45 10 26 7 12 6
High SIRT1 gene 
expression 24 9 11 6 20 5
Overall 69 21 37 13 32 11
Breast cancer patients with 
NPI between 3.4-5.4
Breast cancer patients with 
ER+veSIRT1 Tertile
All breast cancer patients
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Figure 3.28: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT1 expression. 
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed that time to recurrence was shorter in patients 
with tumours that expressed high levels of SIRT1 (n = 23, 8.98 years, 95% C.I. 6.16-11.72) 
when compared to those whose tumours express low levels of SIRT1 (n = 46, 12.08 years, 
95% C.I. 10.30 -13.86, Kaplan-Meier p = 0.08. 
3.4.5.2.2 Recurrence analysis in NPI selected patients according to SIRT1 levels. 
 
When tumour recurrence among patients with moderately good prognosis (NPI between 
3.4-5.4) was analysed (Table 3.5), there was a significant difference according to the levels 
of SIRT1 gene expression. The Kaplan-Meier recurrence analysis showed that time to 
recurrence was significantly shorter in patients with tumours that expressed high levels of 
SIRT1 (n = 11, 6.62 years, 2.66-10.58) when compared to those whose tumours expressed 
low levels of SIRT1 (n = 26, 12.02 years, 95% C.I. 9.75 -14.29, Kaplan-Meier p= 0.024; 
Figure 3.29). 
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Figure 3.29: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT1 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed that time to recurrence was significantly shorter in 
patients with tumours that expressed high levels of SIRT1 (n = 11, 6.62 years, 95% C.I. 2.66-
10.58) when compared to those whose tumours express low levels of SIRT1 (n = 26, 12.02 
years, 95% C.I. 9.75 -14.29, Kaplan-Meier p = 0.025. 
 
 
 
 
 
 
Figure 3.30: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT1 expression in patient with ER+ve tumours.  
High and low SIRT1 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed no significant difference in time to recurrence 
between patients with tumours that expressed high levels of SIRT1 (n = 14, 8.97 years, 95% 
C.I. 5.17-12.77) when compared to those whose tumours express low levels of SIRT1 (n = 18, 
10.22 years, 95% C.I. 7.13-13.31, Kaplan-Meier p = 0.728).  
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3.4.5.2.3 Recurrence analysis in ER +ve patients according to SIRT1 levels.  
 
Further analysis of recurrence within the subgroup of patients with ER+ve tumours (Table 
3.5) failed to reveal any significant difference in the time to recurrence between patients 
with tumours that expressed high levels of SIRT1 (n = 14, 8.97 years, 95% C.I. 5.17-
12.77) when compared to those whose tumours expressed low levels of SIRT1 (n = 18, 
10.22 years, 95% C.I. 7.13-13.31, Kaplan-Meier p = 0.728; Figure 3. 30). 
 
Table 3.6: p values for comparisons of the relative transcriptional expression of all sirtuin 
genes in the three patient groups and in the malignant biopsies according to the known 
pathological markers.  
 
 
 
 
Size Node
Overall N-NM N-M NM-M Overall 1~2 1~3 2~3 Overall
SIRT1 0.001 0.001 0.001 0.001 0.018 0.044 0.005 0.13 0.312 0.652
SIRT2 0.001 0.704 0.001 0.001 0.086 0.033 0.057 0.417 0.495 0.592
SIRT3 0.001 0.301 0.001 0.001 0.049 0.717 0.217 0.022 0.312 0.305
SIRT4 0.001 0.001 0.729 0.001 0.875 0.846 0.669 0.723 0.648 0.059
SIRT5 0.001 0.001 0.001 0.072 0.973 0.978 0.714 0.971 0.162 0.508
SIRT6 0.001 0.019 0.001 0.001 0.002 0.61 0.03 0.001 0.478 0.697
SIRT7 0.001 0.001 0.001 0.51 0.075 0.048 0.062 0.237 0.678 0.763
overall NPI ER+ve overall NPI
SIRT1 0.183 0.584 0.143 0.235 0.03 0.452 0.088 0.024
SIRT2 0.445 0.933 0.237 0.529 0.619 0.73 0.947 0.764
SIRT3 0.216 0.662 0.782 0.789 0.968 0.487 0.866 0.903
SIRT4 0.347 0.473 0.464 0.38 0.384 0.135 0.098 0.125
SIRT5 0.335 0.242 0.57 0.305 0.983 0.538 0.272 0.287
SIRT6 0.508 0.392 0.309 0.009 0.004 0.002 0.178 0.067
SIRT7 0.486 0.317 0.21 0.05 0.1 0.045 0.677 0.994
0.531
0.282
0.684
0.728
0.352
0.519
0.023
Grade
Gene ER LV NPI Survival RecurrenceER+ve
Gene Biopsy type
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3.4.6 Conclusions. 
3.4.6.1 Breast biopsies and the characteristics of patient cohorts. 
The relative transcriptional expression levels of sirtuin genes were determined in a sample 
of archival breast biopsies; normal (n = 25), non-malignant (n = 78) and malignant (n = 73) 
breast biopsies.  
Patient’s age was normally distributed in all patient groups. Patient’s age was significantly 
different in normal when compared with patient’s age in both non-malignant and malignant 
groups.  
The Kaplan-Meier analysis for cancer specific survival according to the known prognostic 
markers (Table 3.1) was only significant when breast cancer patients were grouped 
according to nodal status (p = 0.003) and according to the NPI (p = 0.015). Tumour size 
showed significant association with survival only when patients were grouped, according 
to the tumour size, into patients with small tumours (T1 and T2) and patients with large 
tumours (T3 and T4) (p = 0.013). 
The Kaplan-Meier analysis for breast cancer recurrence according to the known prognostic 
markers was only significant (Table 3.2) when breast cancer patients were grouped 
according to nodal status (p = 0.006). 
3.4.6.2 The relative transcriptional expression levels of sirtuin 1 in breast 
biopsies. 
This study investigated the relative transcriptional expression levels of the SIRT1 gene in 
(25) normal, (76) non-malignant and (72) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT1, as the data distributions were positively skewed in all patient groups. 
The analysis of the relative transcriptional expression of SIRT1 with age in  “ normal 
patients” (normal and non-malignant patients) showed marginally significant correlation 
between increasing chronological age and decreasing the relative transcriptional levels of 
SIRT1 (p = 0.059).  
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The data for SIRT1 gene expression variation between breast cancer biopsies showed that 
there were significant differences in SIRT1 gene expression between biopsies from 
malignant, non-malignant and normal patient groups. The expression level for SIRT1 is 
significantly lower, in malignant compared to both non-malignant and normal patient 
groups. SIRT1 gene expression also differs significantly between the non-malignant and 
normal patient groups, which differ in their age distributions, even when corrected for age 
(Table 3.6). 
The relative transcriptional expression level of SIRT1 was only significantly associated 
with tumour grade when breast cancer patients were divided according to the known 
histopathological markers. There was a significant correlation between decreased SIRT1 
gene expression and higher tumour grade. 
The Kaplan-Meier analysis for cancer specific survival and tumour recurrence according to 
relative transcriptional expression level of SIRT1, showed no significant association 
between SIRT1 levels and survival period or time to recurrence when all patients were 
included. However, analysis of the data showed clearly that the survival curves, according 
to SIRT1 levels, dissociate after 5 years. Usually, breast cancer patients with aggressive 
tumours experience recurrence or metastasis in the first two years. Those patients with 
such a poor prognosis can be readily evaluated using the commonly used criterion of an 
NPI > 5.4. Therefore, further analysis of the breast cancer specific survival and time to 
recurrence data, according to relative transcriptional expression level of SIRT1, was 
performed in a patient group selected as having an intermediate clinical prognosis using 
the NPI (NPI between 3.4 and 5.4). This analysis showed that lower SIRT1 gene 
expression is prognostic of better long-term patient survival and lower tumour recurrence 
in a patient group selected by NPI to have an intermediate clinical prognosis.  
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(a) (b) 
N Percent N Percent N Percent
Normal 24 92.30% 2 7.70% 26 100.00%
Non-Malignant 75 96.20% 3 3.80% 78 100.00%
Malignant 73 100.00% 0 0.00% 73 100.00%
Relative SIRT2 
Expression
TotalMissingValidSample Type
Cases
3.2 The relative transcriptional expression levels of 
SIRT2 in breast biopsies.  
3.2.1 The relative transcriptional expression levels of SIRT2 gene 
and patients age. 
The relative transcriptional expression levels of  SIRT2 gene were determined in 24 
normal biopsies, 75 non-malignant and 73 malignant patient biopsies (Table 3.7).  
Table 3.7 Patient biopsies used in the SIRT2 study. 
The correlation between the relative level of SIRT2 gene expression and patient’s age was 
investigated in a patient group that combines both normal and non-malignant patients 
(Figure 3. 31a).  The median age of this patient group was 51 years (20 years – 84 years).  
This data showed that there was no significant association between the relative 
transcription levels of SIRT2 and chronological age (Spearman's rank correlation 
coefficient; p = 0.173; Figure 3. 32b).  
Figure 3.31: (a) Distribution of patient’s age in patient group that combines both normal and 
non-malignant patients. (b) Correlation between relative transcription levels of SIRT2 and 
patient’s age in patient group that combines both normal and non-malignant patients 
(spearman test, p = 0.173). 
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3.2.2 Data distribution of the relative transcriptional expression 
levels of SIRT2. 
The distribution of the relative transcriptional gene expression of SIRT2 was investigated 
in the three different studied biopsy types (Figure 3. 32). The histograms of the distribution 
of the relative transcriptional gene expression of SIRT2 showed that the range of the 
SIRT2 gene expression values was not normally distributed; instead the SIRT2 gene 
expression distribution was positive skewed in all groups (Figure 3.32). Therefore, non-
parametric statistical tests were used for future data analysis for the relative transcriptional 
gene expression of SIRT2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: Distribution of the relative transcriptional gene expression of SIRT2 in three 
different groups. 
Relative transcriptional gene expression of SIRT2 in normal breast biopsies, (b) Relative 
transcriptional gene expression of SIRT2 in non-malignant breast biopsies, (c) Relative 
transcriptional gene expression of SIRT2 in malignant breast biopsies. 
  
 
(a) (b) 
(c)  
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3.2.3 Comparison of the relative transcriptional expression levels 
of SIRT2 between patient groups. 
The level of SIRT2 relative transcriptional expression was compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT2 was significantly different between the three groups of breast biopsies (p < 
0.001, Figure 3. 33). This experiment showed that malignant samples have significantly 
lower levels of SIRT2 gene expression compared to both non-malignant and normal 
samples (p < 0.001, Figure 3.33).  
 
 
 
 
 
 
 
Figure 3.33:   Box plot showing the transcriptional expression of SIRT2 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown to the right of each box plot (p<0.001). 
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3. 6) 
showed that all the malignant groups differed significantly in SIRT2 gene expression from 
both non-malignant and normal groups (malignant versus non-malignant p < 0.001, 
malignant versus normal; p < 0.001). However, there was no significant difference 
between the malignant and non-malignant groups (p < 0.704). 
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3.2.4 Comparison of the relative transcriptional expression levels 
of SIRT2 according to histopathological markers. 
The relationships between SIRT2 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
3.2.4.1 Comparison of the relative transcriptional expression levels of SIRT2 
according to tumour grades. 
Analysis of the data for the relationship between SIRT2 gene expression and tumour grade 
showed a trend toward significance when the levels of SIRT2 gene expression were 
compared between all three tumour grades together (Kruskal-Wallis test p = 0.086) (Fig 
3.34).  
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3. 6) 
showed that grade 1 tumour groups differed significantly in SIRT2 gene expression from 
both grade 2 (p = 0.033) and grade 3 tumours (p = 0.057). The expression of SIRT2 
decreased with increasing severity (higher grade) of tumour. There was no significant 
difference between grade 2 and grade 3 tumours (p = 0.417; Figure 3.34). 
 
 
 
 
 
 
Figure 3.34: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by tumour grade. 
n = 4 for grade 1, n =  32 for grade 2 and n = 31 for grade 3 (Kruskal Wallis Test, p = 0.089). 
The median value for each patient group is shown to the right of each box plot. 
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3.2.4.2 Comparison of the relative transcriptional expression levels of SIRT2 
according to tumour size, nodal status, oestrogen receptor status 
and lymphovascular invasion. 
Analysis of the data for the relationship between SIRT2 gene expression and tumour size, 
nodal status, oestrogen receptor status and lymphovascular invasion showed no significant 
differences in the relative transcriptional expression levels of SIRT2 between any 
categories when compared together (Figure 3.35 a, b, c, and d). Table 3.6 shows the 
Kruskal-Wallis test p values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35: Box plots showing the relative transcriptional expression of SIRT2 in breast 
cancer biopsies by:  
(a) Tumour size, n = 11 for T1, n = 45 for T2 ,n =  14 for T3 and 2for T4 (Kruskal Wallis Test, 
p=0.495). (b) Nodal status, n = 20 for node –ve and n =  44 for node +ve (Mann Whitney test p 
= 0.592). (c) Oestrogen receptor status, n  =  21 for ER-ve and n =32 for ER+ve (Mann Whitney 
test p = 0.445). d) Lymphovascular invasion (LV) n = 19 for LV–ve and n = 29 for LV+ve (Mann 
Whitney test p = 0.933).  The median value for each patient group is shown right of each 
box. 
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Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT2 gene 
expression 22 6 11 3 9 3
High SIRT2 gene 
expression 48 15 25 7 22 7
Overall 70 21 36 11 31 10
SIRT2 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
3.2.5 The relationship of relative SIRT2 gene expression in breast 
cancer biopsies to patient survival and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT2 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT2 gene expression. In analyses shown below, the two tertiles with higher SIRT2 
gene expression levels have been combined and are compared to the lowest level of SIRT2 
gene expression tertile group. Table 3.10 and Table 3.11 show the numbers of patients 
included in each group. 
3.2.5.1 SIRT2 and survival.  
3.2.5.1.1 Survival analysis in entire patient cohort according to SIRT2 levels. 
 
Analysis of the survival data for the entire patient group using the Kaplan-Meier test 
showed no significant difference in survival period when all patients are included (Table 
3.8). The survival period was non-significantly shorter in patients with tumours that 
expressed high levels of SIRT2 (n = 48, 10.79 years, 95% C.I. 9.14 -12.44) when 
compared to those whose tumours expressed low levels of SIRT2 (n = 22, 11.49 years, 
95% C.I. 9.08 – 13.09, Kaplan-Meier p = 0.529 (Figure 3. 36). 
Table 3.8:Number of breast cancer patient and cancer specific deaths of all breast cancer 
patients groups included in the Kaplan-Meier survival analysis.  
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Figure 3.36: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT2 expression. 
High and low SIRT2 expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows a non significant decrease in the survival period for 
patients with tumours that express high levels SIRT2 (n = 48, 10.79 years, 95% C.I. 9.14 -
12.44) when compared to those whose tumours express low levels of SIRT2 (n = 22, 11.49 
years, 95% C.I. 9.08 – 13.09, Kaplan-Meier p = 0.529. 
3.2.5.1.2 Survival analysis in NPI selected patients according to SIRT2 levels.  
 
Analysis of the survival data for the NPI-selected patient group (Table 3. 8) using the 
Kaplan-Meier test did not show any significant difference in the survival period in patients 
with tumours that expressed high levels of SIRT2 (n = 25, 11.72 years, 95% C.I. 9.75 -
15.07) when compared to those whose tumours expressed low levels of SIRT2 (n = 11, 
12.30 years, 95% C.I. 9.53 – 15.07, Kaplan-Meier p = 0.619; Figure 3. 37). 
3.2.5.1.3 Survival analysis ER+ve selected patients according to SIRT2 levels.  
 
Analysis of the survival data for the ER+ve patient group (Table 3.10) using the Kaplan-
Meier test showed no significant difference in the survival period in patients with tumours 
that expressed high levels of SIRT2 (n = 22, 10.74 years, 95% C.I. 6.78-14.7) when 
compared to those whose tumours expressed low levels of SIRT2 (n = 9, 10.07 years, 95% 
C.I. 7.58 – 12.57, Kaplan-Meier p = 0.73 Figure 3. 38). 
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Figure 3.37: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT2 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT2  expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows nonsignificant difference in the survival period in 
patients with tumours that express high levels of SIRT2 (n = 25, 11.72 years, 95% C.I. 9.75 -
15.07) when compared to those whose tumours express low levels of SIRT2 (n = 11, 12.30 
years, 95% C.I. 9.53 – 15.07, Kaplan-Meier p = 0.619). 
 
 
 
 
 
 
 
 
Figure 3.38: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT2 expression in patients with ER+ve tumours. 
High and low SIRT2 expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows no significant difference in the survival period in 
patients with tumours that express high levels of SIRT2 (n = 22, 10.74 years, 95% C.I. 6.78-
14.7) when compared to those whose tumours express low levels of SIRT2 (n = 9, 10.07 
years, 95% C.I. 7.58 – 12.57, Kaplan-Meier p = 0.73. 
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Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT2 gene 
expression 22 6 12 4 10 5
High SIRT2 gene 
expression 48 13 25 9 22 6
Overall 70 19 27 13 32 11
Breast cancer patients with 
ER+veSIRT2 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
3.2.5.2 SIRT2 and recurrence. 
3.2.5.2.1 Recurrence analysis in entire patient cohort according to SIRT2 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, in all breast cancer 
patients, patient numbers are shown in Table 3.9. There was no significant differences in 
the recurrence interval between patients with tumours that expressed high levels of SIRT2 
(n = 48, 11.15 years, 95% C.I. 9.27-13.0) when compared to those whose tumours 
expressed low levels of SIRT2 (n = 22, 10.95 years, 95% C.I. 8.22 -13.68, Kaplan-Meier p 
= 0.947, Figure 3.39). 
Table 3.9: Number of breast cancer patient and tumour recurrences of all breast cancer 
patients groups included in the Kaplan-Meier survival analysis 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT2 expression. 
High and low SIRT2 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed a non significant decrease in the time to 
recurrence in patients with tumours that express low levels of SIRT2 (n = 22, 10.95 years, 
95% C.I. 8.22 -13.68, when compared to those whose tumours express high levels of SIRT2 
(n = 48, 11.15 years, 95% C.I. 9.27-13.0, Kaplan-Meier p = 0.947). 
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3.2.5.2.2 Recurrence analysis in NPI selected patients according to SIRT2 levels.  
 
When tumour recurrence among the NPI-selected patient group was analysed, there was 
also no significant difference according to the level of SIRT2 gene expression. Patient 
numbers are shown in Table 3.9 and the recurrence data in Figure (3.40). Time to 
recurrence was not significantly shorter in patients with tumours that expressed high levels 
of SIRT2 (n = 25, 10.51 years, 95% C.I. 7.87-13.16) when compared to those whose 
tumours express low levels of SIRT2 (n = 12, 10.56 years, 95% C.I. 6.99 -14.13, Kaplan-
Meier p = 0.764, Figure 3. 40).  
3.2.5.2.3 Recurrence analysis in ER +ve patients according to SIRT2 levels.  
 
Further analysis of recurrence within the subgroup of patients with oestrogen receptor 
positive tumours (ER+ve) failed to reveal any significant difference in time to recurrence 
between patients with tumours that expressed high levels of SIRT2 (n = 22, 10.46 years, 
95% C.I. 7.58-13.35) when compared to those whose tumours express low levels of SIRT2 
(n = 10, 8.24 years, 95% C.I. 4.02-12.45, Kaplan-Meier p = 0.352. Figure 3. 41). Patient 
numbers are shown in (Table 3.9). 
 
 
 
 
 
 
Figure 3.40: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT2 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT2 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed a insignificant decrease in the time to recurrence 
in patients with tumours that express high levels of SIRT2 (n = 25, 10.51 years, 95% C.I. 7.87-
13.16) when compared to those whose tumours express low levels of SIRT2 (n = 12, 10.56 
years, 95% C.I. 6.99 -14.13, Kaplan-Meier p = 0.764.  
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT2 expression in patients with ER+ve tumours. 
High and low SIRT2 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed a non significant decrease in the time to 
recurrence in patients with tumours that express high levels of SIRT2 (n = 22, 10.46 years, 
95% C.I. 7.58-13.35) when compared to those whose tumours express low levels of SIRT2 (n 
= 10, 8.24 years, 95% C.I. 4.02-12.45, Kaplan-Meier p = 0.352). 
3.2.6 Conclusions. 
This study investigated the relative transcriptional expression levels of the SIRT2 gene in 
(24) normal, (75) non-malignant and (73) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT2 as the data distributions were positively skewed in all patient groups. 
The data for SIRT2 gene expression variation between breast biopsies showed that there 
were significant differences in SIRT2 gene expression between biopsies from malignant, 
non-malignant and normal patient groups in a three-way comparison. The expression level 
of SIRT2 is significantly lower in malignant compared to both non-malignant and normal 
patient groups. SIRT2 gene expression does not differ significantly between the non-
malignant and normal patient groups, which differ in their age distributions (Table 3.6). 
There was a significant correlation between decreased SIRT2 gene expression levels and 
higher tumour grade. 
SIRT2 gene expression did not show significant correlation with patient survival and 
tumour recurrence, either in the entire patient set, or in a patient group selected by NPI ,or 
ER+ve status, to have an intermediate clinical prognosis.  
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N Percent N Percent N Percent
Normal 25 96.20% 1 3.80% 26 100.00%
Non-Malignant 75 96.20% 3 3.80% 78 100.00%
Malignant 72 98.60% 1 1.40% 73 100.00%
Sample Type
Cases
Valid Missing Total
Relative SIRT3 
Expression
3.3 The relative transcriptional expression levels of 
SIRT3 in breast biopsies.  
3.3.1 The relative transcriptional expression levels of SIRT3 and 
patient’s age. 
The relative transcriptional expression levels of the SIRT3 gene were determined in 25 
normal biopsies, 75 non-malignant and 72 malignant patient biopsies (Table 3.10).  
Table 3.10 Patient biopsies used in the SIRT3 study. 
The correlation between the level of SIRT3 relative transcriptional expression and patient’s 
age was investigated in a patient group that combines both normal and non-malignant 
patients (Figure 3. 42a).  The median age of this patient group was 51 years (20years - 
84years).  This data showed that there was no significant association between the relative 
transcription levels of SIRT3 and chronological age (Spearman's rank correlation 
coefficient; p = 0.766; Figure 3. 42b).  
 
 
 
 
 
Figure 3.42: (a) Distribution of patient’s age in patient group that combines both normal and 
non-malignant patients. (b) Correlation between relative transcription levels of SIRT3 and 
patient’s age in patient group that combines both normal and non-malignant patients 
(Spearman test, p = 0.766). 
  
(a) (b) 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
174 
3.3.2 Data distribution of the relative transcriptional expression 
levels of SIRT3.  
The distribution of the relative transcriptional gene expression of SIRT3 was investigated 
in the three different studied biopsy types (Figure 3. 43). The histograms of the relative 
transcriptional gene expression of SIRT3 distribution showed that the range of the SIRT3 
gene expression values was not normally distributed; instead the SIRT3 gene expression 
distribution was positive skewed in all groups (Figure 3. 43). Therefore, non-parametric 
statistical tests were used for future data analysis for the relative transcriptional gene 
expression of SIRT3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43: Distribution of the relative transcriptional gene expression of SIRT3 in three 
different groups.  
(a) Relative transcriptional gene expression of SIRT3 in normal breast biopsies, (b) Relative 
transcriptional gene expression of SIRT3 in non-malignant breast biopsies, (c) Relative 
transcriptional gene expression of SIRT3 in malignant breast biopsies. 
 
 
  
 
(a) (b) 
(c)  
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3.3.3 Comparison of the relative transcriptional expression levels 
of SIRT3 between patient groups.  
The relative transcriptional expression levels of SIRT3 were compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT3 was significantly different between the three groups of breast biopsies (p < 
0.001, Figure 3. 44). This experiment showed that malignant samples have significantly 
lower levels of SIRT3 gene expression compared to both non-malignant and normal 
samples (p < 0.001, Figure 3. 44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.44: Box plot showing the transcriptional expression of SIRT3 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown to the right of each box plot (p < 0.001).  
Pairwise comparisons of the three groups using the Mann-Whitney test  (Table 3.6) 
showed that the malignant group differed significantly in SIRT3 gene expression from both 
non-malignant and normal groups (malignant versus non-malignant p < 0.001, malignant 
versus normal; p < 0.001). However, there was no significant difference between the 
normal and non-malignant groups (p  = 0.301). 
3.3.4 Comparison of the relative transcriptional expression levels 
of SIRT3 according to histopathological markers 
The relationships between SIRT3 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
176 
3.3.4.1 Comparison of the relative transcriptional expression levels of SIRT3 
according to tumour grades. 
Analysis of the data for the relationship between SIRT3 gene expression and tumour grade 
showed a significant difference in the relative transcriptional expression levels of SIRT3 
between all three tumour grades when compared together (Kruskal-Wallis test p < 0.049) 
(Figure 3. 45).  
Pairwise comparisons of the three groups using the Mann-Whitney test showed that grade 
3 tumours groups differed significantly in SIRT3 gene expression from grade 2 (p = 0.022) 
but not from grade 1 tumours (p = 0.217, Table 3.6). This could be attributed to the small 
number of patients (3) included in grade 1 groups. However, it could be said that the 
overall trend toward decreased levels of SIRT3 expression with increasing tumour grade is 
consistent. Thus the expression of SIRT3 decreases with increasing severity (higher grade) 
of tumour. There was no significant difference between grade 2 and grade 1 tumours         
(p = 0.717; Figure 3. 45). 
 
 
 
 
 
 
 
Figure 3.45: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by tumour grade. 
 n = 3 for grade 1, n = 32 for grade 2 and n = 31 for grade 3 (Kruskal Wallis Test, p = 0.001). 
The median value for each patient group is shown to the right of each box plot. 
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3.3.4.2 Comparison of SIRT3 gene transcription levels according to tumour 
size, nodal status, oestrogen receptor status and lymphovascular 
invasion. 
Analysis of the data for the relationship between SIRT3 gene expression and tumour size, 
nodal status, oestrogen receptor status and lymphovascular invasion all showed no 
significant differences in the relative transcriptional expression levels of SIRT3 between 
any categories when compared together (Figure 3. 46 a, b, c, and d). Table 3.6 shows the 
Kruskal-Wallis test p values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
Figure 3.46: Box plots showing the relative transcriptional expression of SIRT3 in breast 
cancer biopsies by: 
(a) tumour size, n = 10 for T1, n = 45 for T2 , n = 14 for T3 and 2 for T4 ( Kruskal Wallis Test, 
p = 0.312), (b) Nodal status, n = 21 for node –ve and n = 44 for node +ve (Mann Whitney test 
p = 0.305) , (c) Oestrogen receptor status, n  =  21 for ER-ve and n = 32 for ER+ve (Mann 
Whitney test p = 0.216). (d) Lymphovascular invasion (LV) n = 18 for LV–ve and n = 29 for 
LV+ve (Mann Whitney test p = 0.662).  The median value for each patient group is shown right 
of each box. 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c)  (d) 
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3.3.5 The relationship of the relative transcriptional expression 
levels of SIRT3 to patient survival and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT3 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT3 gene expression. In analyses shown below, the two tertiles with lower SIRT3 
gene expression levels have been combined and are compared to the highest levels of 
SIRT3 gene expression tertile group. Table 3.11 and Table 3.12 show the numbers of 
patients included in each group. 
3.3.5.1 SIRT3 and survival  
3.3.5.1.1 Survival analysis in entire patient cohort according to SIRT3 levels. 
 
Analysis of the survival data for the entire patient group using the Kaplan-Meier test shows 
no significant difference in survival period when all patients are included (Table 3.11). The 
survival period was non-significantly shorter in patients with tumours that expressed high 
levels of SIRT3 (n = 24, 10.75 years, 95% C.I. 8.2 -12.76) when compared to those whose 
tumours expressed low levels of SIRT3 (n = 45, 11.13 years, 95% C.I. 9.5– 12.76, Kaplan-
Meier p = 0.789; Figure 3. 47). 
Table 3.11: Number of breast cancer patient and cancer specific deaths of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis.  
 
 
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT3 gene 
expression 45 14 24 7 17 7
High SIRT3 gene 
expression 24 7 12 3 13 3
Overall 69 21 36 10 30 10
SIRT3 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
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Figure 3.47: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT3 expression. 
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a non significant decrease in the survival period for 
patients with tumours that express high levels SIRT3 (n = 24, 10.75 years, 95% C.I. 8.2 -
12.76) when compared to those whose tumours express low levels of SIRT3 (n = 45, 11.13 
years, 95% C.I. 9.5– 12.76, Kaplan-Meier p = 0.789). 
 
 
3.3.5.1.2 Survival analysis in NPI selected patients according to SIRT3 levels. 
 
Analysis of the survival data for the NPI-selected patient group (Table 3. 11) using the 
Kaplan-Meier test did not show any significant difference in the survival period in patients 
with tumours that expressed low levels of SIRT3 (n = 24, 12.02 years, 95% C.I. 10.19 -
13.84) when compared to those whose tumours expressed high levels of SIRT3 (n = 12, 
11.78 years, 95% C.I. 8.67 – 14.88, Kaplan-Meier p = 0.968, Figure 3. 48). 
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Figure 3.48: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT3 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4).  
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows insignificant difference in the survival period in 
patients with tumours that express high levels of SIRT3 (n = 12, 11.78 years, 95% C.I. 8.67 – 
14.88), when compared to those whose tumours express low levels of SIRT3 (n = 24, 12.02 
years, 95% C.I. 10.19 -13.84; Kaplan-Meier p = 0.968).  
 
3.3.5.1.3 Survival analysis in ER+ve selected patients according to SIRT3 levels.  
 
Analysis of the survival data for the ER+ve patient group (Table 3. 11) using the Kaplan-
Meier test showed no significant difference in the survival period in patients with tumours 
that expressed low levels of SIRT3 (n = 17, 9.76 years, 95% C.I. 6.91-12.62) when 
compared to those whose tumours expressed high levels of SIRT3 (n = 13, 11.74 years, 
95% C.I. 8.78 – 14.70, Kaplan-Meier p = 0.487, Figure 3.46). 
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Figure 3.49: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT3 expression in patients with ER+ve tumours. 
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows no significant difference in the survival period in 
patients with tumours that express low levels of SIRT3 (n = 17, 9.76 years, 95% C.I. 6.91-
12.62) when compared to those whose tumours express high levels of SIRT3 (n = 13, 11.74 
years, 95% C.I. 8.78 – 14.70, Kaplan-Meier p = 0.487). 
3.3.5.2 SIRT3 and Recurrence. 
3.3.5.2.1 Recurrence analysis in entire patient cohort according to SIRT3 levels. 
 
Recurrence of tumours was analysed using the Kaplan-Meier test, in all breast cancer 
patients, patient numbers are shown in Table 3.12. There was no significant differences in 
the recurrence interval between patients with tumours that expressed high levels of SIRT3 
(n = 23, 10.91 years, 95% C.I. 7.67-14.15) when compared to those whose tumours 
expressed low levels of SIRT3 (n = 46, 11.03 years, 95% C.I. 9.23 -12.8, Kaplan-Meier p 
= 0.866, Figure 3. 50) 
Table 3.12: Number of breast cancer patient and tumour recurrences of all breast cancer  
patient groups included in the Kaplan-Meier survival analysis 
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT3 gene 
expression 46 13 25 9 18 8
High SIRT3 gene 
expression 23 6 12 4 13 3
Overall 69 19 37 13 32 11
SIRT3 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
Breast cancer patients with 
ER+ve
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Figure 3.50: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT3 expression. 
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a non significant difference in the time to 
recurrence in patients with tumours that express high levels of SIRT3 (n = 23, 10.91 years, 
95% C.I. 7.67-14.15) when compared to those whose tumours express low levels of SIRT3 (n 
= 46, 11.03 years, 95% C.I. 9.23 -12.8, Kaplan-Meier p = 0.866. 
3.3.5.2.2 Recurrence analysis in NPI selected patients according to SIRT3 levels. 
 
When tumour recurrence among the NPI-selected patient group was analysed (Table 3. 
12), there was also no significant difference according to the level of SIRT3 gene 
expression in patients with tumours that expressed low levels of SIRT3 (n = 25, 10.51 
years, 95% C.I. 8.19-12.89) when compared to those whose tumours expressed high levels 
of SIRT3 (n = 12, 10.46 years, 95% C.I. 5.62 -15.30, Kaplan-Meier p = 0.903, Figure 
3.51). 
3.3.5.2.3 Recurrence analysis in ER+ve patients according to SIRT3 levels.  
 
Further analysis of recurrence within the subgroup of patients with ER+ve tumours (Table 
3.14) failed to reveal any significant difference in time to recurrence between patients with 
tumours that expressed low levels of SIRT3 (n = 18, 8.96 years, 95% C.I. 5.86 -12.05) 
when compared to those whose tumours express high levels of SIRT3 (n = 13, 10.46 years, 
95% C.I. 6.33-14.6, Kaplan-Meier p = 0.519, Figure 3. 52). 
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Figure 3.51: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT3 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4).  
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a non significant difference in the time to 
recurrence period in patients with tumours that express low levels of SIRT3 (n = 25, 10.51 
years, 95% C.I. 8.19-12.89) when compared to those whose tumours express high levels of 
SIRT3 (n = 12, 10.46 years, 95% C.I. 5.62 -15.30, Kaplan-Meier p = 0.903). 
 
 
 
 
 
 
 
 
 
 
Figure 3.52: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT3 expression in patients with ER+ve tumours. 
High and low SIRT3 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a insignificant difference in the time to 
recurrence in patients with tumours that express low levels of SIRT3 (n = 18, 8.96 years, 
95% C.I. 5.86 -12.05) when compared to those whose tumours express high levels of SIRT3 
(n = 13, 10.46 years, 95% C.I. 6.33-14.6, Kaplan-Meier p = 0.519). 
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3.3.6 Conclusion. 
This study investigated the relative transcriptional expression levels of the SIRT3 gene in 
(25) normal, (75) non-malignant and (72) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT3 as the data distributions were positively skewed in all patient groups. 
The data for SIRT3 gene expression variation between breast biopsies showed that there 
were significant differences in SIRT3 gene expression between biopsies from malignant, 
non-malignant and normal patient groups in a three-way comparison. The expression level 
of SIRT3 is significantly lower in malignant compared to both non-malignant and normal 
patient groups. SIRT3 gene expression does not differ significantly between the non-
malignant and normal patient groups (Table 3.6), which differ in their age distributions. 
There was a significant correlation between decreased SIRT3 gene expression level and 
higher tumour grade. 
SIRT3 gene expression did not show significant correlation with patient survival or tumour 
recurrence either in the entire patient set or in a patient group selected by NPI, or ER+ve 
status, to have an intermediate clinical prognosis.  
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N Percent N Percent N Percent
Normal 25 96.20% 1 3.80% 26 100.00%
Non-Malignant 72 92.30% 6 7.70% 78 100.00%
Malignant 69 94.50% 4 5.50% 73 100.00%
Sample Type
Cases
Valid Missing Total
Relative SIRT4 
Expression
 
3.4 The relative transcriptional expression levels of 
SIRT4 in breast biopsies.  
3.4.1 The relative transcriptional expression levels of SIRT4 and 
patients age. 
The relative transcriptional expression levels of the SIRT4 gene were determined in 25 
normal biopsies, 72 non-malignant and 69 malignant patient biopsies (Table 3.13).  
Table 3.13: Patient biopsies used in the SIRT4 study. 
The correlation between the level of SIRT4 relative transcriptional expression and patient’s 
age was investigated in a patient group that combines both normal and non-malignant 
patients (Figure 3.53 a).  The median age of this patient group was 51years (20 years – 84 
years).  This data showed that there was a significant association between increasing levels 
of SIRT4 relative transcription and chronological age (Spearman's rank correlation 
coefficient; p < 0.001; Figure 3. 53b).  
 
 
 
 
 
Figure 3.53: (a) Histogram shows the distribution of patient’s age patient group that 
combines both normal and non-malignant patients. (b) Correlation between relative 
transcription levels of SIRT4 and patient’s age in patient group that combines both normal 
and non-malignant patients (spearman test, p <0.001). 
  
(a) (b) 
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3.4.2 Data distribution of the relative transcriptional expression 
levels of SIRT4. 
 
The distribution of the relative transcriptional gene expression of SIRT4 was investigated 
in the three different studied biopsy types, (Figure 3. 54). The histograms of the relative 
transcriptional gene expression of SIRT4 distribution showed that the range of the SIRT4 
gene expression values was not normally distributed; instead the SIRT4 gene expression 
distribution was positive skewed in all groups (Figure 3. 54 a, b and c). Therefore, non-
parametric statistical tests were used for future data analysis for the relative transcriptional 
gene expression of SIRT4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.54: Distribution of the relative transcriptional gene expression of SIRT4 in three 
different groups.  
(a) Relative transcriptional gene expression of SIRT4 in normal breast biopsies. (b) Relative 
transcriptional gene expression of SIRT4 in non-malignant breast biopsies. (c) Relative 
transcriptional gene expression of SIRT4 in malignant breast biopsies. 
 
 
  
 
(a) (b) 
(c)  
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3.4.3 Comparison of the relative transcriptional expression levels 
of SIRT4 between patient groups. 
The level of SIRT4 relative transcriptional expression was compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT4 was significantly different between the three groups of breast biopsies (p < 
0.001, (Figure 3. 55). This experiment showed that non-malignant samples have 
significantly higher levels of SIRT4 gene expression compared to both malignant and 
normal samples (p < 0.001, Figure 3. 55).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.55:  Box plot showing the transcriptional expression of SIRT4 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown to the right of each box plot ( p < 0.001). 
 
 
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3.6) showed 
that the non-malignant group differed significantly in SIRT4 gene expression from both 
malignant and normal groups (non-malignant versus malignant p < 0.001, non-malignant 
versus normal; p < 0.001). However, there was no significant difference between the 
malignant and normal groups (p = 0.729). 
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3.4.4 Comparison of SIRT4 gene transcription levels according to 
histopathological markers. 
The relationships between SIRT4 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
3.4.4.1 Comparison of SIRT4 gene transcription levels according to nodal 
status. 
Analysis of the data for the relationship between SIRT4 gene expression and nodal status 
showed a marginally significant difference in the relative transcriptional expression levels 
of SIRT4 between node positive and node negative tumours (Mann- Whitney p < 0.059; 
Figure 3. 56).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.56: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by nodal status. 
n = 41 for node positive tumours, n = 19 for node negative  tumours (Mann- Whitney test, p = 
0.059). The median value for each patient group is shown to the right of each box plot. 
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3.4.4.2 Comparison of the relative transcriptional expression levels of SIRT4 
according to tumour grade, tumour size, oestrogen receptor status 
and lymphovascular invasion 
Analysis of the data for the relationship between SIRT4 gene expression and tumour grade, 
tumour size, ER status and lymphovascular invasion all showed no significant differences 
in the relative transcriptional expression levels of SIRT4 between any categories when 
compared together (Figure 3. 57 a, b, c and d). Table 3.6 shows the Kruskal-Wallis test p 
values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
Figure 3.57: Box plots showing the relative transcriptional expression of SIRT4 in breast 
cancer biopsies by known prognostic markers: 
(a) tumour grade, n = 3 for G1, n = 32 for G2, and n = 29 for G3 (Mann Whitney test p = 
0.875). (b) tumour size, n = 10 for T1, n = 43 for T2 , n = 13 for T3 and n = 2 for T4 (Kruskal 
Wallis Test, p = 648), (c) oestrogen receptor status, n  =  20 for ER-ve and n = 32 for 
ER+ve(Mann Whitney test p = 0.347. (d) Lymphovascular invasion (LV) n = 18 for LV–ve and n 
= 27 for LV+ve (Mann Whitney test p = 0.473).  The median value for each patient group is 
shown right of each box. 
 
 
(a) (b) 
(C)  (d) 
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Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT4 gene 
expression 22 8 10 4 8 4
High SIRT4 gene 
expression 44 12 25 5 22 6
Overall 66 20 35 9 30 10
SIRT4 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
3.4.5 The relationship of the relative transcriptional expression 
levels of SIRT4 in breast cancer biopsies to patient survival 
and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT4 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT4 gene expression. In the analysis shown below, the two tertiles with higher levels 
of SIRT4 gene expression have been combined and are compared to the lowest level of 
SIRT4 gene expression tertile group. Table 3.14 and Table 3.15 show the numbers of 
patients included in each group. 
3.4.5.1 SIRT4 and survival. 
3.4.5.1.1 Survival analysis in entire patient cohort according to SIRT4 levels.  
 
Analysis of the survival data for the entire patient group using the Kaplan-Meier test shows 
no significant difference in survival period when all patients are included (Table 3. 14). 
The survival period was non-significantly shorter in patients with tumours that expressed 
low levels of SIRT4 (n = 22, 10.07 years, 95% C.I. 7.42 -12.72) when compared to those 
whose tumours expressed low levels of SIRT4 (n = 44, 11.65 years, 95% C.I. 10.09 – 
13.21, Kaplan-Meier p = 0.38, Figure 3. 58). 
Table 3.14: Number of breast cancer patient and cancer specific deaths of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis.  
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Figure 3.58: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT4 expression.  
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows a non significant decrease in the survival period for 
patients with tumours that express low levels of SIRT4 (n = 22, 10.07 years, 95% C.I. 7.42 -
12.72) when compared to those whose tumours express low levels of SIRT4 (n = 44, 11.65 
years, 95% C.I. 10.09 – 13.21, Kaplan-Meier p = 0.38). 
 
3.4.5.1.2 Survival analysis in NPI selected patients according to SIRT4 levels.  
 
Analysis of the survival data for the NPI-selected patient group (Table 3.14) using the 
Kaplan-Meier test did not show any significant difference in the survival period in patients 
with tumours that express low levels of SIRT4 (n = 10, 10.99 years, 95% C.I. 7.73 -14.23) 
when compared to those whose tumours express high levels of SIRT4 (n = 25, 12.82 years, 
95% C.I. 11.18 – 14.47, Kaplan-Meier p = 0.384; Figure 3. 59). 
3.4.5.1.3 Survival analysis in ER+ve selected patients according to SIRT4 levels.  
 
Analysis of the survival data for the ER+ve patient group (Table 3.14) using the Kaplan-
Meier test showed non-significant difference in the survival period in patients with 
tumours that expressed low levels of SIRT4 (n = 8, 7.76 years, 95% C.I. 3.18 -12.34) when 
compared to those whose tumours expressed high levels of SIRT4 (n = 22, 11.32 years, 
95% C.I. 9.02 – 13.62, Kaplan-Meier p = 0.135; Figure 3. 60).  
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Figure 3.59: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT4 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows insignificant difference in the survival period in 
patients with tumours that express low levels of SIRT4 (n = 10, 10.99 years, 95% C.I. 7.73 -
14.23) when compared to those whose tumours express high levels of SIRT4 (n = 25, 12.82 
years, 95% C.I. 11.18 – 14.47, Kaplan-Meier p = 0.384). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.60: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT4 expression in patients with ER+ve tumours. 
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The survival curve shows no significant difference in the survival period in 
patients with tumours that express low levels of SIRT4 (n = 8, 7.76 years, 95% C.I. 3.18 -
12.34) when compared to those whose tumours express high levels of SIRT4 (n = 22, 11.32 
years, 95% C.I. 9.02 – 13.62, Kaplan-Meier p = 0.135). 
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Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT4 gene 
expression 23 9 11 6 9 6
High SIRT4 gene 
expression 43 9 25 6 22 5
Overall 66 18 36 12 31 11
SIRT4 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
Breast cancer patients with 
ER+ve
3.4.5.2 SIRT4 and Recurrence. 
3.4.5.2.1 Recurrence analysis in entire patient cohort according to SIRT4 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, in all breast cancer 
patients, patient numbers are shown in Table 3.15. Kaplan-Meier analysis showed that the 
time to recurrence was not significantly shorter in patients with tumours that expressed low 
levels of SIRT4 (n = 23, 9.89 years, 95% C.I. 6.89 -12.88, when compared to those whose 
tumours expressed high levels of SIRT4 (n = 43, 11.96 years, 95% C.I. 10.26-13.67), 
Kaplan-Meier p = 0.098; Figure 3. 61). 
Table 3.15: Number of breast cancer patient and tumour recurrences of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.61: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT4 expression. 
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed insignificant decrease in the time to recurrence 
in patients with tumours that express low levels of SIRT4 (n = 23, 9.89 years, 95% C.I. 6.89 -
12.88, when compared to those whose tumours express high levels of SIRT4 (n = 43, 11.96 
years, 95% C.I. 10.26-13.67, Kaplan-Meier p = 0.098). 
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3.4.5.2.2 Recurrence analysis in NPI selected patients according to SIRT4 levels.  
 
When tumour recurrence among the NPI-selected patient group was analysed, there was  
no significant difference according to the level of SIRT4 gene expression. Patient numbers 
are shown in Table 3.15 and the recurrence data in (Figure 3.62). Time to recurrence was 
shorter in patients with tumours that expressed low levels of SIRT4 (n = 11, 8.87 years, 
95% C.I. 4.49-13.25) when compared to those whose tumours expressed low levels of 
SIRT4 (n = 25, 11.78 years, 95% C.I. 9.57 -13.99; Figure 3. 62). However the difference 
was not significant (Kaplan-Meier p = 0.125). 
 
 
 
 
 
 
 
Figure 3.62: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT4 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed a non-significant decrease in the survival period 
in patients with tumours that express low levels of SIRT4 (n = 11, 8.87 years, 95% C.I. 4.49-
13.25) when compared to those whose tumours express low levels of SIRT4 (n = 25, 11.78 
years, 95% C.I. 9.57 -13.99, Kaplan-Meier p = 0.125).  
 
 
 
 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
195 
3.4.5.2.3 Recurrence analysis in ER+ve patients according to SIRT4 levels. 
 
Further analysis of recurrence within the subgroup of patients with ER+ve)  tumours showed 
a significant difference in time to recurrence according to the level of SIRT4 gene 
expression. Patient numbers are shown in (Table 3.15). Time to recurrence was 
significantly shorter in patients with tumours that expressed low levels of SIRT4 (n = 9, 
5.79 years, 95% C.I. 1.59-9.99) when compared to those whose tumours expressed high 
levels of SIRT4 (n = 22, 11.29 years, 95% C.I. 8.57 -14.01, Kaplan-Meier p = 0.023, 
Figure 3.63). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.63: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT4 expression in patients with ER+ve tumours. 
High and low SIRT4 expression groups were determined as above or below the lower tertile 
cutoff value. The recurrence curve showed a significant decrease in the time to recurrence 
in patients with tumours that express low levels of SIRT4 (n = 9, 5.79 years, 95% C.I. 1.59-
9.99) when compared to those whose tumours express high levels of SIRT4 (n = 22, 11.29 
years, 95% C.I. 8.57 -14.01, Kaplan-Meier p = 0.023). 
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3.4.6 Conclusion. 
This study investigated the relative transcriptional expression levels of the SIRT4 gene in 
(25) normal, (72) non-malignant and (69) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT4 as the data distributions were positively skewed in all patient groups. 
The data for SIRT4 gene expression variation between breast biopsies showed that the 
SIRT4 levels were significantly lower in malignant group when compared to the non-
malignant group with a similar age distribution. However, the expression level of SIRT4 
did not show any significant difference when the malignant group was compared with a 
younger normal cohort.  
There was a significant association between increasing relative transcription levels of 
SIRT4 and chronological age. 
SIRT4 gene expression did not show significant correlation with patient survival, either in 
the entire patient set, or in a patient group selected by NPI, or ER+ve status, to have an 
intermediate clinical prognosis. SIRT4 gene expression did not show significant 
correlation with tumour recurrences, either in the entire patient set, or in a patient group 
selected by NPI to have an intermediate clinical prognosis. However, there was a 
significant difference in the recurrence time in ER+ve breast cancer patients, with shorter 
recurrence time associated with lower SIRT4 expression. There was a marginally 
significant correlation between decreased SIRT4 gene expression level and the presence of 
metastasis  
The data for SIRT4 gene expression variation between breast biopsies showed that the 
malignant group differs significantly from the non-malignant group of similar age. 
However, the expression level of SIRT4 did not show any significant difference when the 
malignant group was compared with a younger normal cohort.  
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3.5 The relative transcriptional expression levels of 
SIRT5 in breast biopsies.  
3.5.1 The relative transcriptional expression levels of SIRT5 and 
patients age. 
The relative transcriptional expression levels of the SIRT5 gene were determined in 24 
normal biopsies, 69 non-malignant and 69 malignant patient biopsies (Table 3.16).  
Table 3.16 Patient biopsies used in the SIRT5 study. 
The correlation between the level of SIRT5 relative transcriptional expression and patient’s 
age was investigated in a patient group that combines both normal and non-malignant 
patients (Figure 3.64 a).  The median age of this patient group was 51years (20 years - 84 
years). This data showed that there was no correlation between the relative transcriptional 
levels of SIRT5 and chronological age (Spearman's rank correlation coefficient; p = 0.129; 
Figure 3. 64b). 
 
 
 
 
 
Figure 3.64: (a) Histogram shows the distribution of patient’s age patient group that 
combines both normal and non-malignant patients. (b) Correlation between relative 
transcription levels of SIRT5 and patient’s age in patient group that combines both normal 
and non-malignant patients (Spearman test,  p = 0.129). 
  
(a) (b) 
N Percent N Percent N Percent
Normal 24 92.30% 2 7.70% 26 100.00%
Non-Malignant 69 88.50% 9 11.50% 78 100.00%
Malignant 69 94.50% 4 5.50% 73 100.00%
Sample Type
Cases
Valid Missing Total
Relative SIRT5 
Expression
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3.5.2 Data distribution of the relative transcriptional expression 
levels of SIRT5. 
 
The distribution of the relative transcriptional gene expression of SIRT5 was investigated 
in the three different studied biopsy types (Figure 3.65). The histograms of the distribution 
of the relative transcriptional gene expression of SIRT5 showed that the range of the 
SIRT5 gene expression values was not normally distributed; instead the SIRT5 gene 
expression distribution was positive skewed in all groups (Figure 3. 65). Therefore, non-
parametric statistical tests were used for future data analysis for the relative transcriptional 
gene expression of SIRT5.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.65: Distribution of the relative transcriptional gene expression of SIRT5 in Three 
different groups. 
(a) Relative transcriptional gene expression of SIRT5 in normal breast biopsies. (b) Relative 
transcriptional gene expression of SIRT5 in non-malignant breast biopsies. (c) Relative 
transcriptional gene expression of SIRT5 in malignant breast biopsies. 
 
  
 
(a) (b) 
(c)  
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3.5.3 Comparison of the relative transcriptional expression levels 
of SIRT5 between patient groups 
 
The level of SIRT5 relative transcriptional expression was compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT5 was significantly different between the three groups of breast biopsies (p < 
0.001, Figure 3.66). This experiment showed that normal samples have significantly lower 
levels of SIRT5 gene expression compared to both malignant and non-malignant samples 
(p < 0.001, Figure 3. 66).  
 
 
 
 
 
 
 
Figure 3.66:   Box plot showing the transcriptional expression of SIRT5 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown to the right of each box plot (p < 0.001).  
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3. 6) 
showed that the normal group differed significantly in SIRT5 gene expression from both 
malignant and non-malignant groups (normal versus non-malignant p < 0.001, normal 
versus malignant; p < 0.001). However, at the 5% level of significance the data showed no 
significant difference between the malignant and non-malignant groups (p = 0. 072). 
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3.5.4 Comparison of the relative transcriptional expression levels 
of SIRT5 according to histopathological markers. 
The relationships between SIRT5 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
3.5.4.1 Comparison of the relative transcriptional expression levels of SIRT5 
according to tumour grade, tumour size, nodal status, oestrogen 
receptor status and lymphovascular invasion 
Analysis of the data for the relationship between SIRT5 gene expression and tumour grade, 
tumour size, nodal status, oestrogen receptor status and lymphovascular invasion all 
showed no significant differences in the relative transcriptional expression levels of SIRT5 
between any categories when compared together (Figure 3. 67 a, b, c, d and e). Table 3.6 
shows the Kruskal-Wallis test p values for all comparisons.  
 
3.5.5 The relationship of the relative transcriptional expression 
levels of SIRT5 in breast cancer biopsies to patient survival 
and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT5 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT5 gene expression. In analyses shown below, the two tertiles with lower SIRT5 
gene expression levels have been combined and are compared to the highest level of 
SIRT5 gene expression tertile group. Table 3.17 and Table 3.18 show the numbers of 
patients included in each group. 
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Figure 3.67: Box plots showing the relative transcriptional expression of SIRT5 in breast 
cancer biopsies by known prognostic markers:  
(a) tumour grade, n = 3 for G1, n = 32 for G2, and n = 29 for G3 (Mann Whitney test p = 
0.978). (b) tumour size, n = 10 for T1, n = 43 for T2 , n = 13 for T3 and n = 2 for T4 (Kruskal 
Wallis Test, p = 0.168), (c) nodal status, n = 18 for node negative  and n =  42 for node 
positive (Mann Whitney test p = 0.508. (d) oestrogen receptor status, n = 20 for ER-ve  and n = 
31 for ER+ve (Mann Whitney test p = 0.365. e) Lymphovascular invasion (LV) n = 17 for LV–ve 
and n = 28 for LV+ve (Mann Whitney test p = 0.242).  The median value for each patient group 
is shown right of each box. 
  
 
 
 
 
 
(a) (b) 
(c)  (d) 
(e) 
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Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT5 gene 
expression 43 15 22 6 18 7
High SIRT5 gene 
expression 23 5 12 3 11 3
Overall 66 20 34 9 29 10
SIRT5 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
3.5.5.1 SIRT5 and survival  
3.5.5.1.1 Survival analysis in entire patient cohort according to SIRT5 levels.  
 
Analysis of the survival data for the entire patient group using the Kaplan-Meier test 
showed no significant difference in survival period when all patients were included (Table 
3.17). The survival period was not significantly shorter in patients with tumours that 
expressed low levels of SIRT5 (n = 43, 10.48 years, 95% C.I. 8.7 -12.26) when compared 
to those whose tumours expressed high levels of SIRT5 (n = 23, 12.28 years, 95% C.I. 
10.24 – 14.31, Kaplan-Meier p = 0.305; Figure 3. 68). 
Table 3.17: Number of breast cancer patient and cancer specific deaths of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis.  
 
 
 
 
 
 
 
Figure 3.68: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT5 expression. 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a non significant decrease in tumours that express 
low levels of SIRT5 (n = 43, 10.48 years, 95% C.I. 8.7 -12.26) when compared to those whose 
tumours express high levels of SIRT5 (n = 23, 12.28 years, 95% C.I. 10.24 – 14.31, Kaplan-
Meier p = 0.305). 
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3.5.5.1.2 Survival analysis in NPI selected patients according to SIRT5 levels.  
 
Analysis of the survival data for the NPI-selected patient group (Table 3.17) using the 
Kaplan-Meier test did not show any significant difference in the survival period in patients 
with tumours that expressed low levels of SIRT5 (n = 22, 12.11 years, 95% C.I. 10.11 -
14.1) when compared to those whose tumours expressed high levels of SIRT5 (n = 12, 
12.25 years, 95% C.I. 9.695 – 14.8, Kaplan-Meier p = 0.983; Figure 3. 69). 
 
 
 
 
 
 
Figure 3.69: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT5 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows insignificant difference in the survival period in 
patients with tumours that express low levels of SIRT5 (n = 22, 12.11 years, 95% C.I. 10.11 -
14.1) when compared to those whose tumours express high levels of SIRT5 (n = 12.25 years, 
95% C.I. 9.695 – 14.8, Kaplan-Meier p = 0.983).  
 
3.5.5.1.3 Survival analysis in ER+ve selected patients according to SIRT5 levels.  
 
Analysis of the survival data for the ER+ve patient group (Table 3. 17) using the Kaplan-
Meier test showed no significant difference in the survival period in patients with tumours 
that expressed low levels of SIRT5 (n = 18, 9.53 years, 95% C.I. 6.59-12.97) when 
compared to those whose tumours expressed high levels of SIRT5 (n = 11, 11.33 years, 
95% C.I. 8.17 – 14.5, Kaplan-Meier p = 0.538, Figure 3.70). 
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Figure 3.70: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT5 expression in patients with ER+ve tumours. 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows non significant difference in the survival period in 
patients with tumours that express low levels of SIRT5 (n = 18, 9.53 years, 95% C.I. 6.59-
12.97) when compared to those whose tumours express high levels of SIRT5 (n = 11, 11.33 
years, 95% C.I. 8.17 – 14.5, Kaplan-Meier p = 0.538. 
 
3.5.5.2 SIRT5 and Recurrence. 
3.5.5.2.1 Recurrence analysis in entire patient cohort according to SIRT5 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, in all breast cancer 
patients, patient numbers are shown in (Table 3.18). There was no significant differences 
in the recurrence interval between patients with tumours that expressed low levels of 
SIRT5 (n = 43, 10.61 years, 95% C.I. 10.61-12.63) when compared to those whose 
tumours express high levels of SIRT5 (n = 23, 12.32 years, 95% C.I. 10.0 -14.63, Kaplan-
Meier p = 0.272, Figure 3.71). 
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Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT5 gene 
expression 43 14 23 10 19 8
High SIRT5 gene 
expression 23 4 12 2 11 3
Overall 66 18 33 12 29 11
SIRT5 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
Breast cancer patients with 
ER+ve
 
Table 3.18: Number of breast cancer patient and tumour recurrences of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3.71: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT5 expression. 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a non significant difference in the time to 
recurrence in patients with tumours that express low levels of SIRT5 (n = 43, 10.61 years, 
95% C.I. 10.61-12.63) when compared to those whose tumours express high levels of SIRT5 
(n = 23, 12.32 years, 95% C.I. 10.0 -14.63, Kaplan-Meier p = 0.272. 
 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
206 
3.5.5.2.2 Recurrence analysis in NPI selected patients according to SIRT5 levels. 
 
When tumour recurrence among the NPI-selected patient group was analysed (Table 3. 
18), there was no significant difference according to the level of SIRT5 gene expression in 
patients with tumours that expressed low levels of SIRT5 (n = 23, 10.04 years, 95% C.I. 
7.35-12.72) when compared to those whose tumours expressed high levels of SIRT5 (n = 
12, 12.49 years, 95% C.I. 9.37 -15.61, Kaplan-Meier p = 0.287; Figure 3.72). 
 
 
 
 
 
 
 
Figure 3.72: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT5 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a non significant difference in the time to 
recurrence period in patients with tumours that express low levels of SIRT5 (n = 23, 10.04 
years, 95% C.I. 7.35-12.72) when compared to those whose tumours express high levels of 
SIRT5 (n = 12, 12.49 years, 95% C.I. 9.37 -15.61, Kaplan-Meier p = 0.287). 
 
3.5.5.2.3 Recurrence analysis in ER+ve patients according to SIRT5 levels. 
 
Further analysis of recurrence within the subgroup of patients with ER+ve tumours failed to 
reveal any significant difference in time to recurrence between patients with tumours that 
expressed low levels of SIRT5 (n = 19, 8.82 years, 95% C.I. 5.66 -11.98) when compared 
to those whose tumours expressed high levels of SIRT5 (n = 11, 10.46 years, 95% C.I. 
6.41-14.51, Kaplan-Meier p = 0.531, Figure 3.73).  Patient numbers for each group are 
shown in Table 3.18. 
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Figure 3.73: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT5 expression in patients with ER+ve tumours. 
High and low SIRT5 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence curve showed a insignificant difference in the time to 
recurrence in patients with tumours that express low levels of SIRT5 (n = 19, 8.82 years, 
95% C.I. 5.66 -11.98) when compared to those whose tumours express high levels of SIRT5 
(n = 11, 10.46 years, 95% C.I. 6.41-14.51, Kaplan-Meier p = 0.531). 
 
3.5.6 Conclusion 
 
This study investigated the relative transcriptional expression levels of the SIRT5 gene in 
(25) normal, (69) non-malignant and (69) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT5 as the data distributions were positively skewed in all patient groups. 
The data for SIRT5 gene expression variation between breast biopsies did not show a clear 
significant difference between the malignant and non-malignant groups of similar age, 
although there may be a trend towards decreased expression associated with malignant 
changes. Interestingly, the expression level of SIRT5 did show significant differences 
when the normal group was compared with both non-malignant and malignant groups. 
SIRT5 gene expression did not show significant correlation with patient survival, or 
tumour recurrence, either in the entire patient set, or in a patient group selected by NPI, or 
ER+ve status to have an intermediate clinical prognosis.  
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N Percent N Percent N Percent
Normal 25 96.20% 1 3.80% 26 100.00%
Non-Malignant 73 93.60% 5 6.40% 78 100.00%
Malignant 70 95.90% 3 4.10% 73 100.00%
Sample Type
Cases
Valid Missing Total
Relative SIRT6 
Expression
3.6 The relative transcriptional expression levels of 
SIRT6 in breast biopsies.  
3.6.1 The relative transcriptional expression levels of SIRT6 and 
patients age. 
The relative transcriptional expression levels of SIRT6 gene were determined in 25 normal 
biopsies, (73) non-malignant and (70) malignant (Table 3. 19).  
Table 3.19: Patient biopsies used in the SIRT6 study. 
 
The correlation between the level of SIRT6 relative transcriptional expression and patient’s 
age was investigated in a patient group that combines both normal and non-malignant 
patients (Figure 3.74 a).  The median age of this patient group was 51years (20 years -84 
years).  This data showed that there was no significant correlation between the relative 
transcriptional levels of SIRT6 and chronological age (Spearman's rank correlation 
coefficient; p = 0.153; Figure 3.74 b). 
 
 
 
   
 
Figure 3.74: (a) Distribution of patient’s age patient group that combines both normal and 
non-malignant patients. (b) Correlation between relative transcription levels of SIRT6 and 
patient’s age in patient group that combines both normal and non-malignant patients 
(Spearman test, p = 0.153). 
  
(a) (b) 
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3.6.2 Data distribution of the relative transcriptional expression 
levels of SIRT6. 
The distribution of the relative transcriptional gene expression of SIRT6 was investigated 
in the three different studied biopsy types, (Figure 3.75). The histograms of the distribution 
of the relative transcriptional gene expression of SIRT6 showed that the range of the 
SIRT1 gene expression values was not normally distributed; instead the SIRT6 gene 
expression distribution was positively skewed in normal and non-malignant groups. 
However, SIRT6 gene expression data was normally distributed in the malignant group. 
(Figure 3.75) Therefore, non-parametric statistical tests were used for future data analysis 
for the relative transcriptional gene expression of SIRT6. 
 
 
 
 
 
 
 
 
 
 
Figure 3.75: Distribution of the relative transcriptional gene expression of SIRT6 in Three 
different groups. 
(a) Relative transcriptional gene expression of SIRT6 in normal breast biopsies. (b) Relative 
transcriptional gene expression of SIRT6 in non-malignant breast biopsies. (c) Relative 
transcriptional gene expression of SIRT6 in malignant breast biopsies. 
 
  
 
(a) (b) 
(c)  
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3.6.3 Comparison of the relative transcriptional expression levels 
of SIRT6 between patient groups. 
First, the level of SIRT6 relative transcriptional expression was compared between all 
three groups. A Kruskal-Wallis test demonstrated that the relative transcriptional 
expression level for SIRT6 was significantly different between the three groups of breast 
biopsies (p < 0.001, Figure 3.76). This experiment showed that malignant samples have 
significantly lower levels of SIRT6 gene expression compared to both normal and non-
malignant samples (p < 0.001, Figure 3.76). 
 
 
 
 
 
 
Figure 3.76: Box plot showing the transcriptional expression of SIRT6 in normal, non-
malignant and malignant breast biopsies, relative to HPRT.  
The median value for each patient group is shown in the clear box to the right of each box 
plot (p < 0.001). 
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3.6) showed 
that the malignant groups had significantly lower levels of SIRT6 gene expression when 
compared with both (p < 0.001) normal and non- malignant (p < 0.001) groups. However, 
there was a significant increase in the levels of SIRT6 gene expression in the non-
malignant when compared with normal breast biopsies (p = 0.019, Figure 3.76, Table 3.6). 
3.6.4 Comparison of SIRT6 gene transcription levels according to 
histopathological markers 
The relationships between SIRT6 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
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3.6.4.1 Comparison of the relative transcriptional expression levels of SIRT6 
according to tumour grades. 
Analysis of the data for the relationship between SIRT6 gene expression and tumour grade 
showed a significant difference in the relative transcriptional expression levels of SIRT6 
between all three tumour grades when compared together (Kruskal-Wallis test p = 0.002) 
(Figure 3.77). The relative transcriptional expression of SIRT6 decreases with increasing 
severity (higher tumour grade) of tumour. 
 
 
 
 
 
 
 
 
 
Figure 3.77: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by tumour grade. 
n = 4 for grade 1, 32 for grade 2 and 29 for grade 3 (Kruskal Wallis Test, p = 0.002). The 
median value for each patient group is shown in the clear box to the right of each box plot. 
 
Pairwise comparisons of the three groups using the Mann-Whitney test (Table 3.6) showed 
that grade 3 tumours groups differed significantly in SIRT6 gene expression from both 
grade 1 (p = 0.04) and grade 2 tumours (p = 0.001), whereas there was no significant 
difference between grade 1 and grade 2 tumours (p = 0.610; Figure 3. 77). 
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3.6.4.2 Comparison of the relative transcriptional expression levels of SIRT6 
according to tumour size, nodal status, oestrogen receptor status 
and lymphovascular invasion 
Analysis of the data for the relationship between SIRT6 gene expression and tumour size, 
nodal status, ER status and lymphovascular invasion all showed no significant difference 
in the relative transcriptional expression levels of SIRT6 between any categories when 
compared together (Figure 3. 78 a, b, c and d). Table 3.6 shows the Kruskal-Wallis test p 
values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
Figure 3.78 : Box plots showing the relative transcriptional expression of SIRT6 in breast 
cancer biopsies by known prognostic markers: 
(a) tumour size, n = 11 for T1,n = 43 for T2 , n = 13 for T3 and n = 2 for T4 (Kruskal Wallis 
Test, p = 0.478). (b) nodal status n = 19 for node negative and n = 42 for node positive,  
(Kruskal Wallis Test p = 0.697), (c) oestrogen receptor status n = 19 for ER negative and n = 
32 for ER positive (Kruskal Wallis Test,  p = 0.508). (d) lymphovascular invasion, n = 18 for 
negative lymphovascular invasion and n = 28 for positive negative lymphovascular invasion 
(Kruskal Wallis Test,  p = 0.392).  The median value for each patient group is shown in the 
clear box to the right of each box plot. 
   
 
(a) (b) 
(c)  (d) 
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3.6.5 The relationship of the relative transcriptional expression 
levels of SIRT6 in breast cancer biopsies to patient survival 
and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT6 relative gene expression, the patients were grouped in tertiles according to the level 
of SIRT6 gene expression. In analyses shown below, the two tertiles with lower SIRT6 
gene expression have been combined and are compared to the highest levels of SIRT6 gene 
expression tertile group. Table 3.20 and Table 3. 22 show the numbers of patients included 
in each group. 
3.6.5.1 SIRT6 and survival.  
3.6.5.1.1 Survival analysis in entire patient cohort according to SIRT6 levels.  
 
Analysis of the survival data for the entire patient group (Table 3. 20) using the Kaplan-
Meier test showed that the mean survival period was significantly shorter in patients with 
lower SIRT6 expression (n = 43, 9.67 years, 95% C.I. 7.8 -11.5) when compared with 
those with higher SIRT6 expression (n = 24, 13.6 years, 95% C.I. 12.35 -15.04, Kaplan-
Meier, p = 0.009, Figure 3. 79). Furthermore, Cox-regression analysis of the hazard ratios 
revealed that patients with decreased tumour expression for SIRT6 were 1.5 times  (95% 
CI 1.31-15.41, p = 0.017) more likely to die as a consequence of breast cancer disease than 
those patients with high levels of SIRT6. 
Table 3.20: Number of breast cancer patient and cancer specific deaths of all patient groups 
included in the Kaplan-Meier survival analysis.  
 
 
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT6 gene 
expression 43 17 17 8 19 10
High SIRT6 gene 
expression 24 3 17 1 11 0
Overall 67 20 34 9 30 10
SIRT6 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
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Figure 3.79: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT6 expression. 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a significant decrease in the survival period for 
patients with tumours that express low levels SIRT6 (n = 43, 9.67 years, 95% C.I. 7.8 -11.5) 
when compared to those whose tumours express high levels of SIRT6 (n = 24, 13.6 years, 
95% C.I. 12.35 -15.04, Kaplan-Meier survival analysis, p = 0.009). 
Multivariate Cox-regression analysis demonstrated that the relative transcriptional level of 
SIRT6 gene was independent of tumour size, grade, nodal status, ER status, 
lymphovascular invasion status, and Nottingham Prognostic Index (NPI) in influencing 
survival (p = 0.035, Table 3.21).  
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Table 3.21: Multivariate Cox-regression stepwise analysis for breast cancer specific survival 
for SIRT6 and prognostic factors.  
p values, Hazard ratio (HR) for death and confidence interval (CI) for the HR for SIRT6 and 
each prognostic factor are displayed in the table.  
 
 
 
 
 
 
SIRT6 0.028 -3.034 0.003 0.716
Tumour Grade 0.335 -1.12 0.034 3.179
Tumour Size 0.183 1.234 0.558 21.152
N 0.135 1.928 0.549 86.074
ER 0.059 -2.989 0.002 1.118
LV 0.362 -1.267 0.019 4.283
NPI 0.547 0.868 0.141 40.118
SIRT6 0.024 -2.859 0.005 0.685
Tumour Grade 0.445 -0.621 0.109 2.643
Tumour Size 0.097 1.431 0.77 22.705
N 0.007 2.47 1.94 72.124
ER 0.042 -2.493 0.007 0.915
LV 0.444 -0.886 0.043 3.984
SIRT6 0.034 -2.502 0.008 0.824
Tumour Size 0.123 1.295 0.704 18.932
N 0.011 2.412 1.734 71.832
ER 0.055 -2.28 0.01 1.049
LV 0.535 -0.686 0.058 4.394
SIRT6 0.038 0.089 0.009 0.879
Tumour Size 0.05 4.645 1.001 21.562
N 0.014 10.672 1.625 70.096
ER 0.034 0.163 0.03 0 .874
Lower Upper
Step 1
Step 2
Step 3
Step 4
95.0% CI Sig. HR
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3.6.5.1.2 Survival analysis in NPI selected patients according to SIRT6 levels.  
 
Analysis of the survival data in patients with (NPI between 3.4-5.4, Table 3.20) 
demonstrated that lower SIRT6 expression remained significantly associated with shorter 
survival. Mean survival period was significantly shorter (n = 17, 9.87 years, 95% C.I. 7.37-
12.37) in patients with tumours that expressed low levels of SIRT6 when compared with 
those with high level of SIRT6 (n = 17, 14.5 years, 95% C.I. 13.6-15.4, Log Rank, 
p=0.004, Figure 3. 80). 
 
 
 
 
 
 
 
Figure 3.80: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT6 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows a significant decrease in the survival period for 
patients with tumours that express low levels SIRT6 (n = 17, 9.87 years, 95% C.I. 7.37-12.37) 
when compared to those whose tumours express high levels of SIRT6 (n = 17, 14.5 years, 
95% C.I. 13.6-15.4, Kaplan-Meier, p=0.004). 
3.6.5.1.3  Survival analysis in ER+ve patients according to SIRT6 levels.  
 
Analysis of the cancer specific survival data in patients with ER+ve tumours (Table 3.20) 
showed significant differences in the survival period between patients with tumours that 
expressed high levels of SIRT6 (n = 19) when compared to those whose tumours expressed 
low levels of SIRT6  (n = 11, Kaplan-Meier p = 0.002, Figure 3.81). The mean survival 
time could not be calculated for patient with high SIRT6 gene expression because of the 
small number of patients and lack of complete (15 years) follow up data. 
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Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT6 gene 
expression 43 13 18 8 20 8
High SIRT6 gene 
expression 24 5 17 4 11 3
Overall 67 18 35 12 31 11
SIRT6 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
Breast cancer patients with 
ER+ve
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.81: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT1 expression in patients with ER+ve. 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The survival curve shows significant difference in the survival period for 
patients with tumours that express high levels SIRT6 (n = 19) when compared to those 
whose tumours express low levels of SIRT6 (n = 11; Kaplan-Meier p = 0.002). 
3.6.5.2 SIRT6 and recurrence. 
3.6.5.2.1 Recurrence analysis in entire patient cohort according to SIRT6 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, and showed a 
statistically non-significant decrease in the recurrence interval in patients with high levels 
of SIRT6 gene expression when all patients were included. Patient numbers are shown in 
Table 3.22. Time to recurrence was statistically non significantly shorter in patients with 
tumours that expressed low levels of SIRT6 (n = 43, 10.45 years, 95% C.I. 8.28-12.62) 
when compared to those whose tumours expressed high levels of SIRT6 (n = 24, 12.24 
years, 95% C.I. 10.10 -14.38, Kaplan-Meier p = 0.178, Figure 3.82). 
Table 3.22 Number of breast cancer patient and tumour recurrences of all patient groups 
included in the Kaplan-Meier recurrence analysis. 
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Figure 3.82: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT6 expression. 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed that time to recurrence was non significantly 
shorter in patients with tumours that expressed low levels of SIRT6 (n = 43, 10.45 years, 
95% C.I. 8.28-12.62) when compared to those whose tumours express high levels of SIRT6 
(n = 24, 12.24 years, 95% C.I. 10.10 -14.38, Kaplan-Meier p = 0.178). 
 
3.6.5.2.2 Recurrence analysis in NPI selected patients according to SIRT6 levels.  
 
When tumour recurrence among patients with moderately good prognosis (NPI between 
3.4 and 5.4; Table 3.22), was analysed according to the level of SIRT6 gene expression 
there was a trend toward significant in the time to recurrence. Kaplan-Meier recurrence 
analysis showed that time to recurrence was shorter in patients with tumours that expressed 
low levels of SIRT6 (n = 18, 9.05 years, 95% C.I. 5.59-12.5) when compared to those 
whose tumours expressed high levels of SIRT6 (n = 17, 12.14 years, 95% C.I. 9.67 -14.6, 
Kaplan-Meier p = 0.067, Figure 3.83).  
3.6.5.2.3 Recurrence analysis in ER+ve selected patients according to SIRT6 
levels.  
 
Further analysis of recurrence within the subgroup of patients with ER+ve tumours (Table 
3.22 ) failed to reveal any significant difference in time to recurrence between patients with 
tumours that expressed low levels of SIRT6  (n = 20, 6.95 years, 95% C.I. 4.48-9.42) when 
compared to those whose tumours expressed high levels of SIRT6 (n = 11, 11.14 years, 
95% C.I. 7.47, 14.8, Kaplan-Meier p = 0.282, Figure 3.84). 
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Figure 3.83:  Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT6 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed that time to recurrence was shorter in patients 
with tumours that expressed low levels of SIRT6 (n = 18, 9.05 years, 95% C.I. 5.59-12.5) when 
compared to those whose tumours express high levels of SIRT6 (n = 17, 12.14 years, 95% 
C.I. 9.67 -14.6, Kaplan-Meier p = 0.067). 
 
 
 
 
 
 
 
Figure 3.84: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT6 expression in patients with ER+ve tumours. 
High and low SIRT6 expression groups were determined as above or below the upper tertile 
cutoff value. The recurrence plot showed that time to recurrence was significantly shorter in 
patients with tumours that expressed low levels of SIRT6  (n = 20, 6.95 years, 95% C.I. 4.48-
9.42) when compared to those whose tumours express high levels of SIRT6 (n = 11, 11.14 
years, 95% C.I. 7.47, 14.8, Kaplan-Meier p = 0.282).  
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3.6.6 Conclusion 
This study investigated the relative transcriptional expression levels of the SIRT6 gene in 
(25) normal, (73) non-malignant and (70) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT6 as the data were not normally distributed in all patient groups. 
The data for SIRT6 gene expression variation between biopsies showed that there were 
significant differences in SIRT6 gene expression between biopsies from malignant, non-
malignant and normal patient groups. The expression level of SIRT6 was significantly 
lower in malignant compared to both normal and non-malignant patient groups. SIRT6 
gene expression increased significantly in the non-malignant when compared to normal 
patient groups.  
The relative transcriptional expression level of SIRT6 showed significant association only 
with tumour grade, when breast cancer patients were divided according to the known 
histopathological markers. There was a significant correlation between decreased SIRT6 
gene expression and higher tumour grade.  
The Kaplan-Meier analysis for cancer specific survival according to relative transcriptional 
expression levels of SIRT6 showed that there was a significant association between SIRT6 
levels and survival period in all patients cohort and in patients’ subgroups, selected to have 
moderate prognosis (ER+ve and NPI between 3.4 and 5.4). Breast cancer patients with 
tumours that expressed low levels of SIRT6, were 1.5 times more likely to die as a 
consequence of the breast cancer disease, than those with tumours expressing high levels 
of SIRT6. 
Multivariate Cox-regression analysis demonstrated that the relative transcriptional level of 
the SIRT6 gene was independent of tumour size, grade, nodal status, oestrogen receptor 
status, lymphovascular invasion status, and the NPI in influencing survival. 
The Kaplan-Meier analysis for recurrence time according to relative transcriptional 
expression levels of SIRT6 showed that there was a trend towards a significant difference 
between decreased levels of SIRT6 and shorter recurrence time, only in breast cancer 
patients selected to have a moderate prognosis according the NPI.  
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N Percent N Percent N Percent
Normal 25 96.20% 1 3.80% 26 100.00%
Non-Malignant 76 97.40% 2 2.60% 78 100.00%
Malignant 72 98.60% 1 1.40% 73 100.00%
Relative SIRT7 
Expression
Sample Type
Cases
Valid Missing Total
3.7  The relative transcriptional expression levels of 
SIRT7 in breast biopsies. 
3.7.1 The relative transcriptional expression levels of SIRT7 and 
patients age. 
The relative transcriptional expression levels of SIRT7 gene were determined in 25 normal 
biopsies, (76) non-malignant and (72) malignant (Table 3.23).  
Table 3.23 Patient biopsies used in the SIRT7 study. 
 
The correlation between the level of SIRT7 relative transcriptional expression and patient’s 
age was investigated in a patient group that combines both normal and non-malignant 
patients (Figure 3. 85).  The median age of this patient group was 51years (20years - 
84years).  This data showed that there was negative correlation between the relative 
transcription levels of SIRT7 and chronological age. However, this correlation was not 
significant (Spearman's rank correlation coefficient; p = 0.119; Figure 3.85 b).  
 
 
 
 
 
 
Figure 3.85: (a) Distribution of patient’s age in patient group that combines both normal and 
non-malignant patients. (b) Correlation between relative transcription levels of SIRT7 and 
patient’s age in patient group that combines both normal and non-malignant patients 
(Spearman test, p = 0.173). 
  
(a) (b) 
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3.7.2 Data distribution of the relative transcriptional expression 
levels of SIRT7. 
The distribution of the relative transcriptional gene expression of SIRT7 was investigated 
in the three different studied biopsy types, (Figure 3.86). The histograms of the distribution 
of the relative transcriptional gene expression of SIRT7 showed that the range of the 
SIRT1 gene expression values was not normally distributed; instead the SIRT7 gene 
expression distribution was positive skewed in all groups (Figure 3.86). Therefore, non-
parametric statistical tests were used for future data analysis for the relative transcriptional 
gene expression of SIRT7.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.86: Distribution of the relative transcriptional gene expression of SIRT7 in three 
different groups.  
(a) Relative transcriptional gene expression of SIRT7 in normal breast biopsies. (b) Relative 
transcriptional gene expression of SIRT7 in non-malignant breast biopsies. (c) Relative 
transcriptional gene expression of SIRT7 in malignant breast biopsies. 
 
 
  
 
(a) (b) 
(c)  
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3.7.3 Comparison of the relative transcriptional expression levels 
of SIRT7 between patient groups. 
 
The level of SIRT7 relative transcriptional expression was compared between all three 
groups. A Kruskal-Wallis test demonstrated that the relative transcriptional expression 
level for SIRT7 was significantly different between the three groups of breast biopsies (p < 
0.001, Figure 3. 87). This experiment showed that normal samples have significantly 
higher levels of SIRT7 gene expression compared to both non-malignant and malignant 
samples (p < 0.001, Figure 3.87). 
 
 
 
 
 
 
 
 
 
 
Figure 3.87: Box plot showing the transcriptional expression of SIRT7 in normal, non-
malignant and malignant breast biopsies, relative to HPRT. 
(p < 0.001). The median value for each patient group is shown in the clear box to the right of 
each box plot. 
 
Pairwise comparisons of the three groups using the Mann-Whitney test showed that the 
normal groups differed significantly (Table 3.6) in SIRT7 gene expression from both non- 
malignant (p < 0.001) and malignant (p < 0.001) groups. However, there was no significant 
difference in the levels of SIRT7 gene expression between the non-malignant and 
malignant groups (p = 0.51) 
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3.7.4 Comparison of the relative transcriptional expression levels 
of SIRT7 according to histopathological markers. 
The relationships between SIRT7 and the standard histopathological parameters commonly 
used in describing breast cancer tumours were investigated and analysed. The data for each 
parameter is presented in the following sections. 
3.7.4.1 Comparison the relative transcriptional expression levels of SIRT7 
according to tumour grades. 
Analysis of the data for the relationship between SIRT7 gene expression and tumour grade 
showed a trend toward significance at the 5% significance level when all three tumour 
grades were compared together (Kruskal-Wallis test p < 0.067) (Figure 3. 88). Assuming a 
valid trend then the level of SIRT7 expression decreases with increasing severity (higher 
grade) of tumour. 
Pairwise comparisons of the three groups using the Mann-Whitney test showed that there 
was a marginal significant increase (Table 3.6) in the levels of SIRT7 in G 1 tumours when 
compared to both G2 and G3 (p = 0.048 and p = 0.062 respectively, Figure 3. 88). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.88: Box plot showing the relative transcriptional expression of in breast cancer 
biopsies by tumour grade. 
n = 4 for grade 1, n =  32 for grade 2 and n = 29 for grade 3 (Kruskal Wallis Test, p = 0.002). 
The median value for each patient group is shown in the clear box to the right of each box 
plot. 
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3.7.4.2 Comparison of the relative transcriptional expression levels of SIRT7 
according to tumour size, nodal status, oestrogen receptor status 
and lymphovascular invasion. 
Analysis of the data for the relationship between SIRT7 gene expression and tumour size, 
nodal status, ER status and lymphovascular invasion all showed no significant difference 
in the relative transcriptional expression levels of SIRT7 between any categories when 
compared together (Figure 3. 89 a, b, c and d). Table 3.8 shows the Kruskal-Wallis test p 
values for all comparisons.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.89: Box plots showing the relative transcriptional expression of SIRT7 in breast 
cancer biopsies by known prognostic markers:  
a) tumour size, n = 11 for T1, n = 45 for T2 , n = 13 for T3 and n = 2 for T4 (Kruskal Wallis 
Test, p = 0.756). b) nodal status n = 20 for node negative and n = 43 for node positive,  
(Kruskal Wallis Test p = 0.690), c) oestrogen receptor status n = 20 for ER negative and n = 
32 for ER positive (Kruskal Wallis Test,  p = 0.607). d) lymphovascular invasion, n = 19 for 
negative lymphovascular invasion and n = 29 for positive negative lymphovascular invasion 
(Kruskal Wallis Test,  p = 0.317).  The median value for each patient group is shown in the 
clear box to the right of each box plot. 
  
  
(a) (b) 
(c)  (d) 
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Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Patients 
Number
Number of Cancer 
specific deaths
Low SIRT7 gene 
expression 35 13 17 6 21 9
High SIRT7 gene 
expression 34 7 18 3 10 1
Overall 69 20 35 9 31 10
SIRT7 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4 Breast cancer patients with ER
+ve
 
3.7.5 The relationship of the relative transcriptional expression 
levels of SIRT7 in breast cancer biopsies to patient survival 
and tumour recurrence. 
In order to investigate the relationship between patient survival, tumour recurrence and 
SIRT7 relative gene expression, the patients were grouped into two groups using the 
median level of SIRT7 gene expression as a cutoff value. Table 3.24 and Table 3.26 show 
the numbers of patients included in each group. 
3.7.5.1 SIRT7 and survival  
3.7.5.1.1 Survival analysis in entire patient cohort according to SIRT7 levels.  
 
Analysis of the survival data for the entire patient group (Table 3.24) using the Kaplan-
Meier test showed that the survival period was significantly shorter in patients with 
tumours that expressed low levels of SIRT7 (n = 35, 9.82 years, 95% C.I. 7.74 -11.90) 
when compared to those whose tumours expressed high levels of SIRT7 (n = 34, 12.64 
years, 95% C.I. 11.10-14.17, Kaplan-Meier p = 0.05, Figure 3.90).  
 
Table 3.24: Number of breast cancer patient and cancer specific deaths of both patient 
groups included in the Kaplan-Meier survival analysis.  
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SIRT7 0.1 1.612 0.735 34.19
Tumour Grade 0.503 -0.65 0.078 3.499
Tumour Size 0.005 -3.228 0.004 0.386
N 0.054 -2.754 0.004 1.052
ER 0.126 1.336 0.686 21.104
LV 0.623 -0.423 0.121 3.544
NPI 0.759 0.376 0.132 16.026
SIRT7 0.098 1.505 0.757 26.795
Tumour Grade 0.525 -0.452 0.157 2.57
Tumour Size 0.004 -3.108 0.005 0.364
N 0.011 -2.432 0.014 0.572
ER 0.129 1.291 0.687 19.251
LV 0.651 -0.386 0.128 3.609
SIRT7 0.106 1.448 0.736 24.614
Tumour Grade 0.6 -0.363 0.18 2.696
Tumour Size 0.003 -2.981 0.007 0.364
N 0.011 -2.402 0.014 0.572
ER 0.071 1.436 0.886 19.959
SIRT7 0.107 1.373 0.744 20.964
Tumour Size 0.002 -3.034 0.007 0.338
N 0.01 -2.443 0.014 0.555
ER 0.059 1.491 0.945 20.874
Step 4
Step 1
Step 2
Step 3
Sig. HR
95.0% CI 
Lower Upper
Multivariate Cox-regression analysis demonstrated that the relative transcriptional level of 
SIRT7 gene was not independent of tumour size, grade, nodal status, ER status, 
lymphovascular invasion, and NPI in influencing survival (p = 0.107, Table 3.25).  
Table 3.25: Multivariate Cox-regression stepwise analysis for breast cancer specific survival 
for SIRT7 and prognostic factors.  
P values, Hazard ratio (HR) for death and confidence interval (CI) for the HR for SIRT7 and 
each prognostic factors are displayed in the table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
228 
 
 
 
 
 
Figure 3.90:  Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT7 expression. 
High and low SIRT7 expression groups were determined as above or below the median 
cutoff value. The survival curve shows a significant decrease in the survival period for 
patients with tumours that express low levels of SIRT7 (n = 35, 9.82 years, 95% C.I. 7.74 -
11.90) when compared to those whose tumours express high levels of SIRT7 (n = 34, 12.64 
years, 95% C.I. 11.10-14.17, Kaplan-Meier p = 0.05). 
 
3.7.5.1.2  Survival analysis in NPI selected patients according to SIRT7 levels.  
 
Analysis of the survival data in patients with moderately good prognosis (NPI between 3.4-
5.4, Table 3. 24) demonstrated that there was no significant difference in the cancer 
specific survival period in patients with tumours that expressed low levels of SIRT7 (n = 
17, 10 .94 years, 95% C.I. 8.46-13.42) when compared to those whose tumours expressed 
high levels of SIRT7 (n = 18, 13.42 years, 95% C.I. 11.74 -15.10, Kaplan-Meier p = 0.1, 
Figure 3.91). 
3.7.5.1.3  Survival analysis in ER+ve patients according to SIRT7 levels.  
 
Analysis of the survival data for the ER+ve patient group (Table 3.24) using the Kaplan-
Meier test showed a significant decrease in the survival period in patients with tumours 
that expressed low levels of SIRT7 (n = 21, 8.80 years, 95% C.I. 6.12-11.48) when 
compared to those whose tumours expressed high levels of SIRT7 (n = 10, 13.86 years, 
95% C.I. 11.82 –15.89, Kaplan-Meier p = 0.045, Figure 3.92). 
 
 Samer Zino, 2010                                                                                                       Chapter III, 
 
 
229 
 
 
 
 
 
 
 
Figure 3.91: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT7 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4).  
H High and low SIRT7 expression groups were determined as above or below the median 
cutoff value. The survival curve shows a non-significant decrease in the survival period for 
patients with tumours that express low levels of SIRT7 (n = 17, 10 .94 years, 95% C.I. 8.46-
13.42) when compared to those whose tumours express high levels of SIRT7 (n = 18, 13.42 
years, 95% C.I. 11.74 -15.10, Kaplan-Meier p = 0.1). 
 
 
 
 
Figure 3.92: Kaplan-Meier Survival plot for breast cancer patients according to the level of 
SIRT7 expression in patients with ER+ve tumours.  
High and low SIRT7 expression groups were determined as above or below the median 
cutoff value. The survival curve shows a significant decrease in the survival period in 
patients with tumours that express low levels of SIRT7 (n = 21, 8.80 years, 95% C.I. 6.12-
11.48) when compared to those whose tumours express high levels of SIRT7 (n = 10, 13.86 
years, 95% C.I. 11.82 –15.89 , Kaplan-Meier p = 0.045). 
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Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Patients 
Number
Number of 
recurrences
Low SIRT7 gene 
expression 34 7 17 5 21 6
High SIRT7 gene 
expression 35 11 19 7 11 5
Overall 69 18 36 12 32 11
SIRT7 Tertile
All breast cancer patients Breast cancer patients with NPI between 3.4-5.4
Breast cancer patients with 
ER+ve
3.7.5.2 SIRT7 and recurrence.  
3.7.5.2.1 Recurrence analysis in entire patient cohort according to SIRT7 levels.  
 
Recurrence of tumours was analysed using the Kaplan-Meier test, in all breast cancer 
patients, patient numbers are shown in Table 3. 26. There was no significant differences in 
the recurrence interval between patients with tumours that expressed low levels of SIRT7 
(n = 34, 11.45 years, 95% C.I. 9.22-13.68) when compared to those whose tumours 
expressed high levels of SIRT7 (n = 35, 11.14 years, 95% C.I. 9.03 -13.25, Kaplan-Meier p 
= 0.677, Figure 3.93). 
Table 3.26: Number of breast cancer patient and tumour recurrences of all breast cancer 
patient groups included in the Kaplan-Meier survival analysis. 
 
 
3.7.5.2.2  Recurrence analysis in NPI selected patients according to SIRT7 levels.  
 
When tumour recurrence among the NPI-selected patient group was analysed (Table 3. 
26), there was no significant difference according to the level of SIRT7 gene expression in 
patients with tumours that expressed low levels of SIRT7 (n = 17, 10.67 years, 95% C.I. 
7.67-13.68) when compared to those whose tumours expressed high levels of SIRT7 (n = 
19, 10.86 years, 95% C.I. 7.86 -13.85, Kaplan-Meier p = 0.994, Figure 3.94). 
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Figure 3.93: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT7 expression. 
 High and low SIRT7 expression groups were determined as above or below the median 
cutoff value. The recurrence curve showed a non significant difference in the time to 
recurrence in patients with tumours low levels of SIRT7 (n = 34, 11.45 years, 95% C.I. 9.22-
13.68) when compared to those whose tumours express high levels of SIRT7 (n = 35, 11.14 
years, 95% C.I. 9.03 -13.25, Kaplan-Meier p = 0.677). 
 
 
 
 
 
 
 
Figure 3.94: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT7 expression in patients group with moderate prognosis (NPI between 3.4 and 5.4). 
High and low SIRT7 expression groups were determined as above or below the median 
cutoff value. The recurrence curve showed a non-significant difference in the time to 
recurrence period in patients with tumours that express low levels of SIRT7 (n = 17, 10.67 
years, 95% C.I. 7.67-13.68) when compared to those whose tumours express high levels of 
SIRT7 (n = 19, 10.86 years, 95% C.I. 7.86 -13.85, Kaplan-Meier p = 0.994). 
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3.7.5.2.3 Recurrence analysis in ER+ve patients according to SIRT7 levels.  
 
Further analysis of recurrence within the subgroup of patients with ER+ve tumours  (Table 
3.26 ) failed to reveal any significant difference in time to recurrence between patients with 
tumours that expressed low levels of SIRT7 (n = 21, 10 years, 95% C.I. 6.86 -13.14) when 
compared to those whose tumours expressed high levels of SIRT7 (n = 13, 9.21 years, 95% 
C.I. 5.38-13.04, Kaplan-Meier p = 0.684, Figure 3.95) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.95: Kaplan-Meier recurrence plot for breast cancer patients according to the level 
of SIRT7 expression in patients with ER+ve tumours. 
High and low SIRT7 expression groups were determined as above or below the upper 
median value. The recurrence curve showed a non-significant difference in the time to 
recurrence in patients with tumours that express low levels of SIRT7 (n = 21, 10years, 95% 
C.I. 6.86 -13.14) when compared to those whose tumours express high levels of SIRT7 (n = 
13, 9.21 years, 95% C.I. 5.38-13.04, Kaplan-Meier p = 0.684). 
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3.7.6 Conclusion 
This study investigated the relative transcriptional expression levels of the SIRT7 gene in 
(25) normal, (76) non-malignant and (72) malignant breast biopsies. Non-parametric 
statistical tests were used to analyse the data for relative transcriptional gene expression of 
SIRT7 as the data distributions were positively skewed in all patient groups.  
The data for SIRT7 gene expression variation between breast cancer biopsies showed that 
there were significant differences in SIRT7 gene expression between biopsies from 
malignant, non-malignant and normal patient groups. The expression level of SIRT7 was 
significantly higher in normal compared to both non-malignant and malignant patient 
groups. There was no significant difference in the levels of SIRT7 expression between 
non- malignant and malignant patient groups.  
There was a marginal significant increase in the levels of SIRT7 in G1 tumours when 
compared to both G2 and G3 (p = 0.048 and p = 0.062 respectively). 
The Kaplan-Meier analysis for cancer specific survival according to relative transcriptional 
expression levels of SIRT7 showed that there was a significant association between higher 
levels of SIRT7 and longer survival period in all patients cohort and in ER+ve breast cancer 
patients.  However, SIRT7 gene expression was not independent of tumour size, grade, 
nodal status, ER status, lymphovascular invasion, and NPI in influencing survival.  
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The relative transcriptional 
expression of sirtuins in breast 
cancer 
 
4.1 Summary of experimental results. 
The relative transcriptional expression levels of the sirtuin genes were investigated in (25) 
normal, (78) non-malignant and (73) malignant breast biopsies. Non-parametric tests were 
used to compare the relative transcriptional expression levels of the Sirtuin genes between 
these three groups and to compare sirtuins levels in breast cancer biopsies grouped 
according to the known histopathological and prognostic factors. The Kaplan-Meier 
statistical analysis was used to investigate whether there was significant association 
between the relative transcriptional expression levels of the sirtuin genes, tumour 
recurrence and cancer specific survival.  
This discussion is based on the significant results of this experiment that are presented in 
Table 6.1: refer to Table 3.6 for p values. 
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Table 4.1:summary of the significant experimental results for sirtuins genes expression in 
breast biopsy.  
 
The work presented in this thesis differs technically in two key ways from the study by 
(Ashraf et al, 2006). The number of patients has been increased, a new control group 
added, and HPRT used as the housekeeping gene. Crucially, the validation experiments 
reported here in relation to the use of 18S rRNA demonstrate that 18S rRNA was not ideal 
as a housekeeping gene comparator for any of these genes, and very poor for SIRT4, 
SIRT5, and SIRT6 (Chapter 3.1). Therefore, HPRT was used instead of the 18S rRNA 
gene as a housekeeping gene after being validated. A review of the validation experiment 
for the previous study by (Ashraf et al, 2006) supported this decision (Appendix 3). One 
explanation for these observations is that the combination of increased patient numbers and 
a more appropriate housekeeping gene comparator, may contribute to the observed 
differences between the two studies and indicates that the work presented here should be 
regarded as more appropriate.  
Genes  Significant results 
Lower in malignant when compared with normal  and non-malignant breast biopsies.
Association between decreased levels and higher tumour grade. 
Lower in malignant when compared with normal  and non-malignant breast biopsies. 
Association between decreased levels and higher tumour grade.
Lower in malignant when compared with normal  and non-malignant breast biopsies. 
Association between decreased levels and higher tumour grade.
Lower in malignant when compared with non-malignant breast biopsies.
Positive correlation with increasing age. 
Lower levels are associated with early recrrence in ER+ve breast cancer patients.
Lower in normal when compared with non-malignant and  malignant breast biopsies. 
Lower in malignant when compared with normal  and non-malignant breast biopsies. 
Association between decreased levels and higher tumour grade. 
Independent predictor of survival.
Higher in normal when compared with non-malignant and malignant breast biopsies. 
Higher in grade 1 when compared with grade 2 The relative transcriptional 
expression of SIRT7 gene Higher levels are associated with longer survival period in all patients cohort and in
ER+ve breast cancer patients. 
The relative transcriptional 
expression of SIRT4 gene
The relative transcriptional 
expression of SIRT5 gene Trend of decreased expression associated with malignant changes when compared to non-malignant.
The relative transcriptional 
expression of SIRT6 gene
Higher levels are  associated with longer survival period in all patients cohort and in  
patient selected with ( ER+ve and NPI between 3.4 and 5.4). 
The relative transcriptional 
expression of SIRT1 gene Lower levels are associated with longer survival period (patient selected according to 
NPI between 3.4-5.4).
The relative transcriptional 
expression of SIRT2 gene
The relative transcriptional 
expression of SIRT3 gene
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4.2 Breast biopsies and the characteristics of patient 
cohorts.   
Patient’s age was significantly different in normal when compared with patient’s age in 
both non-malignant and malignant groups. Since, the incidence of breast cancer increases 
rapidly with age, it was expected that average age of patients with breast cancer disease (61 
years would be greater than those (young ladies) who require reduction mammoplasty 
(41.6). 
This study confirms that the presence, or absence of axillary nodal metastases is the single 
most important prognostic factor, for both survival and recurrence in breast cancer. The 
loss of significance for other prognostic markers in this patient cohort is likely to be due to 
the small number and the unequal distribution of cancer biopsies according to these 
prognostic factors. The NPI was able to correct for these differences and showed 
significant association with cancer specific survival in this study.   
4.3 The relative transcriptional expression level of Sirtuin 
in breast biopsies.  
4.3.1 The relative transcriptional expression level of SIRT1 in 
breast biopsies. 
The decreased levels of SIRT1 with increasing age in the “normal patient group” is 
consistent with another study showing that the level of SIRT1 decreases significantly with 
serial cell passage in both human and mice cells (309).  
 
The anti-apoptotic and pro-apoptotic effects of SIRT1 reflect its complicated biological 
functions, and are indicative of its intricate potential involvement in cancer disease (refer 
to introduction chapter; 1.6.2). The data presented here is interesting, as it is consistent 
with the anti-tumourgenic effect of SIRT1. Several studies suggest that SIRT1 may act as a 
tumour suppressor. MEFs derived from SIRT1-null mice are prone to spontaneous 
immortalization, suggesting that SIRT1 behaves as a growth-suppressive gene in culture 
(310). Furthermore, hematopoietic stem cells from SIRT1-null mice have increased 
proliferation potential, and siRNA knockdown of SIRT1 in human fibroblasts accelerates 
cell proliferation (230, 326). SIRT1 has also been shown to inhibit androgen receptor 
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dependent cell proliferation in prostate tumour cells (277). Furthermore, transgenic over-
expression of SIRT1 in the intestine, inhibited polyp formation in the ApcMin mice (327), 
whereas SIRT1 deficiency led to increased tumour formation in p53-null mice (328). 
These observations suggest that SIRT1 may suppress tumour growth under certain 
conditions, and that SIRT1 activators could be used for cancer treatment, or prevention 
(329). 
The decreased relative transcriptional expression levels of SIRT1 observed in this study, in 
breast cancer biopsies, when compared with both normal and non-malignant biopsies, is 
consistent with a recent study reporting increased levels of SIRT1 in normal colon mucosa 
and benign adenomas, and decreased levels of SIRT1 in approximately 30% of carcinomas 
(330). Consistent with this effect, it has been found that elimination of SIRT1 accelerates 
tumour xenograft formation by HCT116 cells, whereas SIRT1 over expression inhibits 
tumour formation (330). Furthermore, the pharmacological inhibition of SIRT1 stimulates 
cell proliferation under conditions of growth factor deprivation (330). 
This study also showed that decreased relative transcriptional levels of SIRT1 gene were 
associated with increasing tumour grade (Figure 3.20). Our finding is in consistent with the 
study by Kabra et al showing that over-expression of SIRT1 was observed in 25% of stage 
I/II/III colorectal adenocarcinomas, but rarely found in advanced stage IV tumours (330). 
Kabra et al 2009 suggested that hyper-phosphorylation of pRb as an indirect result of 
SIRT1 inhibition, might be responsible for this tumourigenic effect of decreased SIRT1. A 
decrease in SIRT1 activity results in activation of E2F1 thus promoting pRb hyper-
phosphorylation indirectly through inducing cyclinD/cdk4 phosphorylation activity  (330).  
Furthermore, decreased relative transcriptional expression of SIRT1, as observed in breast 
malignant biopsies, might promote tumourogenesis through the known interaction between 
SIRT1 and NFκB. SIRT1 can deacetylate and inactivate NF-κB, thereby sensitising cells 
to tumour necrosis factor α (TNFα) induced apoptosis (218). Therefore a decreased level 
of SIRT1 might be beneficial to the tumour cell because it will increase NF-κB activity, 
thus promoting cell proliferation. Furthermore, it has been reported that in breast cancer, 
SIRT1 is recruited to suppress the activity of NF-κB by neddylated breast cancer 
associated protein 3 (BCA-3) (261). This provides an alternative way in which decreased 
SIRT1 activity can enhance the transcriptional activity of NF-κB  
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The anti-cancer effect of SIRT1 observed in this study is probably due to the interaction 
between SIRT1 and NFκB, an important regulator of ageing-related cellular processes. 
This result might indicate a potential role for NF-kB in breast cancer tumourigenesis that 
might be promoted thorough decreased levels of SIRT1.  
This study, along with that of Kabra et al, provides evidence that decreased SIRT1 at both 
mRNA and protein level is associated with cancer (breast and colon). This study showed 
that decreased relative transcriptional expression levels of SIRT1 were associated with 
malignant breast biopsies and with increasing tumour grade (anti-cancer effect). 
It is therefore surprising that high levels of SIRT1 are shown to be associated with worse 
prognosis in breast cancer disease (cancer promoting effect). The data presented here 
showed that higher levels of the relative transcriptional expression of SIRT1, rather than 
lower levels are associated with worse survival and early recurrence in patients with 
moderate prognosis according to the NPI. These data seem to be consistent with a cancer 
promoting effect of SIRT1. 
There are two possible hypothesises to explain our findings: 
There is an apparent contradiction between the observed results for SIRT1; between results 
indicating that increased levels of SIRT1 are associated with poor prognosis in breast 
cancer patients and the results showing decreased levels of SIRT1 are associated with 
higher tumour grade. Possible explanations for this are either, that in tumours with poor 
prognosis, increased SIRT1 is an important primary component of tumourigenesis 
(primary event), or that the affected cells are attempting to enter apoptosis by increasing 
SIRT1 despite the ongoing tumourigenesis process (secondary response). 
Primary event: Increased SIRT1 might cause different patterns (motifs) of TSGs 
expression, especially of those who have regulatory effect on SIRT1.  
These tumour suppresser genes are associated with cancer disease. Therefore, changes in 
gene silencing profile, mutations, and/ or expression of any of the TSGs which are 
involved in regulating SIRT1 might be responsible for the increase in the relative 
transcriptional levels of SIRT1 that is associated with shorter survival and early recurrence 
in breast tumours that already showed low levels of SIRT1. 
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If SIRT1 suppresses certain TSGs, there may be a resulting increase in SIRT1 expression 
itself because of the loss of known TSG repression of SIRT1 transcription. This could also 
happen independently of any involvement of SIRT1 with TSGs, for example, in the case of 
a loss of function mutation in a TSG like p53. It has been shown that SIRT1 could be 
regulated by different tumour suppressor genes such as p53 and DBC1 (247, 250, 322, 
344). SIRT1 can be regulated by p53 directly in a FOXO-dependent manner (247),or 
indirectly thorough trans-activating  HIC1 transcription, a protein that binds directly to the 
SIRT1 promoter and represses its expression.  (248). Furthermore, indirect control of 
SIRT1 by p53 could be exercised by DeltaNp63alpha that down-regulates SIRT1 (249). 
Another TSG (DBC1) was shown to interact with SIRT1 and repress SIRT1 deacetyaltion 
of p53, resulting in an increase in p53-dependent apoptotic responses (250).   
Secondary response: Increasing SIRT1 levels in clinically aggressive tumours might 
indicate a last resort defensive cellular response, aimed at deactivating the (NFκB) cancer 
promoting pathway, thus sensitising cancerous cells to apoptosis. This might be consistent 
with increased necrotic tissue in aggressive tumours.  
To conclude, it might be possible that such subtle irregularity, or an individual variation of 
SIRT1 levels, that might result from either/ or primary event or secondary response, are 
responsible for such aggressive clinical behaviour for breast cancer tumours that express 
higher level of SIRT1, when compared with tumours that express low levels of SIRT1, in 
malignant biopsies with overall decreased levels of SIRT1, when compared to normal 
biopsies.  
The observed association between decreased levels of SIRT1 and higher tumour grade 
observed in our study is consistent with the study by Kabra et al., reporting that SIRT1 
over-expression was observed in 25% of stage I/II/III colorectal adenocarcinomas but is 
rarely found in advanced stage IV tumours (330). By definition, high-grade tumours are 
poorly differentiated tumours (Table 1.4). In keeping with the role of SIRT1 in growth and 
differentiation, it is possible that altered levels of SIRT1 are implicated in the loss of 
differentiation observed in high-grade tumours. It is impossible at present to explain these 
results fully in the light of the limited information currently available concerning the 
involvement of SIRT1 in embryonic development, growth and differentiation. However, it 
seems reasonable to suggest a potential role for SIRT1 in tumour differentiation state and 
histopathological appearance. 
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4.3.2 The relative transcriptional expression level of SIRT2 in 
breast biopsies. 
SIRT2 might be implicated in cancer disease through its role in mitosis and cell cycle 
control. SIRT2 deacetylates the α-tubulin subunit of microtubules in the spindle apparatus 
resulting in cellular arrest during cytokinesis and SIRT2 overexpression results in delay in 
cell cycle progression (201). Furthermore, SIRT2 is negatively regulated by CDC14B 
phosphatase, released in late M phase, allowing cell cycle progression (286).  
Our data showed that the relative transcriptional level of the SIRT2 gene was significantly 
decreased in the malignant biopsies, when compared with both normal and non malignant 
breast  biopsies. This finding is consistent with the anti-proliferation effect of SIRT2 and in 
agreement with a previous study that reported down-regulation of SIRT2 in gliomas, and 
showed that ectopic expression of SIRT2 suppresses the growth of glioma cell lines (336).  
There was no significant difference in the relative transcriptional levels of SIRT2 between 
the normal and non-malignant groups. This might indicate a non-significant difference in 
breast cell proliferation rate between the two groups, or might result from a cell cycle 
phase dependent expression of SIRT2. 
The pathological grading system for breast cancer is based on tubule formation 
(differentiation), nuclear pleomorphism and mitotic count. The association between 
decreased levels of SIRT2 and higher tumour grade observed in this study might be 
indicative of increased mitotic count (rate of cell division) for grade 3 tumours. 
Furthermore, similar to SIRT1, a role for SIRT2 in mammalian development was 
suggested through its interaction with the homeobox transcription factor 10 (Hoxa10) 
(289). These findings might be supportive of the potential involvement of SIRT2 in 
development and differentiation. 
This study did not support the suggested potential role for SIRT2 in tumour invasion and 
metastasis, as it did not show any significant association between SIRT2 gene expression 
and patient survival or tumour recurrence. 
The findings of this work suggest that a decrease in SIRT2 activity might assist DNA-
damaged tumour cells in escaping cell cycle arrest during tumour initiation and 
progression. Furthermore, the decrease in SIRT2 levels might also be implicated in the 
poor differentiation and higher mitotic count associated with higher tumour grades. 
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4.3.3 The relative transcriptional expression level of SIRT3 in 
breast biopsies. 
 
The data presented in this study are consistent with a pro-apoptotic role for SIRT3 (295). 
The decreased levels of SIRT3 in breast cancer biopsies and in higher grade tumours might 
be indicative of suppression of the mitochondrial apoptotic pathway, thus implicating 
SIRT3 in tumourigenesis.  
This study showed no significant difference in the relative transcriptional levels of SIRT3 
between normal and non-malignant groups. In the light of the available data this could be 
interpreted by the absence of any significant difference in breast cell proliferation and/or 
metabolic status between the two groups.  
4.3.4 The relative transcriptional expression level of SIRT4 in 
breast biopsies. 
SIRT4 is one of the mitochondrial sirtuins and has a NAD-dependent ADP-
ribosyltransferase activity. It down-regulates mitochondrial glutamate dehydrogenase 
within pancreatic β cells and it involvement in insulin/ glucose metabolism (204) represent 
its known biological function.  
Therefore, it is impossible to interpret our results in the light of the available information 
concerning SIRT4. However, the observed decrease in SIRT4 levels in malignant, when 
compared with non-malignant breast biopsies and the significant association between 
recurrence and low levels of SIRT4 in ER+ve breast cancer patients, is suggestive of 
potential involvement of SIRT4 in breast cancer disease and metastasis. The difference in 
levels of SIRT4 expression between non-malignant group and both normal and malignant 
breast biopsies might indicate changes in the metabolic status of cells resulting from, either 
increasing age, or changes in the available nutrients for normal breast tissue adjacent to 
malignant biopsies.  
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4.3.5 The relative transcriptional expression level of SIRT5 in 
breast biopsies. 
Differences observed in this study in the relative transcriptional levels of SIRT5 between 
the three studied groups, is possibly due to changes in metabolic and or redox status, that   
are associated with ageing, or with cancerous transformation. These results cannot exclude, 
or confirm, the possible involvement of SIRT5 in the cancer disease process as the 
available information for SIRT5 is very limited.  
 
4.3.6 The relative transcriptional expression level of SIRT6 in 
breast biopsies. 
Our data are consistent with the anti-cancer effect of SIRT6. SIRT6 has a negative effect 
on cellular proliferation through its interaction with the NF-κB RELA subunit and 
deacetylation of histone at NF-κB target gene promoters. This interaction results in 
attenuating NF-κB signalling, increasing cellular sensitivity to stress-induced apoptosis 
(302). Our data demonstrate that the relative transcriptional expression of SIRT6 is 
significantly decreased in breast cancer biopsies, when compared with both normal and 
non-malignant tissue. Furthermore, low SIRT6 levels were associated with higher tumour 
grade, short survival period and early recurrence time.  
Decreased SIRT6 expression in breast cancer biopsies could be indicative of increasing 
genomic instability associated with the development of cancer. Interestingly, this decrease 
in SIRT6 expression was also significantly associated with higher tumour grades. While 
the grading system takes into account nuclear pleomorphism (nuclear abnormalities in size, 
chromatin pattern and organization), which indicates the histological features of genomic 
and chromosomal abnormalities, SIRT6 expression may provide a molecular correlate of 
these histological features. 
In mammals, regulation of genomic stability at the cellular level has been linked to both 
tumour suppression and ageing (345). Various pathways are employed to repair specific 
types of DNA damage. Double Strand Breaks (DSBs) are repaired by non-homologous 
end-joining or homologous recombination. Single Strand Breaks (SSBs) which result from 
endogenous oxidation, alkylation, and deamination events, are repaired mainly by BER. 
SIRT6 has been found to be functionally linked to BER and appears to function upstream 
of the polymerase β (Polβ) deoxyribosyl phosphate lyase reaction in BER (300). Polβ? is 
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the major polymerase used for base excision repair in mammals (346, 347). It has been 
suggested that SIRT6 may regulate BER indirectly, by creating accessibility for BER 
factors, via modification of histones or other chromatin related factors (300). Decreased 
expression of SIRT6 in breast cancer tissue is intriguing, as it may indicate an increased 
incidence of un-repaired and/or improperly repaired DNA damage. Such a situation would 
have serious consequences for the cell, potentially leading to cell death, senescence, de-
regulation of cellular function, genomic instability, or oncogenic transformation.  
Increased relative transcriptional expression of SIRT6 in non-malignant breast biopsies, 
when compared to normal breast tissue, may be indicative of the accumulation of age-
associated DNA damage, as the normal group is significantly younger in age compared to 
the non-malignant group. Increased SIRT6 expression in the non-malignant group could be 
a compensatory mechanism to overcome the age-associated decreased activity of BER and 
polβ? (348, 349). 
A number of other genes involved directly in DNA damage repair have been associated 
with breast cancer susceptibility. These include BRCA1 and BRCA2, which are 
responsible for 21%–40% of hereditary breast cancers that account for 5%–10% of all 
breast cancer cases (3, 4). BRCA1 plays an important role in the repair of DNA damage 
through associations with proteins involved in the repair of DNA double strand breaks (5, 
6). Somatic BRCA1 mutations are observed rarely in sporadic breast cancer; however, both 
BRCA1 mRNA and protein expression are downregulated in approximately 30% of 
sporadic breast cancers and 70% of ovarian cancer cases (350). Characteristically, 
BRCA1-mutated breast tumours are poorly differentiated, occur at an early age of onset, 
are generally ER, progesterone receptor (PgR), epidermal growth factor receptor 
(HER2/neu) negative and are associated with a poor prognosis. The data obtained is in 
keeping with such a scenario, whereby the transcriptional expression of SIRT6 is 
decreased in breast cancer and lower SIRT6 expression is associated with grade 3 tumours 
and a shorter overall survival period. However, SIRT6 is involved in the repair of less 
severe DNA damage (SSBs) when compared with BRCA1 (DSBs). This could explain the 
older chronological age at which sporadic breast cancer occurs, when compared with 
familial breast cancers. Furthermore, these data suggest that decreased expression of 
SIRT6 might predispose individuals to sporadic breast cancer. 
SIRT6 might be  positively regulated by GCIP, a negative regulator of proliferation (106). 
GCIP is significantly down-regulated in several human tumours and may function as a 
tumour suppressor gene. Other than acting as a transcription repressor for cyclin D1, it is 
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possible that GCIP could suppress tumourigenesis and promote DNA damage resistance 
through its interaction with SIRT6 (106). Therefore, a decreased SIRT6 level, as observed 
in breast cancer, could be indicative of GCIP down regulation, thus promoting the disease. 
The involvement of SIRT6 in inflammation has been reported recently (303). Although 
inflammation is not a risk factor in breast cancer, it might still be possible that changes in 
the inflammatory mediators, at the cellular level in mammary epithelial cells, are involved 
in breast cancer tumourigeneis.  This possibility highlights the potential implication for 
SIRT6 in inflammation and cancer.   
Our results show that SIRT6 is an independent predictor of survival, with a significant 
association between high levels of SIRT6 expression and a better prognosis. These data 
suggest that SIRT6 may be used as a biological marker for predicting survival outcome.  
In addition, high levels of SIRT6 are significantly associated with longer survival in breast 
cancer patients with moderate prognosis (NPI between 3.4-5.4), or ER+ve tumours. 
Moreover, there was a trend observed toward shorter recurrence time in patients with NPI 
between 3.4-5.4, who have tumours that express low levels of SIRT6.   
This study has demonstrated a strong association between SIRT6 expression and breast 
cancer and suggests that SIRT6 might be implicated in breast cancer pathogenesis 
(initiation and progression). These findings indicate that the SIRT6 levels could be used as 
an additional prognostic marker in breast cancer patients, especially in those individuals 
who have equivocal prognostic pathological markers. It may be particularly useful in 
providing a more accurate prognosis for those breast cancer cases that behave 
unexpectedly, according to the known pathological prognostic markers. Therefore, 
stratifying breast cancer patients according to the level of SIRT6 expression might improve 
predicting breast cancer disease outcomes. 
Furthermore, the association between high levels of SIRT6 and better tumour behaviour 
and disease prognosis indicates that enhancing SIRT6 activity may confer benefit to breast 
cancer patients. Our study suggests SIRT6 as potential novel anticancer agent. 
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4.3.7 The relative transcriptional expression levels of SIRT7 in 
breast biopsies. 
The data presented in this study, showed that lower SIRT7 gene expression is prognostic of 
better long term patient survival and lower tumour recurrence in a patient group selected 
by NPI to have an intermediate clinical prognosis.  
The involvement of SIRT7 in cancer disease is complicated, as the available evidence 
suggests both negative and positive effects on tumourigenesis associated with SIRT7. A 
recent study reported decreased expression of SIRT7 to be associated with different murine 
tumourigenic cell lines. This study only showed increased levels of SIRT7 in normal 
biopsies, when compared with both malignant and non-malignant breast biopsies, an effect 
that could be due to the age difference between the two groups. Nevertheless, our study 
does provide some support for a negative effect of SIRT7 on tumourigenesis, because of 
the significant association between decreased levels of SIRT7 and shorter survival period.  
A potential mechanism for an anti-cancer action of SIRT7 is via activation of p53- and c-
myc-dependent transcription, thus promoting apoptosis (306). Furthermore, decreased 
expression of SIRT7 was observed in murine tumourigenic cell lines: P19 
(teratocarcinoma), NB41A3 (neuroblastoma), C3H/MCA (transformed fibroblast-derived 
cell line) as compared to the control non-tumourigenic cell line C3H/10T1/2 (306). 
Therefore, decreased SIRT7 levels have been suggested to promote the cancer disease 
process.  
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Introduction: 
We have previously shown that sirtuin expression is altered in breast cancer and associated 
with survival. However, sirtuin expression has not been explored in the context of 
antitumour therapies. This study aimed to investigate sirtuin expression in different 
mammary cancer cell lines, in response to different antitumour treatments. Docetaxel and 
tamoxifen was chosen for this experiment as they represent the main two treatments 
commonly used in breast cancer patients. Tamoxifen is used in postmenopausal women 
with ER+ve Tumour and Docetaxel is used in ER-ve tumours. 
5.1.1 Oestrogen receptor status of breast cancer cell lines. 
Three different types of immortalized tumourigenic human mammary cell lines (MCF-7, 
MDA-MB-453 and MDA-MB-231) were used in this study, as described in the Materials 
and Methods. These cell lines represented both ER positive (MCF-7) and ER negative 
(MDA-MB-453 and MDA-MB-231) breast cancers. All three breast cancer cell lines 
showed epithelial characteristics when grown in culture media, as described in the 
literature (Figure 5.1). In the literature it was reported that different variants of the MCF-7 
cell line are present and that MCF-7 cells may lose their ER+ve status with passage (351, 
352). Altered ER status for the cell studied could change the response to tested drugs. 
Therefore, it was decided to test for ER status in all the studied breast cancer cell lines, 
using two different techniques (Immunofluorescence and Western blotting).  
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Figure 5.1: Microscopic morphology of MCF-7, MDA-MB-231, and MDA-MB-453 breast 
cancer cell lines in culture media.   
 
5.1.2 ERα Immunofluorescence on MCF-7, MDA-MB-231 and 
MDA-MB-453.   
The mouse anti-human ERα antibody was used to test for the ERα status in the MCF-7, 
MDA-MB-231 and MDA-MB-453 cell lines.  MCF-7 cells not treated with the primary 
antibody were included as a negative control. The IF study confirmed that the MCF-7 cells 
used in this study express high levels of ERα (Figure 5.2). Both MDA-MB-231 and MDA-
MB-453 showed no nuclear staining for ERα. Since there were traces of ER antibody 
staining outside the nuclei, which may be artifactual, Western blotting was carried out to 
confirm the ER status of the cell lines and to test for the specificity of the antibody used. 
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Figure 5.2. ERα: Immunofluorescence on MCF-7, MDA-MB-231 and MDA-MB-453.   
Three breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-453) were stained with 
ERα antibody (1:250). A negative control (MCF-7) cells not treated with the primary 
antibody) was included in this study. MCF-7 showed a positive staining for ERα . Both MDA-
MB-231 and MDA-MB-453 did not stain for ERαin the nuclei. 
5.1.3 Western blotting for ERα in MCF-7, MDA-MB-231 and MDA-
MB-453 cell lines. 
Protein extracted from three different breast cancer cell lines (MCF-7, MDA-MB-231 and 
MDA-MB-453) was probed for ERα (66KDa). Protein was extracted from cells at two 
different passages to investigate for ERα status during the period of the study. Samples 
from the growth medium, HBSS, and cell lysis buffer were included as negative controls. 
ERα was detected only in the MCF-7 cells but not in the MDA-MB-231 or the MDA-MB-
453 cells. The MCF-7 cells used in this study were ER+ve between passages 12 and 46 
(Figure 5. 3).  The same membrane was probed for tubulin (55kDa) as a loading control, 
after stripping off the ERα antibody (Figure 5. 3). 
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Figure 5.3: Western blotting for ERα in MCF-7, MDA-MB-231 and MDA-MB-453 cellular 
protein extracts. 
Western blotting for protein extracted from the three studied cancer cell lines (MCF-7, MDA-
MB-231 and MDA-MB-453) probed for ERα (66KDa). Protein from two different passages was 
probed for ERα to test for ER variation with time. ERα was detected only in the MCF-7 cells 
at passage 12 and passage 46. No ERα was detected in the MDA-MB-231 or the MDA-MB-
453 cells. Tubulin (55kDa) was used as a loading control. Lane1: Medium, 2: HBSS, 3:cell 
lysis buffer, 4+ 5:MCF-7 passage 12, 6+ 7: MCF-7 Passage 46, 8+ 9: MDA-MB-453 passage 
28, 10+11, MDA-MB-231 passage 49, and 11+12: MDA-MB-231passage 69   
 
 
These data clearly show that the MCF-7 cell line used in this study was ERα positive and 
that MDA-MB-231 and MDA-MB-453 cell lines were ERα  negative. 
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5.2  Sirtuin gene expression in response to Docetaxel 
treatment in an ER-ve breast cancer cell line (MDA-MB-
231).   
 
5.2.1 Introduction:  
Docetaxel and paclitaxel belong to Taxane anti-cancer agent, a relatively new anticancer 
drugs group, are classified as mitotic poisons that are commonly used as cytotoxic agents 
in treating metastatic and locally advanced breast cancers especially ER –ve tumours. 
Docetaxel binds to and stabilizes the β−tubulin subunit of microtubules, preventing 
depolymerization of the mitotic spindle thus leading to cell cycle arrest and apoptosis. (77, 
78). 
Although, the effect of Taxane (paclitaxel) is mediated by its interaction with microtubules 
causing mitotic arrest, apoptosis and different modes of cellular death have also been 
implicated in the Taxanes treatment. Consequently, this may lead to the variation in 
cellular sensitivity to Taxanes. Moreover, the mechanism by which microtubule-interfering 
agents induce cell death is complicated and not fully understood.  
Docetaxel, a semi-synthetic analogue of paclitaxel, is a microtubule-stabilizing taxane 
which has recently been approved for use in the clinic for the treatment of breast and 
prostate cancers and small cell carcinoma of the lung (353). Since the mechanism by which 
microtubule-interfering agents induce cell death is poorly understood, factors involved in 
ageing might also be involved in mediating response to such anticancer treatments. As 
previously discussed the sirtuins are implicated in both the ageing process and cancer 
development and progression, possibly through their involvements in the MTR trinity. 
Therefore this study aimed to investigate sirtuin expression in an ER negative breast cancer 
cell line (MDA-MB-231) in response to Docetaxel treatment.  
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5.2.2 Establishment of experimental conditions for Docetaxel 
treatments. 
This experiment was undertaken to determine the optimal conditions for measuring sirtuin 
gene expression following treatment of cells with Docetaxel. An established ER-ve 
mammary cancer cell line, MDA-MB-231, was used.  
5.2.2.1 MDA-MB-231 cell number titration.   
A cell titration experiment was performed first to determine the optimal number of MDA-
MB-231 cells to be seeded per well in the 96-well plate for this experiment. MDA-MB-231 
cells were seeded at four different numbers per well  (2500, 5000, 7500, and 10000) for 
three different time periods of 3, 4 and 5 days. The experiment with the MDA-MB-231 
cells required incubating cells with Docetaxel for 3 days. In order to prepare for a future 
study of the response of sirtuin genes to Tamoxifen in the MDA-MB-231 cells, the cells 
were also incubated for 4 and 5 days. The data showed that a cell number of between 2500 
and 5000 was the best for a 3day incubation period (Figure 5.4). Therefore in the following 
experiments, the number of MDA-MB-231 cells to be seeded was selected depending on 
the incubation period in the 96-well plate. 
 
Figure 5.4: MDA-MB-231 cell titration in the 96-well plate. 
5.2.2.2 Optimisation of Docetaxel concentration. 
The WST proliferation assay was used to determine the conditions under which cell 
proliferation was strongly suppressed (50%), with minimal cytotoxic effect. Dose response 
experiments were performed using two different incubation times (48hrs and 72 hrs) to 
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determine the suitable concentration of Docetaxel. The effect of various concentrations 
(0.5nM, 1nM, 2nM, 5nM 10nM, 20nM, 50nM, 100nM, 1000nM) of Docetaxel on cellular 
proliferation were determined using the WST proliferation assay. Cell proliferation data for 
Docetaxel (in DMSO) treated cells are given relative to cells treated with DMSO alone 
(Figure 5.5a). The lower concentrations of DMSO had little effect on cell proliferation, in 
contrast to the higher concentrations of DMSO, which were not used in the subsequent 
experiments (Figure 5. 5 a). The 72 hrs incubation data are shown in (Figure 5. 5 b): 48h 
incubation (data not shown) was not subsequently used. The 10nM concentration of 
Docetaxel suppressed 50% of cellular proliferation. In order to have a range of 
concentrations around the 50% suppression point, concentrations of 1nM, 10nM and 
100nM were selected for future experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Optimisation of Docetaxel concentration for treating the MDA-MB-231 cells. 
(a) DMSO effect on cell proliferation of the MDA-MB-231 cell line at 72 hrs.  (b) Docetaxel 
dose response curve for the MDA-MB-231 breast cancer cell line.This experiment was 
performed in duplicate using two different cell numbers in order to investigate whether the 
available space for the growing cells in 96-well-plate has an effect on cellular proliferation. 
 
 
a 
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5.2.2.3 Optimization of Docetaxel treatment time.  
A suitable incubation time was decided upon following an experiment investigating the 
effects of the selected three concentrations (1nM, 10nM and 100nM) of Docetaxel at four 
different time points: 24hrs, 48hrs, 72hrs and 96hrs. Figure 5. 6 a shows the results of this 
experiment. 72hrs was chosen as a suitable incubation time because there was a significant 
suppression of proliferation (50%) but a sufficient number of cells remained alive to enable 
RNA preparation. Simultaneously, a control experiment was performed to determine the 
effect of the experimental concentration of DMSO on MDA-MB-231 cell proliferation. 
The data showed that the concentrations of DMSO used (2.E-05%, 2.E-04% and 2.E-03%) 
have no negative effect on MDA-MB-231 cell proliferation using the WST proliferation 
assay (Figure 5. 6 b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Optimization of Docetaxel treatment time in the MDA-MB-231 cell line.  
(a) The MDA-MB-231 cells were incubated for various time (24hrs, 48hrs, 72hrs and 96hrs) 
using three different concentration of Docetaxel (1nM, 10nM and 100nM). Cell proliferation 
was measured using the WST assay. (b) MDA-MB-231 cellular proliferation after being 
treated with the experimental concentration of DMSO alone.  
 
 
 
a 
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In all experiments described below, the MDA-MB-231 cells were therefore treated for 72 
hours using the three selected concentrations of Docetaxel, at which point the RNA was 
prepared in order to study sirtuin gene expression. The concentration of the DMSO was 
adjusted to be the same in all experiment (2.E-03 (0.002%)). This concentration is the 
same as used in the 100 nM Docetaxel treatment described above. In each experiment a 
DMSO-only control was included which was used as a “Calibrator” for determining 
relative gene expression. 
All experiments were carried out in duplicate using the same cell preparation, media and 
treatments. In order to allow comparison of these duplicate experiments and to identify any 
significant differences between them, the same calibrator was used for both experiments 
(control cells treated with DMSO only in experiment A). First the statistical analysis was 
performed for each experiment separately, then for both experiments combined together. 
The Analysis of variance (ANOVA) p value will be presented for each duplicate 
experiment separately in the graphs and in the text; whereas the detailed two-way Dunnett 
t-test p value will be presented for each treatment within each duplicate experiment in 
Table 5.1. Similarly, the Analysis of variance (ANOVA) p value will be presented for the 
combined experiments in the text and the detailed two-way Dunnett t-test p value for the 
combined data will be presented (Table 5.1). 
5.2.3 Gene expression of p21, Ki67, XRCC5 and BCL2 in response 
to Docetaxel treatment in MDA-MB-231 cells. 
Four different control genes that were expected to respond to the drug treatments were 
studied before analysing sirtuin gene expression, using the same RNA preparation. These 
genes were chosen for the following reasons; p21 is a well-known cell stress response 
marker; Ki67 is a marker of cellular proliferation, expressed by proliferating cells in all 
phases of the active cell cycle (G1, S, G2 and M phase) but absent in resting (G0) cells. 
XRCC5 is a DNA damage response marker, and BCL2 is an anti-apoptotic marker. Real 
time PCR was used to quantify the transcriptional expression of four control genes in 
relation to HPRT as a housekeeping gene as described in the Material and Methods. 
(Figure 5.7 a, b, c, and d) shows the relative gene expression of the four genes following 
Docetaxel treatment. 
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5.2.3.1 Separate analysis of duplicate experiments.  
The control experiment showed that, as expected, 10 nM and 100 nM Docetaxel caused a 
significant increase in the relative gene expression of p21. This is consistent with higher 
levels of cellular stress being associated with Docetaxel treatment (p < 0.001; Table 5.1). 
In both experiments, there were significant changes in the relative gene expression of Ki67 
following Docetaxel treatment (p = 0.016 for Exp. A and p < 0.001 for Exp. B). 
Interestingly, there was a significant decrease in the relative gene expression of KI67 in 
cells treated with 10nM (p < 0.001) and 100nM (p < 0.001) Docetaxel when compared 
with those treated with 1nM Docetaxel (Figure 5. 7). 
Both experiments showed significant changes in the relative gene expression of XRCC5 
after Docetaxel treatments (p = 0.033 for Exp. A and p < 0.014 for Exp. B). In experiment 
B the observed increase in gene expression was only significant with 10nM Docetaxel 
treatment (p = 0.009), whereas in experiment A the observed increase in gene expression 
was not significant (100nM Docetaxel treatment; P = 0.073; Table 5.1). However, when 
data from both experiments were analysed together (see below, Table 5.1), the increases in 
gene expression with both 10nM (p = 0.006) and 100nM (p = 0.031) Docetaxel treatment 
were found to be significant (Table 5.1). 
There was no significant change in the level of BCL2 gene expression in response to 
Docetaxel treatment at any particular Docetaxel concentration (Table 5.1), however the 
analysis of the overall variance of the changes in BCL2 gene expression did show 
significance for experiment B and the combined analysis (Table 5.1).  
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Figure 5.7: Relative transcriptional expression of p21 (a), Ki67 (b), XRCC5 (c) and BCL2 (d) 
genes in the MDA -MB-231 cell line in response to Docetaxel treatment.  
All experiments have been done in duplicate: Exp. A dark column, and Exp. B light column. 
5.2.3.2  Combined analysis of duplicate experiments.  
Generalized linear model statistical analysis of both experiments together showed that 
there were no significant differences between the experiments for any of the control genes 
(p 21, p = 0.658; KI67, p = 0.340; XRCC5, p = 0.397; BCL2, p = 0.597; Table 5.1). 
Therefore, the combined data from both experiments can legitimately be analysed.  
The combined analysis showed a significant increase in the relative transcriptional gene 
expression of p21 and XRCC5 after Docetaxel treatment (Figure 5. 8, p < 0.001 for both 
genes).  
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There was an overall significant change in the relative gene expression of KI67 (p = 0.002) 
and BCL2 (p = 0.028, Figure 5. 8 and Table 5.1). As can be seen from Figure 5.8 and 
Table 5.1, there was a trend to increased gene expression of both genes (KI67 and BCL2) 
at 1nM and 10nM Docetaxel concentration. However, no further increase were observed at 
the highest Docetaxel concentration (100nM). Instead, the relative transcriptional levels of 
both genes decreased at 100 nM Docetaxel treatment.  The p value for Dunnett t-test 
analysis for each treatment is shown in Table 5.1. 
 
 
 
 
 
 
 
 
 
Figure 5.8: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of p21, Ki67, XRCC5 and BCL2 genes in the MDA-MB-231 cell line 
in response to Docetaxel treatment.  
 
5.2.4 SIRT1 gene expression in response to Docetaxel treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the relative transcriptional expression of SIRT1 in 
relation to HPRT a housekeeping gene as described in the Material and Methods. Figure 
5.9 shows the relative gene expression of SIRT1 in 1nM, 10nM and 100nM Docetaxel 
treated cells after 72hrs.  
The data shows that there was a significant increase in relative transcriptional expression 
of SIRT1 gene in response to increasing concentrations of Docetaxel in MDA-MB-231 
cells in both experiments  (p < 0.001 for both Exp A and B). The p value for Dunnett t-test 
analysis for each treatment is shown in Table 5.1. 
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Figure 5.9: Relative transcriptional gene expression of SIRT1 in the MDA-MB-231 cell line in 
response to Docetaxel treatment.  
A similar significant increases were observed for the relative transcriptional expression of 
SIRT1 gene when both experiments were combined and analysed together (P < 0.001, 
Figure 5.10). Both experiments could be combined and analysed together since the 
generalized linear model statistical analysis proved that there was no significant difference 
between the experiments (p = 0.105, Table 5.1). 
 
 
 
 
 
 
Figure 5.10: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT1 and SIRT2 genes in the MDA-MB-231 cell line in 
response to Docetaxel treatment.  
5.2.5 SIRT2 gene expression in response to Docetaxel treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the relative transcriptional expression of SIRT2 in 
relation to HPRT a housekeeping gene as described in the Material and Methods. Figure 
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5.11 shows the relative gene expression of SIRT2 in 1nM, 10nM and 100nM cells treated 
with Docetaxel for 72hrs.  
 
 
 
 
 
 
Figure 5.11: Relative transcriptional gene expression of SIRT2 in the MDA-MB-231 cell line 
in response to Docetaxel treatment.  
Both duplicate experiments (Figure 5.11) showed that there was a significant increase in 
the relative transcriptional expression levels of SIRT2 gene in response to increasing 
concentration of Docetaxel in MDA-MB-231 cells (p < 0.001 for Exp. A and p = 0.003 for 
Exp. B). The p value for Dunnett t-test analysis for each treatment is shown in Table 5.1. 
Although, the generalized linear model statistical analysis proved that there was a 
significant difference between the duplicate experiments (p = 0.009, Table 5.1), a similar 
significant increases for relative transcriptional expression of the SIRT2 gene were 
observed when both experiments were combined and analysed together (P < 0.001, Figure 
5.10).  
5.2.6 SIRT3, SIRT4 & SIRT5 gene expression in response to 
Docetaxel treatment in MDA-MB-231 cells. 
SIRT3, SIRT4 & SIRT5 are known to be mitochondrial related sirtuins and all show 
similar responses to Docetaxel treatment. Therefore they are presented together in this 
section. Real time PCR was used to quantify the transcriptional expression of SIRT3, 4 and 
5 in relation to HPRT a housekeeping gene as described in the Material and Methods. 
Figure 5.12 a, b, and c shows the relative gene expression of SIRT3, 4 and 5 in 1nM, 10nM 
and 100nM Docetaxel treated cells after 72hrs.  
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5.2.6.1 Separate analysis of duplicate experiments.  
Our data shows that in both experiments there were significant increases in the relative 
transcriptional expression levels of SIRT3, SIRT4 and SIRT5 genes in response to 
Docetaxel treatment (in Exp. A:  p = 0.004, p < 0.001 and p = 0.005 and in Exp. B: p < 
0.001, p < 0.001 and p = 0.001 for SIRT3 and SIRT4 and SIRT5 respectively). 
The significant increase in the relative transcriptional expression levels of SIRT3, SIRT4 
and SIRT5 genes were observed mainly at the high concentrations of Docetaxel (10nM and 
100nM, Figure 5.12). No reproducibly significant changes in gene expression of all three 
studied sirtuins were observed in response to 1 nM Docetaxel treatment. The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.1. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Relative transcriptional gene expression of SIRT3 (a), SIRT4 (b), and SIRT5 (c) 
in the MDA-MB-231 cell line in response to Docetaxel treatment. 
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5.2.6.2 Combined analysis of duplicate experiments.  
Generalized linear model statistical analysis of both duplicate experiments combined 
together showed that there was no significant difference between the experiments for all 
three genes (SIRT3, p = 0.195; SIRT4, p = 0.052; SIRT5, p = 0.712; Table 5.1). Therefore, 
the combined data form both experiments can legitimately be analysed.  
The combined analysis for both experiments showed significant changes in the relative 
transcriptional expression of SIRT3 (p < 0.001), SIRT4 ( p < 0.001) and SIRT5 (p = 0.012) 
after Docetaxel treatment (Figure 5.13). There was a significant increase in the relative 
transcriptional expression levels of SIRT3 and SIRT4 at the high concentrations of 
Docetaxel (10nM and 100nM,). Whereas, the significant increase in the relative 
transcriptional expression levels of SIRT5 was observed only at 100 nM Docetaxel 
treatment. The p value from the Dunnett t-test analysis for each treatment is shown in 
Table 5.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Combined data of the duplicate experiments measuring relative transcriptional 
gene expression of SIRT3 and SIRT5 (a) and SIRT4 (b) and in the MDA-MB-231 cell line in 
response to Docetaxel treatment. 
5.2.7 SIRT6 gene expression in response to Docetaxel treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT6 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.14 shows 
the relative gene expression of SIRT6 in 1nM, 10nM and 100nM Docetaxel treated cells 
after 72hrs.  
  
 
 
 
a 
b 
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This experiment shows that the relative transcriptional gene expression of SIRT6 increased 
significantly in the MDA-MB-231 cell line when treated with 10 nM and 100 nM 
Docetaxel for 72 hours (p < 0.001 for both Exp. A and B). No significant difference in 
SIRT6 gene expression was observed in response to 1 nM Docetaxel (Figure 5.14). The p 
value for Dunnett t-test analysis for each treatment is shown in (Table 5.1). 
Similar significant increases in the relative transcriptional gene expression of SIRT6 at 
10nM and 100 nM Docetaxel were observed when both experiments were combined and 
analysed together (P < 0.001, Figure 5.16). Both experiments could be combined and 
analysed together since the generalized linear model statistical analysis proved that there 
was no significant difference between the experiments (p = 0.083, Table 5.1). 
 
 
 
 
 
 
Figure 5.14: Relative transcriptional gene expression of SIRT6 in the MDA-MB-231 cell line 
in response to Docetaxel treatment. 
5.2.8 SIRT7 gene expression in response to Docetaxel treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT7 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.15 shows 
the relative gene expression of SIRT7 in 1nM, 10nM and 100nM Docetaxel treated cells 
after 72hrs.  
This experiment shows that the relative gene expression of SIRT7 increased significantly 
in the MDA-MB-231 cell line when treated with 10 nM and 100 nM Docetaxel for 72 
hours  (p < 0.003 for Exp. A and p < 0.001 for exp B). No significant difference in SIRT7 
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gene expression was observed in response to 1 nM Docetaxel treatment (Figure 5.15). The 
p value for Dunnett t-test analysis for each treatment is shown in Table 5.1. 
 
 
 
 
 
 
Figure 5.15: Relative transcriptional gene expression of SIRT7 in the MDA-MB-231 cell line 
in response to Docetaxel treatment.  
Similar significant increases in the relative transcriptional gene expression of SIRT7 at 
10nM and 100 nM Docetaxel were observed when both experiments were combined and 
analysed together (P < 0.001, Figure 5.16). Both experiments could be combined and 
analysed together since the generalized linear model statistical analysis proved that there 
was no significant difference between the experiments (p = 0.697, Table 5.1). 
 
 
 
 
 
 
Figure 5.16: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT6 and SIRT7 genes in the MDA-MB-231 cell line in 
response to Docetaxel treatment. 
Samer Zino, 2010                                                                                                         Chapter V, 
 
266 
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 1.0 p = 1 p = 1
10nM Docetaxel p = 0.61 p = 0.003 p < 0.001
100 nM Docetaxel p = 0.006 p = 0.001 p = 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.009 p < 0.001 p < 0.001
10nM Docetaxel p = 0.033 p = 0.002 p = 0.002
100 nM Docetaxel p = 0.296 p = 0.766 p = 0.770
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.674 p = 0.914 p = 0.997
10nM Docetaxel p = 0.471 p = 0.009 p = 0.006
100 nM Docetaxel p = 0.073 p = 0.203 p = 0.031
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.50 p=0.096 p = 0.085
10nM Docetaxel p = 0.135 p = 0.611 p = 0.074
100 nM Docetaxel p = 0.818 p = 0.444 p = 0.999
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.625 p = 0.997 p = 0.997
10nM Docetaxel p = 0.008 p < 0.001 p < 0.001
100 nM Docetaxel p <0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.424 p = 0.037 p = 0.129
10nM Docetaxel p = 0.002 p = 0.013 p < 0.001
100 nM Docetaxel p  <0.001 p = 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.839 p = 0.062 p = 0.387
10nM Docetaxel p = 0.005 p = 0.207 p = 0.005
100 nM Docetaxel p = 0.008 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 737 p = 0.997 p = 0.728
10nM Docetaxel p < 0.001 p < 0.001 p < 0.001
100 nM Docetaxel p< 0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.554 p = 0.001 p = 0.025
10nM Docetaxel p = 0.007 p = 0.868 p = 0.104
100 nM Docetaxel p = 0.006 p = 0.016 p = 0.006
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 1.0 p = 0.404 p = 0.726
10nM Docetaxel p = 0.001 p < 0.001 p < 0.001
100 nM Docetaxel p < 0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
1nM Docetaxel p = 0.972 p = 0.858 p = 0.1
10nM Docetaxel p = 0.020 p < 0.001 p < 0.001
100 nM Docetaxel p = 0.006 p = 0.001 p = 0.001
P < 0.001
P < 0.001
P21
Ki67
XRCC5
BCL2
SIRT1 
SIRT2 
SIRT3 
P < 0.001
P = 0.012
SIRT5
SIRT6
p = 0.712
p = 0.052
P < 0.001
P < 0.001
SIRT4 
p = 0.195
p = 0.009
Combined Experiments 
P < 0.001
 P = 0.002
P < 0.001
SIRT7 SIRT7
P = 0.003 P < 0.001
P = 0.001
SIRT6 SIRT6
P < 0.001 P < 0.001
P = 0.005
SIRT4 
P < 0.001 P < 0.001
SIRT5 SIRT5
SIRT4 
P = 0.003
SIRT3 SIRT3 
P = 0.004 P < 0.001
P < 0.001
SIRT1 
P < 0.001 P < 0.001 
SIRT2 SIRT2 
SIRT1 
P = 0.014
BCL2 BCL2
P = 0.238 P = 0.029
P = 0.033
Ki67
P = 0.016 P < 0.001
XRCC5 XRCC5
Ki67
Experiment B
P21 P21
P = 0.005 P < 0.001
Experiment A
SIRT7
p = 0.658
p = 0.697
p = 0.083
p = 0.105
p = 0.597
p = 0.397
 p= 0.340
P = 0.028
p < 0.001 
Table 5.1: Probability levels for Docetaxel treatment experiments.  
ANOVA test was used to determine the overall probability of gene expression changes as a 
result of Docetaxel treatment. The probability of deviation of each treatment (concentration 
of drug) from the control (DMSO only) was investigated using the Dunnett t-test. The 
statistical analysis was performed for each experiment separately and when the data form 
both experiments were combined together.  
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5.3  Sirtuin gene expression in response to Tamoxifen 
treatment in an ER +ve breast cancer cell line (MCF-7).   
5.3.1 Introduction. 
Endocrine treatment plays an important role in the management of hormone-dependent 
breast cancer. The non-steroidal antiestrogen Tamoxifen (TAM), a selective oestrogen 
receptor modulator (SERM) is the treatment of choice for most women with hormone 
receptor-positive, invasive breast carcinoma. Tamoxifen is a key treatment due to its good 
tolerability profile and its efficacy, both in adjuvant and first-line settings (354, 355). 
However, resistance to treatment is always a challenging event and it is a limiting factor in 
Tamoxifen treatment (356). 
Tamoxifen is believed to inhibit the growth of breast cancer mainly through competing 
with oestrogen for oestrogen receptor binding. However, the precise mechanism by which 
Tamoxifen can induce apoptosis is not fully understood. Several studies have demonstrated 
that Tamoxifen can cause DNA damage (357), induce oxidative stress, mitochondrial 
dysfunction and activation of caspases (358-361). Moreover, Tamoxifen can induce 
apoptosis by ER-dependent and ER-independent mechanisms (360, 361). 
Given the well-known involvement of sirtuins in DNA damage repair and the link between 
sirtuins and the mitochondrion (2), it is reasonable to propose a role for sirtuins in the 
mechanism of action of Tamoxifen. To address this question, we decided to investigate 
whether the relative transcriptional levels of sirtuin genes are altered in response to 
Tamoxifen treatment in both ER+ve and ER-ve cell lines.  
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5.3.2 Establishment of experimental conditions for Tamoxifen 
treatments 
This experiment was undertaken to determine the optimal conditions for measuring sirtuin 
gene expression following treatment of cell lines with Tamoxifen. An established ER 
positive mammary cancer cell line, MCF 7 was used. 
5.3.2.1 MCF-7 cell number titration.   
A cell titration experiment was performed first to determine the optimal number of MCF-7 
cells to be seeded per well in the 96-well plate for this experiment. MCF-7 cells were 
seeded at three different numbers per well (5000, 10000, and 15000) for three different 
time periods of 3, 4, and 5 days. The experiment with the MCF-7 cells involve a maximum 
of 5 days incubation in the 96-well plate; 2 days in Oestrogen free media and then a 
maximum of three days with the drug. The data showed that cell number between 5000 and 
10000 were the best for a 5 day incubation period in the 96-well plate (Figure 5.17). Cell 
proliferation was limited by the well size when large cell numbers were seeded, 
consequently when 20000 cells were seeded it was deemed inappropriate to measure 
proliferation on day 5. Therefore in the following experiments, the number of MCF-7 cells 
to be seeded was decided depending on the incubation period in the 96-well plate. 
 
Figure 5.17: MCF-7 cell titration in the 96-well plate. 
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5.3.2.2 Optimisation of Tamoxifen concentration in the MCF-7 cell line. 
The WST proliferation assay was used to determine the conditions under which cell 
proliferation was strongly suppressed (50%), with minimal cytotoxic effect. MCF-7 cells 
were incubated in phenol-free media supplemented with 5% charcoal stripped foetal calf 
serum for 48h before being treated with Tamoxifen for the tested period, to eliminate the 
effect of oestrogen on cellular growth (Refer to Materials and Methods).  However, growth 
media was supplemented with oestrogen in the presence of tamoxifen, to a final 
concentration of 1nM.  
The effects of various concentrations (2 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 
µM and 12 µM) of Tamoxifen on cellular proliferation were determined using the WST 
proliferation assay. Cell proliferation data for cells treated with Tamoxifen (in DMSO) are 
given relative to those cells treated only with DMSO.  The concentration of DMSO used 
had in little effect on cell proliferation  (Figure 5.18a). The dose-response data for cells 
treated with Tamoxifen for 72 hours are shown in Figure 5.18b. 
The 8 µM concentration of Tamoxifen suppressed 50% of cellular proliferation. In order to 
have a range of concentrations around the 50% suppression point, concentrations of 5 µM, 
8 µM and 10 µM were selected for subsequent experiments. 
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Figure 5.18: Optimisation of Tamoxifen concentration for treating MCF-7 cells. 
(a) DMSO effect on cell proliferation of MCF-7 cell line at 72 hrs. (b) Tamoxifen dose 
response curve for the MCF-7 breast cancer cell line, This experiment was performed in 
duplicate using two different cell numbers (A (black column) = 2000 cells, B (grey column) = 
5000 cells ) in order to investigate whether the available space for the growing cells in 96-
well-plate has an effect on cellular proliferation. 
 
5.3.2.3 Optimization of Tamoxifen treatment time in the MCF-7 cell line. 
A suitable incubation time was decided upon following an experiment investigating the 
effects of the selected three concentration (5 µM, 8 µM and 10 µM) of Tamoxifen at four 
different time points: 24 hrs, 48 hrs, 72 hrs and 96 hrs). Figure 5.19 a shows the results of 
this experiment. 72 hrs was chosen as a suitable incubation time because there was a 
 
 
a 
b 
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significant suppression of proliferation (50%) but a sufficient number of cells remained 
alive to enable RNA preparation at 8µM. Simultaneously, a control experiment was 
performed to determine the effect of the experimental concentration of DMSO on MCF-7 
cell proliferation. The data showed that the concentrations of DMSO used (0.05%, 0.08% 
and 0.1%) have no negative effect on MCF-7 cell proliferation using the WST proliferation 
assay (Figure. 4.19 b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 5.19. Optimization of Tamoxifen treatment time in the MCF-7 cell line. 
(a) The MCF-7 cells were incubated for various time (24hrs, 48hrs, 72hrs and 96hrs) using 
three different concentration of Tamoxifen (5µM, 8µM and 10µM). Cell proliferation was 
measured using the WST assay. (b) MCF-7 cellular proliferation after being treated with the 
experimental concentration of DMSO alone.  
 
b 
 
a 
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In all experiments described below the MCF-7 cells were therefore treated for 72 hours 
using the three selected concentrations of Tamoxifen, in phenol-free media supplemented 
with 5% charcoal stripped fetal calf serum and 1nM β-estradiol. After 72hrs, RNA was 
prepared in order to study sirtuin gene expression. The concentration of the DMSO was 
adjusted to be the same in all experiments: 0.1%. This concentration is the same as that 
used in the 10 µM Tamoxifen treatment described above. In each experiment a DMSO-
only control was included, which was used as a “Calibrator” for determining relative gene 
expression. In practice it proved that 10 µM of Tamoxifen was too cytotoxic and RNA 
could not be extracted successfully. Therefore in the following sections data for 5µM and 
8µM only are shown. 
All experiments were carried out in duplicate using the same cell preparation, media and 
treatments in parallel. However, the data were analysed separately for each duplicate 
experiment because the mathematical treatment of the RNA expression data don’t allow 
combination of data for statistical analysis. Therefore, the p value will be presented for 
each duplicate experiment separately; the Analysis of variance (ANOVA) p value will be 
presented in the text, whereas the detailed two-way Dunnett t-test p value will be presented 
for each treatment within each duplicate experiment in Table 5.2.   
5.3.3 Gene expression of p21, Ki67, XRCC5 and BCL2 in response 
to Tamoxifen treatment in MCF-7 cells. 
Four different control genes that were expected to respond to Tamoxifen treatment(p21, 
KI67, BCL2 and XRCC5) were studied before analysing sirtuin gene expression. using the 
same RNA preparation. Figure 5.20 a, b, c, and d shows the relative gene expression of 
these genes in MCF-7 cells treated for 72 hours with 5 µM and 8 µM Tamoxifen. 
5.3.3.1 Separate analysis of duplicate experiments.  
This control experiment showed that, as expected, 8 µM Tamoxifen caused significant 
increases in the relative expression of p21 indicating higher levels of cellular stress (p = 
0.003 and p < 0.001 for experiment A and B respectively, Figure 5.20 a). The relative 
expression of Ki67 was significantly decreased following the 8µM Tamoxifen treatment (p 
< 0.001 for experiment A and p = 0.002 for experiment B, Figure 5.20 b). This correlates 
with the anti-proliferative effect of Tamoxifen on ER+ve cell lines.  
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Figure 5.20: Relative transcriptional expression of p21 (a), Ki67 (b), XRCC5 (c) and BCL2 (d) 
genes in the MCF-7 cell line in response to Tamoxifen treatment. 
All experiments have been done in duplicate: Exp. A dark column, and Exp. B light column. 
 
Both experiments showed no significant changes in the relative transcriptional gene 
expression of XRCC5 after Tamoxifen treatment (P = 0.797 for Exp. A and p = 0.088 for 
Exp B, Figure 5.20 c). 
Experiment B showed that the relative transcriptional gene expression of BCL2 decreased 
significantly in response to Tamoxifen treatment (p = 0.005, Figure 5.20 d). However, a 
non-significant decrease was observed for BCL2 gene expression following Tamoxifen 
treatment in experiment A (p = 0.084, Figure 5. 20 d). The p value for Dunnett t-test 
analysis for each treatment is shown in Table 5.2. 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
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5.3.3.2 Combined analysis of duplicate experiments.  
Generalized linear model statistical analysis of both duplicate experiments together showed 
that there was no significant difference between the experiments for all control genes (p 
21, p = 0.098; KI67, p = 0.306; XRCC5, p = 0.814; BCL2, p = 0.738; Table 5.2). 
Therefore, the combined data from both experiments can legitimately be analysed.  
 
 
 
 
 
 
Figure 5.21: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of p21, Ki67, XRCC5 and BCL2 genes in the MDA-MB-231 cell line 
in response to Tamoxifen treatment.  
The combined analysis showed a significant increase in the relative transcriptional gene 
expression of p21 after Tamoxifen treatment (Figure 5.21, p < 0.001). However, the 
increase in the relative transcriptional gene expression of XRCC5 was not significant 
following 5µM and 8µM Tamoxifen treatment (Figure 5.21 and Table 5.2). 
The combined analysis of data from both experiments showed a significant decrease in the 
relative transcriptional gene expression of KI67 (p < 0.001) and BCL2 (p = 0.005) after an 
8µM Tamoxifen treatment (Figure 5. 21and Table 5.2). 
5.3.4 SIRT1 gene expression in response to Tamoxifen treatment 
in MCF-7 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT1 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.22 shows 
the relative gene expression of SIRT1 in 5µM and 8µM Tamoxifen treated cells after 
72hrs.  
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Figure 5.22: Relative gene expression of SIRT1 in the MCF-7 cell line in response to 
Tamoxifen treatment. 
 
The data showed that there was a significant increase in the relative transcriptional gene 
expression of SIRT1 in the MCF-7 cells in response to increasing concentrations of 
Tamoxifen treatment (p = 0.022 for experiment A and p = 0.001 for experiment B, Figure 
5. 22). The p value for Dunnett t-test analysis for each treatment is shown in Table 5.2. 
Similar significant increases were observed when both experiments were combined and 
analysed together (P < 0.001, Figure 5. 24). Both experiments could be combined and 
analysed together since the generalized linear model statistical analysis proved that there 
was no significant difference between the experiments (p = 0.358, Table 5.2). 
5.3.5 SIRT2 gene expression in response to Tamoxifen treatment 
in MCF-7 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT2 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.20 shows 
the relative gene expression of SIRT2 in MCF-7 cells treated with 5µM and 8µM 
Tamoxifen for 72 hrs.  
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Figure 5.23: Relative transcriptional gene expression of SIRT2 in the MCF-7 cell line in 
response to Tamoxifen treatment.  
The data shows that there was a significant increase in SIRT2 gene expression in response 
to increasing concentrations of Tamoxifen in the MCF-7 cells (p < 0.001 for both 
experiments; A and B, Figure 5. 23). The p value for Dunnett t-test analysis for each 
treatment is shown in Table 5.2. 
The generalized linear model statistical analysis proved that there was no significant 
experimental difference between the duplicate experiments (p = 0.948, Table 5.1). The 
analysis of the combined data showed that there was a significant increase in the relative 
transcriptional gene expression of SIRT2 following Tamoxifen treatment (P < 0.001, 
Figure 5.24, Table 5.2).  
 
 
 
 
 
 
Figure 5.24: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT1 and SIRT2 genes in the MCF-7 cell line in response to 
Tamoxifen treatment.  
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5.3.6 SIRT3, SIRT4 & SIRT5 gene expression in response to 
Tamoxifen treatment in MCF-7 cells. 
SIRT3, SIRT4 & SIRT5 are known to be mitochondrial related sirtuins and all show 
similar responses to Tamoxifen treatment. Therefore they are presented together in this 
section. Real time PCR was used to quantify the transcriptional expression of SIRT3, 
SIRT4 and SIRT5 in relation to HPRT a housekeeping gene as described in the Material 
and Methods. Figure 5.25 a, b, and c shows the relative transcriptional expression levels of 
SIRT3, SIRT4 and SIRT5 genes in 5µM and 8µM Tamoxifen treated cells after 72hrs.  
 
Figure 5.25: Relative transcriptional gene expression of SIRT3 (a), SIRT4 (b), and SIRT5 (c) 
in the MCF-7 cell line in response to Tamoxifen treatment.  
Both experiment A and B showed that there was a significant increase in the relative 
transcriptional levels of SIRT3, SIRT4 and SIRT5 genes in response to Tamoxifen 
treatment (p = 0.022, p = 0.007 and p = 0.014 respectively for experiment A and p = 0.017, 
p < 0.001 and p = 0.016 for experiment B, Figure 5.25 a, b, and c). The significant increase 
Samer Zino, 2010                                                                                                         Chapter V, 
 
278 
was observed following treatment with the highest concentrations of Tamoxifen treatment 
(8 µM). The p value for Dunnett t-test analysis is shown in Table 5.2. 
Generalized linear model statistical analysis of both duplicate experiments together showed 
that there was no significant difference between the experiments for all three genes 
(SIRT3, p = 0.618; SIRT4, p = 0.09; SIRT5, p = 0.634; Table 5.2). Therefore, the 
combined data form both experiments can legitimately be analysed.  
The combined analysis for both experiments showed significant changes in the relative 
transcriptional expression of SIRT3 (p < 0.001), SIRT4 (p < 0.001) and SIRT5 (p = 0.001) 
after Tamoxifen treatment (Figure 5.26). The significant increases in the relative 
transcriptional expression of SIRT3, SIRT4 and SIRT5 genes were only observed at the 
8µM Tamoxifen concentration. The p value for Dunnett t-test analysis for each treatment is 
shown in Table 5.2. 
 
 
 
 
 
Figure 5.26: Combined data of the duplicate experiments measuring relative transcriptional 
gene expression of SIRT3, SIRT4 and SIRT5 in the MCF-7 cell line in response to Tamoxifen 
treatment.  
5.3.7 SIRT6 gene expression in response to Tamoxifen treatment 
in MCF-7 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT6 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.27 shows 
the relative gene expression of SIRT6 in MCF-7 cells treated with 5µM and 8µM 
Tamoxifen for 72 hrs.  
This experiment showed that the relative gene expression of SIRT6 increased significantly 
in the MCF-7 cell line when treated with 5 µM and 8 µM Tamoxifen for 72 hours (p < 
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0.001 and p = 0.002 for experiment A and B respectively, Figure 5.27). The 8µM 
Tamoxifen treatment showed a significant increase in both duplicate experiments. 
Whereas, only experiment A showed a significant increase the relative transcriptional 
levels of SIRT6 in the MCF-7 cells treated with 5µM Tamoxifen for 72hrs. The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.2. 
 
 
 
 
 
 
 
Figure 5.27: Relative gene expression of SIRT6 in the MCF-7 cell line in response to 
Tamoxifen treatment.  
Similar significant increases in the relative transcriptional gene expression of SIRT6 at 
8µM Tamoxifen were observed when both experiments were combined and analysed 
together (P < 0.001, Figure 5.29). Both experiments could be combined and analysed 
together since the generalized linear model statistical analysis proved that there was no 
significant difference between the experiments (p = 0.247, Table 5.2). 
5.3.8 SIRT7 gene expression in response to Tamoxifen treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT7 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.28 shows 
the relative gene expression of SIRT7 in 5µM and 8µM Tamoxifen treated cells after 
72hrs.  
Both duplicate experiments showed that relative transcriptional gene expression of SIRT7 
increased significantly in the MCF-7 cells when treated with Tamoxifen for 72 hrs (p = 
0.004 and p = 0.016 for experiment A and B respectively, Figure 5.28). The significant 
increase of the relative transcriptional gene expression of SIRT7 was mainly observed 
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following treatment with the highest concentration of Tamoxifen (8 µM). The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.2. 
Although, the generalized linear model statistical analysis showed that there was 
significant experimental difference between the duplicate experiments (p = 0.001, Table 
5.2), similar significant increases for relative transcriptional gene expression of SIRT7 was 
observed when both experiments were combined and analysed together (P < 0.001, Figure 
5.29).  
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Relative gene expression of SIRT6 in the MCF-7 cell line in response to 
Tamoxifen treatment.  
 
 
 
 
 
 
 
Figure 5.29: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT6 and SIRT7 genes in the MCF-7 cell line in response to 
Tamoxifen treatment. 
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ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.412 p = 0.027 p = 0.024
p = 0.002 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.94 p = 0.974 p = 0.919
p < 0.001 p = 0.002 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.735 p = 0.375 p = 0.327
p = 0.961 p = 0.059 p = 0.102
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.239 p = 0.143 p = 0.946
p = 0.493 p = 0.003 p = 0.006
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.091 p = 0.051 p = 0.001
p = 0.014 p = 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.038 p = 0.132 p = 0.003
p < 0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.485 p = 0.286 p = 0.131
p = 0.006 p = 0.011 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.911 p = 0.058 p = 0.118
p = 0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.965 p = 0.077 p = 0.333
p = 0.019 p = 0.010 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.017 p = 0.460 p = 0.186
p < 0.001 p = 0.001 p = 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.456 p = 0.269 p = 0.186
p = 0.003 p = 0.010 p < 0.001
p = 0.948
p = 0.618
p < 0.001
SIRT5
p = 0.001
SIRT6
p = 0.09
p = 0.634
p < 0.001
XRCC5
p = 0.148
BCL2
p = 0.306
p = 0.814
Combined Experiments 
P21
Ki67
p < 0.001 p = 0.098
Ki67 Ki67
p < 0.001 p = 0.001
SIRT7
p < 0.001 p = 0.247
SIRT4 
p < 0.001
SIRT1 
p = 0.005
p < 0.001
SIRT2 
p < 0.001
SIRT3 
p = 0.738
p = 0.358
p =  0.004 p = 0.016
p < 0.001 p = 0.002
SIRT7 SIRT7
p = 0.014 p = 0.016
SIRT6 SIRT6
p = 0.001 p < 0.001
SIRT5 SIRT5
p = 0.007 p = 0.017
SIRT4 SIRT4 
p<0.001 p < 0.001
SIRT3 SIRT3 
p = 0.022 p = 0.001
SIRT2 SIRT2 
p = 0.084 p = 0.005
SIRT1 SIRT1 
p = 0.797 p = 0.088
BCL2 BCL2
p < 0.001 p = 0.002
XRCC5 XRCC5
P = 0.003 p < 0.001
Experiment A Experiment B
P21 P21
Table 5.2: Probability levels for Tamoxifen treatment experiments in the MCF-7 cell line.  
ANOVA test was used to determine the overall probability of gene expression changes as a 
result of Tamoxifen treatment. The probability of deviation of each treatment (concentration 
of drug) from the control (DMSO only) was investigated using the Dunnett t-test. The 
statistical analysis was performed for each experiment separately and when the data form 
both experiments were combined together.  
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5.4 Sirtuin gene expression in response to Tamoxifen 
treatment in an ER -ve breast cancer cell line (MDA-
MB-453).    
5.4.1 Introduction.  
Tamoxifen (TAM) is commonly used for adjuvant therapy in breast cancer in patients with 
ER+ve tumours and is a key drug for chemoprevention of breast cancer in high-risk women. 
Tamoxifen is believed to inhibit the growth of breast cancer mainly through competing 
with oestrogen for oestrogen receptors binding. However, we hypothesize that sirtuins 
might be involved in the mechanism of action of Tamoxifen treatment. In the previous 
experiment we proved that sirtuin gene expression was altered after treating the ER+ve   
MCF-7 cell line with increasing concentrations of Tamoxifen. The experiment described in 
this section was designed to investigate whether the effect of Tamoxifen on sirtuin gene 
expression is mediated through the oestrogen receptors. In order to address this question, 
we decided to investigate whether the relative transcriptional levels of sirtuin genes are 
altered in response to Tamoxifen treatment in a cell line that is known to be ER–ve (MDA-
MB-453). 
5.4.2 Establishment of experimental conditions for Tamoxifen 
treatments. 
This experiment was undertaken to determine the optimal conditions for measuring sirtuin 
gene expression following treatment of cell lines with Tamoxifen. An established ER 
negative mammary cancer cell line, MDA-MB-453 was used. 
5.4.2.1 MDA-MB-453 cell number titration.   
A cell titration experiment was performed first to determine the optimal number of MDA-
MB-453 cells to be seeded per well in the 96-well plate for this experiment. MDA-MB-453 
cells were seeded at four different numbers per well (5000, 10000, 15000 and 20000) for 
three different time periods of 3, 4, and 5 days. The experiment with the MDA-MB-453 
cells involve a maximum of 5 days incubation in the 96-well plate; 2 days in oestrogen free 
media and then a maximum of three days with the drug. The data showed that cell number 
equal to 5000 was the best for a 5 day incubation period in the 96-well plate (Figure 5.30). 
Cell proliferation was affected by the well size when larger cell numbers were seeded, 
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consequently when 20000 cells were seeded it was not possible to measure the 
proliferation on day 5. Therefore in the following experiments, the number of MDA-MB-
453 cells to be seeded was decided depending on the incubation period in the 96-well plate. 
 
 
 
 
 
 
Figure 5.30: MDA-MB-453 cell titration in the 96-well plate.   
5.4.2.2 Optimisation of Tamoxifen concentration.  
The WST proliferation assay was used to determine the conditions under which cell 
proliferation was strongly suppressed (50%), with minimal cytotoxic effect. MDA-MB-
453 cells was incubated in phenol-free media supplemented with 5% charcoal stripped 
foetal calf serum for 48h before being treated with Tamoxifen for the tested period to 
eliminate the effect of oestrogen on cellular growth. However, growth media was 
supplemented with oestrogen in the presence of Tamoxifen, to a final concentration of 
1nM. 
The effects of various concentrations (2 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 
µM and 12 µM) of Tamoxifen on cellular proliferation were determined using the WST 
proliferation assay. Cell proliferation data for cells treated with Tamoxifen (in DMSO) are 
given relative to cells treated with DMSO alone.  The concentration of DMSO used had 
little effect on cell proliferation  (Figure. 4. 31b). The dose-response data for 72 h 
incubation with Tamoxifen are shown in Figure.  4. 31a. 
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Figure 5.31. Optimisation of Tamoxifen concentration for treating MDA-MB-453 cells  
The MDA-MB-453 cells were incubated for various time (24hrs, 48hrs, 72hrs and 96hrs) 
using three different concentration of Tamoxifen (5µM, 8µM and 10µM). Cell proliferation 
was measured using the WST assay. b) MDA-MB-453 cellular proliferation after being 
treated with the experimental concentration of DMSO alone.  
 
The 8µM concentration of Tamoxifen suppressed 50% of cellular proliferation. In order to 
have a range of concentrations around the 50% suppression point, concentrations of 5µM, 
8µM and 10µM were selected for subsequent experiments. 
 
 
a 
b 
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5.4.2.3 Optimization of Tamoxifen treatment time in the MDA-MB-453 cell 
line. 
The same incubation period of 72 hrs with Tamoxifen was chosen for MDA-MB-453 cells 
as for the MCF-7 cells, since the response to 72hrs incubation with increasing dose of the 
Tamoxifen was similar for both MDA-MB-453 and MCF-7 cells (Figure 5.32). Figure 
5.32a shows the effect of 72hrs incubation with three different concentrations of 
Tamoxifen (5 µM, 8 µM and 10 µM), and demonstrates that treating the MDA-MB-453 
cells with 8 µM of Tamoxifen for 72hrs resulted in a significant suppression of 
proliferation (50%), and that a sufficient number of cells remain alive to enable RNA 
preparation. Simultaneously, a control experiment was performed to determine the effect 
of the experimental concentration of DMSO on MDA-MB-453 cell proliferation. The data 
showed that the concentrations of DMSO used (0.05%, 0.08% and 0.1%) had no negative 
effect on MDA-MB-453 cell proliferation using the WST proliferation assay (Figure. 4.32 
b). 
In all experiments described below the MDA-MB-453 cells were therefore treated for 72 
hours using the three selected concentrations of Tamoxifen, in phenol-free media 
supplemented with 5% charcoal stripped fetal calf serum and 1nM and 1nM β-estradiol. 
After 72hrs, RNA was prepared in order to study sirtuin gene expression. The 
concentration of the DMSO was adjusted to be the same in all experiments: 0.1%. This 
concentration is the same as that used in the 10µM Tamoxifen treatment described above. 
In each experiment a DMSO-only control was included which was used as a “Calibrator” 
for determining relative gene expression. In contrast  to the MCF-7 cells the highest 
concentration of Tamoxifen was not too cytotoxic for the MDA-MB-453 and RNA was 
extracted successfully from cells treated with 10µM Tamoxifen.  
All experiments were carried out in duplicate using the same cell preparation, media and 
treatments in parallel. However, the data were analysed separately for each duplicate 
experiment because the mathematical treatment of the RNA expression data don’t allow 
combination of data for statistical analysis. Therefore, the p value will be presented for 
each duplicate experiment separately; the Analysis of variance (ANOVA) p value will be 
presented in the text, whereas the detailed two-way Dunnett t-test p value will be presented 
for each treatment within each duplicate experiment in Table 5.2.   
 
Samer Zino, 2010                                                                                                         Chapter V, 
 
286 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32: Optimization of Tamoxifen treatment time in the MDA-MB-453 cell line. 
(a) The MDA-MB-453 cells were incubated for 72hrs using three different concentration of 
Tamoxifen (5µM, 8µM and 10µM). Cell proliferation was measured using the WST assay. (b) 
MDA-MB-453 cellular proliferation after being treated with the experimental concentration of 
DMSO alone for 72hrs.  
5.4.3 Gene expression of p21, Ki67, XRCC5 and BCL2 in response 
to Tamoxifen treatment in MDA-MB-453 cells. 
Four different control genes that were expected to respond to Tamoxifen treatments (p21, 
KI67, BCL2 and XRCC5) were studied before analysisng the sirtuin gene expression using 
the same RNA preparation. Figure 5.33 a, b, c, and d shows the relative transcriptional 
 
 
a 
b 
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expression of these genes in MDA-MB-453 cells treated for 72 hours with 5µM and 8µM 
Tamoxifen. 
5.4.3.1 Separate analysis of duplicate experiments.  
This control experiment showed that, as expected, 8µM and 10 µM Tamoxifen caused a 
significant increase in the relative transcriptional gene expression of p21 indicating higher 
levels of cellular stress (p < 0.001 for both experiment A and B, Figure 5.33 a). In both 
experiments the relative expression of Ki67 was significantly decreased following 
Tamoxifen treatment at all concentrations used (p < 0.001 for both experiment A and B; 
Figure 5.33 b). This correlates with its known anti-proliferative effect. The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.33: Relative transcriptional expression of p21 (a), Ki67 (b), XRCC5 (c) and BCL2 (d) 
genes in the MDA-MB-453 cell line in response to Tamoxifen treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
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Only experiment A showed significant changes in the relative transcriptional gene 
expression of XRCC5 in response to Tamoxifen treatment (p = 0.008 for experiment A and 
p = 0.118 for experiment B; Figure 5.33 c). The significant increase the relative 
transcriptional gene expression of XRCC5 was only observed following treatment with 
8µM Tamoxifen (Table 5.3).  
In both experiments A and B there were significant changes in the relative gene expression 
of BCL2 in response to Tamoxifen treatment (P < 0.001 for both Experiments; Figure 
5.33d). The p value for Dunnett t-test analysis for each treatment is shown in Table 5.3. 
5.4.3.2 Combined analysis of duplicate experiments.  
Generalized linear model statistical analysis of both duplicate experiments together showed 
that there was no significant difference between the experiments (p 21, p = 0.501; XRCC5, 
p = 0.891; BCL2, p = 0.106; Table 5.3). Therefore, the combined data from both 
experiments can legitimately be analysed.  
 
 
 
 
 
 
Figure 5.34: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of p21, Ki67, XRCC5 and BCL2 genes in the MCF-7 cell line in 
response to Tamoxifen treatment.  
The combined analysis showed that there was a significant increase in the relative 
transcriptional gene expression of p21 after Tamoxifen treatment (Figure 5.34, p < 0.001).  
There was a significant changes in the relative transcriptional gene expression of XRCC5 
after Tamoxifen treatment p = 0.001; with a significant increase in the relative 
transcriptional gene expression of XRCC5 at 8µM Tamoxifen concentration (Figure 5.34 
and Table 5.3). 
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The combined analysis of data from both experiments showed a significant decrease in the 
relative transcriptional gene expression of BCL2 (p < 0.001) after treatment with 8µM 
Tamoxifen (Figure 5.18 and Table 5.2). In spite of the presence of significant experimental 
difference between the duplicate experiments for KI67, p = 0.005), the combined analysis 
of data from both experiments showed a significant decrease in the relative transcriptional 
gene expression of KI67 genes in response to increasing concentrations of Tamoxifen (p < 
0.001, Figure 5.34). The p value for Dunnett t-test analysis for each treatment is shown in 
Table 5.3. 
5.4.4 SIRT1 gene expression in response to Tamoxifen treatment 
in MDA-MB-453 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT1 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5. 35 shows 
the relative gene expression of SIRT1 in 5µM and 8µM Tamoxifen treated cells after 
72hrs.  
 
 
 
 
 
 
Figure 5.35: Relative transcriptional gene expression of SIRT1 in the MDA-MB-453 cell line 
in response to Tamoxifen treatment. 
This experiment has been performed in duplicate: Exp. A dark column, and Exp. B light 
column. 
 
The data shows that there was a significant increase in the relative transcriptional gene 
expression of SIRT1 in response to increasing concentrations of Tamoxifen in the MDA-
MB-453 cells (p = 0.002 for experiment A and p = 0.004 for experiment B, Figure 5.35). 
The p value for Dunnett t-test analysis for each treatment is shown in Table 5.3. 
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Although the generalized linear model statistical analysis showed a significant difference 
between the two duplicate experiments that there was no significant difference between the 
experiments (p = 0.039, Figure 5.37), similar significant increases were observed for 
relative transcriptional gene expression of SIRT1 in response to increasing concentrations 
of Tamoxifen when both experiments were combined and analysed together (P < 0.001, 
Figure 5.37). The p value for Dunnett t-test analysis for each treatment is shown in Table 
5.3. 
 
5.4.5 SIRT2 gene expression in response to Tamoxifen treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the relative transcriptional gene expression of SIRT2 
in relation to HPRT a housekeeping gene as described in the Material and Methods. Figure 
5.36 shows the relative gene expression of SIRT2 in MDA-MB-453 cells treated with 
Tamoxifen for 72 hrs.  
The data showed that there was a significant increase in the relative transcriptional gene 
expression of SIRT2 in response to increasing concentrations of Tamoxifen in the MDA-
MB-453 cells (p < 0.001 for both experiment A and B, Figure 5.36). The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.3. 
 
 
 
 
 
 
Figure 5.36: Relative transcriptional gene expression of SIRT2 in the MDA-MB-453 cell line 
in response to Tamoxifen treatment. 
The generalized linear model statistical analysis proved that there was no significant 
experimental difference between the duplicate experiments (p = 0.932, Table 5.3). The 
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analysis of the combined data showed that there was a significant increase in the relative 
transcriptional gene expression of SIRT2 following Tamoxifen treatment (p < 0.001, 
Figure 5.37, Table 5.3).  
 
 
 
 
 
 
Figure 5.37: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT1 and SIRT2 genes in the MDA-MB-453 cell line in 
response to Tamoxifen treatment.  
 
5.4.6 SIRT3, SIRT4 & SIRT5 gene expression in response to 
Tamoxifen treatment in MDA-MB-231 cells. 
SIRT3, SIRT4 & SIRT5 are known to be mitochondrial related sirtuins and all show 
responses to Tamoxifen treatment. Therefore they are presented together in this section. 
Real time PCR was used to quantify the transcriptional expression of SIRT3, SIRT4 and 
SIRT5 in relation to HPRT a housekeeping gene as described in the Material and Methods. 
Figure 5.38 a, b, and c shows the relative gene expression of SIRT3, SIRT4 and SIRT5 in 
5µM and 8µM Tamoxifen treated cells after 72hrs.  
5.4.6.1 Separate analysis of duplicate experiments.  
Experiment A showed that there were significant overall changes in the relative 
transcriptional levels of SIRT3, SIRT4 and SIRT5 genes in response to Tamoxifen 
treatment (p < 0.001, p = 0.004 and p = 0.045 respectively; Figure 5.38 a, b, and c). 
However, in experiment B overall significant changes were observed for SIRT3 p = 0.054 
and SIRT4 p = 0.003 but not for SIRT5 p = 0.179 (Figure 5.38 a, b, and c). It is also clear 
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from Figure 5.35 that the changes in SIRT4 gene expression are better correlated with 
increasing concentration of Tamoxifen than the changes in SIRT3 and SIRT5 gene 
expression. The p value for Dunnett t-test analysis for each treatment is shown in Table 
5.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.38: Relative transcriptional expression of SIRT3 (a), SIRT4 (b), and SIRT5 (c) genes 
in the MDA-MB-453 cell line in response to Tamoxifen treatment. 
 
5.4.6.2 Combined analysis of duplicate experiments.  
Generalized linear model statistical analysis of both duplicate experiments together showed 
that there was no significant difference between the experiments for all three genes 
(SIRT3, p = 0.096; SIRT4, p = 0.991; SIRT5, p = 0.171; Table 5.3). Therefore, the 
combined data from both experiments can legitimately be analysed.  
The combined analysis for both experiments showed significant changes in the relative 
transcriptional expression of SIRT3 (p < 0.001), and  SIRT4 (p < 0.001) after Tamoxifen 
 
 
 
 
 
 
 
 
 
 
a b 
c 
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treatment (Figure 5.39). Conversely, changes in the relative transcriptional expression of 
SIRT5 gene after Tamoxifen treatment were not significant (p = 0.098, Figure 5.39). The 
significant increase in the relative transcriptional expression of SIRT3 was observed only 
at the 8µM Tamoxifen concentration. Whereas, the significant increase in the relative 
transcriptional expression of SIRT4 was observed at the 8µM and 10µM Tamoxifen 
concentration. The p value for Dunnett t-test analysis for each treatment is shown in Table 
5.3. 
 
 
 
 
 
 
Figure 5.39: Combined data of the duplicate experiments measuring relative transcriptional 
gene expression of SIRT3, SIRT4 and SIRT5 in the MDA-MB-453 cell line in response to 
Tamoxifen treatment.  
5.4.7 SIRT6 gene expression in response to Tamoxifen treatment 
in MDA-MB-453 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT6 in relation to 
HPRT a housekeeping gene as described in the Material and Methods. Figure 5.40 shows  
the relative gene expression of SIRT6 in MDA-MB-453 cells treated with Tamoxifen for 
72 hrs.  
Experiment A showed no significant changes for relative gene expression of SIRT6 in the 
MDA-MB-453 cell line when treated with Tamoxifen for 72 hours (p < 0.113 Figure 5.40). 
However, there were significant changes in the relative levels of SIRT6 gene expression 
following Tamoxifen treatment in experiment B (p = 0.037; Figure 5.37). The p value for 
Dunnett t-test analysis for each treatment is shown in Table 5.3. 
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Figure 5.40: Relative transcriptional gene expression of SIRT6 in the MDA-MB-453 cell line 
in response to Tamoxifen treatment. 
The generalized linear model statistical analysis indicated that there was no significant 
difference between the experiments (p = 0.989, Table 5.3). Therefore, both experiments 
could be combined and analysed together.  
The combined analysis for both experiments showed significant changes in the relative 
transcriptional expression of SIRT6 after Tamoxifen treatment (P < 0.019, Figure 5.42). 
The significant increase in the relative transcriptional expression levels of SIRT6 gene was 
mainly observed at 10 µM Tamoxifen concentration. The p value for Dunnett t-test 
analysis for each treatment is shown in Table 5.3. 
5.4.8 SIRT7 gene expression in response to Tamoxifen treatment 
in MDA-MB-231 cells. 
Real time PCR was used to quantify the transcriptional expression of SIRT7 in relation to 
HPRT as a housekeeping gene as described in the Material and Methods. Figure 5.41 
shows the relative gene expression of SIRT7 in Tamoxifen treated cells after 72hrs.  
Both duplicate experiments showed that relative transcriptional gene expression of SIRT7 
increased significantly in the MDA-MB-453 cells when treated with Tamoxifen for 72 hrs 
(p = 0.039 and p = 0.022 for experiment A and B respectively, Figure 5.41). The p value 
for Dunnett t-test analysis for each treatment is shown in Table 5.3. 
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Figure 5.41: Relative transcriptional gene expression of SIRT7 in the MDA-MB-453 cell line 
in response to Tamoxifen treatment.  
The generalized linear model statistical analysis indicated that there was no significant 
difference between the experiments (p = 0.636, Table 5.3). Therefore, both experiments 
could be combined and analysed together. The combined analysis for both experiments 
showed significant changes in the relative transcriptional expression of SIRT7 after 
Tamoxifen treatment (P < 0.003, Figure 5.42). The significant increase in the relative 
transcriptional expression levels of SIRT7 gene was observed at 8µM and 10 µM 
Tamoxifen concentration. The p value for Dunnett t-test analysis for each treatment is 
shown in Table 5.3. 
 
 
 
 
 
 
Figure 5.42: Combined data of the duplicate experiments measuring the relative 
transcriptional expression of SIRT6 and SIRT7 genes in the MDA-MB-453 cell line in 
response to Tamoxifen treatment. 
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Table 5.3: Probability levels for Tamoxifen treatment experiments in the MDA-MB-453 cell 
line. 
ANOVA test was used to determine the overall probability of gene expression changes as a 
result of Tamoxifen treatment. The probability of deviation of each treatment (concentration 
of drug) from the control (DMSO only) was investigated using the Dunnett t-test. The 
statistical analysis was performed for each experiment separately and when the data form 
both experiments were combined together.  
 
 
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.446 p = 0.876 p = 0.537
p = 0.048 p = 0.39 p = 0.045
p < 0.001 p = 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p < 0.001 p = 0.01 p < 0.001
p < 0.001 p < 0.001 p < 0.001
p < 0.001 p < 0.001 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.988 p = 0.621 p = 0.822
p = 0.045 p = 0.244 p = 0.010
p = 0.197 p = 0.742 p = 0.176
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.056 p = 0.078 p = 0.908
p = 0.209 p < 0.001 p = 0.001
p = 0.002 p = 0.002 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
0.144 p = 0.549 p = 0.07
0.009 p = 0.115 p = 0.001
0.001 p = 0.002 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.43 p =  0.581 p =  0.259
p = 0.004 p = 0.165 p = 0.001
p = 0.001 p = 0.003 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.002 p = 0.052 p = 0.408
p = 0.001 p = 0.06 p < 0.001
p = 0.906 p = 0.057 p = 0.079
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.348 p = 0.769 p = 0.408
p = 0.024 p = 0.382 p = 0.033
p = 0.002 p = 0.002 p < 0.001
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.332 p = 0.98 p = 0.868
p = 0.019 p = 0.769 p = 0.325
p = 0.226 p = 0.117 p = 0.052
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.205 p = 0.413 p = 0.128
p = 0.059 p = 0.811 p = 0.123
p = 0.216 p = 0.02 p = 0.006
ANOVA Dunnett t-test ANOVA Dunnett t-test ANOVA Dunnett t-test Experimental difference
p = 0.627 p = 0.357 p = 0.266
p = 0.02 p = 0.245 p = 0.009
p = 0.155 p = 0.009 p = 0.002
p = 0.501
p = 0.005
p = 0.891
p = 0.106
BCL2
p < 0.001
SIRT4 
p < 0.001
SIRT5
p = 0.098
p = 0.991
p = 0.171
SIRT2 
p < 0.001
SIRT3 
p < 0.001
p = 0.932
p = 0.096
SIRT1 
p < 0.001 p = 0.039
Combined Experiments 
P21
p < 0.001
Ki67
p < 0.001
XRCC5
p = 0.001
SIRT6
p = 0.019
SIRT7
p = 0.003
p = 0.989
p = 0.636p = 0.039 p = 0.022
p = 0.113 p = 0.037
SIRT7 SIRT7
p = 0.045 p = 0.179
SIRT6 SIRT6
p = 0.004 p = 0.003
SIRT5 SIRT5
p < 0.001 p = 0.054
SIRT4 SIRT4 
p = 0.001 p = 0.007
SIRT3 SIRT3 
p = 0.002 p = 0.004
SIRT2 SIRT2 
p < 0.001 p < 0.001
SIRT1 SIRT1 
p = 0.008 p = 0.118
BCL2 BCL2
p < 0.001 p < 0.001
XRCC5 XRCC5
p < 0.001 p = 0.001
Ki67 Ki67
Experiment A Experiment B
P21 P21
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Sirtuin gene expression in 
response to anti-tumour drug 
treatments  
 
6.1 Sirtuin gene expression in response to Docetaxel 
treatment in an ER-ve breast cancer cell line (MDA-MB-
231).   
6.1.1 Docetaxel. 
Taxanes are antitumour agents shown to arrest cells in mitosis, through microtubule 
stabilization and to induce apoptosis.  Taxanes stabilize microtubules, enhancing the rate 
and extent of tubulin polymerization and inhibit depolymerization, through binding to the 
beta subunit of the tubulin within the microtubule. This results in inhibition of mitotic cell 
division and cell proliferation, leading to cell death by apoptosis (77, 78). Similarly, the 
cytotoxic effect of paclitaxel has been correlated both with its ability to interfere with 
normal microtubule function and with its ability to induce apoptosis (362, 363). 
Docetaxel, a semi-synthetic analogue of paclitaxel, is a microtubule-stabilizing taxane, 
which has recently been approved for use in the clinic for the treatment of breast and 
prostate cancers and small cell carcinoma of the lung (353).  Docetaxel has increased 
affinity for tubulin (364) and has higher antitumour activity compared with paclitaxel 
(365).  
There is no consensus about the main effect of Docetaxel. Initially Docetaxel was shown to 
interrupt the normal mitotic process, through the disruption of microtubules (78).  
However, despite the clear connection to mitosis, apoptosis has generally been accepted to 
be the predominant mechanism of cell death in response to taxane chemotherapy (366-
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369). Docetaxel activates several apoptotic cellular signals, such as protein kinases and 
caspases (369, 370) and decreases structural and anti-oxidative gene expression (66, 371). 
However, other data have indicated that other modes of cell death may also contribute 
significantly to the overall therapeutic response (372-374). This is supported by the 
observation that the degree of therapeutic response does not correlate with apoptosis and 
that anti-apoptotic mutations, or altered expression of genes, such as bcl-2, p21, and p53, 
are not negative predictors of therapeutic efficacy (375-378). Other forms of death include 
mitotic catastrophe, (379, 380) treatment-induced senescence and lytic necrosis (381).  
Adding to the complexity of Docetaxel action, like paclitaxel (382), Docetaxel provoked 
striking differences in the cell cycle according to the dose administered (383, 384). At low 
dose Docetaxel induced aberrant mitosis followed by aneuploidy, whereas at high 
concentration it induced sustained mitotic arrest followed by mitotic slippage (383, 384). 
Recently, a dose dependent response to Docetaxel in human breast carcinoma cells has 
been reported, with no apoptosis triggered at low doses in MCF-7 breast cancer cells (383, 
385). Moreover, the Bayet-Robert study showed significant dose-dependent differences in 
12 of 30 measured metabolites, suggesting dose-dependent metabolic changes in treated 
cells (385).  
Adding together, the mechanism of action of taxanes is not fully understood. The 
published data from both in vitro and clinical studies indicate significant variation in 
cellular sensitivity to paclitaxel, suggesting that alternative mechanisms may be 
responsible for the drug’s activity. Although this group of drugs is know as non DNA-
damaging agents, it has been reported that Docetaxel can causes DNA damage (386). 
The main effects of Docetaxel, especially those could be related to this study have been 
present above. Given the involvement of sirtuins in the MTR and their role in cancer and 
given the data of this thesis, showing significant alterations in sirtuin gene expression in 
breast cancer biopsies, these experiments were performed to investigate if sirtuin gene 
expression is affected by Docetaxel treatment in an ER-VE cell line. 
6.1.2 Conclusions and discussion 
The relative transcriptional expression of genes of interest was determined in the MDA-
MB-231 (ER-ve breast cancer) cell line after 72 hours of Docetaxel (1nM, 10nM, 100nM) 
treatment. The treatment conditions (time and concentration) were decided upon following 
relevant optimization experiments.  
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The control experiment studying four genes that were expected to give responses in gene 
expression level after Docetaxel treatment showed:  
 Dose dependent increases in the levels of p21 gene expression, indicating cellular 
stress proportional to increasing Docetaxel concentration, and supporting a cell 
senescence effect of Docetaxel treatment.  
 Significant increases in the levels of XRCC5 gene expression (DNA damage 
response marker) after Docetaxel treatment, suggesting an accumulation of DNA 
damage in proportion to the Docetaxel concentration. 
 An initial increase in the level of KI67 gene expression (proliferation marker) at 1 
nM Docetaxel, followed by a significant decrease at higher concentrations of 
Docetaxel (10nM and 100nM). These changes might reflect different cellular 
responses at different concentrations of Docetaxel. The observed increase in Ki67 
at low Docetaxel concentrations might indicate a defensive cellular response to 
overcome the cell cycle suppressive effect of Docetaxel. This increase is in keeping 
with the initial increase of NF-κB that is observed at low concentrations of 
Docetaxel and with increased cellular sensitivity to Docetaxel treatment after NF-
κB inhibition (387-389). 
 An initial increase in the levels of BCL2 (anti-apoptotic marker) gene expression at 
1 nM and 10 nM followed by a significant decrease at 100 nM. These results 
suggest that an apoptotic response is triggered at high concentrations of Docetaxel.  
The experiment investigating the relative gene expression of sirtuins in response to 
Docetaxel treatment in MDA-MB-231 cells showed: 
 An increase in the level of SIRT1 gene expression, especially at high levels of 
Docetaxel treatment. This is in keeping with the pro-apoptotic role for SIRT1 in 
cancer as observed in the biopsy study. It is also consistent with the data for 
expression of the control genes BCl2 and Ki67, and with a possible apoptotic 
response at high concentrations.  
 Increases in the levels of SIRT2 gene expression proportional to the increasing 
concentrations of Docetaxel treatments. This is suggestive of a potential 
involvement of SIRT2 (microtubule deacetylase) in the mitotic arrest caused by 
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Docetaxel through its contribution to microtubule dysfunction. Furthermore, this 
result might suggest that mitotic arrest is present, to varying extents, at all the 
concentrations of Docetaxel used. This supports mitotic interference as the primary 
mechanism of action of Docetaxel.  
 Increases in the levels of SIRT3, SIRT4, and SIRT5 gene expression in response to 
Docetaxel treatment. This increase was more significant at higher concentrations of 
Docetaxel and is in keeping with the pro-apoptotic role for SIRT3 in cancer, as 
observed in our biopsy study. The increased expression of SIRT3, especially at 
high concentration of Docetaxel, is in agreement with the BCL2, KI67 and SIRT1 
results, suggesting that a higher concentration of Docetaxel is required to induce 
apoptosis. Similarly, the increased levels of SIRT4 and SIRT5 following Docetaxel 
treatment could reflect metabolic changes associated with Docetaxel treatment, as 
suggested by (385). Furthermore, these results might suggest that the potential role 
of SIRT4 and SIRT5 in tumourigenesis is likely to be anti-cancer in similar way to 
SIRT3 (pro-apoptotic and anti-cancer). 
 Increases in the level of SIRT6 gene expression in response to increasing 
concentrations of Docetaxel. This result is in keeping with the anticancer role of 
SIRT6 through its involvement in DNA repair and interaction with NF-κB. This 
result suggests that there is an increase in SSB DNA damage as result of Docetaxel 
treatment as well as DSB DNA damage. The presence of DSB DNA damage as 
was indicated by the increase in XRCC5 gene expression after Docetaxel treatment. 
Furthermore, this result suggests that suppression of NF-κB-dependent gene 
expression through increased expression of SIRT6 might be involved in the in 
mechanistic action of Docetaxel. Previous study showed that inhibition of NF-κB 
augments Docetaxel-induced apoptosis in different cancer cell lines (387-389). 
 Increases in the level of SIRT7 gene expression in response to increasing 
concentrations of Docetaxel. This result is in keeping with the anti-cancer role of 
SIRT7 that has been supported by the results of the biopsy studies (Chapter 1. 4. 4. 
7). Since increased SIRT7 is able to activate p53- and c-myc-dependent 
transcription, thus promoting apoptosis, the SIRT7 data are in agreement with our 
previous findings (BCL2, KI67, SIRT1, SIRT3, SIRT4, SIRT5) suggesting that the 
apoptotic pathway is induced by high concentrations of Docetaxel.  
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This study demonstrates changes in levels of sirtuin gene expression in response to 
Docetaxel treatment in the MDA-MB-231 cell line, and clearly indicates the possible 
involvement of sirtuins in the cellular effects of Docetaxel, particularly mitotic arrest and 
apoptosis and possibly in other modes of cell death.  
 
6.2 Sirtuin gene expression in response to Tamoxifen 
treatment in an ER+ve and ER-ve breast cancer cell 
lines. 
6.2.1 Tamoxifen 
Endocrine treatment plays an important role in the management of hormone-dependent 
breast cancer. The non-steroidal anti-estrogen tamoxifen (TAM), a selective estrogen 
receptor modulator (SERM), is commonly use in breast cancer chemoprevention and it 
remains the treatment of choice for most women with hormone receptor-positive, invasive 
breast carcinoma. However, TAM has limitations in therapy, with resistance to treatment 
being a frequent outcome (356)  and moreover, TAM induces uterine proliferation (agonist 
actions) increasing the risk of endometrial cancer (390). 
The anti-cancer therapeutic efficacy of TAM is thought to derive primarily from its ability 
to compete with estrogens for binding to the Estrogen receptor (ER). This TAM-bound 
form of ER  (TAM-ER) is unable to effectively activate transcription of genes important 
for the growth and development of oestrogen-dependent tumours. However several studies 
suggest that a different mechanism could be involved. TAM can actively induce 
programmed cell death of cancer cells (391, 392). Other data indicated that there are both 
ER-dependent and ER-independent mechanisms mediating the apoptotic effects of TAM 
(360, 361).  
TAM can induce apoptosis in a time- and dose-dependent manner by modulating Bcl-2 
levels in breast cancer cells, and downregulation of Bcl-2 induced by TAM was not 
accompanied by alterations in p53 levels (6). At the same time TAM induces transcription 
factors and genes involved in promoting cell cycle progression, including cyclins E and 
A2, with kinetics that paralleled that of cells cycling in response to oestrogen. Even though 
the Tamoxifen treated cells are not able to transit through the cell cycle (393).  
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TAM treatment also could affect DNA directly through DNA damage and modulation of 
telomerase activity (357, 394). The mechanism of TAM causing DNA damage is not fully 
understood, but it is known that TAM can cause DNA damage (DSB) and be genotoxic for 
normal and cancer cells by free radical generation (357). Furthermore, it has been reported 
that long-term administration of TAM leads to hepatic tumours in rat liver as a result of the 
formation of DNA adducts.  The formation of DNA adducts results from metabolism of 
TAM to reactive intermediates which bind irreversibly to hepatic DNA, forming DNA 
adducts (395).  
Other studies reported that TAM is able to induce oxidative stress, followed by 
mitochondrial dysfunction (358-361, 396).  
Although the main effect of TAM is to suppress ER+ve cell proliferation, a positive effect 
on cell proliferation has been shown for TAM at low concentration (397).  TAM, similar to 
oestrogen but to a lesser extent, is able to stimulate human breast cancer cell proliferation 
at lower concentration in a biphasic mode (397). Furthermore TAM treatment has been 
shown to cause a reduction in oestrogen receptors in vivo (398). 
Only the main effects of TAM, especially those that could be related to this study have 
been presented. Given the well-known involvement of sirtuins in DNA damage repair, the 
link between some sirtuins and the mitochondrion (refer to the MTR trinity), and the 
variety of cellular effects of TAM that involve mitochondria, DNA, and proliferation, this 
study aimed to investigate the potential involvement of sirtuins in TAM treatment by 
determining the effect of TAM treatment on sirtuin gene expression in both ER+ve and ER-
ve cell lines.  
6.2.2 Conclusions and discussion.  
6.2.2.1 Sirtuin gene expression in response to Tamoxifen treatment in an 
ER+ve breast cancer cell line (MCF-7). 
In this experiment the relative transcriptional expression of genes of interest was 
determined in MCF-7 (ER+ve breast cancer) cell line after 72 hours of TAM (5 µM, 8 µM 
and 10 µM treatment. The treatment conditions (time and concentration) were decided 
upon following relevant optimization experiments. Only the results of 5µM and 8µM TAM 
treatment are discussed, as 10µM of Tamoxifen was too cytotoxic and RNA could not be 
extracted successfully.  
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The control experiment studying four genes that were expected to give responses in gene 
expression level after Tamoxifen treatment showed:  
 A dose-dependent increase in the level of p21 gene expression, indicating cellular 
stress proportional to the increasing concentration of TAM. 
 Significant decreases in both KI67 and BCL2 gene expression levels at the highest 
dose of TAM (8µM). This result is consistent with the anti-proliferative effect of 
TAM and with BCL2 induced apoptosis.  No initial increase in cell proliferation 
was observed with the lower dose of TAM used in this study (5µM). 
 No significant changes in the levels of gene expression of the DNA damage marker 
XRCC5, indicating that, if present at all, any DNA damage due to TAM-treatment 
(both 5µM and 8µM) in MCF-7 cells was not significant and is unlikely to be 
responsible for the induced apoptosis.  
The experiment investigating the relative gene expression of sirtuins in response to 
Tamoxifen treatment in MCF-7 cells showed: 
 Increases in the level of SIRT1 gene expression, especially at high TAM 
concentration. This result is consistent with the pro-apoptotic role for SIRT1 in 
cancer as observed in our biopsy study. The data for the control genes BCl2 and 
Ki67, and with TAM-induced apoptosis. Furthermore, the changes in SIRT1 
expression might correlate with its contribution to the loss of ERα that has been 
noticed after modulating SIRT1 activity (400), or with its role in deacetylating 
nuclear receptors including the ERα (328).   
 Increases in the level of SIRT2 gene expression proportional to increasing 
concentrations of TAM. This is suggestive of a potential involvement of SIRT2 in 
the mechanism of action of TAM, explaining the inability of a TAM-treated cell to 
proceed through the cell cycle in spite of the increases in transcription factors and 
genes involved in promoting the cell cycle that are associated with TAM treatment 
(393).  
 Significant increases, especially at high TAM concentration (8µM), in the levels of 
SIRT3, SIRT4, and SIRT5 gene expression in response to TAM treatment. These 
changes are in keeping with the pro-apoptotic role of SIRT3, and indicate, together 
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with the BCL2, KI67 and SIRT1 results, that the apoptotic response is associated 
mainly with the higher concentration of TAM. The increased levels of SIRT4 and 
SIRT5 are suggestive of a potential involvement for these genes in TAM treatment. 
This could be attributed to their involvement in metabolism or to a potential role in 
the cancer disease process, which is more likely to be similar to that of SIRT3 (pro-
apoptotic or anti-cancer). 
 Significant increases, especially at high TAM concentration (8µM), in the level of 
SIRT6 gene expression in response to TAM treatment. This result is in keeping 
with the anticancer role of SIRT6 through its involvement in DNA repair and 
interaction with NF-κB. The observed increase in SIRT6 gene expression might 
reflect its involvement in maintaining telomeric stability, that could be affected by 
TAM (394). Furthermore, these results might suggest that single strand breaks 
DNA damage could be caused by TAM treatment.  
 Significant increases, especially at high concentration (8µM), in the level of SIRT7 
gene expression after TAM treatment.  
6.2.2.2 Sirtuin gene expression in response to Tamoxifen treatment in an 
ER-ve breast cancer cell line (MDA-MB-453).    
In this experiment the relative transcriptional expression of genes of interest was 
determined in the MDA-MB-453 (ER-ve breast cancer) cell line after 72 hours of TAM 
(5µM, 8µM and 10µM treatment. The treatment conditions (time and concentration) were 
decided upon following relevant optimization experiments.  
The changes in the relative transcriptional expression of genes of interest (control genes 
and sirtuins) in response to TAM treatment in MDA-MB 453 were very similar to those 
observed in the MCF-7 cell. Therefore the main differences will be discussed below. 
 Experimentally a major difference was the ability to extract RNA from MDA-MB-
453 treated with all the three chosen concentrations of TAM (5µM, 8µM and 
10µM), indicating less sensitivity of the cells to TAM. 
 The changes in the levels of XRCC5 were more obvious in MDA-MB-453 cells 
and showed non-constant significant increase at 8µM TAM (only experiment A). 
This result is consistent with the DNA damage component of TAM treatment.  
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 All sirtuin genes showed similar changes in their relative transcriptional levels after 
TAM treatment in MDA-MB 453 when compared to the MCF-7. However, greater 
changes in the gene expression of SIRT3 and SIRT4 were observed, suggesting that 
SIRT4 is more informative in this cell line (MDA-MB-453). 
This study demonstrates changes in levels of sirtuin gene expression in response to TAM 
treatment in both MCF-7 and MDA-MB-453 cell lines. There was no significant difference 
in the behaviour of sirtuin gene expression in response to TAM treatment between these 
two cell lines to indicate that sirtuin changes were ER-dependent. These changes indicate 
possible involvement of sirtuins in the cellular effects of TAM. In particular, the evidence 
presented for an involvement of SIRT2 in the mechanism of TAM treatment is a novel 
observation.  
The data obtained from these three experiments demonstrate clear changes in levels of 
sirtuin gene expression in response to Docetaxel treatment in the MDA-MB-231 cell line 
and in response to TAM treatment in both MCF-7 and MDA-MB-453 cell lines. These 
changes support the second part of the hypothesis underpinning this thesis: “sirtuins might 
contribute both to the pathogenesis of cancer and to the response of tissue to anti-tumour 
agents.” 
Therefore, altering the activity of sirtuins with chemical agonists or by the induction of 
increased gene expression might increase cell sensitivity to both TAM and Docetaxel 
activity.  The data presented in this study point the way to further experiments to 
investigate this potential synergistic effect of sirtuins on anticancer agents, in which the 
effects of TAM and Docetaxel on cell lines when the levels of one or more sirtuins are 
increased, reduced or eliminated are investigated.   
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7.1 Final conclusions.   
The experimental evidence accumulated in this thesis provides an insight into the 
involvement of sirtuins in breast cancer disease. The decreased levels of the relative 
transcriptional expression of sirtuin genes in breast cancer biopsies, is consistent with the 
pro-apoptotic (anti-tumourgenic) effect of sirtuins. The pro- apoptotic role was further 
supported after the significant increased in sirtuins relative transcriptional expression 
observed in response to anti-cancer treatments namely: Tamoxifen and Docetaxel. 
7.1.1 In vivo study 
This study compared the relative transcriptional expression levels of the sirtuin genes 
between normal, non-malignant and malignant breast biopsies. This particular experiment 
showed a decrease in sirtuin gene expression in breast cancer biopsies and supports an anti-
tumourgenic effect role for sirtuins. Decreased SIRT2 and SIRT6 in breast cancer biopsies, 
when compared to both normal and non-malignant biopsies, plus the association between 
higher tumour grades and lower levels of relative expression of both SIRT2 and SIRT6, 
gives insight into how DNA damaged cells could escape the mitotic check points.  
The decreased levels of SIRT1 and SIRT6 in breast cancer biopsies and their involvements 
in negatively regulating the NF-κB cell proliferating effect at two different levels, are 
worthy of note. SIRT1 can deacetylate and inactivate NF-κB, whereas SIRT6 inhibits the 
expression of NF-κB target genes through its interaction with the NF-κB RELA subunit. 
This result might indicate a potential role for NF-κB in breast cancer tumourigenesis that 
might be promoted thorough decreased levels of SIRT1 and SIRT6.  
The lower levels of the mitochondrial sirtuins (SIRT3, SIRT4 and SIRT5) in malignant 
biopsies are suggestive of potential involvement in breast cancer disease, possibly through 
interfering with the mitochondrial apoptotic pathway. Finally, lower levels of SIRT7 were 
an interesting finding as it supports the recently discovered pro-apoptotic effect and 
contradicting the previously known proliferative effect for SIRT7. 
The associations between SIRT1, SIRT6, SIRT7 and patient’s outcomes suggest their 
potential use as additional biological prognostic markers in breast cancer disease. The 
levels of SIRT6 expression was found to be independent of known prognostic markers in 
predicting survival and remained significantly associated with survival in breast cancer 
patients selected to have moderate prognosis. Therefore, it might help in predicting 
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survival in individuals who have equivocal prognostic pathological markers and provide an 
explanation for those breast cancer cases that behave unexpectedly, according to the 
known pathological prognostic markers. 
7.1.2 In vitro study. 
This study investigated the changes in relative transcriptional expression levels of sirtuin 
genes in response to Tamoxifen and Docetaxel in breast caner cell lines. Changes in 
relative transcriptional expression levels of p21, Ki67, XRCC5 and BCL2 were determined 
first as a control for used treatments. Both Tamoxifen and Docetaxel caused significant 
increases in the relative transcriptional expression levels of sirtuin genes, supporting the 
pro-apoptotic effect of sirtuins.  
MDA-MB-231 cells treated with Docetaxel for 72 hours showed significant increase in the 
levels of SIRT2 and suggests that SIRT2 might be implicated in mitotic arrest caused by 
Docetaxel, possibly through its microtubule deacetylation effect that contributes to 
microtubule dysfunction. Similarly, an increase in the level of SIRT2 was observed after 
Tamoxifen treatment in both MCF-7 and MDA-MB-453 cell lines. This increase might 
suggest an involvement of SIRT2 in preventing TAM-treated cell from proceeding through 
the cell cycle in spite of increased levels of transcription factors, that promote cell cycle 
progression, observed after Tamoxifen treatment (393). 
Increased levels of SIRT6, XRCC5 is indicative of DNA damage that is associated with 
higher concentration of both Tamoxifen and Docetaxel. A pro-apoptotic role for SIRT1, 
SIRT3 and SIRT7, and speculated pro-apoptotic role for the mitochondrial SIRT4 and 
SIRT5 was indicated by their increased expression in response to both Tamoxifen and 
Docetaxel.  
There was no significant difference in sirtuin changes after Tamoxifen treatment between 
the MCF-7 (ER+ve) and MDA-MB-453 (ER-ve) cell lines to indicate that sirtuin changes 
were ER-dependent. However MDA-MB-453 showed lower sensitivity to Tamoxifen 
treatment. 
These results imply that sirtuins are implicated in breast cancer disease, suggesting the 
possible use of SIRT6 as a novel biological prognostic marker and specify sirtuin 
activators, rather than inhibitors, might be beneficial in breast cancer disease and enhance 
the response to adjuvant chemotherapy. 
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Appendices 
 Appendix 1  
 
Primers and probe sequence of sirtuins and their position on the messenger RNA (mRNA) 
sequence. Black squares represent the exon exom boundaries. The sequence position for 
primers and probe and highlighted with different colours  
 Forward with Green  
 Reverse with Blue  
 Probe with red  
Only mRNA sequence was presented for SIRT4, SIRT5, SIRT6 since the primers and 
probes sequence for these sirtuins are not provided form the supplying company (Applied 
Biosystems). 
Homo sapiens SIRT1  
           
ACCESSION   NM_012238 
VERSION     NM_012238.3  GI:13775598 
 
       1 GTCGAGCGGG AGCAGAGGAG GCGAGGGAGG AGGGCCAGAG AGGCAGTTGG AAGATGGCGG 
       61 ACGAGGCGGC CCTCGCCCTT CAGCCCGGCG GCTCCCCCTC GGCGGCGGGG GCCGACAGGG 
      121 AGGCCGCGTC GTCCCCCGCC GGGGAGCCGC TCCGCAAGAG GCCGCGGAGA GATGGTCCCG 
      181 GCCTCGAGCG GAGCCCGGGC GAGCCCGGTG GGGCGGCCCC AGAGCGTGAG GTGCCGGCGG 
      241 CGGCCAGGGG CTGCCCGGGT GCGGCGGCGG CGGCGCTGTG GCGGGAGGCG GAGGCAGAGG 
      301 CGGCGGCGGC AGGCGGGGAG CAAGAGGCCC AGGCGACTGC GGCGGCTGGG GAAGGAGACA 
      361 ATGGGCCGGG CCTGCAGGGC CCATCTCGGG AGCCACCGCT GGCCGACAAC TTGTACGACG 
      421 AAGACGACGA CGACGAGGGC GAGGAGGAGG AAGAGGCGGC GGCGGCGGCG ATTGGGTACC 
      481 GAG█ATAACCT TCTGTTCGGT GATGAAATTA TCACTAATGG TTTTCATTCC TGTGAAAGTG 
      541 ATGAGGAGGA TAGAGCCTCA CATGCAAGCT CTAGTGACTG GACTCCAAGG CCACGGATAG█ 
      601 GTCCATATAC TTTTGTTCAG CAACATCTTA TGATTGGCAC AGATCCTCGA ACAATTCTTA 
      661 AAGATTTATT GCCGGAAACA ATACCTCCAC CTGAGTTGGA TGATATGACA CTGTGGCAGA 
      721 TTGTTATTAA TATCCTTTCA GAACCACCAA AAAGGAAAAA AAGAAAAGAT ATTAATACAA 
      781 TTGAAGATGC TGTGAAATTA CTGCAAGAGT GCAAAAAAAT TATAGTTCTA ACTGGAGCTG 
      841 GG█GTGTCTGT TTCATGTGGA ATACCTGACT TCAGGTCAAG GGATGGTATT TATGCTCGCC 
      901 TTGCTGTAGA CTTCCCAGAT CTTCCAGATC CTCAAGCGAT GTTTGATATT GAATATTTCA 
      961 GAAAAGATCC AAGACCATTC TTCAAGTTTG CAAAG█GAAAT ATATCCTGGA CAATTCCAGC 
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     1021 CATCTCTCTG TCACAAATTC ATAGCCTTGT CAGATAAGGA AGGAAAACTA CTTCGCAACT 
     1081 ATACCCAGAA CATAGACACG CTGGAACAGG TTGCGGGAAT CCAAAGGATA ATTCAGTGTC 
     1141 ATG█GTTCCTT TGCAACAGCA TCTTGCCTGA TTTGTAAATA CAAAGTTGAC TGTGAAGCTG 
     1201 TACGAGGAGA TATTTTTAAT CAG█GTAGTTC CTCGATGTCC TAGGTGCCCA GCTGATGAAC 
     1261 CGCTTGCTAT CATGAAACCA GAGATTGTGT TTTTTGGTGA AAATTTACCA GAACAGTTTC 
     1321 ATAGAGCCAT GAAGTATGAC AAAGATGAAG TTGACCTCCT CATTGTTATT GGGTCTTCCC 
     1381 TCAAAGTAAG ACCAGTAGCA CTAATTCCAA █GTTCCATACC CCATGAAGTG CCTCAGATAT 
     1441 TAATTAATAG AGAACCTTTG CCTCATCTGC ATTTTGATGT AGAGCTTCTT GGAGACTGTG 
     1501 ATGTCATAAT TAATGAATTG TGTCATAGGT TAGGTGGTGA ATATGCCAAA CTTTGCTGTA 
     1561 ACCCTGTAAA GCTTTCAGAA ATTACTGAAA AACCTCCACG AACACAAAAA GAATTGGCTT 
     1621 ATTTGTCAGA GTTGCCACCC ACACCTCTTC ATGTTTCAGA AGACTCAAGT TCACCAGAAA 
     1681 GAACTTCACC ACCAGATTCT TCAGTGATTG TCACACTTTT AGACCAAGCA GCTAAGAGTA 
     1741 ATGATGATTT AGATGTGTCT GAATCAAAAG GTTGTATGGA AGAAAAACCA CAGGAAGTAC 
     1801 AAACTTCTAG GAATGTTGAA AGTATTGCTG AACAGATGGA AAATCCGGAT TTGAAGAATG 
     1861 TTGGTTCTAG TACTGGGGAG AAAAATGAAA GAACTTCAGT GGCTGGAACA GTGAGAAAAT 
     1921 GCTGGCCTAA TAGAGTGGCA AAGGAGCAGA TTAGTAGGCG GCTTGATG█GT AATCAGTATC 
     1981 TGTTTTTGCC ACCAAATCGT TACATTTTCC ATGGCGCTGA GGTATATTCA GACTCTGAAG 
     2041 ATGACGTCTT ATCCTCTAGT TCTTGTGGCA GTAACAGTGA TAGTGGGACA TGCCAGAGTC 
     2101 CAAGTTTAGA AGAACCCATG GAGGATGAAA GTGAAATTGA AGAATTCTAC AATGGCTTAG 
     2161 AAGATGAGCC TGATGTTCCA GAGAGAGCTG GAGGAGCTGG ATTTGGGACT GATGGAGATG 
     2221 ATCAAGAGGC AATTAATGAA GCTATATCTG TGAAACAGGA AGTAACAGAC ATGAACTATC 
     2281 CATCAAACAA ATCATAGTGT AATAATTGTG CAGGTACAGG AATTGTTCCA CCAGCATTAG 
     2341 GAACTTTAGC ATGTCAAAAT GAATGTTTAC TTGTGAACTC GATAGAGCAA GGAAACCAGA 
     2401 AAGGTGTAAT ATTTATAGGT TGGTAAAATA GATTGTTTTT CATGGATAAT TTTTAACTTC 
     2461 ATTATTTCTG TACTTGTACA AACTCAACAC TAACTTTTTT TTTTTTAAAA AAAAAAAGGT 
     2521 ACTAAGTATC TTCAATCAGC TGTTGGTCAA GACTAACTTT CTTTTAAAGG TTCATTTGTA 
     2581 TGATAAATTC ATATGTGTAT ATATAATTTT TTTTGTTTTG TCTAGTGAGT TTCAACATTT 
     2641 TTAAAGTTTT CAAAAAGCCA TCGGAATGTT AAATTAATGT AAAGGGACAG CTAATCTAGA 
     2701 CCAAAGAATG GTATTTTCAC TTTTCTTTGT AACATTGAAT GGTTTGAAGT ACTCAAAATC 
     2761 TGTTACGCTA AACTTTTGAT TCTTTAACAC AATTATTTTT AAACACTGGC ATTTTCCAAA 
     2821 ACTGTGGCAG CTAACTTTTT AAAATCTCAA ATGACATGCA GTGTGAGTAG AAGGAAGTCA 
     2881 ACAATATGTG GGGAGAGCAC TCGGTTGTCT TTACTTTTAA AAGTAATACT TGGTGCTAAG 
     2941 AATTTCAGGA TTATTGTATT TACGTTCAAA TGAAGATGGC TTTTGTACTT CCTGTGGACA 
     3001 TGTAGTAATG TCTATATTGG CTCATAAAAC TAACCTGAAA AACAAATAAA TGCTTTGGAA 
     3061 ATGTTTCAGT TGCTTTAGAA ACATTAGTGC CTGCCTGGAT CCCCTTAGTT TTGAAATATT 
     3121 TGCCATTGTT GTTTAAATAC CTATCACTGT GGTAGAGCTT GCATTGATCT TTTCCACAAG 
     3181 TATTAAACTG CCAAAATGTG AATATGCAAA GCCTTTCTGA ATCTATAATA ATGGTACTTC 
     3241 TACTGGGGAG AGTGTAATAT TTTGGACTGC TGTTTTCCAT TAATGAGGAG AGCAACAGGC 
     3301 CCCTGATTAT ACAGTTCCAA AGTAATAAGA TGTTAATTGT AATTCAGCCA GAAAGTACAT 
     3361 GTCTCCCATT GGGAGGATTT GGTGTTAAAT ACCAAACTGC TAGCCCTAGT ATTATGGAGA 
     3421 TGAACATGAT GATGTAACTT GTAATAGCAG AATAGTTAAT GAATGAAACT AGTTCTTATA 
     3481 ATTTATCTTT ATTTAAAAGC TTAGCCTGCC TTAAAACTAG AGATCAACTT TCTCAGCTGC 
     3541 AAAAGCTTCT AGTCTTTCAA GAAGTTCATA CTTTATGAAA TTGCACAGTA AGCATTTATT 
     3601 TTTCAGACCA TTTTTGAACA TCACTCCTAA ATTAATAAAG TATTCCTCTG TTGCTTTAGT 
     3661 ATTTATTACA ATAAAAAGGG TTTGAAATAT AGCTGTTCTT TATGCATAAA ACACCCAGCT 
     3721 AGGACCATTA CTGCCAGAGA AAAAAATCGT ATTGAATGGC CATTTCCCTA CTTATAAGAT 
     3781 GTCTCAATCT GAATTTATTT GGCTACACTA AAGAATGCAG TATATTTAGT TTTCCATTTG 
     3841 CATGATGTTT GTGTGCTATA GATGATATTT TAAATTGAAA AGTTTGTTTT AAATTATTTT 
     3901 TACAGTGAAG ACTGTTTTCA GCTCTTTTTA TATTGTACAT AGTCTTTTAT GTAATTTACT 
     3961 GGCATATGTT TTGTAGACTG TTTAATGACT GGATATCTTC CTTCAACTTT TGAAATACAA 
     4021 AACCAGTGTT TTTTACTTGT ACACTGTTTT AAAGTCTATT AAAATTGTCA TTTGACTTTT 
     4081 TTCTGTTAAA AAAAAAAAAA AAAAAAA 
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Homo sapiens SIRT2            
 
ACCESSION   NM_012237 
VERSION     NM_012237.2  GI:13775599 
 
     1 GTGTTGTACG AAAGCGCGTC TGCGGCCGCA ATGTCTGCTG AGAGTTGTAG TTCTGTGCCC 
       61 TATCACGGCC ACTCCCATTT CTGGTGCCGT CACGGGACAG AGCAGTCGGT GACAGGACAG 
      121 AGCAGTCGGT GACGGGACAC AGTGGTTGGT GACGGGACAG AGCGGTCGGT GACAGCCTCA 
      181 AGGGCTTCAG CACCGCGCCC ATGGCAGAGC CAGACC█CCTC TCACCCTCTG GAGACCCAGG 
      241 CAGGGAAGGT GCAGGAGGCT CAG█GACTCAG ATTCAGACTC TGAGGGAGGA GCCGCTGGTG 
      301 GAGAAGCAGA CA█TGGACTTC CTGCGGAACT TATTCTCCCA GACGCTCAGC CTGGGCAGCC 
      361 AGAAGGAGCG TCTGCTGGAC GAGCTGACCT TGGAAGGGGT GGCCCGGTAC ATGCAGAGCG 
      421 AACGCT█GTCG CAGAGTCATC TGTTTGGTGG GAGCTGGAAT CTCCACA█TCC GCAGGCATCC 
      481 CCGACTTTCG CTCTCCATCC ACCGGCCTCT ATGACAACCT AGAGAAGTAC CATCTTCCCT 
      541 ACCCAGAGGC CATCTTTGAG ATCAGCTATT TCAAG█AAACA TCCGGAACCC TTCTTCGCCC 
      601 TCGCCAAGGA ACTCTATCCT GGGCAGTTCA AG█CCAACCAT CTGTCACTAC TTCATGCGCC 
      661 TGCTGAAGGA CAAGGGGCTA CTCCTGCGCT GCTACACGCA G█AACATAGAT ACCCTGGAGC 
      721 GAATAGCCGG GCTGGAACAG GAGGACTTGG TGGAGGCGCA CGGCACCTTC TACACATCAC 
      781 ACTGCGTCAG CGCCAGCTGC CGGCACGAAT ACCCGCTAAG CTGGATGAAA G█AGAAGATCT 
      841 TCTCTGAGGT GACGCCCAAG TGTGAAGACT GTCAGAGCCT GGTGAAGCCT G█ATATCGTCT 
      901 TTTTTGGTGA GAGCCTCCCA GCGCGTTTCT TCTCCTGTAT GCAGTCA█GAC TTCCTGAAGG 
      961 TGGACCTCCT CCTGGTCATG GGTACCTCCT TGCAGGTGCA GCCCTTTGCC TCCCTCATCA 
     1021 GCAA█GGCACC CCTCTCCACC CCTCGCCTGC TCATCAACAA GGAGAAAGCT GGCCAG█TCGG 
     1081 ACCCTTTCCT GGGGATGATT ATGGGCCTCG GAGGAGGCAT GGACTTTGAC TCCAAGAAGG 
     1141 CCTACAG█GGA CGTGGCCTGG CTGGGTGAAT GCGACCAGGG CTGCCTGGCC CTTGCTGAGC 
     1201 TCCTTGGATG GAAG█AAGGAG CTGGAGGACC TTGTCCGGAG GGAGCACGCC AGCATAGATG 
     1261 CCCAGTCGGG GGCGGGGGTC CCCAACCCCA GCACTTCAGC TTCCCCCAAG AAGTCCCCGC 
     1321 CACCTGCCAA GGACGAGGCC AGGACAACAG AGAGGGAGAA ACCCCAGTGA CAGCTGCATC 
     1381 TCCCAGGCGG GATGCCGAGC TCCTCAGGGA CAGCTGAGCC CCAACCGGGC CTGGCCCCCT 
     1441 CTTAACCAGC AGTTCTTGTC TGGGGAGCTC AGAACATCCC CCAATCTCTT ACAGCTCCCT 
     1501 CCCCAAAACT GGGGTCCCAG CAACCCTGGC CCCCAACCCC AGCAAATCTC TAACACCTCC 
     1561 TAGAGGCCAA GGCTTAAACA GGCATCTCTA CCAGCCCCAC TGTCTCTAAC CACTCCTGGG 
     1621 CTAAGGAGTA ACCTCCCTCA TCTCTAACTG CCCCCACGGG GCCAGGGCTA CCCCAGAACT 
     1681 TTTAACTCTT CCAGGACAGG GAGCTTCGGG CCCCCACTCT GTCTCCTGCC CCCGGGGGCC 
     1741 TGTGGCTAAG TAAACCATAC CTAACCTACC CCAGTGTGGG TGTGGGCCTC TGAATATAAC 
     1801 CCACACCCAG CGTAGGGGGA GTCTGAGCCG GGAGGGCTCC CGAGTCTCTG CCTTCAGCTC 
     1861 CCAAAGTGGG TGGTGGGCCC CCTTCACGTG GGACCCACTT CCCATGCTGG ATGGGCAGAA 
     1921 GACATTGCTT ATTGGAGACA AATTAAAAAC AAAAACAACT AAC 
 
 
 
 
 
 
 
 
 
 
 
 
333 
 
 
Homo sapiens SIRT3 
 
ACCESSION   AF083108 
VERSION     AF083108.2  GI:13259626 
 
      1 GGCGCCGGGG GCGGGGGTGG GAGGCGGAGG CGGGGCCGGG GCGCCGCGGG CGGGGCGCCG 
       61 GGGGCGGGGC GAGTCCGGAG GACTCCTCGG ACTGCGCGGA ACATGGCGTT CTGGGGTTGG 
      121 CGCGCCGCGG CAGCCCTCCG GCTGTGGGGC CGGGTAGTTG AACGGGTCGA GGCCGGGGGA 
      181 GGCGTGGGGC CGTTTCAGGC CTGCGGCTGT CGGCTGGTGC TTGGCGGCAG GGACGATGTG 
      241 AGTGCGGGGC TGAGAGGCAG CCATGGGGCC CGCGGTGAGC CCTTGGACCC GGCGCGCCCC 
      301 TTGCAGAGGC CTCCCAGACC CGAGGTGCCC AGGGCATTCC GGAGGCAGCC GAGGGCAGCA 
      361 GCTCCCAGTT TCTTCTTTTC GAG█TATTAAA GGTGGAAGAA GGTCCATATC TTTTTCTGTG 
      421 GGTGCTTCAA GTGTTGTTGG AAGTGGAGGC AGCAGTGACA AGGGGAAGCT TTCCCTGCAG 
      481 GATGTAGCTG AGCTGATTCG GGCCAGAGCC TGCCAGAGGG TGGTGGTCAT GGTGGGGGCC 
      541 GGCATCAGCA CACCCAGTGG CATTCCAGAC TTCAG█ATCGC CGGGGAGTGG CCTGTACAGC 
      601 AACCTCCAGC AGTACGATCT CCCGTACCCC GAGGCCATTT TTGAACTCCC ATTCTTCTTT 
      661 CACAACCCCA AGCCCTTTTT CACTTTGGCC AAGGAGCTGT ACCCTGGAAA CTACAAGCCC 
      721 AACGTCACTC ACTACTTTCT CCGGCTGCTT CATGACAAGG GGCTGCTTCT GCGGCTCTAC 
      781 ACGCAGAACA TCGATGGGCT TGAGAGAG█TG TCGGGCATCC CTGCCTCAAA GCTGGTTGAA 
      841 GCTCATGGAA CCTTTGCCTC TGCCACCTGC ACAGTCTGCC AAAGACCCTT CCCAGGGGAG 
      901 GACATTCGG█G CTGACGTGAT GGCAGACAGG GTTCCCCGCT GCCCGGTCTG CACCGGCGTT 
      961 GTGAAGCCCG ACATTGTGTT CTTTGGGGAG CCGCTGCCCC AGAGGTTCTT GCTGCATGTG 
     1021 GTTGATTTCC CCATGGCAGA TCTGCTGCTC ATCCTTGGGA CCTCCCTGGA G█GTGGAGCCT 
     1081 TTTGCCAGCT TGACCGAGGC CGTGCGGAGC TCAGTTCCCC GACTGCTCAT CAACCGGGAC 
     1141 TTGGTGGGGC CCTTGGCTTG GCATCCTCGC AGCAGGGACG TGGCCCAGCT GGGGGACGTG 
     1201 GTTCACGGCG TGGAAAGCCT AGTGGAGCTT CTGGGCTGGA CAGAAGAGAT GCGGGACCTT 
     1261 GTGCAGCGGG AAACTGGGAA G█CTTGATGGA CCAGACAAAT AGGATGATGG CTGCCCCCAC 
     1321 ACAATAAATG GTAACATAGG AGACATCCAC ATCCCAATTC TGACAAGACC TCATGCCTGA 
     1381 AGACAGCTTG GGCAGGTGAA ACCAGAATAT GTGAACTGAG TGGACACCCG AGGCTGCCAC 
     1441 TGGAATGTCT TCTCAGGCCA TGAGCTGCAG TGACTGGTAG GGCTGTGTTT ACAGTCAGGG 
     1501 CCACCCCGTC ACATATACAA AGGAGCTGCC TGCCTGTTTG CTGTGTTGAA CTCTTCACTC 
     1561 TGCTGAAGCT CCTAATGGAA AAAGCTTTCT TCTGACTGTG ACCCTCTTGA ACTGAATCAG 
     1621 ACCAACTGGA ATCCCAGACC GAGTCTGCTT TCTGTGCCTA GTTGAACGGC AAGCTCGGCA 
     1681 TCTGTTGGTT ACAAGATCCA GACTTGGGCC GAGCGGTCCC CAGCCCTCTT CATGTTCCGA 
     1741 AGTGTAGTCT TGAGGCCCTG GTGCCGCACT TCTAGCATGT TGGTCTCCTT TAGTGGGGCT 
     1801 ATTTTTAATG AGAGAAAATC TGTTCTTTCC AGCATGAAAT ACATTTAGTC TCCTCAAAAA 
     1861 AAAAAAACA 
 
Homo sapiens SIRT4  
ACCESSION   NM_012240 
VERSION     NM_012240.1  GI:6912661 
 
      1 GTCCGTAGAG CTGTGAGAG█A ATGAAGATGA GCTTTGCGTT GACTTTCAGG TCAGCAAAAG 
       61 GCCGTTGGAT CGCAAACCCC AGCCAGCCGT GCTCGAAAGC CTCCATTGGG TTATTTGTGC 
      121 CAGCAAGTCC TCCTCTGGAC CCTGAGAAGG TCAAAGAGTT ACAGCGCTTC ATCACCCTTT 
      181 CCAAGAGACT CCTTGTGATG ACTGGGGCAG GAATCTCCAC CGAATCGGGG ATACCAGACT 
      241 ACAGGTCAGA AAAAGTGGGG CTTTATGCCC GCACTGACCG CAGGCCCATC CAGCATGGTG 
      301 ATTTTGTCCG GAGTGCCCCA ATCCGCCAGC GGTACTGGGC GAGAAACTTC GTAGGCTGGC 
      361 CTCAATTCTC CTCCCACCAG CCTAACCCTG CACACTGGGC TTTGAGCACC TGGGAGAAAC 
      421 TCGGAAAGCT GTACTGGTTG GTGACCCAAA ATGTGGATGC TTTGCACACC AAGGCGGGGA 
      481 GTCGGCGCCT GACAGAGCTC CACGGATGCA TGGACAG█GGT CCTGTGCTTG GATTGTGGGG 
      541 AACAGACTCC CCGGGGGGTG CTGCAAGAGC GTTTCCAAGT CCTGAACCCC ACCTGGAGTG 
      601 CTGAGGCCCA TGGCCTGGCT CCTGATGGTG ACGTCTTTCT CTCAGAGGAG CAAGTCCGGA 
      661 GCTTTCAGGT CCCAACCTGC GTTCAATGTG GAGGCCATCT GAAACCAGAT GTCGTTTTCT 
      721 TCGGGGACAC AGTGAACCCT GACAAGGTTG ATTTTGTGCA CAAGCGTGTA AAAGAAGCCG 
      781 ACTCCCTCTT GGTGGTGGGA TCATCCTTGC AG█GTATACTC TGGTTACAGG TTTATCCTCA 
      841 CTGCCTGGGA GAAGAAGCTC CCGATTGCAA TACTGAACAT TGGGCCCACA CGGTCGGATG 
      901 ACTTGGCGTG TCTGAAACTG AATTCTCGTT GTGGAGAGTT GCTGCCTTTG ATAGACCCAT 
      961 GCTGACCACA GCCTGATATT CCAGAACCTG GAACAGGGAC TTTCACTTGA ATCTTGCTGC 
     1021 TAAATGTAAA TGCCTTCTCA AATGACAGAT TCCAGTTCCC ATTCAACAGA GTAGGGTGCA 
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     1081 CTGACAAAGT ATAGAAGGTT CTAGGTATCT TAATGTGTGG ATATTCTTAA TTAAAACTCA 
     1141 TTTTTTTTAA ATAAAAAATT GTTCAGCTTT AAAA 
 
Homo sapiens SIRT5 
 
ACCESSION   NM_031244     
VERSION     NM_031244.1  GI:13787214 
 
        1 ATTCGGGGGC GCGAGCTGCC CCAG█TAAATG GAAATGTTTT CTAACATATA AAAACCTACA 
       61 GAAGAAGAAA ATAATTTTCT GGATCAAATT AGAAGTCTGT ATTATATTGA TGTCTCCAGA 
      121 TTCAAATATA TTAGAAAGCA GCCGTGGAGA CAACCATCTT CATTTTGGGC GAAATAACTA 
      181 AAG█CCCGCCT CAAGCATTAG AACTACAGAC AAACCCTGAT GCGACCTCTC CAGATTGTCC 
      241 CAAGTCGATT GATTTCCCAG CTATATTGTG GCCTGAAGCC TCCAGCGTCC ACACGAAACC 
      301 AGATTTGCCT GAAAATGGCT CGGCCAAGTT CAA█GTATGGC AGATTTTCGA AAGTTTTTTG 
      361 CAAAAGCAAA GCACATAGTC ATCATCTCAG GAGCTGGTGT TAGTGCAGAA AGTGGTGTTC 
      421 CGACCTTCAG AGGAGCTGGA GGTTATTGGA GAAAATGGCAAGCCCAG█GAC CTGGCGACTC 
      481 CCCTGGCCTT TGCCCACAAC CCGTCCCGGG TGTGGGAGTT CTACCACTAC CGGCGGGAGG 
      541 TCATGGGGAG CAAGGAGCCC AACGCCGGGC ACCGCGCCAT AGCCGAGTGT GAGACCCGGC 
      601 TGGGCAAGCA GGGCCGGCGA GTCGTGGTCA TCACCCAGAA CATCGATGAG CTGCACCGCA 
      661 AGGCTGGCAC CAAGAACCTT CTGGAGATCC ATG█GTAGCTT ATTTAAAACT CGATGTACCT 
      721 CTTGTGGAGT TGTGGCTGAG AATTACAAGA GTCCAATTTG TCCAGCTTTA TCAGGAAAAG 
      781 G█TGCTCCAGA ACCTGGAACTCAAGATGCCAGCATCCCAGT TGAGAAACTT CCCCG█GTGTG 
      841 AAGAGGCAGG CTGCGGGGGC TTGCTGCGAC CTCACGTCGT GTGGTTTGGA GAAAACCTGG 
      901 ATCCTGCCAT TCTGGAGGAG GTTGACAGAG AGCTCGCCCA CTGTGATTTA TGTCTAGTG█G 
      961 TGGGCACTTC CTCTGTGGTG TACCCAGCAG CCATGTTTGC CCCCCAGGTG GCTGCCAGGG 
     1021 GCGTGCCAGT GGCTGAATTT AACACGGAGA CCACCCCAGC TACGAACAGA TTCAG█TCATT 
     1081 TGATCTCCAT CTCATCTCTA ATTATTATAA AGAATTAAAA CAAGTCATCA TTGTAGAAAA 
     1141 GCAAGAAAAT GCAGATAGAG AAAAAGAAGA AAATAAAACT GGAGTATTTCCACAACCCAA 
     1201 GTTTAGAGTT GGCCCCCACC TCCCATGCCA TGGACTGAGC AGCAGGGGCC CAGCATCCCT 
     1261 TGGATATGGT GGCTGTGTCT TCATGTGAAA GAAACTGAAC TTGGTGGTTT TTCCTGCCAG 
     1321 TTCAGGAGAG ATTCTTGGCA TGTAATATAT ATCACTGCTC AAGTCAAGCC TCCTAAAACC 
     1381 ACAGACCTGT TTCAGCTGCT ACTTCAGCCA AAATTCTTCA GCTTCATATT GTCTTGAAAA 
     1441 CCTATGATTG TCTCTAACAA ACAGGCTACT TGCTAGTTAG AAATTCTTAT CAATTTGGCA 
     1501 AGCTACTTAT CAACCAGACT GACCACAAGA ACTGTCATCT CATCAATGAA GGAGTAACTG 
     1561 ATCAATGAAG CCAGCAATGC TTTTTTCTTG GCATCATCAA AGCTGACATT TAGAAGAGAT 
     1621 GCTGGTGATA GTCATCTCAT CCTACTCAAT TTTTCAAAGG CAGAAACCAA CCCTGGAGCA 
     1681 ATTGAGAGGA CTGTTTAAAC ACAGAGCTTA ACAATGGCAG AATTGTATAT CTCGTGCTTA 
     1741 ACAGATTTTG GTTGAACTTT ACCCTAGGTC AGGGGTCAGC AAACTACTGC CTGTGGGCCA 
     1801 AATTTGCCCA CCACCTGTAT CTGTAAATAA GGTTTCATTG GAACACAGCT GTGGCCATAT 
     1861 GTTTGTATAT TGTGTGTGGC TGCTTTTGCA TTAGGATGAC AGAGGTGAAT AGTTGCAACA 
     1921 GAGACTGGCT GGTCTGCAAA GCCTAAAATA TGTCCTGTGT GGCCCTTTAC AGAAAAAGTT 
     1981 TTCTAACCCC TGCTCTAGGT TACGGAGAAA AAAAAATGGA ATAATGTTCT CTGCTACTTT 
     2041 TAACCTGATT TTCTTTGTAC CTAAATAGGC AGCTAGAATG CTGCCTATAT TTTAATAAGG 
     2101 ATTTGGATCT CACAAGACAC CTTAGGCCTA CACAAGTTGT TCAGATTCTT TGCCCCAGTT 
     2161 CTAATCTAGT GACAAAGGCA TAGAATTCTC CTCCCACAGG AATGTATTTC TATTTTCAAG 
     2221 GTGTTAATTA GTTCCAGTTT TGGTTTTGTC GTTTTCCCCA TGTCCGATGC TTATATTGGA 
     2281 TGATTTCTGA TAAACCTGAC TATTCCAATA AACCCTAGGC ATTTTTGAAT TTAAAAAAAA 
     2341 AAAAAAAAAA 
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Homo sapiens SIRT6 
 
ACCESSION   NM_016539 
VERSION     NM_016539.1  GI:7706709 
 
1 GCTTCCGGCG GAAGCGGCCT CAACAAGGGA AACTTTATTG TTCCCGTGGG GCAGTCGAGG 
       61 ATGTCGGTGA ATTACGCGGC GGGGCTGTCG CCGTACGCGG ACAAGGGCAA GTGCGGCCTC 
      121 CCGG█AGATCT TCGACCCCCC GGAGGAGCTG GAGCGGAAGG TGTGGGAACT GGCGAGGCTG 
      181 GTCTGGCAGT CTTCCAGTGT GGTGTTCCAC ACGGGTGCCG GCATCAGCAC TGCCTCTGGC 
      241 ATCCCCGACT TCAGG█GGTCC CCACGGAGTC TGGACCATGG AGGAGCGAGG TCTGGCCCCC 
      301 AAGTTCGACA CCACCTTTGA GAGCGCGCGG CCCACGCAGA CCCACATGGC GCTGGTGCAG 
      361 CTGGAGCGCG TGGGCCTCCT CCGCTTCCTG GTCAGCCAGA ACGTGGACGG GCTCCATGTG 
      421 CGCTCAGG║CT TCCCCAGG█GA CAAACTGGCA GAGCTCCACG GGAACATGTT TGTGGAAGAA 
      481 TGTGCCAAGT GTAAGAC█GCA GTACGTCCGA GACACAGTCG TGGGCACCAT GGGCCTGAAG 
      541 GCCACGGGCC GGCTCTGCAC CGTGGCTAAG GCAAGGGGGC TGCGAGCC║TG CAGGGGAG█AG 
      601 CTGAGGGACA CCATCCTAGA CTGGGAGGAC TCCCTGCCCG ACCGGGACCT GGCACTCGCC 
      661 GATGAGGCCA G█CAGG║AACGC CGACCTGTCC ATCACGCTGG GTACATCGCT GCAGATCCGG 
      721 CCCAGCGGGA ACCTGCCGCT GGCTACCAAG CGCCGGGGAG GCCGCCTGGT CATCGTCAAC 
      781 CTGCAGCCCA CCAA║GCACG█A CCGCCATGCT GACCTCCGCA TCCATGGCTA CGTTGACGAG 
      841 GTCATGACCC GGCTCATGGA GCACCTGGGG CTGGAGATCC CCGCCTGGGA CGGCCCCCGT 
      901 GTGCTGGAGA GGGCGCTGCC ACCCCTGCCC CGCCCGCCCA CCCCCAAGCT GGAGCCCAAG 
      961 GAGGAATCTC CCACCCGGAT CAACGGCTCT ATCCCCGCCG GCCCCAAGCA GGAGCCCTGC 
     1021 GCCCAGCACA ACGGCTCAGA GCCCGCCAGC CCCAAACGGG AGCGGCCCAC CAGCCCTGCC 
     1081 CCCCACAGAC CCCCCAAAAG GGTGAAGGCC AAGGCGGTCC CCAGCTGACC AGGGTGCTTG 
     1141 GGGAGGGTGG GGCTTTTTGT AGAAACTGTG GATTCTTTTT CTCTCGTGGT CTCACTTTGT 
     1201 TACTTGTTTC TGTCCCCGGG AGCCTCAGGG CTCTGAGAGC TGTGCTCCAG GCCAGGGGTT 
     1261 ACACCTGCCC TCCGTGGTCC CTCCCTGGGC TCCAGGGGCC TCTGGTGCGG TTCCGGGAAG 
     1321 AAGCCACACC CCAGAGGTGA CAGCTGAGCC CCTGCCACAC CCCAGCCTCT GACTTGCTGT 
     1381 GTTGTCCAGA GGTGAGGCTG GGCCCTCCCT GGTCTCCAGC TTAAACAGGA GTGAACTCCC 
     1441 TCTGTCCCCA GGGCCTCCCT TCTGGGCCCC CTACAGCCCA CCCTACCCCT CCTCCATGGG 
     1501 CCCTGCAGGA GGGGAGACCC ACCTTGAAGT GGGGGATCAG TAGAGGCTTG CACTGCCTTT 
     1561 GGGGCTGGAG GGAGACGTGG GTCCACCAGG CTTCTGGAAA AGTCCTCAAT GCAATAAAAA 
     1621 CAATTTCTTT CTTGCAAA 
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Homo sapiens SIRT7 
 
ACCESSION   NM_016538 
VERSION     NM_016538.1  GI:7706711 
 
      1 GCGGAAGCGG AAGAGCAGGT CTCCAGGGGA GCGATGGCAG CCGGGGGTCT GAGCCGCTCC 
       61 GAGCGCAAAG CGGCGGAGCG GGTCCGGAGG TTGCGGGAGG AGCAGCAGAG GGAGCGCCTC 
      121 CGCCAG█GTGT CGCGCATCCT GAGGAAGGCG GCGGCGGAGC GCAGCGCCGA GGAGGGCCGG 
      181 CTGCTGGCCG AGAGCGCGGA CCTGGTAACG GAGCTGCAGG GCCGGAGCCG GCGGCGCGAG 
      241 GGCCTGAAGC GGCGGCAGGA GGAG█GTGTGC GACGACCCGG AGGAGCTGCG GGGGAAGGTC 
      301 CGGGAGCTGG CCAGCGCCGT CCGGAACGCC AAATACTTGG TCGTCTACAC AGGCGCGGGA 
      361 ATCAGCACG█G CAGCGTCTAT CCCAGACTAC CGGGGCCCTA ATGGAGTGTG GACACTGCTT 
      421 CAGAAAGGGA GAAGCGTTAG█ TGCTGCCGAC CTGAGCGAGG CCGAGCCAAC CCTCACCCAC 
      481 ATGAGCATCA CCCGTCTGCA TGAGCAGAAG CTG█GTGCAGC ATGTGGTGTC TCAGAACTGT 
      541 GACGGGCTCC ACCTGAGGAG TGGGCTGCCG CGCACGGCCA TCTCCGAGCT CCACGGGAAC 
      601 ATGTACATTG AA█GTCTGTAC CTCCTGCGTT CCCAACAGGG AGTACGTGCG GGTGTTCGAT 
      661 GTGACGGAGC GCACTGCCCT CCACAGACAC CAGACAGGCC GGACCTGCCA CAAGTGTGGG 
      721 ACCCAGCTGC GGGACACCAT TGTGCACTTT GGGGAGAGGG GGACGTTGGG GCAGCCTCTG 
      781 AACTGGGAAG CGGCGACCGA GGCTGCCAGC AGAGCAGACA CCATCCTGTG TCTAGGGTCC 
      841 AGCCTGAAG█G TTCTAAAGAA GTACCCACGC CTCTGGTGCA TGACCAAGCC CCCTAGCCGG 
      901 CGGCCGAAGC TTTACATCGT GAACCTGCAG█ TGGACCCCGA AGGATGACTG GGCTGCCCTG 
      961 AAGCTACATG GGAAGTGTGA TGACGTCATG CGGCTCCTCA TGGCCGAGCT GGGCTTGGAG 
     1021 ATCCCCGCCT ATAGCAG█GTG GCAGGATCCC ATTTTCTCAC TGGCGACTCC CCTGCGTGCT 
     1081 GGTGAAGAAG GCAGCCACAG TCGGAAGTCG CTGTGCAGAA GCAGAGAGGA GGCCCCGCCT 
     1141 GGGGACCGGG GTGCACCGCT TAGCTCGGCC CCCATCCTAG GGGGCTGGTT TGGCAGGGGC 
     1201 TGCACAAAAC GCACAAAAAG GAAGAAAGTG ACGTAATCAC GTGCTCGATG AAGAACAGTT 
     1261 GGCACTTTGC AGATGGCCAG TGTCACGGTG AAGGCTGGGT TGCCCCCACG GGTCTAGGGA 
     1321 GAACGAACTC TTTGGGGATG ACATTTTCAC CGTGACATTT TTAGCCATTT GTCCTTGAGG 
     1381 AAGCCCCTTG CACTGCTGCG GTTGTACCCT GATACGGCCT GGCCATCGAG GACACCTGCC 
     1441 CATCCGGCCT CTGTGTCAAG AGGTGGCAGC CGCACCTTTC TGTGAGAACG GAACTCGGGT 
     1501 TATTTCAGCC CCGGCCTGCA GAGTGGAAGC GCCCAGCGGC CTTTCCTCGC TCACCAGGCC 
     1561 AGTCTCAGGG CCTCACCGTA TTTCTACTAC TACTTAATGA AAAAGTGTGA ACTTTATAGA 
     1621 ATCCTCTCTG TACTGGATGT GCGGCAGAGG GGTGGCTCCG AGCCTCGGCT CTATGCAGAC 
     1681 CTTTTTATTT CTATTAAACG TTTCTGCACT GGCAAAAA 
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Appendix 2 
Determination of Protein Concentration in Prepared Samples 
Before performing immunoblotting, it was necessary to determine the concentration of 
protein present in the samples to be tested. Knowing this enabled experimental 
consistency, as the same volume of protein was used from all the samples. The method 
used was Bio-Rad's protein assay, which was based on the Bradford dye-binding procedure 
(Bradford 1976), and involves a colorimetric assay for measuring total protein 
concentration. 
Samples were prepared for a low-concentration assay in disposable cuvettes (Gibco). First, 
200µl of Bio-Rad Protein Assay Reagent (Bio-Rad) was added to the cuvette, followed by 
795µl of dH2O. Subsequently 5µl of protein sample was included to the mix. The solution 
was thoroughly mixed with a pipette to ensure even distribution of the protein for an 
accurate concentration reading. In order to have something to compare the concentration of 
the samples with, protein standards were prepared using Bovine Serum Albumin (BSA) 
(Sigma). The BSA was supplied at a concentration of 2mg/ml, but for the purpose of this 
study it was diluted to 1mg/ml with dH2O. One reference and seven protein standards were 
prepared in cuvettes as follows. 
Volume of 1mg/ml BSA required (ml)   Volume of dH2O required (ml) 
      
0 (REFERENCE)   800 
1   799 
5   795 
10   790 
15   785 
20   780 
25   775 
50   750 
 
To each of these was added 200ml of Bio-Rad Protein Assay Reagent. A gradual increase 
in the intensity of the blue colour was observed in parallel to the increasing concentration 
of the standards. Once prepared the reference and standards were used to calibrate the 
spectrophotometer (Bio-Rad) Protein 595 assay programme. This assay is based on a 
colour change of Coomassie brilliant blue G-250 dye in response to the binding of the dye 
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to basic and aromatic acid residues. Protein concentration was determined due to the 
change in the absorbance of the coomassie dye when bound to protein. When bound it has 
an absorption spectrum maximum of 595nm, whereas unbound it has an absorbance 
maximum of 470nm. Therefore, the increase of absorbance at 595nm is proportional to the 
amount of protein within the sample. 
The optical density at 595nm (O.D. 595nm) was measured for the reference and the seven 
protein standards. The O.D 595 was then read for all the samples and the concentration of 
protein present generated from the standards concentration. The spectrophotometer 
calculated the amount of protein (µg/ml) present, but the theory behind it involves plotting 
a graph of absorbance at 595nm against protein concentration of standards. This standard 
curve is then used to determine the concentration of the protein present in the samples from 
its O.D. 595 value.  
However, the concentration (µg/ml) was calculated from a diluted protein sample (1:200). 
From this the final concentration in mg/ml was determined as follows: 
Protein reading (µg/ml) x 0.2 = Final protein concentration (mg/ml) 
For western blotting either 25µg or 40µg of protein was used and the volume of sample 
required was calculated from the final concentration. 
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Appendix 3 
Validation experiment for SIRT1, SIRT2, SIRT3, SIRT7 in relation 
to 18S (From Nadeem Ashraf experiment).  
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